0001144204-13-014818.txt : 20130313 0001144204-13-014818.hdr.sgml : 20130313 20130313162053 ACCESSION NUMBER: 0001144204-13-014818 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20130131 FILED AS OF DATE: 20130313 DATE AS OF CHANGE: 20130313 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CHAMPIONS ONCOLOGY, INC. CENTRAL INDEX KEY: 0000771856 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 521401755 STATE OF INCORPORATION: DE FISCAL YEAR END: 0430 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-17263 FILM NUMBER: 13687699 BUSINESS ADDRESS: STREET 1: 855 N. WOLFE STREET STREET 2: SUITE 619 CITY: BALTIMORE STATE: MD ZIP: 21205 BUSINESS PHONE: 410-369-0365 MAIL ADDRESS: STREET 1: 855 N. WOLFE STREET STREET 2: SUITE 619 CITY: BALTIMORE STATE: MD ZIP: 21205 FORMER COMPANY: FORMER CONFORMED NAME: CHAMPIONS BIOTECHNOLOGY, INC. DATE OF NAME CHANGE: 20070220 FORMER COMPANY: FORMER CONFORMED NAME: CHAMPIONS SPORTS INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: INTERNATIONAL GROUP INC DATE OF NAME CHANGE: 19860319 10-Q 1 v336385_10q.htm FORM 10-Q

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)
þ	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended January 31, 2013
Or
¨	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from to

Commission file number 0-17263

CHAMPIONS ONCOLOGY, INC.

(Exact name of registrant as defined in its charter)

Delaware	52-1401755
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

One University Plaza, Suite 307	07601
Hackensack, New Jersey	(Zip Code)
(Address of principal executive offices)

(201) 808-8400

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ¨	Accelerated filer ¨	Non-accelerated filer ¨	Smaller reporting company þ
		(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ

The number of Common Shares of the Registrant outstanding as of February 28, 2013 was 66,752,100.

DOCUMENTS INCORPORATED BY REFERENCE - None

INDEX TO FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JANUARY 31, 2013

PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements.
Condensed Consolidated Balance Sheets as of January 31, 2013 (unaudited) and April 30, 2012		2
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended January 31, 2013 and 2012		3
Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended January 31, 2013 and 2012		4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	15
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	20
Item 4.	Controls and Procedures	20

PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	20
Item 1A.	Risk Factors	21
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	21
Item 3.	Defaults Upon Senior Securities	21
Item 4.	Mine Safety Disclosures	21
Item 5.	Other Information	21
Item 6.	Exhibits	21

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

CHAMPIONS ONCOLOGY, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Dollars in Thousands)

	January 31,			April 30,
	2013			2012
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	10,769		$	4,716
Accounts receivable, net		642			584
Prepaid expenses and other current assets		300			205

Total current assets		11,711			5,505

Restricted cash		190			188
Property and equipment, net		442			560
Goodwill		669			669

Total assets	$	13,012		$	6,922

LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' DEFICIT

Current liabilities:
Accounts payable	$	1,101		$	1,676
Accrued liabilities		566			625
Deferred revenue		1,017			1,185

Total current liabilities		2,684			3,486

Warrant liability		993			555

Total liabilities		3,677			4,041

Commitments and contingencies

Redeemable common stock; $0.001 par value; 31,133,333 and 12,533,333 contingently puttable common shares outstanding as of January 31, 2013 and April 30, 2012		16,936			8,159

Stockholders' equity:
Preferred stock, $10 par value; 56,075 shares authorized; no shares issued and outstanding as of January 31, 2013 and April 30, 2012		-			-
Common stock, $.001 par value; 125,000,000 shares authorized, including redeemable common stock, 38,855,003 and 37,740,345 shares is sued and 35,618,767 and 34,529,000 shares outstanding as of January 31, 2013 and April 30, 2012, respectively		39			38
Treasury stock, at cost, 3,236,000 common shares as of January 31, 2013 and April 30, 2012		(1,252	)		(1,252	)
Additional paid-in capital		23,136			21,204
Accumulated deficit		(29,425	)		(25,143	)
Accumulated other comprehensive loss		(99	)		(125	)

Total stockholders' deficit		(7,601	)		(5,278	)

Total liabilities, redeemable common stock and stockholders' deficit	$	13,012		$	6,922

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

CHAMPIONS ONCOLOGY, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Dollars in Thousands Except Per Share Amounts)

	Three Months Ended						Nine Months Ended
	January 31,						January 31,
	2013			2012			2013			2012
Operating revenue:
Personalized oncology solutions	$	473		$	649		$	1,850		$	1,837
Translational oncology solutions		2,444			1,747			4,631			3,931

Total operating revenue		2,917			2,396			6,481			5,768

Costs and operating expenses:
Cost of personalized oncology solutions		676			528			2,030			1,463
Cost of translational oncology solutions		566			801			1,740			1,904
Research and development		592			930			1,415			2,558
Sales and marketing		658			623			2,047			1,885
General and administrative		1,145			1,287			3,484			4,421

Total costs and operating expenses		3,637			4,169			10,716			12,231

Loss from operations		(720	)		(1,773	)		(4,235	)		(6,463	)

Other (expense) income:
Change in fair value of warrant liability		(255	)		66			(21	)		354
Other (expense) income		(10	)		(12	)		(22	)		(2	)

Total other (expense) income		(265	)		54			(43	)		352

Loss before provision for income taxes		(985	)		(1,719	)		(4,278	)		(6,111	)
Provision for income taxes		5			-			6			-

Net loss	$	(990	)	$	(1,719	)	$	(4,284	)	$	(6,111	)

Net loss per common share outstanding, including redeemable common stock, basic and diluted	$	(0.02	)	$	(0.04	)	$	(0.09	)	$	(0.13	)

Weighted average common shares outstanding, including redeemable common stock, basic and diluted		47,737,000			46,738,000			47,294,000			47,000,000

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Dollars in Thousands)

Net loss	$	(990	)	$	(1,719	)	$	(4,284	)	$	(6,111	)
Foreign currency translation adjustment		1			(13	)		24			2

Comprehensive loss	$	(989	)	$	(1,732	)	$	(4,260	)	$	(6,109	)

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

CHAMPIONS ONCOLOGY, INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Dollars in Thousands)

	Nine Months Ended
	January 31,
	2013			2012
Operating activities:
Net loss	$	(4,284	)	$	(6,111	)

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense		1,934			2,612
Depreciation expense		153			65
Change in fair value of warrant liability		21			(354	)
Changes in operating assets and liabilities:
Accounts receivable		(58	)		88
Prepaid expenses, deposits and other		(96	)		178
Restricted cash		(2	)		(150	)
Accounts payable		(574	)		43
Accrued liabilities		(58	)		42
Deferred revenue		(168	)		(117	)

Net cash used in operating activities		(3,132	)		(3,704	)

Investing activities:
Purchase of property and equipment		(35	)		(371	)

Net cash used in investing activities		(35	)		(371	)

Financing activities:
Private placement of common shares and warrants		9,195			-
Proceeds from exercise of options and warrants		-			98

Net cash provided by financing activities		9,195			98

Exchange rate effect on cash and cash equivalents		25			2

Increase in cash and cash equivalents		6,053			(3,975	)
Cash and cash equivalents, beginning of period		4,716			10,457

Cash and cash equivalents, end of period	$	10,769		$	6,482

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

CHAMPIONS ONCOLOGY, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Note 1. Organization, Use of Estimates and Basis of Presentation

Champions Oncology, Inc. (the “Company”), is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company’s Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology to derive revenue for two customer groups: Personalized Oncology Solutions (“POS”) and Translational Oncology Solutions (“TOS”). POS assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug studies and related personalized oncology services. The Company’s TOS business offers a technology platform to pharmaceutical and biotechnology companies using proprietary Tumorgraft studies, which have been shown to be predictive of how drugs may perform in clinical settings.

The Company has three operating subsidiaries: Champions Oncology (Israel), Limited, Champions Biotechnology U.K., Limited and Champions Oncology Singapore, PTE LTD. For the three and nine months ended January 31, 2013 and 2012, there were no material revenues earned by these subsidiaries. All material intercompany transactions have been eliminated in consolidation. The financial statements of the Company’s foreign subsidiaries, all of which have a functional currency other than the U.S. dollar, have been translated into the U.S. dollar for each period presented. Translation gains and losses are recognized as a component of accumulated other comprehensive loss. The Company is subject to foreign exchange rate fluctuations in connection with the Company’s international operations.

These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). All significant intercompany transactions and accounts have been eliminated. All figures are presented in U.S. dollars, except where expressly stated otherwise. Certain information related to the Company’s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company’s annual consolidated financial statements for the year ended April 30, 2012, as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments necessary to fairly state the Company’s financial position, results of operations, and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company’s Annual Report on Form 10-K for the year ended April 30, 2012. Certain reclassifications have been made to the prior period financial statement amounts to conform to current presentation.

The preparation of financial statements in conformity with Generally Accepted Accounting Principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include valuation assumptions used for share-based compensation and warrant liability, accrued expenses and deferred taxes.

Basic loss per share is calculated by dividing loss available to common shareholders by the weighted average number of common shares (including redeemable common stock) outstanding for the period. Diluted loss per share is calculated based on the weighted average number of common shares (including redeemable common stock) outstanding for the period, plus the dilutive effect of common stock purchase warrants, stock options and restricted stock units using the treasury stock method. Contingently issuable shares are included in the calculation of basic earnings per share when all contingencies surrounding the issuance of the shares are met and the shares are issued or issuable. Contingently issuable shares are included in the calculation of dilutive earnings per share as of the beginning of the reporting period if, at the end of the reporting period, all contingencies surrounding the issuance of the shares are satisfied, or would be satisfied, if the end of the reporting period were the end of the contingency period. Due to the net losses for the three and nine months ended January 31, 2013 and 2012, basic and diluted loss per share were the same, as the effect of potentially dilutive securities would have been anti-dilutive.

CHAMPIONS ONCOLOGY, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The following table reflects the total potential share-based instruments outstanding at January 31, 2013 and 2012 that could have an effect on the future computation of dilution per common share:

	January 31,
	2013		2012

Stock options		15,018,955		15,064,866
Warrants		3,276,667		1,416,667
Restricted stock		75,000		37,500

Total common stock equivalents		18,370,622		16,519,033

Note 2. Recently Issued Accounting Pronouncements

During July 2012, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2012-02, “Testing Indefinite-Lived Intangible Assets for Impairment”. The revised standard is intended to reduce the cost and complexity of testing indefinite-lived intangible assets other than goodwill for impairment by providing entities with an option to perform a "qualitative" assessment to determine whether further impairment testing is necessary. The revised standard allows an entity first to assess qualitative factors to determine whether events and circumstances indicate that it is more likely than not that an indefinite-lived intangible asset is impaired. If it is more likely than not that the asset is impaired, the entity must calculate the fair value of the asset, compare the fair value to its carrying amount, and record an impairment charge, if the carrying amount exceeds fair value. However, if an entity concludes that it is not more likely than not that the asset is impaired, no further action is required. The qualitative assessment is not an accounting policy election. An entity can choose to perform the qualitative assessment on none, some, or all of its indefinite-lived intangible assets. Moreover, an entity can bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to the quantitative impairment test, and then choose to perform the qualitative assessment in any subsequent period. The revised standard is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. The Company does not expect the adoption of this standard to have a material impact on its financial position or results of operations.

During September 2011, the FASB issued ASU No. 2011-08, “Testing Goodwill for Impairment” (“ASU 2011-08”). ASU 2011-08 is intended to simplify the testing of goodwill for impairment by permitting an entity to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test, which is currently required for all companies that report goodwill. The amendments are effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011, although early adoption is permitted. The Company has adopted this standard, which had no impact on its financial position or results of operations.

Note 3. Property and Equipment

Property and equipment is recorded at cost and consists of laboratory equipment, furniture and fixtures, and computer hardware and software. Depreciation is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to seven years. Property and equipment consisted of the following (in thousands):

CHAMPIONS ONCOLOGY, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

	January 31,			April 30,
	2013			2012
	(unaudited)
Furniture and fixtures	$	58		$	58
Computer equipment and software		526			287
Laboratory equipment		179			167
Leasehold improvements		2			2
Software in-progress		-			216

Total property and equipment		765			730
Less: Accumulated depreciation		(323	)		(170	)

Property and equipment, net	$	442		$	560

Depreciation expense was $51,000 and $16,000 for the three months ended January 31, 2013 and 2012, respectively, and $153,000 and $65,000 for the nine months ended January 31, 2012 and 2011, respectively.

Note 4. Share-Based Payments

The Company has in place the 2010 Equity Incentive Plan, the 2008 Equity Incentive Plan, and the Director Compensation Plan of 2010. In general, these plans provide for stock-based compensation in the form (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights to the Company’s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards. Stock-based compensation in the amount of $570,000 and $743,000 was recognized for the three months ended January 31, 2013 and 2012, respectively, and $1,934,000 and $2,612,000 for the nine months ended January 31, 2013 and 2012, respectively. Stock-based compensation expense was recognized as follows (in thousands):

	Three Months Ended					Nine Months Ended
	January 31,					January 31,
	2013		2012			2013		2012

General and administrative	$	500	$	701		$	1,619	$	2,370
Sales and marketing		56		49			199		168
Research and development		4		(8	)		33		72
TOS cost of sales		4		1			16		2
POS cost of sales		6		-			67		-

Total stock-based compensation expense	$	570	$	743		$	1,934	$	2,612

CHAMPIONS ONCOLOGY, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Stock Option Grants

Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2013 and 2012 were as follows:

	Three Months Ended				Nine Months Ended
	January 31,				January 31,
	2013		2012		2013		2012

Expected term in years		6.0		3.0 - 6.0		6.0		3.0 - 6.0
Risk-free interest rates		0.9% - 1.0%		0.4% - 1.9%		0.8% - 1.0%		0.4% - 2.2%
Volatility		100% - 102%		90% - 101%		99% - 102%		90% - 108%
Dividend yield		0%		0%		0%		0%

The weighted average fair value of stock options granted during the three months ended January 31, 2013 and 2012 was $0.27 and $0.52, respectively. The weighted average fair value of stock options granted during the nine months ended January 31, 2013 and 2012 was $0.36 and $0.57, respectively. The Company’s stock option activity for the nine months ended January 31, 2013 was as follows:

												Weighted
										Weighted		Average
				Directors						Average		Remaining		Aggregate
	Non-			and						Exercise		Contractual		Intrinsic
	Employees			Employees			Total			Price		Life (Years)		Value

Outstanding, May 1, 2012		1,410,000			13,456,038			14,866,038		$	0.88		7.0	$	-
Granted		130,000			586,250			716,250			0.41
Forfeited		-			(22,500	)		(22,500	)		0.67
Expired		(500,000	)		(15,833	)		(515,833	)		0.76
Canceled		-			(25,000	)		(25,000	)		0.62

Outstanding, January 31, 2013		1,040,000			13,978,955			15,018,955			0.86		7.1		96,000

Vested and expected to vest as of January 31, 2013		1,040,000			13,978,955			15,018,955

Exercisable as of January 31, 2013		933,334			9,735,078			10,668,412			0.88		6.8		14,000

Restricted Stock Grants

A summary of the activity related to restricted stock grants is as follows (in thousands):

				Weighted
				Average Grant
				Date Fair Value
	Shares			Per Share

Nonvested as of May 1, 2012		25,000		$	0.75
Granted		100,000			0.30
Vested		(50,000	)		0.53
Forfeited		-			-
Expired		-			-

Nonvested as of January 31, 2013		75,000			-

CHAMPIONS ONCOLOGY, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The aggregate fair value of shares vested during the nine months ended January 31, 2013 and 2012 was $26,000 and $84,000, respectively.

Stock Purchase Warrants

As of January 31, 2013, the Company had warrants outstanding for the purchase of 3,276,667 shares of its common stock, all of which were exercisable. Of these warrants, 1,266,667 were issued in connection with the April 2011Private Placement (see Note 5) and 1,860,000 were issued in connection with the January 2013 Private Placement (see Note 5) and are accounted for as liabilities as further discussed in Note 5. The remaining 150,000 warrants are accounted for as equity instruments and expire July 31, 2014. As of January 31, 2013, the weighted average exercise price of all warrants outstanding was $0.77. As of January 31, 2013 and April 30, 2012, the warrants intrinsic value was $13,000 and $0, respectively, and had weighted average remaining contractual lives of 4.2 years and 3.8 years, respectively.

Note 5. Redeemable Common Stock and Stock Purchase Warrant

On January 28, 2013, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale of an aggregate 18,600,000 shares of the Company’s Common Stock at a purchase price of $0.50 per share, for aggregate proceeds of $9.3 million, $0.5 million of which was sold to officers and directors of the Company. This private placement transaction closed on January 28, 2013 (the “January 2013 Private Placement”). As part of this transaction, the Company also issued warrants to purchase an aggregate 1,860,000 shares of Common Stock at an exercise price of $0.66 per share. These warrants expire five years after the closing date . The Company also entered into an Amended and Restated Registration Rights Agreement on January 28, 2013 which provided certain registration rights with respect to the shares of Common Stock issued and the shares of Common Stock issuable upon exercise of the warrants. Furthermore, certain investors will have the right to require the Company to redeem the purchased common shares held by all of the investors (the “January 2013 Private Placement Put Option”) for cash of $0.50 per share upon a change of control or sale or exclusive license of substantially all of the Company’s assets. The January 2013 Private Placement Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement for the January 2013 Private Placement. The January 2013 Private Placement investors also have certain participation rights with respect to future financings of the Company. The terms of the January 2013 Private Placement resulted in the issuance of an additional 1,064,658 common shares to the investors of the April 2011 Private Placement under the anti-dilution protections granted such investors.

On March 24, 2011, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale of an aggregate 12,533,333 shares of the Company’s Common Stock at a purchase price of $0.75 per share, for aggregate proceeds of $9.4 million, $0.5 million of which was sold to officers and directors of the Company. This private placement transaction closed April 4, 2011 (the “April 2011 Private Placement”). As part of this transaction, the Company also issued warrants to purchase an aggregate 1,266,667 shares of Common Stock at an exercise price of $0.90 per share. These warrants expire five years after the closing date. The Securities Purchase Agreement governing the April 2011 Private Placement contains certain anti-dilution protections for the investors. The Amended and Restated Registration Rights Agreement referenced above provides certain registration rights with respect to the shares of Common Stock issued and the shares of Common Stock issuable upon exercise of the warrants. Furthermore, certain investors have the right to require the Company to redeem the purchased common shares held by all of the investors (the “April 2011 Private Placement Put Option”) for cash for $0.75 per share upon a change of control or sale or exclusive license of substantially all of the Company’s assets. The April 2011 Private Placement Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement for the April 2011 Private Placement.

Due to the April 2011 Private Placement Put Option and the January 2013 Private Placement Put Option described above, the Company has accounted for the Common Stock for the April 2011 Private Placement and January 2013 Private Placement as temporary equity, which is reflected under the caption “redeemable common stock” on the accompanying condensed consolidated balance sheets. The total amount allocated to the redeemable common stock was $8.8 million for the January 2013 Private Placement and $8.2 million for the April 2011 Private Placement. For the January 2013 Private Placement, this allocation is equal to the total proceeds of $9.3 million less the amount allocated to the warrants of $0.4 million and is also net of the direct and incremental costs associated with the January 2013 Private Placement of $0.1 million. For the April 2011 Private Placement, this allocation is equal to the total proceeds of $9.4 million, less the amount allocated to the warrants of $0.9 million and is also net of direct and incremental costs associated with the April 2011 Private Placement of $0.3 million.

CHAMPIONS ONCOLOGY, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The warrants issued in connection with both the April 2011 Private Placement and January 2013 Private Placement contain certain exercise price reset provisions. Under these provisions, the exercise price of the warrants may be adjusted downward should the Company have future sales of its Common Stock for no consideration or for a consideration per share less than the Per Share Price (as such term is defined in the April 2011 Private Placement and January 2013 Private Placement). These exercise price reset provisions resulted in a downward adjustment to the exercise price of the warrants issued in the April 2011 Private Placement from $0.90 to $0.50.

The Company has granted demand registration rights in connection with the investment in common shares and the common shares underlying the warrants for both the April 2011 Private Placement and January 2013 Private Placement. These rights include the requirement of the Company to file certain registration statements within a specified time period and to have these registration statements declared effective within a specified time period. If the Company is not able to comply with these registration requirements, the Company will be required to pay cash penalties equal to 1.0% of the aggregate Purchase Price paid by the investors for each 30-day period in which a Registration Default, as defined in the Securities Purchase Agreement, exists. These penalties are subject to a 10% limit of the aggregate Purchase Price paid by the investors. The Company may become subject to these penalty provisions if it fails to have a registration statement for the common shares declared effective, or to maintain the effectiveness of such registration statement. The total amount of potential penalties under this registration payment arrangement ranges from $50,000 to $130,000 for each 30-day period in which a registration default exists; however, as of January 31, 2013 and through the date of this filing, the Company does not believe these penalties to be probable and accordingly, has not established an accrual for such registration payment arrangements.

The Company has accounted for the warrants issued in connection with the April 2011 Private Placement and January 2013 Private Placement as a liability based on the exercise price reset provisions described above. This liability, which is recorded at fair value on the accompanying consolidated balance sheets, totaled $0.8 million at the time of the close of the January 2013 Private Placement Agreement. As of January 31, 2013 and April 30, 2012, the fair value of these warrants was $1 million and $0.6 million, respectively. The change in fair value of these warrants has been, and will be, recognized as other income (expense) on the Company’s condensed consolidated statements of operations. The fair value of these warrants was calculated by the Monte Carlo simulation valuation method. Assumptions used to calculate the fair value of these warrants were as follows:

	January 31,		April 30,
	2013		2012

Risk-free interest rates		0.46% - 0.88%		0.6%
Volatility		84.9% - 102%		102%
Dividend yield		0%		0%

The Company will continue to adjust the warrant liability for changes in fair value until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. As of January 31, 2013, the Company changed its method used to calculate expected volatility from an index, which was based on the Company’s historic volatility and certain comparable guideline companies, to the use of only the Company’s historic volatility which had an immaterial effect on the financial statements

Note 6. Related Party Transactions

Related party transactions include transactions between the Company and its shareholders, management, and affiliates. The transactions discussed in this footnote were in the normal course of operations and were measured at the exchange amount, which is the amount of consideration established and agreed to by the parties.

Consulting Services

During the nine months ended January 31, 2013 and 2012, the Company paid one of its former directors and former Chief Executive Officer, $30,000 and $18,000, respectively, in consulting fees. During the nine months ended January 31, 2013 and 2012, the Company paid certain members of its Board of Directors $122,500 and $103,000, respectively, for consulting services unrelated to their duties as board members. During the nine months ended January 31, 2013, the Company paid a substantial stockholder and former member of its Board of Directors $3,000 for consulting services. No such payment was made during the nine months ended January 31, 2012. During the nine months ended January 31, 2013, the Company paid a prospective board member’s company $8,300 for consulting services. No such payment was made during the nine months January 31, 2012. All of the amounts paid to these related parties have been expensed.

CHAMPIONS ONCOLOGY, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Revenue

During the nine months ended January 31, 2013, the Company earned no revenues through related party transactions. During the nine months ended January 31, 2012, the Company recognized $20,000 in revenues from a company whose board members were also members of the Company’s Board of Directors.

Note 7. Commitments and Contingencies

Operating Leases

As of January 31, 2013, the Company leases the following facilities under non-cancelable operating lease agreements:

One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company’s corporate headquarters. This lease expires in April 2014. The Company recorded $52,000 and $52,000 of rental expense relative to this lease for the nine months ended January 31, 2013 and 2012, respectively.

855 North Wolfe Street, Suite 619, Baltimore, Maryland 21205, which consists of laboratories and office space where the Company conducts operations related to its primary service offerings. This lease expires in June 2014. The Company recorded $69,000 and $49,000 of rental expense relative to this lease in the nine months ended January 31, 2013 and 2012, respectively.

17 Hatidhar Street, Ra’anana, Israel, which serves as office headquarters for Champions Oncology, Israel. The lease expires in July 2013. The Company recorded $21,000 and $18,000 of rental expense relative to this lease for the nine months ended January 31, 2013 and 2012, respectively.

Legal Matters

The Company is party to certain legal matters arising in the ordinary course of its business. The Company has evaluated its potential exposure to these legal matters and noted no such exposures. The Company is not aware of any other matters that would have a material impact on the Company’s financial position or results of operations.

Registration Payment Arrangements

The Company has entered into an Amended and Restated Registration Rights Agreement in connection with the April 2011 Private Placement and January 2013 Private Placement and is discussed more fully in Note 5 above. This Amended and Restated Registration Rights Agreement contains provisions that may call for the Company to pay penalties in certain circumstances. This registration payment arrangement primarily relates to the Company’s ability to file a registration statement within a particular time period, have a registration statement declared effective within a particular time period and to maintain the effectiveness of the registration statement for a particular time period. The Company does not believe it is probable that penalty payments will be made for the Amended and Restated Registration Rights Agreement discussed in Note 5 above and, accordingly, has not accrued for such potential penalties as of January 31, 2013 or April 30, 2012.

Note 8. Licensing Agreements

In February 2010, the Company entered into an exclusive option agreement with a Canadian company for which it paid and expensed $40,000 (Canadian) during the Company’s fiscal 2010 year. The option agreement granted the Company the exclusive right to review Irinophore C, a nanoparticle drug compound, for the treatment of various forms of cancer, including melanoma, prostate, breast, and lung cancer through April 2011. During the option year, the Company performed various TumorGraft tests on the nanoparticle compound. In March 2011, the Company exercised its option to license Irinophore C, a liposomal formulation of Irinotecan. Under the terms of the agreement, the Company’s exercise of the option resulted in amounts due to the Canadian company of $85,000 (Canadian) comprised of the option exercise price and reimbursement to the Canadian company for past patent costs, which was expensed in the Company’s fiscal year ended April 30, 2011. The Company satisfied this obligation during fiscal 2012. On the first anniversary of the agreement (March 2012), an additional license fee of $45,000 (Canadian) became due, which was recognized as a liability as of April 30, 2012 and was satisfied during the nine months ended January 31, 2013. Commencing with the second anniversary of the agreement (March 2013), the Company will be obligated to pay a minimum annual royalty of $10,000 (Canadian), unless the agreement is terminated by either party in advance of the anniversary date. Under the terms of the license agreement, the Company will be required to pay up to $3.0 million in development milestones, if achieved. Upon commercialization, the Company would also be required to make royalty and sales milestone payments based upon revenues. As of January 31, 2013 the Company has accrued for the annual royalty payment of $10,000 (Canadian).

CHAMPIONS ONCOLOGY, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Note 9. Cephalon Agreement

On March 16, 2011, the Company entered into an agreement with Cephalon, Inc., (“Cephalon”), a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., pursuant to which the Company conducts TumorGraft studies on two proprietary chemical compounds provided by Cephalon to determine the activity or response of these compounds in potential clinical indications. Under the agreement, Cephalon will, under certain conditions, pay the Company various amounts upon achieving certain milestones, which are based on the performance of the compounds in preclinical testing and are dependent upon testing the compound in clinical settings and obtaining FDA approval. Potential milestone payments that could be received under the Agreement total $27 million per compound. No milestones have been achieved to date. In addition, under certain conditions, Cephalon would pay the Company royalties on any commercialized products developed under the Agreement. No royalties have been received or earned to date. Cephalon reserves the right to exercise and pay a one-time fee of in lieu of the milestone or royalty payments, which are $460,000 for one compound and $880,000 for the second compound.

On November 30, 2012, Cephalon exercised the option to pay the one-time fee of $880,000 to the Company, in lieu of any future milestone or royalty payments, for one compound tested under the agreement described above. Written notice was provided to the Company on December 3, 2012 and payment was received on December 19, 2012. This fee has been recognized as revenue during the three and nine months ended January 31, 2013. As of January 31, 2013, the remaining compound is still being evaluated.

In April 2011, Cephalon paid an initiation fee of $1.4 million to the Company, which was initially reflected within deferred revenue on the Company’s balance sheet as of April 30, 2011. As models, along with required reports, are delivered, the deferred revenue is recognized on a proportionate basis in accordance with the Company’s revenue recognition policies. Revenues of $317,000 and $681,000 were recognized during the nine months ended January 31, 2013 and 2012.

Note 10. Supplemental Schedule of Cash Flow Information

There was no cash paid for interest or income taxes during the nine months ended January 31, 2013 and 2012.

Note 11. Grant Income

In October 2010, the Company was notified that it was awarded total cash grants of approximately $1.5 million under the Qualifying Therapeutic Discovery Project program administered under section 48D of the Internal Revenue Code, of which approximately $1.0 million related to qualifying expenses the Company had previously incurred during fiscal 2010 and $0.5 million related to qualifying expenses which the Company expected to incur during fiscal 2011. In November 2010, the Company received approximately $1.0 million related to the 2010 expenditures. The Company received a final payment of $0.5 million related to 2011 expenditures on February 13, 2012.

On August 8, 2011 the Company was notified that it was selected for a tax examination by the Internal Revenue Service (“IRS”) on the Application for Certification of Qualified Investments Eligible for Credits and Grants Under the Qualifying Therapeutic Discovery Project program filed under the Patient Protection and Affordable Care Act of 2010 for the 2009 and 2010 tax years. The examination commenced during the second quarter of fiscal 2012. The IRS expanded its scope to include the fiscal year 2011 tax return, which was filed in January 2012. The examinations of fiscal 2009 and 2010 were completed in the fourth quarter of fiscal 2012. The examination of fiscal 2011 was completed in the first quarter of fiscal 2013. The audit of all three fiscal years ending April 30, 2011, 2010 and 2009 resulted in no additional tax due or receivable.

Note 12. Fair Value

The carrying value of cash and cash equivalents, accounts receivable, prepaid expenses, deposits and other receivables, accounts payable and accrued liabilities approximate their fair value based on the liquidity or the short-term maturities of these instruments. The fair value hierarchy promulgated by GAAP consists of three levels:

Level one — Quoted market prices in active markets for identical assets or liabilities;

CHAMPIONS ONCOLOGY, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Level two — Inputs other than level one inputs that are either directly or indirectly observable; and

Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.

Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company has one liability measured at fair value on a recurring basis, which are warrants that were issued in connection with the January 2013 Private Placement and April 2012 Private Placement which is discussed more fully in Note 5. As of January 31, 2013 and April 30, 2012, these warrants had an estimated fair value of $1 million and $0.6 million, respectively, which was calculated by the Monte Carlo simulation valuation method using level three inputs. The Company has no assets that are measured at fair value on a recurring basis and there were no assets or liabilities measured at fair value on a non-recurring basis as of January 31, 2013 and April 30, 2012 or during the nine months ended January 31, 2013 and 2012.

The following table presents information about the Company’s warrants liability, which was the only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at January 31, 2013 (in thousands):

Balance, May 1, 2012	$	555
Transfers to (from) Level 3		-
Total (gains) losses included in earnings		21
Purchases, issuances and settlements, net		417

Balance, January 31, 2013	$	993

Note 13. Business Segment Information

The Company operates in two segments, POS and TOS. The accounting policies of the Company’s segments are the same as those described in Note 2 of the Company’s annual consolidated financial statements for the year ended April 30, 2012, as filed on Form 10-K. The Company evaluates performance of its segments based on profit or loss from operations before stock-based compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes (“segment profit”). Management uses segment profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment, and employee compensation, among other matters. The following tables summarize, for the periods indicated, operating results by business segment (in thousands):

				Translational
	Personalized			Oncology			Unallocated
	Oncology			Solutions			Corporate
Three Months Ended January 31, 2013	Solutions (POS)			(TOS)			Overhead			Consolidated
Net revenue	$	473		$	2,444		$	-		$	2,917
Direct cost of services		(661	)		(561	)		-			(1,222	)
Sales and marketing costs		(361	)		(220	)		-			(581	)
Other operating expenses		-			(627	)		(637	)		(1,264	)
Stock- based compensation expense (1)		-			-			(570	)		(570	)

Segment profit (loss)	$	(549	)	$	1,036		$	(1,207	)	$	(720	)

CHAMPIONS ONCOLOGY, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

				Translational
	Personalized			Oncology			Unallocated
	Oncology			Solutions			Corporate
Three Months Ended January 31, 2012	Solutions (POS)			(TOS)			Overhead			Consolidated
Net revenue	$	649		$	1,747		$	-		$	2,396
Direct cost of services		(528	)		(801	)		-			(1,329	)
Sales and marketing costs		(242	)		(175	)		-			(417	)
Other operating expenses		-			(851	)		(829	)		(1,680	)
Stock- based compensation expense (1)		-			-			(743	)		(743	)

Segment profit (loss)	$	(121	)	$	(80	)	$	(1,572	)	$	(1,773	)

				Translational
	Personalized			Oncology			Unallocated
	Oncology			Solutions			Corporate
Nine Months Ended January 31, 2013	Solutions (POS)			(TOS)			Overhead			Consolidated
Net revenue	$	1,850		$	4,631		$	-		$	6,481
Direct cost of services		(2,030	)		(1,740	)		-			(3,770	)
Sales and marketing costs		(495	)		(636	)		-			(1,131	)
Other operating expenses		-			(1,463	)		(2,418	)		(3,881	)
Stock- based compensation expense (1)		-			-			(1,934	)		(1,934	)

Segment profit (loss)	$	(675	)	$	792		$	(4,352	)	$	(4,235	)

				Translational
	Personalized			Oncology			Unallocated
	Oncology			Solutions			Corporate
Nine Months Ended January 31, 2012	Solutions (POS)			(TOS)			Overhead			Consolidated
Net revenue	$	1,837		$	3,931		$	-		$	5,768
Direct cost of services		(1,463	)		(1,904	)		-			(3,367	)
Sales and marketing costs		(718	)		(626	)		-			(1,344	)
Other operating expenses		-			(2,419	)		(2,489	)		(4,908	)
Stock- based compensation expense (1)		-			-			(2,612	)		(2,612	)

Segment profit (loss)	$	(344	)	$	(1,018	)	$	(5,101	)	$	(6,463	)

(1)

Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.

All of the Company’s revenue is recorded in the United States and substantially all of its long-lived assets are in the United States.

Note 14. Subsequent Events

None.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our historical results of operations and our liquidity and capital resources should be read in conjunction with the condensed consolidated financial statements and related notes that appear elsewhere in this report and our most recent annual report for the year ended April 30, 2012, as filed on Form 10-K.

Forward-Looking Statements

This Quarterly Report on Form 10-Q, including Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains certain “forward-looking statements,” which include information relating to future events, future financial performance, strategies, expectations, competitive environment, regulation, and availability of resources. These forward-looking statements include, without limitation, statements regarding: proposed new programs; expectations that regulatory developments or other matters will not have a material adverse effect on our financial position, results of operations, or liquidity; statements concerning projections, predictions, expectations, estimates, or forecasts as to our business, financial and operational results, and future economic performance; and statements of management’s goals and objectives and other similar expressions concerning matters that are not historical facts. Words such as “may,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar expressions, as well as statements in future tense, identify forward-looking statements.

Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made or management’s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

Forward-looking statements speak only as of the date the statements are made. Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to, those described in “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2012, as updated in our subsequent reports filed with the SEC, including any updates found in Part II, Item 1A of this or other reports on Form 10-Q. You should not put undue reliance on any forward-looking statements. We assume no obligation to update forward-looking statements to reflect actual results, changes in assumptions, or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. If we do update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Overview and Recent Developments

Champions Oncology, Inc. is engaged in the development of advanced technology solutions to personalize the development and use of oncology drugs. The Company’s TumorGraft Technology Platform is a novel approach to personalizing cancer care, based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology, in conjunction with related services, to offer solutions for two customer groups:

Our Personalized Oncology Solutions (“POS”) business, which provides services to physicians and patients looking for information to help guide the development of personalized treatment plans.

Our Translational Oncology Solutions (“TOS”) business, which provides services to pharmaceutical and biotechnology companies seeking personalized approaches to drug development that will lower costs and increase the speed of developing new drugs, as well as increase the adoption of existing drugs.

We plan to continue our efforts to expand our TumorGraft Technology Platform in order to expand our POS and TOS programs. In fiscal 2012, we modified our POS business strategy to focus on growing our core technology products, which includes TumorGraft implants and drug studies. As part of this strategy, which we continue to execute in fiscal 2013, we significantly reduced the price of our core technology products to make the products affordable to a broader patient base, maximize synergies between our POS and TOS businesses, increase our tumor model offerings to our TOS sponsors, and increase the number of models in our Tumorbank. We will continue to offer related personalized oncology services to our customers; however, we expect future POS revenue to be driven by our core products.

During the second half of fiscal 2012, we transitioned the laboratory activities that support the POS and TOS services from a third-party contract research organization (“CRO”) to our facility in Baltimore, Maryland. To facilitate this strategy and support the increase in current and expected volume, we have invested in the infrastructure and increased our laboratory staff and are evaluating options to increase our lab capacity to meet the future demand. We believe that bringing these activities in-house will significantly reduce the future cost of providing our services and allow us to maintain a more competitive pricing strategy.

On March 16, 2011, the Company entered into an agreement with Cephalon, Inc. (“Cephalon”), a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., pursuant to which the Company conducts TumorGraft studies on two proprietary chemical compounds provided by Cephalon to determine the activity or response of these compounds in potential clinical indications. Under the agreement, Cephalon will, under certain conditions, pay the Company various amounts upon achieving certain milestones, which are based on the performance of the compounds in preclinical testing and are dependent upon testing the compound in clinical settings and obtaining FDA approval. Potential milestone payments that could be received under the Agreement total $27 million per compound. No milestones have been achieved to date. In addition, under certain conditions, Cephalon would pay the Company royalties on any commercialized products developed under the Agreement. No royalties have been received or earned to date. Cephalon reserves the right to exercise and pay a one-time fee of in lieu of the milestone or royalty payments, which are $460,000 for one compound and $880,000 for the second compound.

On November 30, 2012, Cephalon exercised the option to pay this one-time fee of $880,000 to the Company, in lieu of any future milestone or royalty payments, for one compound tested under the agreement described above. Written notice was provided to the Company on December 3, 2012 and payment was received on December 19, 2012. This fee has been recognized as revenue during the three and nine months ended January 31, 2013. As of January 31, 2013, the remaining compound is still being evaluated.

Operating Results

The following table summarizes our operating results for the periods presented below:

	For the Three Months Ended January 31,
				% of						% of			%
	2013			Revenue			2012			Revenue			Change
Operating revenue:
Personalized oncology solutions	$	0.5			17.2	%	$	0.7			29.2	%		(28.6	)%
Translational oncology solutions		2.4			82.8			1.7			70.8			41.2

Total operating revenue		2.9			100.0			2.4			100.0			20.8

Costs and operating expenses:
Cost of personalized oncology solutions		0.7			24.1			0.5			20.8			40.0
Cost of translational oncology solutions		0.6			20.7			0.8			33.3			(25.0	)
Research and development		0.6			20.7			0.9			37.5			(33.3	)
Sales and marketing		0.6			20.7			0.6			25.0			-
General and administrative		1.1			37.9			1.3			54.3			(15.4	)

Total costs and operating expenses		3.6			124.1			4.1			170.8			(12.2	)

Operating loss	$	(0.7	)		(24.1	)%	$	(1.7	)		(70.8	)%		(58.8	)

	For the Nine Months Ended January 31,
				% of						% of			%
	2013			Revenue			2012			Revenue			Change
Operating revenue:
Personalized oncology solutions	$	1.9			29.2	%	$	1.8			31.6	%		5.6	%
Translational oncology solutions		4.6			70.8			3.9			68.4			17.9

Total operating revenue		6.5			100.0			5.7			100.0			14.0

Costs and operating expenses:
Cost of personalized oncology solutions		2.0			30.8			1.5			26.3			33.3
Cost of translational oncology solutions		1.7			26.2			1.9			33.3			(10.5	)
Research and development		1.4			21.5			2.5			43.9			(44.0	)
Sales and marketing		2.1			32.3			1.9			33.3			10.5
General and administrative		3.5			53.8			4.4			77.2			(20.5	)

Total costs and operating expenses		10.7			164.6			12.2			214.0			(12.3	)

Operating loss	$	(4.2	)		(64.6	)%	$	(6.5	)		(114.0	)%		(35.4	)

Operating Revenues

Operating revenues were $2.9 million and $2.4 million for the three months ended January 31, 2013 and 2012, respectively, an increase of $0.5 million or 21%. Operating revenues were $6.5 million and $5.7 million for the nine months ended January 31, 2013 and 2012, respectively, an increase of $0.8 million or 14%.

Personalized Oncology Solutions (POS)

POS unit volumes continued to grow rapidly during the quarter. The number of implants during the quarter and year to date were 41 and 113, an increase of 64% and 61% over the same periods last year. The increase in implants is the result of growing visibility with patients and physicians, an increase in the number of free implants offered to physicians to enable them to get direct experience with TumorGraft technology and the recent opening of an office in Singapore. The number of patients for whom studies were completed was 11 and 34 for the quarter and year to date, an increase of 160% and 209% over the same periods last year. The increase in patient studies is the result of higher implant volumes in the recent quarters which lead to studies in subsequent quarters. POS revenues were $0.5 million and $0.7 million for the three months ended January 31, 2013 and 2012, respectively, a decrease of $0.2 million, or 29%. For the nine months ended January 31, 2013 and 2012, POS revenues were $1.9 million and $1.8 million, respectively, an increase of $0.1 million, or 6%. The changes in POS revenues were driven by the increased number of implants and drug studies completed during the three and nine months ended January 31, 2013 compared to the same period in the previous year, offset by a decline in revenue per implant and revenue per study. The decline in pricing is part of the company’s strategy to increase volumes to grow the TumorBank and provide physicians with more experience with TumorGraft technology.

Cost of Personalized Oncology Solutions

POS cost of sales was $0.7 million and $0.5 million for the three months ended January 31, 2013 and 2012, respectively, an increase of $0.2 million, or 40%. For the nine months ended January 31, 2013 and 2012, POS cost of sales was $2.0 million and $1.5 million, respectively, an increase of $0.5 million, or 33%. For the three months ended January 31, 2013 and 2012, gross margins for POS were -40% and 29%, respectively. For the nine months ended January 31, 2013 and 2012, gross margins for POS were -5% and 17%, respectively. The increases in cost of sales and the declines in gross margins can be attributed to increased volumes of implants and drug studies performed, in line with management’s strategy to obtain more tumors to increase our tumor model offerings to our TOS sponsors and increase the number of models in our Tumorbank.

Translational Oncology Solutions (TOS)

TOS revenues were $2.4 million and $1.7 million for the three months ended January 31, 2013 and 2012, respectively, an increase of $0.7 million, or 41%. TOS revenues were $4.6 million and $3.9 million for the nine month periods ending January 31, 2013 and 2012, respectively, an increase of $0.7 million, or 18%. The increase in TOS revenues was due primarily to the one-time buyout payment, described below, from the successful completion of a TumorGraft technology collaboration with Cephalon, a subsidiary of Teva Pharmaceutical Industries.

On November 30, 2012, Cephalon exercised the option to pay a one-time fee of $880,000 to the Company, in lieu of any future milestone or royalty payments relative to a March 16, 2011 agreement between Cephalon and the Company, which is discussed further above. This fee has been recognized as revenue during the three and nine months ended January 31, 2013.

Cost of Translational Oncology Solutions

TOS cost of sales was $0.6 million and $0.8 million for the three months ended January 31, 2013 and 2012, respectively, a decrease of $0.2 million, or 25%. For the nine months ended January 31, 2013 and 2012, TOS cost of sales was $1.7 million and $1.9 million, respectively, decrease of $0.2 million, or 11%. For the three months ended January 31, 2013 and 2012, gross margins for TOS were 75% and 53%. For the nine months ended January 31, 2013 and 2012, gross margins for TOS were 63% and 51%, respectively.

Research and Development

Research and development expense was $0.6 million and $0.9 million for three months ended January 31, 2013 and 2012, respectively, a decrease of $0.3 million, or 33%. For the nine months ended January 31, 2013 and 2012, research and development expense was $1.4 million and $2.5 million, respectively, a decrease of $1.1 million, or 44%. This decrease is primarily related to decreased laboratory maintenance costs associated with research and development efforts, in line with our strategy to focus on our POS and TOS lines of business. Additionally, the decrease can be attributed to decreased tumor procurement costs, resulting from our strategy to source models from our POS business.

Sales and Marketing

Sales and marketing expense was $0.6 million and $0.6 million for the three months ended January 31, 2013 and 2012. For the nine months ended January 31, 2013 and 2012, sales and marketing expense was $2.1 million and $1.9 million, respectively, an increase of $0.2 million, or 11%.

General and Administrative

General and administrative expense was $1.1 million and $1.3 million for the three months ended January 31, 2013 and 2012, respectively, a decrease of $0.2 million, or 15%. For the nine months ended January 31, 2013 and 2012, general and administrative expense was $3.5 million and $4.4 million, respectively, a decrease of $0.9 million, or 21%. This decrease can be attributed to reductions in stock-based compensation expenses and consultant costs. The decrease in stock-based compensation expense is primarily due to large prior period stock option grants that contain performance conditions and were, and continue to be, accounted for using the accelerated attribution method.

Other Income (Expense)

Other income (expense) consists of the change in the fair value of warrants that are accounted for as liabilities and are described further below and in Note 6 to the accompanying unaudited condensed consolidated financial statements. Other income (expense) was $(0.3) million and $0.1 million for the three months ended January 31, 2013 and 2012, respectively. For the nine months ended January 31, 2013 and 2012, other income (expense) was $(0.1) million and $0.4 million, respectively. The Company will continue to adjust the warrant liability for changes in fair value, until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. This change in the fair value of the warrant liability was a result of revaluing the warrant liability based on the Monte Carlo simulation valuation model, impacted primarily by the quoted price of the Company's common stock. The revaluation of the warrant liability has no impact on our cash balances.

Liquidity and Capital Resources

Our liquidity needs have typically arisen from the funding of our research and development programs and the launch of new products, working capital requirements, and other strategic initiatives. In the past, we have met these cash requirements through our cash and cash equivalents, working capital management, and proceeds from certain private placements of our securities. As of January 31, 2013, we had working capital of $9 million and cash and cash equivalents of $10.8 million. We believe that our cash and cash equivalents on hand at January 31, 2013 is adequate to fund operation for at least through our fiscal 2014. Should the Company be required to raise additional capital, there can be no assurance that management would be successful in raising such capital on terms acceptable to us, if at all.

On January 28, 2013, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale of an aggregate 18,600,000 shares of the Company’s Common Stock at a purchase price of $0.50 per share, for aggregate proceeds of $9.3 million, $0.5 million of which was sold to officers and directors of the Company. This private placement transaction closed on January 28, 2013 (the “January 2013 Private Placement”). As part of this transaction, the Company also issued warrants to purchase an aggregate 1,860,000 shares of Common Stock at an exercise price of $0.66 per share. These warrants expire five years after the closing date. The Company also entered into an Amended and Restated Registration Rights Agreement on January 28, 2013 which provided certain registration rights with respect to the shares of Common Stock issued and the shares of Common Stock issuable upon exercise of the warrants. Furthermore, certain investors will have the right to require the Company to redeem the purchased common shares held by all of the investors (the “January 2013 Private Placement Put Option”) for cash of $0.50 per share upon a change of control or sale or exclusive license of substantially all of the Company’s assets. The January 2013 Private Placement Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement for the January 2013 Private Placement. The January 2013 Private Placement investors also have certain participation rights with respect to future financings of the Company.

Due to the January 2013 Private Placement Put Option described above, the Company has accounted for Common Stock issued for the January 2013 Private Placement as temporary equity, which is reflected under the caption “redeemable common stock” on the accompanying condensed consolidated balance sheets. The total amount allocated to these common shares was $8.8 million for the January 2013 Private Placement. For the January 2013 Private Placement, this allocation is equal to the total proceeds of $9.3 million less the amount allocated to the warrants of $0.4 million and is also net of the direct and incremental costs associated with the January 2013 Private Placement of $0.1 million.

The warrants issued in connection with the January 2013 Private Placement contain certain exercise price reset provisions. Under these provisions, the exercise price of the warrants may be adjusted downward should the Company have future sales of its common stock for no consideration or for a consideration per share less than the Per Share Price (as such term is defined in the Securities Purchase Agreement).

Cash Flows

The following discussion relates to the major components of our cash flows:

Cash Flows from Operating Activities

Net cash used in operating activities was $3.1 million and $3.7 million for the nine months ended January 31, 2013 and 2012, respectively. The decrease of $0.6 million cash used in operations relates to reductions in net losses, as a result of better management of expenses and moving laboratory activities in-house.

Cash Flows from Investing Activities

Cash used in investing activities was $35,000 and $371,000 for the nine months ended January 31, 2013 and 2012, respectively. These cash flows primarily relate to the purchase of property and equipment.

Cash Flows from Financing Activities

Net cash provided by financing activities was $9.2 million and $0.1 million for the nine months ended January 31, 2013 and 2012, respectively. These cash flows primarily relate to the private placement of common stock and warrants that occurred on January 28, 2103, which is explained more in Liquidity and Capital Resources, and the exercise of stock options and warrants.

Critical Accounting Estimates and Policies

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to apply methodologies and make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates of the Company include, among other things, accounts receivable realization, valuation allowances for deferred tax assets, valuation of goodwill, and stock compensation assumptions. Actual results could differ from those estimates. The Company’s critical accounting policies are summarized in the Company’s Annual Report on Form 10-K, filed with the SEC on July 18, 2012.

Off-Balance Sheet Financing

We have no off-balance sheet debt or similar obligations. We have no transactions or obligations with related parties that are not disclosed, consolidated into or reflected in our reported results of operations or financial position. We do not guarantee any third-party debt.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

It is management’s responsibility to establish and maintain “disclosure controls and procedures” as such term is defined in Rule 13a-15 under the Securities Exchange Act of 1934 (the “Exchange Act”). Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, have reviewed and evaluated the effectiveness of our disclosure controls and procedures as of a date within ninety (90) days of the filing date of this Form 10-Q quarterly report. Based on that evaluation, our management, including our Chief Executive Officer and our Chief Financial Officer, have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Form 10-Q at the reasonable assurance level in ensuring that information required to be disclosed in the reports that we file or submit under the Securities Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

From time to time we are involved in litigation incidental to the conduct of our business. While the outcome of lawsuits and other proceedings against us cannot be predicted with certainty, in the opinion of management, individually or in the aggregate, no such lawsuits are expected to have a material effect on our financial position or results of operations. As of the date of this filing, we were not involved in any litigation.

Item 1A. Risk Factors

There have been no material changes in risk factors previously disclosed in our Form 10-K for the year ended April 30, 2012.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

None.

Item 5. Other Information

None.

Item 6. Exhibits

No.		Exhibit
31.1		8650 Section 302 Certification of Chief Executive Officer
31.2		8650 Section 302 Certification of Chief Financial Officer
32.1		Certification Pursuant to 18 U.S.C. Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101		Interactive data files providing financial information from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended October 31, 2012 in XBRL (eXtensible Business Reporting Language) pursuant to Rule 405 of Regulation S-T: (i) Consolidated Balance Sheets, January 31, 2013 and April 30, 2012, (ii) Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended January 31, 2013 and 2012, (iii) Consolidated Statements of Cash Flows for the nine months ended January 31, 2013 and 2012, and (v) Notes to Unaudited Condensed Consolidated Financial Statements

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CHAMPIONS ONCOLOGY, INC. (Registrant)

Date: March 13, 2013	By:	/s/ Joel Ackerman
		Joel Ackerman
		Chief Executive Officer

	By:	/s/ Gary G. Gemignani
		Gary G. Gemignani
		Chief Financial Officer

EX-31.1 2 v336385_ex31-1.htm EXHIBIT 31.1

EXHIBIT 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
Section 302 Certification

I, Joel Ackerman, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Champions Oncology, Inc., a Delaware corporation;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting

Date: March 13, 2013	/s/ Joel Ackerman
	Joel Ackerman
	Chief Executive Officer (Principal Executive Officer)

EX-31.2 3 v336385_ex31-2.htm EXHIBIT 31.2

EXHIBIT 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
Section 302 Certification

I, Gary G. Gemignani, certify that:

I have reviewed this Quarterly Report on Form 10-Q of Champions Oncology, Inc., a Delaware corporation;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting

Date: March 13, 2013

/s/ Gary G. Gemignani

Gary G. Gemignani

Chief Financial Officer (Principal Financial Officer)

EX-32.1 4 v336385_ex32-1.htm EXHIBIT 32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Champions Biotechnology, Inc. (the “Company”) on Form 10-Q for the period ending January 31, 2013 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to their knowledge:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: March 13, 2013	/s/ Joel Ackerman
	Joel Ackerman
	Chief Executive Officer (Principal Executive Officer)

Date: March 13, 2013	/s/ Gary G. Gemignani
	Gary G. Gemignani
	Chief Financial Officer (Principal Financial Officer)

EX-101.INS 5 csbr-20130131.xml XBRL INSTANCE DOCUMENT 0000771856 2009-05-01 2010-04-30 0000771856 2010-11-30 0000771856 2011-03-01 2011-03-24 0000771856 csbr:April2011PrivatePlacementMember 2011-03-01 2011-03-24 0000771856 2010-05-01 2011-04-30 0000771856 2011-04-30 0000771856 2011-11-01 2012-01-31 0000771856 us-gaap:ResearchAndDevelopmentExpenseMember 2011-11-01 2012-01-31 0000771856 csbr:UnallocatedCorporateOverheadMember 2011-11-01 2012-01-31 0000771856 us-gaap:GeneralAndAdministrativeExpenseMember 2011-11-01 2012-01-31 0000771856 csbr:TranslationalOncologySolutionsCostOfSalesMember 2011-11-01 2012-01-31 0000771856 us-gaap:SellingAndMarketingExpenseMember 2011-11-01 2012-01-31 0000771856 csbr:ConsolidatedMember 2011-11-01 2012-01-31 0000771856 csbr:PersonalizedOncologySolutionsCostOfSalesMember 2011-11-01 2012-01-31 0000771856 csbr:PersonalizedOncologySolutionsMember 2011-11-01 2012-01-31 0000771856 csbr:TranslationalOncologySolutionsMember 2011-11-01 2012-01-31 0000771856 us-gaap:MinimumMember 2011-11-01 2012-01-31 0000771856 us-gaap:MaximumMember 2011-11-01 2012-01-31 0000771856 2011-05-01 2012-01-31 0000771856 us-gaap:ResearchAndDevelopmentExpenseMember 2011-05-01 2012-01-31 0000771856 csbr:UnallocatedCorporateOverheadMember 2011-05-01 2012-01-31 0000771856 us-gaap:GeneralAndAdministrativeExpenseMember 2011-05-01 2012-01-31 0000771856 csbr:TranslationalOncologySolutionsCostOfSalesMember 2011-05-01 2012-01-31 0000771856 us-gaap:SellingAndMarketingExpenseMember 2011-05-01 2012-01-31 0000771856 csbr:ConsolidatedMember 2011-05-01 2012-01-31 0000771856 csbr:PersonalizedOncologySolutionsCostOfSalesMember 2011-05-01 2012-01-31 0000771856 csbr:PersonalizedOncologySolutionsMember 2011-05-01 2012-01-31 0000771856 csbr:TranslationalOncologySolutionsMember 2011-05-01 2012-01-31 0000771856 us-gaap:MinimumMember 2011-05-01 2012-01-31 0000771856 us-gaap:MaximumMember 2011-05-01 2012-01-31 0000771856 csbr:OfficeHeadquartersMember 2011-05-01 2012-01-31 0000771856 us-gaap:WarrantMember 2011-05-01 2012-01-31 0000771856 us-gaap:ChiefExecutiveOfficerMember 2011-05-01 2012-01-31 0000771856 csbr:LaboratoriesAndOfficeSpaceMember 2011-05-01 2012-01-31 0000771856 us-gaap:StockOptionsMember 2011-05-01 2012-01-31 0000771856 us-gaap:BoardOfDirectorsChairmanMember 2011-05-01 2012-01-31 0000771856 csbr:SubstantialStockholdersMember 2011-05-01 2012-01-31 0000771856 csbr:CorporateHeadquartersMember 2011-05-01 2012-01-31 0000771856 us-gaap:RestrictedStockMember 2011-05-01 2012-01-31 0000771856 2012-01-31 0000771856 2012-02-13 0000771856 us-gaap:WarrantMember 2012-02-01 2012-04-30 0000771856 2011-05-01 2012-04-30 0000771856 2012-04-30 0000771856 us-gaap:FairValueInputsLevel3Member 2012-04-30 0000771856 csbr:DirectorsAndEmployeesMember 2012-04-30 0000771856 us-gaap:RestrictedStockMember 2012-04-30 0000771856 csbr:NonEmployeesMember 2012-04-30 0000771856 2012-11-01 2012-11-30 0000771856 2013-01-01 2013-01-28 0000771856 csbr:January2013PrivatePlacementMember 2013-01-01 2013-01-28 0000771856 2012-11-01 2013-01-31 0000771856 us-gaap:ResearchAndDevelopmentExpenseMember 2012-11-01 2013-01-31 0000771856 csbr:UnallocatedCorporateOverheadMember 2012-11-01 2013-01-31 0000771856 us-gaap:GeneralAndAdministrativeExpenseMember 2012-11-01 2013-01-31 0000771856 csbr:TranslationalOncologySolutionsCostOfSalesMember 2012-11-01 2013-01-31 0000771856 us-gaap:SellingAndMarketingExpenseMember 2012-11-01 2013-01-31 0000771856 csbr:ConsolidatedMember 2012-11-01 2013-01-31 0000771856 csbr:PersonalizedOncologySolutionsCostOfSalesMember 2012-11-01 2013-01-31 0000771856 csbr:PersonalizedOncologySolutionsMember 2012-11-01 2013-01-31 0000771856 csbr:TranslationalOncologySolutionsMember 2012-11-01 2013-01-31 0000771856 2012-05-01 2013-01-31 0000771856 us-gaap:ResearchAndDevelopmentExpenseMember 2012-05-01 2013-01-31 0000771856 csbr:UnallocatedCorporateOverheadMember 2012-05-01 2013-01-31 0000771856 us-gaap:GeneralAndAdministrativeExpenseMember 2012-05-01 2013-01-31 0000771856 csbr:TranslationalOncologySolutionsCostOfSalesMember 2012-05-01 2013-01-31 0000771856 us-gaap:SellingAndMarketingExpenseMember 2012-05-01 2013-01-31 0000771856 csbr:ConsolidatedMember 2012-05-01 2013-01-31 0000771856 csbr:PersonalizedOncologySolutionsCostOfSalesMember 2012-05-01 2013-01-31 0000771856 csbr:PersonalizedOncologySolutionsMember 2012-05-01 2013-01-31 0000771856 csbr:TranslationalOncologySolutionsMember 2012-05-01 2013-01-31 0000771856 csbr:OfficeHeadquartersMember 2012-05-01 2013-01-31 0000771856 us-gaap:WarrantMember 2012-05-01 2013-01-31 0000771856 us-gaap:ChiefExecutiveOfficerMember 2012-05-01 2013-01-31 0000771856 csbr:LaboratoriesAndOfficeSpaceMember 2012-05-01 2013-01-31 0000771856 us-gaap:StockOptionsMember 2012-05-01 2013-01-31 0000771856 us-gaap:BoardOfDirectorsChairmanMember 2012-05-01 2013-01-31 0000771856 csbr:SubstantialStockholdersMember 2012-05-01 2013-01-31 0000771856 csbr:CorporateHeadquartersMember 2012-05-01 2013-01-31 0000771856 us-gaap:RestrictedStockMember 2012-05-01 2013-01-31 0000771856 us-gaap:FairValueInputsLevel3Member 2012-05-01 2013-01-31 0000771856 csbr:DirectorsAndEmployeesMember 2012-05-01 2013-01-31 0000771856 us-gaap:RestrictedStockMember 2012-05-01 2013-01-31 0000771856 csbr:NonEmployeesMember 2012-05-01 2013-01-31 0000771856 csbr:OneCompoundMember 2012-05-01 2013-01-31 0000771856 csbr:SecondCompoundMember 2012-05-01 2013-01-31 0000771856 us-gaap:WarrantMember us-gaap:MinimumMember 2012-05-01 2013-01-31 0000771856 us-gaap:WarrantMember us-gaap:MaximumMember 2012-05-01 2013-01-31 0000771856 csbr:April2011PrivatePlacementMember 2012-05-01 2013-01-31 0000771856 csbr:January2013PrivatePlacementMember 2012-05-01 2013-01-31 0000771856 csbr:EquityInstrumentMember 2012-05-01 2013-01-31 0000771856 csbr:April2011PrivatePlacementMember us-gaap:MinimumMember 2012-05-01 2013-01-31 0000771856 csbr:April2011PrivatePlacementMember us-gaap:MaximumMember 2012-05-01 2013-01-31 0000771856 us-gaap:MinimumMember 2012-05-01 2013-01-31 0000771856 us-gaap:MaximumMember 2012-05-01 2013-01-31 0000771856 2013-01-31 0000771856 us-gaap:FairValueInputsLevel3Member 2013-01-31 0000771856 csbr:DirectorsAndEmployeesMember 2013-01-31 0000771856 us-gaap:RestrictedStockMember 2013-01-31 0000771856 csbr:NonEmployeesMember 2013-01-31 0000771856 2013-02-28 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure iso4217:CAD CHAMPIONS ONCOLOGY, INC. 0000771856 --04-30 Smaller Reporting Company csbr 66752100 10-Q false 2013-01-31 Q3 2013

10457000

6482000

4716000

10769000

584000

642000

205000

300000

5505000

11711000

188000

190000

560000

442000

669000

6922000

13012000

1676000

1101000

625000

566000

1185000

1017000

3486000

2684000

555000

993000

4041000

3677000

8159000

16936000

38000

39000

1252000

21204000

23136000

-25143000

-29425000

-125000

-99000

-5278000

-7601000

6922000

13012000

0.001

12533333

31133333

56075

0.001

125000000

37740345

38855003

34529000

35618767

3236000

649000 1837000 473000 1850000 1747000 3931000 2444000 4631000

2396000

649000

1747000

5768000

1837000

3931000

2917000

473000

2444000

6481000

1850000

4631000

528000 1463000 676000 2030000 801000 1904000 566000 1740000

930000

2558000

592000

1415000

623000

417000

242000

175000

1885000

1344000

718000

626000

658000

581000

361000

220000

2047000

1131000

495000

636000

1287000

4421000

1145000

3484000

4169000

12231000

3637000

10716000

-1773000

-6463000

-720000

-4235000

66000

354000

-255000

-21000

-12000

-2000

-10000

-22000

54000

352000

-265000

-43000

-1719000

-6111000

-985000

-4278000

5000

6000

-1719000

-6111000

-990000

-4284000

-0.04

-0.13

-0.02

-0.09

46738000

47000000

47737000

47294000

-13000

2000

1000

24000

-1732000

-6109000

-989000

-4260000

2612000

1934000

16000

65000

51000

153000

-88000 58000 -178000 96000

-150000

-2000

43000

-574000

42000

-58000

-117000

-168000

-3704000

-3132000

371000

35000

-371000

-35000

98000

9195000

2000

25000

-3975000

6053000

Note 1. Organization, Use of Estimates and Basis of Presentation   Champions Oncology, Inc. (the “Company”), is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company’s Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology to derive revenue for two customer groups: Personalized Oncology Solutions (“POS”) and Translational Oncology Solutions (“TOS”). POS assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug studies and related personalized oncology services. The Company’s TOS business offers a technology platform to pharmaceutical and biotechnology companies using proprietary Tumorgraft studies, which have been shown to be predictive of how drugs may perform in clinical settings.   The Company has three operating subsidiaries: Champions Oncology (Israel), Limited, Champions Biotechnology U.K., Limited and Champions Oncology Singapore, PTE LTD. For the three and nine months ended January 31, 2013 and 2012, there were no material revenues earned by these subsidiaries. All material intercompany transactions have been eliminated in consolidation. The financial statements of the Company’s foreign subsidiaries, all of which have a functional currency other than the U.S. dollar, have been translated into the U.S. dollar for each period presented. Translation gains and losses are recognized as a component of accumulated other comprehensive loss. The Company is subject to foreign exchange rate fluctuations in connection with the Company’s international operations.   These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). All significant intercompany transactions and accounts have been eliminated. All figures are presented in U.S. dollars, except where expressly stated otherwise. Certain information related to the Company’s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company’s annual consolidated financial statements for the year ended April 30, 2012, as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments necessary to fairly state the Company’s financial position, results of operations, and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company’s Annual Report on Form 10-K for the year ended April 30, 2012. Certain reclassifications have been made to the prior period financial statement amounts to conform to current presentation.   The preparation of financial statements in conformity with Generally Accepted Accounting Principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include valuation assumptions used for share-based compensation and warrant liability, accrued expenses and deferred taxes.   Basic loss per share is calculated by dividing loss available to common shareholders by the weighted average number of common shares (including redeemable common stock) outstanding for the period. Diluted loss per share is calculated based on the weighted average number of common shares (including redeemable common stock) outstanding for the period, plus the dilutive effect of common stock purchase warrants, stock options and restricted stock units using the treasury stock method. Contingently issuable shares are included in the calculation of basic earnings per share when all contingencies surrounding the issuance of the shares are met and the shares are issued or issuable. Contingently issuable shares are included in the calculation of dilutive earnings per share as of the beginning of the reporting period if, at the end of the reporting period, all contingencies surrounding the issuance of the shares are satisfied, or would be satisfied, if the end of the reporting period were the end of the contingency period. Due to the net losses for the three and nine months ended January 31, 2013 and 2012, basic and diluted loss per share were the same, as the effect of potentially dilutive securities would have been anti-dilutive.    The following table reflects the total potential share-based instruments outstanding at January 31, 2013 and 2012 that could have an effect on the future computation of dilution per common share:   <table align="center" style="width: 65%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">January 31,</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2013</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 76%;">Stock options</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 9%;">15,018,955</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 9%;">15,064,866</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Warrants</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3,276,667</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,416,667</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Restricted stock</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">75,000</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">37,500</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2.5pt;">Total common stock equivalents</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">18,370,622</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">16,519,033</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>

Note 2. Recently Issued Accounting Pronouncements   During July 2012, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2012-02, “Testing Indefinite-Lived Intangible Assets for Impairment”. The revised standard is intended to reduce the cost and complexity of testing indefinite-lived intangible assets other than goodwill for impairment by providing entities with an option to perform a "qualitative" assessment to determine whether further impairment testing is necessary. The revised standard allows an entity first to assess qualitative factors to determine whether events and circumstances indicate that it is more likely than not that an indefinite-lived intangible asset is impaired. If it is more likely than not that the asset is impaired, the entity must calculate the fair value of the asset, compare the fair value to its carrying amount, and record an impairment charge, if the carrying amount exceeds fair value. However, if an entity concludes that it is not more likely than not that the asset is impaired, no further action is required. The qualitative assessment is not an accounting policy election. An entity can choose to perform the qualitative assessment on none, some, or all of its indefinite-lived intangible assets. Moreover, an entity can bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to the quantitative impairment test, and then choose to perform the qualitative assessment in any subsequent period. The revised standard is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. The Company does not expect the adoption of this standard to have a material impact on its financial position or results of operations.   During September 2011, the FASB issued ASU No. 2011-08, “Testing Goodwill for Impairment” (“ASU 2011-08”). ASU 2011-08 is intended to simplify the testing of goodwill for impairment by permitting an entity to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test, which is currently required for all companies that report goodwill. The amendments are effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011, although early adoption is permitted. The Company has adopted this standard, which had no impact on its financial position or results of operations.

Note 3. Property and Equipment   Property and equipment is recorded at cost and consists of laboratory equipment, furniture and fixtures, and computer hardware and software. Depreciation is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to seven years. Property and equipment consisted of the following (in thousands):   <table align="center" style="font: 10pt/normal times new roman, times, serif; width: 93%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">January 31,</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">April 30,</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2013</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2012</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">(unaudited)</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom; background-color: #ccffcc;"> <td style="width: 76%; text-align: left;">Furniture and fixtures</td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 9%; text-align: right;">58</td> <td style="width: 1%; text-align: left;"> </td> <td style="width: 1%;"> </td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 9%; text-align: right;">58</td> <td style="width: 1%; text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Computer equipment and software</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">526</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">287</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #ccffcc;"> <td style="text-align: left;">Laboratory equipment</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">179</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">167</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Leasehold improvements</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #ccffcc;"> <td style="padding-bottom: 1pt;">Software in-progress</td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">216</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: #ccffcc;"> <td style="text-align: left;">Total property and equipment</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">765</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">730</td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 1pt;">Less: Accumulated depreciation</td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">(323</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"> </td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">(170</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #ccffcc;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 2.5pt;">Property and equipment, net</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">442</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">560</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   Depreciation expense was $51,000 and $16,000 for the three months ended January 31, 2013 and 2012, respectively, and $153,000 and $65,000 for the nine months ended January 31, 2012 and 2011, respectively.

Note 4. Share-Based Payments   The Company has in place the 2010 Equity Incentive Plan, the 2008 Equity Incentive Plan, and the Director Compensation Plan of 2010. In general, these plans provide for stock-based compensation in the form (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights to the Company’s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards. Stock-based compensation in the amount of $570,000 and $743,000 was recognized for the three months ended January 31, 2013 and 2012, respectively, and $1,934,000 and $2,612,000 for the nine months ended January 31, 2013 and 2012, respectively. Stock-based compensation expense was recognized as follows (in thousands):  <table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Three Months Ended</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Nine Months Ended</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">January 31,</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">January 31,</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2013</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2013</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 52%;">General and administrative</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">500</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">701</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">1,619</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">2,370</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Sales and marketing</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">56</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">49</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">199</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">168</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Research and development</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">4</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(8</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">33</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">72</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">TOS cost of sales</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">4</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">16</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">POS cost of sales</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">6</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">67</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2.5pt;">Total stock-based compensation expense</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">570</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">743</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">1,934</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">2,612</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   Stock Option Grants   Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2013 and 2012 were as follows:  <table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Three Months Ended</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Nine Months Ended</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">January 31,</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">January 31,</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2013</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2013</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap"> </td> <td> </td> <td> </td> <td colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap"> </td> <td> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 52%;">Expected term in years</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;" nowrap="nowrap"> </td> <td style="text-align: center; width: 9%;" nowrap="nowrap">6.0</td> <td style="text-align: left; width: 1%;" nowrap="nowrap"> </td> <td style="width: 1%;" nowrap="nowrap"> </td> <td style="text-align: left; width: 1%;" nowrap="nowrap"> </td> <td style="text-align: center; width: 9%;" nowrap="nowrap">3.0 - 6.0</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;" nowrap="nowrap"> </td> <td style="text-align: center; width: 9%;" nowrap="nowrap">6.0</td> <td style="text-align: left; width: 1%;" nowrap="nowrap"> </td> <td style="width: 1%;" nowrap="nowrap"> </td> <td style="text-align: left; width: 1%;" nowrap="nowrap"> </td> <td style="text-align: center; width: 9%;" nowrap="nowrap">3.0 - 6.0</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Risk-free interest rates</td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">0.9% - 1.0%</td> <td style="text-align: left;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">0.4% - 1.9%</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">0.8% - 1.0%</td> <td style="text-align: left;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">0.4% - 2.2%</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Volatility</td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">100% - 102%</td> <td style="text-align: left;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">90% - 101%</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">99% - 102%</td> <td style="text-align: left;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">90% - 108%</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Dividend yield</td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">0%</td> <td style="text-align: left;" nowrap="nowrap"></td> <td nowrap="nowrap"> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">0%</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">0%</td> <td style="text-align: left;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">0%</td> <td style="text-align: left;"> </td> </tr> </table>   The weighted average fair value of stock options granted during the three months ended January 31, 2013 and 2012 was $0.27 and $0.52, respectively. The weighted average fair value of stock options granted during the nine months ended January 31, 2013 and 2012 was $0.36 and $0.57, respectively. The Company’s stock option activity for the nine months ended January 31, 2013 was as follows: <table align="center" style="width: 87%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Average</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Directors</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Average</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Remaining</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Aggregate</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Non-</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">and</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Exercise</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Contractual</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Intrinsic</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Employees</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Employees</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Total</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Price</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Life (Years)</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Value</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="width: 28%;">Outstanding, May 1, 2012</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 9%;">1,410,000</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 9%;">13,456,038</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 9%;">14,866,038</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">0.88</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 9%;">7.0</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">-</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">130,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">586,250</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">716,250</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.41</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Forfeited</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(22,500</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(22,500</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.67</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Expired</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(500,000</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(15,833</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(515,833</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.76</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Canceled</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(25,000</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(25,000</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="text-align: right; padding-bottom: 1pt;">0.62</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="text-align: right; padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="text-align: right; padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-indent: -9pt; padding-left: 9pt;">Outstanding, January 31, 2013</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">1,040,000</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">13,978,955</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">15,018,955</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;">0.86</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;">7.1</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;">96,000</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-indent: -9pt; padding-left: 9pt;">Vested and expected to vest as of January 31, 2013</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">1,040,000</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">13,978,955</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">15,018,955</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-indent: -9pt; padding-left: 9pt;">Exercisable as of January 31, 2013</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">933,334</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">9,735,078</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">10,668,412</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;">0.88</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;">6.8</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;">14,000</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   Restricted Stock Grants   A summary of the activity related to restricted stock grants is as follows (in thousands):  <table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Average Grant</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Date Fair Value</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Shares</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Per Share</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="width: 76%;">Nonvested as of May 1, 2012</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 9%;">25,000</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">0.75</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">100,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.30</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Vested</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(50,000</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.53</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Forfeited</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Expired</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="text-align: right; padding-bottom: 1pt;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;">Nonvested as of January 31, 2013</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">75,000</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;">-</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>   The aggregate fair value of shares vested during the nine months ended January 31, 2013 and 2012 was $26,000 and $84,000, respectively.   Stock Purchase Warrants   As of January 31, 2013, the Company had warrants outstanding for the purchase of 3,276,667 shares of its common stock, all of which were exercisable. Of these warrants, 1,266,667 were issued in connection with the April 2011Private Placement (see Note 5) and 1,860,000 were issued in connection with the January 2013 Private Placement (see Note 5) and are accounted for as liabilities as further discussed in Note 5. The remaining 150,000 warrants are accounted for as equity instruments and expire July 31, 2014. As of January 31, 2013, the weighted average exercise price of all warrants outstanding was $0.77. As of January 31, 2013 and April 30, 2012, the warrants intrinsic value was $13,000 and $0, respectively, and had weighted average remaining contractual lives of 4.2 years and 3.8 years, respectively.

Note 5. Redeemable Common Stock and Stock Purchase Warrant   On January 28, 2013, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale of an aggregate 18,600,000 shares of the Company’s Common Stock at a purchase price of $0.50 per share, for aggregate proceeds of $9.3 million, $0.5 million of which was sold to officers and directors of the Company. This private placement transaction closed on January 28, 2013 (the “January 2013 Private Placement”). As part of this transaction, the Company also issued warrants to purchase an aggregate 1,860,000 shares of Common Stock at an exercise price of $0.66 per share. These warrants expire five years after the closing date . The Company also entered into an Amended and Restated Registration Rights Agreement on January 28, 2013 which provided certain registration rights with respect to the shares of Common Stock issued and the shares of Common Stock issuable upon exercise of the warrants. Furthermore, certain investors will have the right to require the Company to redeem the purchased common shares held by all of the investors (the “January 2013 Private Placement Put Option”) for cash of $0.50 per share upon a change of control or sale or exclusive license of substantially all of the Company’s assets. The January 2013 Private Placement Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement for the January 2013 Private Placement. The January 2013 Private Placement investors also have certain participation rights with respect to future financings of the Company. The terms of the January 2013 Private Placement resulted in the issuance of an additional 1,064,658 common shares to the investors of the April 2011 Private Placement under the anti-dilution protections granted such investors.   On March 24, 2011, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale of an aggregate 12,533,333 shares of the Company’s Common Stock at a purchase price of $0.75 per share, for aggregate proceeds of $9.4 million, $0.5 million of which was sold to officers and directors of the Company. This private placement transaction closed April 4, 2011 (the “April 2011 Private Placement”). As part of this transaction, the Company also issued warrants to purchase an aggregate 1,266,667 shares of Common Stock at an exercise price of $0.90 per share. These warrants expire five years after the closing date. The Securities Purchase Agreement governing the April 2011 Private Placement contains certain anti-dilution protections for the investors. The Amended and Restated Registration Rights Agreement referenced above provides certain registration rights with respect to the shares of Common Stock issued and the shares of Common Stock issuable upon exercise of the warrants. Furthermore, certain investors have the right to require the Company to redeem the purchased common shares held by all of the investors (the “April 2011 Private Placement Put Option”) for cash for $0.75 per share upon a change of control or sale or exclusive license of substantially all of the Company’s assets. The April 2011 Private Placement Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement for the April 2011 Private Placement.   Due to the April 2011 Private Placement Put Option and the January 2013 Private Placement Put Option described above, the Company has accounted for the Common Stock for the April 2011 Private Placement and January 2013 Private Placement as temporary equity, which is reflected under the caption “redeemable common stock” on the accompanying condensed consolidated balance sheets. The total amount allocated to the redeemable common stock was $8.8 million for the January 2013 Private Placement and $8.2 million for the April 2011 Private Placement. For the January 2013 Private Placement, this allocation is equal to the total proceeds of $9.3 million less the amount allocated to the warrants of $0.4 million and is also net of the direct and incremental costs associated with the January 2013 Private Placement of $0.1 million. For the April 2011 Private Placement, this allocation is equal to the total proceeds of $9.4 million, less the amount allocated to the warrants of $0.9 million and is also net of direct and incremental costs associated with the April 2011 Private Placement of $0.3 million.    The warrants issued in connection with both the April 2011 Private Placement and January 2013 Private Placement contain certain exercise price reset provisions. Under these provisions, the exercise price of the warrants may be adjusted downward should the Company have future sales of its Common Stock for no consideration or for a consideration per share less than the Per Share Price (as such term is defined in the April 2011 Private Placement and January 2013 Private Placement). These exercise price reset provisions resulted in a downward adjustment to the exercise price of the warrants issued in the April 2011 Private Placement from $0.90 to $0.50.   The Company has granted demand registration rights in connection with the investment in common shares and the common shares underlying the warrants for both the April 2011 Private Placement and January 2013 Private Placement. These rights include the requirement of the Company to file certain registration statements within a specified time period and to have these registration statements declared effective within a specified time period. If the Company is not able to comply with these registration requirements, the Company will be required to pay cash penalties equal to 1.0% of the aggregate Purchase Price paid by the investors for each 30-day period in which a Registration Default, as defined in the Securities Purchase Agreement, exists. These penalties are subject to a 10% limit of the aggregate Purchase Price paid by the investors. The Company may become subject to these penalty provisions if it fails to have a registration statement for the common shares declared effective, or to maintain the effectiveness of such registration statement. The total amount of potential penalties under this registration payment arrangement ranges from $50,000 to $130,000 for each 30-day period in which a registration default exists; however, as of January 31, 2013 and through the date of this filing, the Company does not believe these penalties to be probable and accordingly, has not established an accrual for such registration payment arrangements.   The Company has accounted for the warrants issued in connection with the April 2011 Private Placement and January 2013 Private Placement as a liability based on the exercise price reset provisions described above. This liability, which is recorded at fair value on the accompanying consolidated balance sheets, totaled $0.8 million at the time of the close of the January 2013 Private Placement Agreement. As of January 31, 2013 and April 30, 2012, the fair value of these warrants was $1 million and $0.6 million, respectively. The change in fair value of these warrants has been, and will be, recognized as other income (expense) on the Company’s condensed consolidated statements of operations. The fair value of these warrants was calculated by the Monte Carlo simulation valuation method. Assumptions used to calculate the fair value of these warrants were as follows: <table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">January 31,</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">April 30,</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2013</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: right;" nowrap="nowrap"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: right;" nowrap="nowrap"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 76%;">Risk-free interest rates</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;" nowrap="nowrap"> </td> <td style="text-align: center; width: 9%;" nowrap="nowrap">0.46% - 0.88%</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;" nowrap="nowrap"> </td> <td style="text-align: center; width: 9%;" nowrap="nowrap">0.6%</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Volatility</td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">84.9% - 102%</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">102%</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Dividend yield</td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">0%</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">0%</td> <td style="text-align: left;"> </td> </tr> </table>   The Company will continue to adjust the warrant liability for changes in fair value until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. As of January 31, 2013, the Company changed its method used to calculate expected volatility from an index, which was based on the Company’s historic volatility and certain comparable guideline companies, to the use of only the Company’s historic volatility which had an immaterial effect on the financial statements

Note 6. Related Party Transactions   Related party transactions include transactions between the Company and its shareholders, management, and affiliates. The transactions discussed in this footnote were in the normal course of operations and were measured at the exchange amount, which is the amount of consideration established and agreed to by the parties.   Consulting Services   During the nine months ended January 31, 2013 and 2012, the Company paid one of its former directors and former Chief Executive Officer, $30,000 and $18,000, respectively, in consulting fees. During the nine months ended January 31, 2013 and 2012, the Company paid certain members of its Board of Directors $122,500 and $103,000, respectively, for consulting services unrelated to their duties as board members. During the nine months ended January 31, 2013, the Company paid a substantial stockholder and former member of its Board of Directors $3,000 for consulting services. No such payment was made during the nine months ended January 31, 2012. During the nine months ended January 31, 2013, the Company paid a prospective board member’s company $8,300 for consulting services. No such payment was made during the nine months January 31, 2012. All of the amounts paid to these related parties have been expensed.    Revenue   During the nine months ended January 31, 2013, the Company earned no revenues through related party transactions. During the nine months ended January 31, 2012, the Company recognized $20,000 in revenues from a company whose board members were also members of the Company’s Board of Directors.

Note 7. Commitments and Contingencies   Operating Leases   As of January 31, 2013, the Company leases the following facilities under non-cancelable operating lease agreements:   <table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 27pt;"></td> <td style="width: 18pt;">·</td> <td style="text-align: justify;">One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company’s corporate headquarters. This lease expires in April 2014. The Company recorded $52,000 and $52,000 of rental expense relative to this lease for the nine months ended January 31, 2013 and 2012, respectively.</td> </tr> </table>   <table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 27pt;"></td> <td style="width: 18pt;">·</td> <td style="text-align: justify;">855 North Wolfe Street, Suite 619, Baltimore, Maryland 21205, which consists of laboratories and office space where the Company conducts operations related to its primary service offerings.  This lease expires in June 2014. The Company recorded $69,000 and $49,000 of rental expense relative to this lease in the nine months ended January 31, 2013 and 2012, respectively.</td> </tr> </table>   <table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 27pt;"></td> <td style="width: 18pt;">·</td> <td style="text-align: justify;">17 Hatidhar Street, Ra’anana, Israel, which serves as office headquarters for Champions Oncology, Israel. The lease expires in July 2013. The Company recorded $21,000 and $18,000 of rental expense relative to this lease for the nine months ended January 31, 2013 and 2012, respectively.</td> </tr> </table>   Legal Matters   The Company is party to certain legal matters arising in the ordinary course of its business. The Company has evaluated its potential exposure to these legal matters and noted no such exposures. The Company is not aware of any other matters that would have a material impact on the Company’s financial position or results of operations.   Registration Payment Arrangements   The Company has entered into an Amended and Restated Registration Rights Agreement in connection with the April 2011 Private Placement and January 2013 Private Placement and is discussed more fully in Note 5 above. This Amended and Restated Registration Rights Agreement contains provisions that may call for the Company to pay penalties in certain circumstances. This registration payment arrangement primarily relates to the Company’s ability to file a registration statement within a particular time period, have a registration statement declared effective within a particular time period and to maintain the effectiveness of the registration statement for a particular time period. The Company does not believe it is probable that penalty payments will be made for the Amended and Restated Registration Rights Agreement discussed in Note 5 above and, accordingly, has not accrued for such potential penalties as of January 31, 2013 or April 30, 2012.

Note 8. Licensing Agreements   In February 2010, the Company entered into an exclusive option agreement with a Canadian company for which it paid and expensed $40,000 (Canadian) during the Company’s fiscal 2010 year. The option agreement granted the Company the exclusive right to review Irinophore C, a nanoparticle drug compound, for the treatment of various forms of cancer, including melanoma, prostate, breast, and lung cancer through April 2011. During the option year, the Company performed various TumorGraft tests on the nanoparticle compound. In March 2011, the Company exercised its option to license Irinophore C, a liposomal formulation of Irinotecan. Under the terms of the agreement, the Company’s exercise of the option resulted in amounts due to the Canadian company of $85,000 (Canadian) comprised of the option exercise price and reimbursement to the Canadian company for past patent costs, which was expensed in the Company’s fiscal year ended April 30, 2011. The Company satisfied this obligation during fiscal 2012. On the first anniversary of the agreement (March 2012), an additional license fee of $45,000 (Canadian) became due, which was recognized as a liability as of April 30, 2012 and was satisfied during the nine months ended January 31, 2013. Commencing with the second anniversary of the agreement (March 2013), the Company will be obligated to pay a minimum annual royalty of $10,000 (Canadian), unless the agreement is terminated by either party in advance of the anniversary date. Under the terms of the license agreement, the Company will be required to pay up to $3.0 million in development milestones, if achieved. Upon commercialization, the Company would also be required to make royalty and sales milestone payments based upon revenues. As of January 31, 2013 the Company has accrued for the annual royalty payment of $10,000 (Canadian). Note 9. Cephalon Agreement   On March 16, 2011, the Company entered into an agreement with Cephalon, Inc., (“Cephalon”), a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., pursuant to which the Company conducts TumorGraft studies on two proprietary chemical compounds provided by Cephalon to determine the activity or response of these compounds in potential clinical indications. Under the agreement, Cephalon will, under certain conditions, pay the Company various amounts upon achieving certain milestones, which are based on the performance of the compounds in preclinical testing and are dependent upon testing the compound in clinical settings and obtaining FDA approval. Potential milestone payments that could be received under the Agreement total $27 million per compound. No milestones have been achieved to date. In addition, under certain conditions, Cephalon would pay the Company royalties on any commercialized products developed under the Agreement. No royalties have been received or earned to date. Cephalon reserves the right to exercise and pay a one-time fee of in lieu of the milestone or royalty payments, which are $460,000 for one compound and $880,000 for the second compound.   On November 30, 2012, Cephalon exercised the option to pay the one-time fee of $880,000 to the Company, in lieu of any future milestone or royalty payments, for one compound tested under the agreement described above. Written notice was provided to the Company on December 3, 2012 and payment was received on December 19, 2012. This fee has been recognized as revenue during the three and nine months ended January 31, 2013. As of January 31, 2013, the remaining compound is still being evaluated.   In April 2011, Cephalon paid an initiation fee of $1.4 million to the Company, which was initially reflected within deferred revenue on the Company’s balance sheet as of April 30, 2011. As models, along with required reports, are delivered, the deferred revenue is recognized on a proportionate basis in accordance with the Company’s revenue recognition policies. Revenues of $317,000 and $681,000 were recognized during the nine months ended January 31, 2013 and 2012.

Note 10. Supplemental Schedule of Cash Flow Information   There was no cash paid for interest or income taxes during the nine months ended January 31, 2013 and 2012.

Note 11. Grant Income   In October 2010, the Company was notified that it was awarded total cash grants of approximately $1.5 million under the Qualifying Therapeutic Discovery Project program administered under section 48D of the Internal Revenue Code, of which approximately $1.0 million related to qualifying expenses the Company had previously incurred during fiscal 2010 and $0.5 million related to qualifying expenses which the Company expected to incur during fiscal 2011. In November 2010, the Company received approximately $1.0 million related to the 2010 expenditures. The Company received a final payment of $0.5 million related to 2011 expenditures on February 13, 2012.   On August 8, 2011 the Company was notified that it was selected for a tax examination by the Internal Revenue Service (“IRS”) on the Application for Certification of Qualified Investments Eligible for Credits and Grants Under the Qualifying Therapeutic Discovery Project program filed under the Patient Protection and Affordable Care Act of 2010 for the 2009 and 2010 tax years. The examination commenced during the second quarter of fiscal 2012. The IRS expanded its scope to include the fiscal year 2011 tax return, which was filed in January 2012. The examinations of fiscal 2009 and 2010 were completed in the fourth quarter of fiscal 2012. The examination of fiscal 2011 was completed in the first quarter of fiscal 2013. The audit of all three fiscal years ending April 30, 2011, 2010 and 2009 resulted in no additional tax due or receivable.

Note 12. Fair Value   The carrying value of cash and cash equivalents, accounts receivable, prepaid expenses, deposits and other receivables, accounts payable and accrued liabilities approximate their fair value based on the liquidity or the short-term maturities of these instruments. The fair value hierarchy promulgated by GAAP consists of three levels:   <table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 9pt;"></td> <td style="width: 18pt;">·</td> <td style="text-align: justify;">Level one — Quoted market prices in active markets for identical assets or liabilities;</td> </tr> </table> <table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 9pt;"></td> <td style="width: 18pt;">·</td> <td style="text-align: justify;">Level two — Inputs other than level one inputs that are either directly or indirectly observable; and</td> </tr> </table> <table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 9pt;"></td> <td style="width: 18pt;">·</td> <td style="text-align: justify;">Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.</td> </tr> </table>   Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company has one liability measured at fair value on a recurring basis, which are warrants that were issued in connection with the January 2013 Private Placement and April 2012 Private Placement which is discussed more fully in Note 5. As of January 31, 2013 and April 30, 2012, these warrants had an estimated fair value of $1 million and $0.6 million, respectively, which was calculated by the Monte Carlo simulation valuation method using level three inputs. The Company has no assets that are measured at fair value on a recurring basis and there were no assets or liabilities measured at fair value on a non-recurring basis as of January 31, 2013 and April 30, 2012 or during the nine months ended January 31, 2013 and 2012.   The following table presents information about the Company’s warrants liability, which was the only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at January 31, 2013 (in thousands):   <table align="center" style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="width: 88%;">Balance, May 1, 2012</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">555</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 0.125in;">Transfers to (from) Level 3</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-left: 0.125in;">Total (gains) losses included in earnings</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">21</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in;">Purchases, issuances and settlements, net</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">417</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;">Balance, January 31, 2013</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">993</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>

Note 13. Business Segment Information   The Company operates in two segments, POS and TOS. The accounting policies of the Company’s segments are the same as those described in Note 2 of the Company’s annual consolidated financial statements for the year ended April 30, 2012, as filed on Form 10-K. The Company evaluates performance of its segments based on profit or loss from operations before stock-based compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes (“segment profit”). Management uses segment profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment, and employee compensation, among other matters. The following tables summarize, for the periods indicated, operating results by business segment (in thousands):   <table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Translational</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Personalized</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Oncology</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Unallocated</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Oncology</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Solutions</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Corporate</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; font-weight: bold;" nowrap="nowrap">Three Months Ended January 31, 2013</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Solutions (POS)</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">(TOS)</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Overhead</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Consolidated</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 52%;">Net revenue</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">473</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">2,444</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">-</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">2,917</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Direct cost of services</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(661</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(561</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,222</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Sales and marketing costs</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(361</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(220</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(581</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Other operating expenses</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(627</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(637</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,264</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Stock- based compensation expense (1)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(570</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(570</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2.5pt;">Segment profit (loss)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(549</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">1,036</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(1,207</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(720</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> </tr> </table>   <table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Translational</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Personalized</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Oncology</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Unallocated</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Oncology</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Solutions</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Corporate</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: justify; font-weight: bold;" nowrap="nowrap">Three Months Ended January 31, 2012</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Solutions (POS)</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">(TOS)</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Overhead</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Consolidated</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; width: 48%;">Net revenue</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">649</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">1,747</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">-</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">2,396</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Direct cost of services</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(528</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(801</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,329</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify;">Sales and marketing costs</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(242</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(175</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(417</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Other operating expenses</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(851</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(829</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,680</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 1pt;">Stock- based compensation expense (1)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(743</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(743</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2.5pt;">Segment profit (loss)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(121</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(80</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(1,572</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(1,773</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> </tr> </table>   <table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Translational</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Personalized</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Oncology</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Unallocated</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Oncology</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Solutions</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Corporate</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: justify; font-weight: bold;" nowrap="nowrap">Nine Months Ended January 31, 2013</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Solutions (POS)</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">(TOS)</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Overhead</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Consolidated</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; width: 48%;">Net revenue</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">1,850</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">4,631</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">-</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">6,481</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Direct cost of services</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(2,030</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,740</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(3,770</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify;">Sales and marketing costs</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(495</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(636</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,131</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Other operating expenses</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,463</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(2,418</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(3,881</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 1pt;">Stock- based compensation expense (1)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(1,934</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(1,934</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2.5pt;">Segment profit (loss)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(675</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">792</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(4,352</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(4,235</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> </tr> </table>   <table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Translational</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Personalized</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Oncology</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Unallocated</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Oncology</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Solutions</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Corporate</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: justify; font-weight: bold;" nowrap="nowrap">Nine Months Ended January 31, 2012</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Solutions (POS)</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">(TOS)</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Overhead</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Consolidated</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; width: 48%;">Net revenue</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">1,837</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">3,931</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">-</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">5,768</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Direct cost of services</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,463</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,904</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(3,367</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify;">Sales and marketing costs</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(718</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(626</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,344</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Other operating expenses</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(2,419</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(2,489</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(4,908</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 1pt;">Stock- based compensation expense (1)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(2,612</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(2,612</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2.5pt;">Segment profit (loss)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(344</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(1,018</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(5,101</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(6,463</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> </tr> </table>   <table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.25in;"></td> <td style="width: 0.25in;">(1)</td> <td style="text-align: justify;">Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.</td> </tr> </table>   All of the Company’s revenue is recorded in the United States and substantially all of its long-lived assets are in the United States.

Note 14. Subsequent Events    None.

The following table reflects the total potential share-based instruments outstanding at January 31, 2013 and 2012 that could have an effect on the future computation of dilution per common share: <table align="center" style="width: 65%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">January 31,</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2013</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 76%;">Stock options</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 9%;">15,018,955</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 9%;">15,064,866</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Warrants</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">3,276,667</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1,416,667</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Restricted stock</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">75,000</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">37,500</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2.5pt;">Total common stock equivalents</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">18,370,622</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">16,519,033</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>

Property and equipment consisted of the following (in thousands):   <table align="center" style="font: 10pt/normal times new roman, times, serif; width: 93%; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"></td> <td style="font-weight: bold;" nowrap="nowrap"></td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">January 31,</td> <td style="font-weight: bold;" nowrap="nowrap"></td> <td style="font-weight: bold;" nowrap="nowrap"></td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">April 30,</td> <td style="font-weight: bold;" nowrap="nowrap"></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2013</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"></td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"></td> <td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;" colspan="2" nowrap="nowrap">2012</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"></td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"></td> <td style="font-weight: bold;" nowrap="nowrap"></td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">(unaudited)</td> <td style="font-weight: bold;" nowrap="nowrap"></td> <td nowrap="nowrap"></td> <td style="text-align: center;" colspan="2" nowrap="nowrap"></td> <td nowrap="nowrap"></td> </tr> <tr style="vertical-align: bottom; background-color: #ccffcc;"> <td style="width: 76%; text-align: left;">Furniture and fixtures</td> <td style="width: 1%;"></td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 9%; text-align: right;">58</td> <td style="width: 1%; text-align: left;"></td> <td style="width: 1%;"></td> <td style="width: 1%; text-align: left;">$</td> <td style="width: 9%; text-align: right;">58</td> <td style="width: 1%; text-align: left;"></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Computer equipment and software</td> <td></td> <td style="text-align: left;"></td> <td style="text-align: right;">526</td> <td style="text-align: left;"></td> <td></td> <td style="text-align: left;"></td> <td style="text-align: right;">287</td> <td style="text-align: left;"></td> </tr> <tr style="vertical-align: bottom; background-color: #ccffcc;"> <td style="text-align: left;">Laboratory equipment</td> <td></td> <td style="text-align: left;"></td> <td style="text-align: right;">179</td> <td style="text-align: left;"></td> <td></td> <td style="text-align: left;"></td> <td style="text-align: right;">167</td> <td style="text-align: left;"></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left;">Leasehold improvements</td> <td></td> <td style="text-align: left;"></td> <td style="text-align: right;">2</td> <td style="text-align: left;"></td> <td></td> <td style="text-align: left;"></td> <td style="text-align: right;">2</td> <td style="text-align: left;"></td> </tr> <tr style="vertical-align: bottom; background-color: #ccffcc;"> <td style="padding-bottom: 1pt;">Software in-progress</td> <td style="padding-bottom: 1pt;"></td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"></td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">-</td> <td style="text-align: left; padding-bottom: 1pt;"></td> <td style="padding-bottom: 1pt;"></td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"></td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">216</td> <td style="text-align: left; padding-bottom: 1pt;"></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td></td> <td></td> <td style="text-align: left;"></td> <td style="text-align: right;"></td> <td style="text-align: left;"></td> <td></td> <td style="text-align: left;"></td> <td style="text-align: right;"></td> <td style="text-align: left;"></td> </tr> <tr style="vertical-align: bottom; background-color: #ccffcc;"> <td style="text-align: left;">Total property and equipment</td> <td></td> <td style="text-align: left;"></td> <td style="text-align: right;">765</td> <td style="text-align: left;"></td> <td></td> <td style="text-align: left;"></td> <td style="text-align: right;">730</td> <td style="text-align: left;"></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 1pt;">Less: Accumulated depreciation</td> <td style="padding-bottom: 1pt;"></td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"></td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">(323</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"></td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;"></td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 1pt; border-bottom-style: solid;">(170</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: #ccffcc;"> <td></td> <td></td> <td style="text-align: left;"></td> <td style="text-align: right;"></td> <td style="text-align: left;"></td> <td></td> <td style="text-align: left;"></td> <td style="text-align: right;"></td> <td style="text-align: left;"></td> </tr> <tr style="vertical-align: bottom; background-color: white;"> <td style="text-align: left; padding-bottom: 2.5pt;">Property and equipment, net</td> <td style="padding-bottom: 2.5pt;"></td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">442</td> <td style="text-align: left; padding-bottom: 2.5pt;"></td> <td style="padding-bottom: 2.5pt;"></td> <td style="text-align: left; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">$</td> <td style="text-align: right; border-bottom-color: black; border-bottom-width: 2.5pt; border-bottom-style: double;">560</td> <td style="text-align: left; padding-bottom: 2.5pt;"></td> </tr> </table>

Stock-based compensation expense was recognized as follows (in thousands):  <table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Three Months Ended</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Nine Months Ended</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">January 31,</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">January 31,</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2013</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2013</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 52%;">General and administrative</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">500</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">701</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">1,619</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">2,370</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Sales and marketing</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">56</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">49</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">199</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">168</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Research and development</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">4</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(8</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">33</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">72</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">TOS cost of sales</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">4</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">1</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">16</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">2</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">POS cost of sales</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">6</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">67</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2.5pt;">Total stock-based compensation expense</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">570</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">743</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">1,934</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">2,612</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>

Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2013 and 2012 were as follows:   <table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Three Months Ended</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">Nine Months Ended</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">January 31,</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="6" nowrap="nowrap">January 31,</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2013</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2013</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap"> </td> <td> </td> <td> </td> <td colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td colspan="2" nowrap="nowrap"> </td> <td> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 52%;">Expected term in years</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;" nowrap="nowrap"> </td> <td style="text-align: center; width: 9%;" nowrap="nowrap">6.0</td> <td style="text-align: left; width: 1%;" nowrap="nowrap"> </td> <td style="width: 1%;" nowrap="nowrap"> </td> <td style="text-align: left; width: 1%;" nowrap="nowrap"> </td> <td style="text-align: center; width: 9%;" nowrap="nowrap">3.0 - 6.0</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;" nowrap="nowrap"> </td> <td style="text-align: center; width: 9%;" nowrap="nowrap">6.0</td> <td style="text-align: left; width: 1%;" nowrap="nowrap"> </td> <td style="width: 1%;" nowrap="nowrap"> </td> <td style="text-align: left; width: 1%;" nowrap="nowrap"> </td> <td style="text-align: center; width: 9%;" nowrap="nowrap">3.0 - 6.0</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Risk-free interest rates</td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">0.9% - 1.0%</td> <td style="text-align: left;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">0.4% - 1.9%</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">0.8% - 1.0%</td> <td style="text-align: left;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">0.4% - 2.2%</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Volatility</td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">100% - 102%</td> <td style="text-align: left;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">90% - 101%</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">99% - 102%</td> <td style="text-align: left;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">90% - 108%</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Dividend yield</td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">0%</td> <td style="text-align: left;" nowrap="nowrap"></td> <td nowrap="nowrap"> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">0%</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">0%</td> <td style="text-align: left;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">0%</td> <td style="text-align: left;"> </td> </tr> </table>

The Company’s stock option activity for the nine months ended January 31, 2013 was as follows: <table align="center" style="width: 87%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Average</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Directors</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Average</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Remaining</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Aggregate</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Non-</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">and</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Exercise</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Contractual</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Intrinsic</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: center;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Employees</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Employees</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Total</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Price</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Life (Years)</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Value</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="width: 28%;">Outstanding, May 1, 2012</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 9%;">1,410,000</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 9%;">13,456,038</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 9%;">14,866,038</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">0.88</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 9%;">7.0</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">-</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">130,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">586,250</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">716,250</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.41</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Forfeited</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(22,500</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(22,500</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.67</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Expired</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(500,000</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(15,833</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(515,833</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.76</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Canceled</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(25,000</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(25,000</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="text-align: right; padding-bottom: 1pt;">0.62</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="text-align: right; padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="text-align: right; padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-indent: -9pt; padding-left: 9pt;">Outstanding, January 31, 2013</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">1,040,000</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">13,978,955</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">15,018,955</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;">0.86</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;">7.1</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;">96,000</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-indent: -9pt; padding-left: 9pt;">Vested and expected to vest as of January 31, 2013</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">1,040,000</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">13,978,955</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">15,018,955</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-indent: -9pt; padding-left: 9pt;">Exercisable as of January 31, 2013</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">933,334</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">9,735,078</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">10,668,412</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;">0.88</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;">6.8</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;">14,000</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>

A summary of the activity related to restricted stock grants is as follows (in thousands):   <table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Weighted</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Average Grant</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Date Fair Value</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Shares</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Per Share</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> <td> </td> <td style="text-align: center;" colspan="2"> </td> <td> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="width: 76%;">Nonvested as of May 1, 2012</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;"> </td> <td style="text-align: right; width: 9%;">25,000</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">0.75</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Granted</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">100,000</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.30</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td>Vested</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(50,000</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">0.53</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Forfeited</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 1pt;">Expired</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="text-align: right; padding-bottom: 1pt;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;">Nonvested as of January 31, 2013</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;"> </td> <td style="border-bottom: black 2.5pt double; text-align: right;">75,000</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="text-align: right; padding-bottom: 2.5pt;">-</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>

Assumptions used to calculate the fair value of these warrants were as follows:   <table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">January 31,</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">April 30,</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2013</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">2012</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: right;" nowrap="nowrap"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: right;" nowrap="nowrap"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 76%;">Risk-free interest rates</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;" nowrap="nowrap"> </td> <td style="text-align: center; width: 9%;" nowrap="nowrap">0.46% - 0.88%</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;" nowrap="nowrap"> </td> <td style="text-align: center; width: 9%;" nowrap="nowrap">0.6%</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td>Volatility</td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">84.9% - 102%</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">102%</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Dividend yield</td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">0%</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;" nowrap="nowrap"> </td> <td style="text-align: center;" nowrap="nowrap">0%</td> <td style="text-align: left;"> </td> </tr> </table>

The following table presents information about the Company’s warrants liability, which was the only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at January 31, 2013 (in thousands): <table align="center" style="width: 80%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="width: 88%;">Balance, May 1, 2012</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">555</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-left: 0.125in;">Transfers to (from) Level 3</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-left: 0.125in;">Total (gains) losses included in earnings</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">21</td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in;">Purchases, issuances and settlements, net</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">417</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="padding-bottom: 2.5pt;">Balance, January 31, 2013</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">993</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> </tr> </table>

The following tables summarize, for the periods indicated, operating results by business segment (in thousands):   <table align="center" style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Translational</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Personalized</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Oncology</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Unallocated</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Oncology</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Solutions</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Corporate</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; font-weight: bold;" nowrap="nowrap">Three Months Ended January 31, 2013</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Solutions (POS)</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">(TOS)</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Overhead</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Consolidated</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; width: 52%;">Net revenue</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">473</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">2,444</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">-</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 9%;">2,917</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Direct cost of services</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(661</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(561</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,222</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left;">Sales and marketing costs</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(361</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(220</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(581</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: left;">Other operating expenses</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(627</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(637</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,264</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 1pt;">Stock- based compensation expense (1)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(570</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(570</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: left; padding-bottom: 2.5pt;">Segment profit (loss)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(549</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">1,036</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(1,207</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(720</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> </tr> </table>   <table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Translational</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Personalized</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Oncology</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Unallocated</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Oncology</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Solutions</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Corporate</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: justify; font-weight: bold;" nowrap="nowrap">Three Months Ended January 31, 2012</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Solutions (POS)</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">(TOS)</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Overhead</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Consolidated</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; width: 48%;">Net revenue</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">649</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">1,747</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">-</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">2,396</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Direct cost of services</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(528</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(801</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,329</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify;">Sales and marketing costs</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(242</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(175</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(417</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Other operating expenses</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(851</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(829</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,680</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 1pt;">Stock- based compensation expense (1)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(743</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(743</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2.5pt;">Segment profit (loss)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(121</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(80</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(1,572</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(1,773</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> </tr> </table>   <table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Translational</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Personalized</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Oncology</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Unallocated</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Oncology</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Solutions</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Corporate</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: justify; font-weight: bold;" nowrap="nowrap">Nine Months Ended January 31, 2013</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Solutions (POS)</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">(TOS)</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Overhead</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Consolidated</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; width: 48%;">Net revenue</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">1,850</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">4,631</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">-</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">6,481</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Direct cost of services</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(2,030</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,740</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(3,770</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify;">Sales and marketing costs</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(495</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(636</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,131</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Other operating expenses</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,463</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(2,418</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(3,881</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 1pt;">Stock- based compensation expense (1)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(1,934</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(1,934</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2.5pt;">Segment profit (loss)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(675</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">792</td> <td style="text-align: left; padding-bottom: 2.5pt;"> </td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(4,352</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(4,235</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> </tr> </table>   <table style="width: 90%; border-collapse: collapse; font: 10pt times new roman, times, serif; margin-left: 0.5in;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Translational</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Personalized</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Oncology</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Unallocated</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="text-align: justify;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Oncology</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Solutions</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td style="text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Corporate</td> <td style="font-weight: bold;" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> <td style="text-align: center;" colspan="2" nowrap="nowrap"> </td> <td nowrap="nowrap"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="border-bottom: black 1pt solid; text-align: justify; font-weight: bold;" nowrap="nowrap">Nine Months Ended January 31, 2012</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Solutions (POS)</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">(TOS)</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Overhead</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> <td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2" nowrap="nowrap">Consolidated</td> <td style="padding-bottom: 1pt; font-weight: bold;" nowrap="nowrap"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; width: 48%;">Net revenue</td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">1,837</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">3,931</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">-</td> <td style="text-align: left; width: 1%;"> </td> <td style="width: 1%;"> </td> <td style="text-align: left; width: 1%;">$</td> <td style="text-align: right; width: 10%;">5,768</td> <td style="text-align: left; width: 1%;"> </td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Direct cost of services</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,463</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,904</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(3,367</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify;">Sales and marketing costs</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(718</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(626</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(1,344</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;">Other operating expenses</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">-</td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(2,419</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(2,489</td> <td style="text-align: left;">)</td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;">(4,908</td> <td style="text-align: left;">)</td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 1pt;">Stock- based compensation expense (1)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">-</td> <td style="text-align: left; padding-bottom: 1pt;"> </td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(2,612</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> <td style="padding-bottom: 1pt;"> </td> <td style="border-bottom: black 1pt solid; text-align: left;"> </td> <td style="border-bottom: black 1pt solid; text-align: right;">(2,612</td> <td style="text-align: left; padding-bottom: 1pt;">)</td> </tr> <tr style="background-color: white; vertical-align: bottom;"> <td style="text-align: justify;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> <td> </td> <td style="text-align: left;"> </td> <td style="text-align: right;"> </td> <td style="text-align: left;"> </td> </tr> <tr style="background-color: #ccffcc; vertical-align: bottom;"> <td style="text-align: justify; padding-bottom: 2.5pt;">Segment profit (loss)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(344</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(1,018</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(5,101</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> <td style="padding-bottom: 2.5pt;"> </td> <td style="border-bottom: black 2.5pt double; text-align: left;">$</td> <td style="border-bottom: black 2.5pt double; text-align: right;">(6,463</td> <td style="text-align: left; padding-bottom: 2.5pt;">)</td> </tr> </table>   <table style="margin-top: 0pt; width: 100%; font: 10pt times new roman, times, serif; margin-bottom: 0pt;" cellspacing="0" cellpadding="0"> <tr style="vertical-align: top;"> <td style="width: 0.25in;"></td> <td style="width: 0.25in;">(1)</td> <td style="text-align: justify;">Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.</td> </tr> </table>

16519033

1416667

15064866

37500

18370622

3276667

15018955

75000

58000

287000

526000

167000

179000

2000

216000

730000

765000

170000

323000

743000

-8000

743000

701000

1000

49000

743000

2612000

72000

2612000

2370000

2000

168000

2612000

570000

4000

570000

500000

4000

56000

570000

6000

1934000

33000

1934000

1619000

16000

199000

1934000

67000

P3Y

P6Y

P3Y

P6Y

0.006

0.0046

0.0088

0.004

0.009

0.008

0.019

0.022

0.010

1.02

0.849

1.02

0.90

1.00

0.99

1.01

1.08

1.02

0.00

14866038

13456038

1410000

15018955

13978955

1040000

716250

586250

130000

22500

515833

15833

500000

25000 25000 0

15018955

13978955

1040000

10668412

9735078

933334

0.88

0.86

0.41

0.67

0.76

0.62

0.88

P7Y

P7Y1M6D

P6Y9M18D

96000

14000

25000

75000

100000

50000

0.75

0.52

0.57

0.27

0.36

0.30

0.53

0 0 84000 26000 3276667 0.77

P3Y9M18D

P4Y2M12D

12533333

18600000

0.75 0.50

9400000

9300000

500000

1266667 1860000 1266667 1860000 150000 0.90 0.66 0.50 0.90 0.25 0.25 9400000 9300000

900000

400000

300000 100000 0.010

800000

600000 1000000

18000

103000

30000

122500

3000

20000

2013-07-30

2014-06-30

2014-04-30

18000

49000

52000

21000

69000

52000

40000

45000

85000 45000

3000000

10000

460000

880000

27000000

1400000

681000

317000

1500000

1000000 500000

1000000

500000

21000

417000

600000 1000000

1329000

528000

801000

3367000

1463000

1904000

1222000

661000

561000

3770000

2030000

1740000

-829000

-1680000

-851000

-2489000

-4908000

-2419000

-637000

-1264000

-627000

-2418000

-3881000

-1463000

-1572000

-1773000

-121000

-80000

-5101000

-6463000

-344000

-1018000

-1207000

-720000

-549000

1036000

-4352000

-4235000

-675000

792000

0 9195000 2014-07-31 0 13000

8300

10000 880000 1064658 0.75 0.50

8200000

8800000

0.10 50000 130000 Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.

EX-101.SCH 6 csbr-20130131.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - DOCUMENT AND ENTITY INFORMATION link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS link:presentationLink link:definitionLink link:calculationLink 006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Organization, Use of Estimates and Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Recently Issued Accounting Pronouncements link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Property and Equipment link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Share-Based Payments link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Redeemable Common Stock and Stock Purchase Warrant link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Licensing Agreements link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Cephalon Agreement link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Supplemental Schedule of Cash Flow Information link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Grant Income link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Fair Value link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Business Segment Information link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Organization, Use of Estimates and Basis of Presentation (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Property and Equipment (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Share-Based Payments (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Redeemable Common Stock and Stock Purchase Warrant (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Fair Value (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Business Segment Information (Tables) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Organization, Use of Estimates and Basis of Presentation (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Property and Equipment (Details) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Property and Equipment (Details Textual) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Share-Based Payments (Details) link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Share-Based Payments (Details 1) link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Share-Based Payments (Details 2) link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Share-Based Payments (Details 3) link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Share-Based Payments (Details Textual) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Redeemable Common Stock and Stock Purchase Warrant (Details) link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Redeemable Common Stock and Stock Purchase Warrant (Details Textual) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Related Party Transactions (Details Textual) link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Licensing Agreements (Details Textual) link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Cephalon Agreement (Details Textual) link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Grant Income (DetailsTextual) link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Fair Value (Details) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Fair Value (Details Textual) link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Business Segment Information (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 csbr-20130131_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 csbr-20130131_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 csbr-20130131_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document and Entity Information [Abstract] Document and Entity Information [Abstract] Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Trading Symbol Trading Symbol Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Period Focus Document Fiscal Period Focus Document Fiscal Year Focus Document Fiscal Year Focus Statement Of Financial Position [Abstract] Statement of Financial Position [Abstract] Assets [Abstract] ASSETS Cash and Cash Equivalents, At Carrying Value Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Accounts Receivable, Net, Current Accounts receivable, net Accounts receivable Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Prepaid expenses and other current assets Assets, Current Total current assets Total current assets Restricted Cash and Cash Equivalents, Noncurrent Restricted cash Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Goodwill Goodwill Goodwill Goodwill, Beginning Balance Goodwill, Ending Balance Assets Total assets Total assets Liabilities and Equity [Abstract] LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' DEFICIT Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Accrued Liabilities, Current Accrued liabilities Accrued Liabilities, Current, Total Deferred Revenue Deferred revenue Deferred revenue Liabilities, Current Total current liabilities Total current liabilities Derivative Liabilities, Noncurrent Balance, Ending Warrant liability Warrant liability Balance, May 1, 2012 Balance, January 31, 2013 Liabilities Total liabilities Total liabilities Commitments and Contingencies Commitments and contingencies Redeemable Noncontrolling Interest, Equity, Common, Carrying Amount Redeemable common stock; $0.001 par value; 31,133,333 and 12,533,333 contingently puttable common shares outstanding as of January 31, 2013 and April 30, 2012 Redeemable common stock; $0.001 par value; 12,533,333 contingently puttable common shares outstanding as of January 31, 2012 and April 30, 2011 Stockholders Equity Attributable To Parent [Abstract] Stockholders' equity: Preferred Stock, Value, Issued Preferred stock, $10 par value; 56,075 shares authorized; no shares issued and outstanding as of January 31, 2013 and April 30, 2012 Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance Common Stock, Value, Issued Common stock, $.001 par value; 125,000,000 shares authorized, including redeemable common stock, 38,855,003 and 37,740,345 shares is sued and 35,618,767 and 34,529,000 shares outstanding as of January 31, 2013 and April 30, 2012, respectively Treasury Stock, Value Treasury stock, at cost, 3,236,000 common shares as of January 31, 2012 and April 30, 2011, respectively Treasury Stock, Value, Beginning Balance Treasury Stock, Value, Ending Balance Treasury stock, at cost, 3,236,000 common shares as of January 31, 2013 and April 30, 2012 Additional Paid In Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Accumulated Other Comprehensive Income (Loss), Net Of Tax Accumulated other comprehensive loss Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax, Beginning Balance Accumulated Other Comprehensive Income (Loss), Net of Tax, Ending Balance Stockholders Equity Attributable To Parent Total stockholders' deficit (equity) Total stockholders' deficit Stockholders' Equity Attributable to Parent, Beginning Balance Stockholders' Equity Attributable to Parent, Ending Balance Liabilities and Equity Total liabilities, redeemable common stock and stockholders' equity (deficit) Total liabilities, redeemable common stock and stockholders' deficit Balance Sheet [Parenthetical] [Abstract] Balance Sheet [Parenthetical] [Abstract] Temporary Equity, Par Or Stated Value Per Share Redeemable common stock, par value (in dollars per share) Temporary Equity, Shares Outstanding Redeemable common stock, shares outstanding Preferred Stock, Par Or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Issued, Total Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Common Stock, Par Or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Treasury Stock, Shares Treasury stock, shares Treasury Stock, Shares, Beginning Balance Treasury Stock, Shares, Ending Balance Income Statement [Abstract] Income Statement [Abstract] Operating Income (Loss) [Abstract] Operating revenue: Personalized Oncology Solutions Personalized oncology solutions Aggregate revenue during the period from personalized oncology solutions. Translational Oncology Solutions Translational oncology solutions Translational oncology solutions Aggregate revenue during the period from translational oncology solutions. Sales Revenue, Services, Net Net revenue Total operating revenue Total operating revenue Operating Expenses [Abstract] Costs and operating expenses: Cost Of Personalized Oncology Solutions Cost of personalized oncology solutions Total costs related to personalized oncology solutions during the reporting period. Cost Of Translational Oncology Solutions Cost of translational oncology solutions Total costs related to translational oncology solutions during the reporting period. Research and Development Expense Research and development Research and development Selling and Marketing Expense Sales and marketing costs Sales and marketing Sales and marketing costs General and Administrative Expense General and administrative General and administrative Operating Expenses Total costs and operating expenses Total costs and operating expenses Operating Income (Loss) Loss from operations Loss from operations Nonoperating Income (Expense) [Abstract] Other (expense) income: Gain (Loss) On Derivative Instruments, Net, Pretax Change in fair value of warrant liability Change in fair value of warrant liability Change in fair value of warrant liability Other Nonoperating Income (Expense), Total Other (expense) income Other income Nonoperating Income (Expense) Total other income Total other (expense) income Income (Loss) From Continuing Operations Before Income Taxes, Extraordinary Items, Noncontrolling Interest Loss before provision for income taxes Loss before provision for income taxes Income Tax Expense (Benefit), Total Provision for income taxes Provision for income taxes Net Income (Loss) Attributable To Parent Net loss Net loss Earnings Per Share, Basic and Diluted Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share) Net loss per common share outstanding, including redeemable common stock, basic and diluted Weighted Average Number Of Shares Outstanding, Basic and Diluted Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares) Statement Of Income and Comprehensive Income [Abstract] Statement of Income and Comprehensive Income [Abstract] Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net Of Tax Foreign currency translation adjustment Foreign currency translation adjustment Comprehensive Income (Loss), Net Of Tax, Attributable To Parent Comprehensive loss Comprehensive loss Statement Of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Net Cash Provided By (Used In) Operating Activities [Abstract] Operating activities: Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Share-Based Compensation Stock-based compensation expense Stock-based compensation expense Increase (Decrease) In Operating Liabilities [Abstract] Changes in operating assets and liabilities: Increase (Decrease) In Account Receivable Accounts receivable The (increase) decrease during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. Accounts receivable Increase (Decrease) In Prepaid Deferred Expenses and Other Assets Prepaid expenses, deposits and other The (increase) decrease during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes. Prepaid expenses, deposits and other Increase (Decrease) In Restricted Cash Restricted cash Increase (Decrease) In Accounts Payable Accounts payable Accounts payable Increase (Decrease) In Accrued Liabilities Accrued liabilities Accrued liabilities Increase (Decrease) In Deferred Revenue Deferred revenue Deferred revenue Net Cash Provided By (Used In) Operating Activities Net cash (used in) provided by operating activities Net cash used in operating activities Net Cash Provided By (Used In) Investing Activities [Abstract] Investing activities: Payments To Acquire Property, Plant, and Equipment Purchase of property and equipment Purchase of property and equipment Purchase of property and equipment Purchase of property and equipment Net Cash Provided By (Used In) Investing Activities Net cash (used in) investing activities Net cash used in investing activities Net Cash Provided By (Used In) Financing Activities [Abstract] Financing activities: Proceeds From Issuance Of Redeemable Common Shares and Warrants In Private Placement Private placement of common shares and warrants The cash inflow associated with the amount received from entity's raising of capital via issuance of common shares and warrants in public placement. Proceeds From Warrant Exercises Proceeds from exercise of options and warrants Proceeds from exercise of options and warrants Net Cash Provided By (Used In) Financing Activities Net cash provided by (used in) financing activities Net cash provided by financing activities Effect Of Exchange Rate On Cash and Cash Equivalents Exchange rate effect on cash and cash equivalents Exchange rate effect on cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Decrease in cash and cash equivalents Increase in cash and cash equivalents Organization, Consolidation and Presentation Of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation Of Financial Statements Disclosure [Text Block] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Abstract] Accounting Changes and Error Corrections [Text Block] Accounting Changes and Error Corrections [Text Block] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment Disclosure [Text Block] Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract] Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Disclosure Of Compensation Related Costs, Share-Based Payments [Text Block] Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Redeemable Common Stock and Stock Purchase Warrant [Abstract] Redeemable Common Stock and Stock Purchase Warrant [Abstract] Equity-based compensation plans and award types, including multiple equity-based payment arrangements. Redeemable Common Stock and Stock Purchase Warrant [Text Block] Redeemable Common Stock and Stock Purchase Warrant [Text Block] Disclosure related to prior period financing in which warrants that are accounted for as liabilities, due to exercise price reset provisions, and common stock accounted for as temporary equity were issued to investors. Disclosure also describes assumptions used to revalue warrants during the reporting period. Related Party Transactions [Abstract] Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Related Party Transactions Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Disclosure [Text Block] Licensing Agreements [Abstract] Licensing Agreements [Abstract] Licensing Agreements Disclosure [Text Block] Licensing Agreements Disclosure [Text Block] The entire disclosure related to several different licensing agreements. Cephalon Agreement [Abstract] Cephalon Agreement [Abstract] Cephalon Agreement [Text Block] Cephalon Agreement [Text Block] The entire disclosure relating to Cephalon Agreement. Supplemental Cash Flow Elements [Abstract] Supplemental Cash Flow Elements [Abstract] Cash Flow, Supplemental Disclosures [Text Block] Cash Flow, Supplemental Disclosures [Text Block] Grant Income [Abstract] Grant Income [Abstract] Grant Income [Text Block] Grant Income [Text Block] The entire disclosure relating to grant income. Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Fair Value Disclosures [Text Block] Fair Value Disclosures [Text Block] Segment Reporting [Abstract] Segment Reporting [Abstract] Segment Reporting Disclosure [Text Block] Segment Reporting Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events [Abstract] Subsequent Events [Text Block] Subsequent Events [Text Block] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Property, Plant and Equipment [Table Text Block] Property, Plant and Equipment [Table Text Block] Schedule Of Employee Service Share-Based Compensation, Allocation Of Recognized Period Costs [Table Text Block] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Schedule Of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Schedule Of Share-Based Compensation, Stock Options, Activity [Table Text Block] Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Schedule Of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block] Schedule of Share-based Payment Award Stock Warrants Valuation Assumptions [Table Text Block] Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions. Fair Value, Liabilities Measured On Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Schedule Of Segment Reporting Information, By Segment [Table Text Block] Schedule of Segment Reporting Information, by Segment [Table Text Block] Antidilutive Securities Excluded From Computation Of Earnings Per Share, By Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Stock Options [Member] Warrant [Member] Restricted Stock [Member] Antidilutive Securities Excluded From Computation Of Earnings Per Share, Amount Common stock equivalents Furniture and Fixtures, Gross Furniture and fixtures Capitalized Computer Software, Gross Computer equipment and software Machinery and Equipment, Gross Laboratory equipment Leasehold Improvements, Gross Leasehold improvements Property, Plant and Equipment, Other, Gross Software in-progress Property, Plant and Equipment, Gross Total property and equipment Total property and equipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: Accumulated depreciation Less: Accumulated depreciation Schedule Of Employee Service Share-Based Compensation, Allocation Of Recognized Period Costs, By Report Line [Axis] Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs, by Report Line [Axis] Employee Service Share-Based Compensation, Allocation Of Recognized Period Costs, Report Line [Domain] Employee Service Share-based Compensation, Allocation of Recognized Period Costs, Report Line [Domain] General and Administrative Expense [Member] Selling and Marketing Expense [Member] Research and Development Expense [Member] Translational Oncology Solutions Cost Of Sales [Member] Translational Oncology Solutions Cost of Sales [Member] Personalized Oncology Solutions Cost Of Sales [Member] Personalized Oncology Solutions Cost of Sales [Member] Allocated Share-Based Compensation Expense Stock- based compensation expense Allocated Share-based Compensation Expense Stock-based compensation expense Stock- based compensation expense Range [Axis] Range [Axis] Range [Domain] Range [Domain] Minimum [Member] Maximum [Member] Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term in years Expected term in years Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rates Risk-free interest rates Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rates Minimum Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rates Maximum Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Volatility Volatility Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Volatility Minimum Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Volatility Maximum Share-Based Compensation Arrangement By Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Dividend yield Deferred Bonus and Profit Sharing Plan By Title Of Individual [Axis] Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual [Axis] Title Of Individual With Relationship To Entity [Domain] Title of Individual with Relationship to Entity [Domain] Non Employees [Member] Non-Employees [Member] Directors and Employees [Member] Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Number Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding, Begining Balance Outstanding, Ending Balance Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Net Of Forfeitures Granted Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Forfeitures In Period Canceled Forfeited Forfeited Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Expirations In Period Expired Expired Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period Canceled The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. Canceled Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Number Vested and expected to vest Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Number Exercisable Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price Outstanding Weighted Average Exercise Price, Outstanding, Begining Balance Weighted Average Exercise Price, Outstanding, Ending Balance Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Grants In Period, Weighted Average Exercise Price Weighted Average Exercise Price, Granted Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Forfeitures In Period, Weighted Average Exercise Price Weighted Average Exercise Price, Forfeited Share-Based Compensation Arrangements By Share-Based Payment Award, Options, Expirations In Period, Weighted Average Exercise Price Weighted Average Exercise Price, Expired Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price Weighted Average Exercise Price, Canceled Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Weighted Average Exercise Price Weighted Average Exercise Price, Vested and expected to vest Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Weighted Average Exercise Price, Exercisable Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term, Outstanding, Begining Balance (in years) Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms1 Weighted Average Remaining Contractual Term, Outstanding, Ending Balance (in years) Weighted average remaining contractual term Ending for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Vested and Expected To Vest, Outstanding, Weighted Average Remaining Contractual Term Weighted Average Remaining Contractual Term, Vested and expected to vest as of January 31, 2013 (in years) EX-101.PRE 10 csbr-20130131_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R39.htm IDEA: XBRL DOCUMENT

Licensing Agreements (Details Textual) (CAD)	9 Months Ended	12 Months Ended
Licensing Agreements (Details Textual) (CAD)	Jan. 31, 2013	Apr. 30, 2011	Apr. 30, 2010	Apr. 30, 2012
License Costs	45,000		40,000
Proceeds from Option Exercises		85,000
Additional License Costs				45,000
Business Acquisition, Contingent Consideration, Potential Cash Payment	3,000,000
Royalty Expense	10,000
Accrued Annual Royalty Payment	10,000

ZIP 12 0001144204-13-014818-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-13-014818-xbrl.zip M4$L#!!0````(`*.";4(LTNM(>7X``"!Z!P`1`!P`8W-B!W87!2/1-N?*DB\EN?%=8/[V/=3#EF39$FW* MEF)=]+:)'CS?.?QX2!Y2AV_^_CPUI#FF-K',MV?R>?-,PJ9FZ<0O2YWSYKE\KDK_W50O M9/5":^1#85""5YQRKF\ MNN==^6!I[A2;CO0%@(T(//N#.!,F_R>"?V`J_10@`/SG[?,>*^IGK)O8UM'B ME?0%46TBR>HKR8?4O53ERY8*D'++N=:)8\7E*.?]A$)PXW'BTIC05B!45BY; M[,]*Z/,3-<@E^UN".C#M2\U^HF_/)HXSN[RXT"9H.@-1M@6U85CCQ;EF33V3 MPA_Y+'C%(.9ORU=^_/AQSHH[M^@8GH1*8+>?P+;AX^RN3I8O1!_N7/@WEX^N M%?U#]9Z5^_W^A7=W^:A-TAZ$0N6+7[Y\?M`F>(H:Q+0=9&HQ+&0+]N3SQ+9: MBMS=]H;_1/B"CF<4:XRN&]_I7T`E4UB09KFF M0Q=QL]E8.Q];\XO@)JL9I=&4&ZNZT5Q*H2EM>B^XF_*BCDGZ.W`CY7'\K$W2 MGV=W4EX@YAS;3OHK_KV4ETQ$-#O]'>\6>T6.OV(3+?T%N)'VN#.C&YZ'.RDO MN'9CC-!L^S08W4K1X-K;PYY?/$5*[#MU"&[A[QMHP:P:7MD?P>SR2 MO&9Q&7!J>^.YF%%KAJE#L!UMIEX!SF(&;]MD.C.6UR84C]Z>,1?1")W`^;.M MGUV$/O3*,AW\[$@/6'.8BXIY&2VX2:`M!`]^O_GU^KO:;`QF7HG-L]73X`&) MLUC]3G1V!?PAE3Q=XZJ%M71U^X^S=TWXK]N5>^W.FXODRZS`BW0)8`EBZ:O? MH>E3!SPKADO,X(UF&RIR]7[T_A*TOGQ!;C::K8;:C`H,[X975B(O8C;:;K2! M_7TX8F;[:LW+9S;?9SJA#:#!1&VPNIO#!ENM<.7:CC7]KK0:T,LQ,\BE,D.< M/4S*'H.P-IF`T]'J'M#YZ)_1W:)3'8(\DGON#I M$Z:',7A@+SQF@L,+.HB$GI)H),`BZ03N^R-(YJ$N-REU]LZ[G:':FXM4*1%C M1P!5G1)Q+USJ=M3D]<)RX5ZXE&:+>>$U&W!YX2TV4+\`<>3&?R&364`IE076 M6ILW=,M/G)IXX":-]9W,3W37P<'0-@RUK@?$#IG.BX8<)HMB;EEY9TQDX M-\0&50/#L#3OI^'H'FO6V"1_8/W.@W)EV8[]?G&/9Q9U8"3I>_%[;&,V$1R` M`GB.#6O&'-?U,RL2E]N3!Z/HRZ)M=/8NE)3#6`?I&TK+5@=*9D68MDV_8.R0K>5I4Z1HA^;'``UHH@-] M2DQB.U`#9(YKEY;JTG*9JV9LD8Q]I,BT#>\59`R#:.J#9;CLBLW>&8X>D('M MFKL1/\MIM9K"15+X`1L&,S;H,]ES=V>;L;/F,=MH$WNK#MAJR(I3+X=1R MJ%F39"-)M@]M7PY+\NAYTC2Y1^;8[[6^P-1\ZDZK4?=+V*MA;PQ_7:=^G:+G M:M=I%/])U6F_2DM;G&NBAS):O;15BN%]V9:V2LO6>FFK+$M;I:5(O;15*I=6 MGJ6MDV5LO;3U4I:V3I;"]=)6I9:V2LO3>FGKY"E0+VV5RW&5=6FKM`2NE[;* ML[1539+42ULU3>JEK9=?I_72U@NITSO_*_#%@_OT+ZPYC]:0#N:(&.C)P#<6 M'J^*1]F2*M(M'K73CA+[Y.F M49&=\8-C:;\-9Q6:OA^D1UXWRTDS\&C=\GL+4?`&'^!Q#;R#?35!A$Z160VJ M'K]GWFZ_FM/'X#3TC5Z&%H(,S\U,+$.OS"S[>)3VQ@E;;7?2=.8?:R[W`)Y. MK&>+RB=-GB)'F/<8FCG1'*Q[+;8:!#O((#/5,B?%PR#/6DD_Q8CE65NS@:@\ M:[X-9+5Q@Y_*;P.E(:OB;>!]9+7,ME>'GU]V^-FC$:?_*2;/8SPY9KE:G@"G M?9CDF.4R6])A%9,<<\T&WV]@8OT3,EQH<\L?/P%T]E'6XC/[),OS/LM[MR8T M6]N[H5;#%^73<.56MJA:A),Y5L4?+8ZP#.K`F^$6RXK,WXX<1=ABN9?$S#L# MF5_1%%=W&A;5X`CSII-S*5\ML_8D/)YDW6#5Y6%P>,#J[(ER#>S6)A'<169RAU@3EX> M6L03[I2Z+7'[(/4P68K4.CE+*3Y0*U=REA*SM4[.4H[D+"6F2)V1G.6$*5PG9ZE06K;6(?.RA,Q+2Y$Z9%XJ MEU:>D/G),K8.F;^4D/G)4K@.F59++2YLZ4<4+3U114M[5>9*K]*EH.?(DEY?- M=9[D"N5)+B^-ZCS)IY$GN;P,K/,D5[1G/GJ>Y)K3=9[D%Y0GN;QTKO,DESY/ M7E89UL\LC))BO#E#H[9>7&;@?.3ED9*M?I+$^EINO\EU7Q M58?)?UD9XJY.T!Z:F%6)Y9H5V4`9.47;7^Y/*E!7;+#_&I[7JUVW:3J<=/4> M;!M'A$A?B+DZH[[L#"K5]HY=>!]>BEF]YORA.8^>:\X?GO-1JY\TYS?FEQ[, M*#'@$?GE99?.4*WF0YUOO.9$'DY<_^Z"AKH9>%BU48<)>8B_7(>2T`5@GW5OL7OCJM@INHVVE*G29/T"Y7\K_8P65K M-A!\@%Z]/Z8\^V..5?'U=I?*+2$?\S#6`S*SWKU2T8JK-Z-4Q9,G,I]VXZ;?GFYM-K^?+MI_;;CV\Z'_N=VZ!\'XC+)#/#VXR%P*3@^A0CVZ7X M7<`2[V8(/KP7_L[*2"GQV\.'M>*(;;44N7L)]_A+^PYF_.ZUEF6Y7BO`[R(/ M?W6GV/M">$?1:^^SBQ^P:4V)F59L7@/%BKB(H]^N^+0E8?O5I\&7N]OA MUP=I^/5J^'GX\==7TNW7J_,W%YO*96!6]ZX`#T4&N$7\_`^\R" MDOS$:M"U2*PG0N8BJE^LW%#D(T5>5[28/EE&/F&LR_'+C;VD_\@-7+/SR?JG&I>Q5DRZ'$9\#BGL[S0YRV*8E&6B$62S MS/GL'[;&-T>&-ZQRKA"E"R"!%PG8PC^UV1C,*),L1_C'.K0(^1H>)UKM;I.Q MCTNT4*Q+*RG;L79:/>7(4)=FS8#:ZLJ=LEA5S6)`M]/?#^M`TRP7'KG'&H;' MGPS\%3M!)R'"FNU>*P9PFSP1N/*:KM-2=L)U1_$,$3U(9LS2P#@33`>VC1U; MH-F49CL&+X=8@2CS&E%EHYC=40JW6KN=,-O^HG,W1;DKR_EDKZ(VZ:T5IM*: M.)O(O5X,5G[IXC'G-F:_*0!S^`$^BYTY+,`)+W@GV4#+%L*V3I+]F^6)P)77 M>JV$:\N+ZZ-EZ3^(D3X$Y[1-)]$OA67SRLOMSG/(\QND$.WZBI+2UOF$Y6X, M*N#)DA;T7G=HP;HN@2Y5[G0[J1UE7-1^8/([V:;,#X:Z6/],T!,QO#W@`HW3 M4=I)..G"]D:4UT+MSEIM92,*0\?W>(Y-5RA[Y%[<0NFB]@.3?[0L=SG!%$,; MM=6+U]+VZBF&*4HG,3+/XHBW]XO,<>0YL2.5=CO)E:TBA:,3L7.AA`KF)42_ MKQX57>'FWT/!R`-"0@S-EKRI[>T@-O=TK=/MYA'+0IC$"5<#F3!BCK&I[:S] MLTTN36*\/7.@,SJ[$"!KL\I;9-UC'>.I-[>'6H8"J>6=4G0+15.88OA;\OT` M;A@P&4S9`$-$I??D=C\QJ]D53O%*Y>Y3.WVU4X!6=S3HF[U`NK#87CQ6D92P M!X"\]LH/(+*.($Q]-1X*2(K857QN_]//+?Z1>FN`"['ZRTH[/I-:%[,[B-Q- MA@_$0->)?W3('2+Z+;29&7&0$3&>D'@C3#$3@=I,N>)0YAZSJG+"V_"AO,<. M(B;6P\^%87;D3ET#.5B'N0#;HR+"E@VE+;?4A%/,$BP.9EYC-I1^*S%_Y8,9 MN>O%>=EZ+\43MC%I#H,SS9KBSY9M?\7.`V-\`%T\99E1-X[? M\U3\_H#YV"H8L%\9`]>96)2=>"B&I^U.L]O>!#(I4@RX_`05"N[6MEU15MM8 MK5%1^P/*;RDA@(0[P0Q4N1Q+0;YO-VB1BPNJ=<^R`R*.(4NOQU9QU/T0"7=T8"-E M8W0MKT-;:3 M.7./KL^@;%E[(.KS())[:K=X2&IBNW?&[F#UT$;*FOA[6RSX(&T_DGI_*LG= M5J3BMDO;!Q07F]2^*A\"%!>?E%:K=7A+99&\PV>I99@.&=@.=M,\8#HG&K8W M;6KDXI.B]N-N'-0WGF$XPTO-L1"B+'O"6;1E$ M9XKDP5VN6MCJZ?*H$_9WI=!F>R/+H\[2YQ:D#Y>O;7<[O0."J6R#Y=.#M\&6 MJQ;V;K#+X6`IU-F_Q2X')`?Q0%D#D;Y[?8<+94 M"FWV;[#+P?I!'%#F%XR]0KU',F-A51LLGQZ\#;94,.NV,CX]\_6;KT`"YZ!=^871\*!Q_T[\^^OKKV8?=FP!^Q]#@+/?4'T-\P^]Q%&KXZ2F&YLE"4.T0''Q+5XIS[;=W>$@5;\S%1I-E-1G].+X.>[?FKMPKFT[[ MM^:.TCFTB\J:M+4/8.;CA9B/KPWWTE`R;'5\%?9NRVJG=#H)B#DKS4,[J,P0 M1W*A^0"0*MZ8BPU"RW(RRGE\'?9?.^H??/Q7?&ONJ+OTS!^QB2DRX*F!/B6F MEXF:Y2T1-G&6E5Z\26=(W!<6W(B2]^:#'X`?'-*14DX2@$(N.BB=A);6(2;(#ME<"*]<3X$ MJZ_1]^=!0^XF]@6DB-D%!1<9&IUPG4LP"BY"-+J)\5TAIL@"T5+4-@^*CXB8 M[-K07"716AUES!94[RAV-B1-X`OIQLF:5[`PL'P[S-NMXZ+EHYZ2R$=W9.-F MPI7W1NMEV?AJF5:SRR:)`B MZ!$]8_OZ&8;R%M6)B>CB%N:P=GKZ/2&C-SD^C"\0[C&MPCF:E!/Y_U^H5?B: M8S^QB/="C<([VDXDV3JH5>#UP.4$)SON[Q+65%F3L2L,KC98'`R^/3LI=5N0 M0;)6W7B1P*!9\$0_T57$!/!)WM,=[R&9T^4E#B\1IG*V6TE$^S9*#O,[AEE0 MWB.;:&SG%C%<9T.FC*T5GYZ110%0S?-F:X4H0_"^&+=29!M&63T8QJUDVFI' MY4AVY,'8WPGCSYB,)W!M,(?^;HR_NFPA93CR7HND!MF/IJGY-UJ=;B(I\FY8 M"M)F,Z'3M>DFD_B42IO-U-^@33<1+"^5-IL;R09ME'Y+L#;;DL;>P'B1C$W_ M*`]MX2U=(N_,7"@KLI`YT/_EVDYP'-3F3+><_;ZZ'CD1CO-(EN#;6/YR[<"W M3/IR[<"W=Z9U8$.D%"ZRG7?5Q+&NF\7M@XIW[-]4,A!0/'.&1*' M&.9$%8[HV':K*9M->E04X"\[B164=$%"H&0>0JFV.*%\P&`[C6P&P+'Q>^&^D_AYP0+,*7>W0LX%XP!J M9)W+UA&B1"0*F"@B?KJN"+LG<@ADB10,+W.)4""XQ`&D`C8[JAGH$A)%P\LR M7KO;$@PP<3ZI`!-F5?"ZT`)`9AIR;0EH3Y2)TTQ%M./$UYN9,D4#S-PZTLDR MXA:`,*QE[?N.6G.B8_W]XAN,[&[-Y?0 ME8FG\MK"6D[AA4'.9');`&)X7,-8]Y;H?T:4(I;>`%.-"-F:WH][LFW"!(+B M.:TR'Z`-MKTA)C(UP51,V"R_Z,(`9PWEY7XN)F9`OAZ-L.8,1]?/V@298WS/ M/G8S64'L"%WXASF).3*8(Q$=PN:172#FK#!K6PCH]"?N,"66GAQKB/"L_406 M!A[Y!>+.W&62B*'L"GM(Q\@D?WBQEZOE)Y!^P!OFN3:4XOTZ'`4-!!G+[_7L M#\36#,MV*7X$#=X;FXX<3:KV[J^&\WHFV<["P&_/V",-9)"Q>2D9>.2\EJ:( MC@G\UIPY\/_S:VD$!5U*,OO=(5-P"R;^(8%71.8K_\(KR0951Z_/_CIV7K/2 MG]@/7RT'2_*Y%%7RE03M7;)&TC7T.U/0Q):0J4MLQ<]FEZ-*LX(NGL(B+V;L MIS__:2-XMB9`1HO]\:/I[/5_R)TFIUCO(C%US(3U9_L;\FH"2+P46>&'EZ\D M(-.Y]#=G@B4?9D]1FJ]9OZU6H%2"6=NF/[7'J$ M1Q/PY.YK6WITIQ8=4S1RI,>5>!CR.2.+3AEX))D6B)#0;$8MI$WB(`@[JH7! MI_`/Q=(3"U)+[LSR5273&1L]^A%3@#5QP<:2PX3:S!QD.G5-W-"](UZ9"E/0 M,X:6*02*3P!)Q#Z`06>?7F")!E,Z@"LY/RQ)`QI84X`SII8[LR^EZ-?`RPJ4 M5FG/_A:IP+OA0[3R/(/&OKS-*N`Q7L"Y!"5*R(9&!7W+;+*P04THCJD>5!PS MX"P*T0'GY/C6$`)RYT8(`)(9;B+NQG"V>:$'B7 MS`S47NA&@!_8'@`IL$9L&5];RM0T+`J-2SQ4O=U6`3'3;O4-ZWPD7GS_+73* M9P2H&5C;BNM/7&-FZ+!$L,.VY:-R]^M]6 M^!AEC93Q'F!6?64[1%7NOGU0/G][WU(^LFW!@<,7+>!&90F8+E#F@E:KP%GK M(P]U-57!,Y<^AOJ0BJ^"O'K&_UBV@D>@`Z=Z($]@`-W!W3-9XY,@5.,XMY0; MTXS>,3#C>)B4WD$0<2D#JA)*,[QI'#(U'ZTJ-C1 M470@_6PK.!.CZZDYJ--X=)B.DSPFX'P`2OP'E&T4`P%Q"%>[%>S*H2;[C^J`V*)SE'-\,3ZU'W^0+R/?&`P&F9E8R/A$8 M6KB02P-.7EC<33WMX<.[Y"F-N]D%&N'IB?-F;VB<0N=AAM3=S0:;&X^^PQD] MW!3(G/&":IBQDN M(3R`4S@SU%C8[HI/ZSG:$8&?:BL>@6XFM\OBHH?BC0N7FR7 M;$V:MFZZ!<>6N<?'ISD_^'G:_XAG-"+-X1$ZA9@ M?(%$-;PU8XO?0CEW$\BYFT@DW44",57Z.82&9-S8)L7E6NI_P;F1\.``<_A+ M;CB">@<+33V0[!REO(>\SQ=)-IB(F2.FC[,-]2C/LKYF;8QK/^D.(GUEX(J3* M6L5S!V/I$3*4LCPVK'A84"DW6`@(K3B@VCVN+R,VJO9@IT^Y.0`&V@M4#48 M*^`$L$:$+'D""WL&;\=]K=BQJXJ39TQ+"4HW\M&@',3=9$<"3556IN^R38HP MHB5%F'B(S82CH`H.>C3L&\[2N$STA\`IQ;3Q(%V)_XB^^L"%0TUS?J4P_WE) M8"\"@=Z%H@1U2MAE%`N.(B553,_$<0*Z<9D[H5Q">)57C,3T9$:](Q165,\# M$!R0,+,`+#HEZJ5<2L5F!A!#^10'B-WC#=0,P"V.1;0$VXCHH7DS(;"?\.?@ MBTT)J!AS-1"]H#MD/:86HPL*.7=NH",'B/!,A>PD\;4QWP4"<[9L/!1!M(XV MD!_J,1:L!W<:S(OY>QC3L',M=7^&T+GZDE"]F8(:[H^5C:J\0<_P<.WUT6R4Q<7-7THM]&]XI"Y"<1EA/9LC^KWG,B)@]:( MFBLEQ!NP?>:*,^UG&BV*;H6+R?;CW/=\:J8M5[ZWL2WA\XIYG4+I^V8O"D[1 MNG".?2(?,NO+%QE!P_AL;*'H++^\8K.\"@!X-F;>XHTRZ/_XLS(!4Y\XUU/T M;*Q<`A#Q3R*(`QJFZ:YTS#_`RD7Z]TJ?S?C?,;"<``@X,&E0(:#$Q/8\>_ES M_%D0%/:SHZ]^><7^32.P-TN\P`?GD*,-+6GE8[1L058VOE%7[W?\-`(GH'5G..""RT"/CB.[;RS'8?EXKEE55&4YDTW MXX44G9:"K29HU.<3"PLE`OFV!9^GC!B4PA=<.8%3XAO!K%Q@TYW!GGC/0OO_ M](&:85ZN0L'&%_&1D,GB='[`$(#NS%SEK0W_)-+#/MX\O$VDA^T&@\?W$O.F MSO;[BJ8WQ*>[>?A=<+:O=HLB>]T&?./5`ZP(5/ED84$$)H!`*Y/L..L M1P-=\;RW!P;#/BU7NN$@H\7F9]EN#GDR7*KT,\`Q^(Q)C31(YMD8//:GA`?@ M7!;RQ#B(2;YCQ@K&YC@L1@2+26$Q(EAX'D@LE_C1MF?/!B9`8J@TA`]#\"M: M:8A#8H"'1CD<]^A_\:F#!&()9QE$`@K6T':*8QE_$7#/J6;;'!Q@6/Y$V-.YHFVN]F3(L^R(/^N/(K5L*MS`P\X\UU$-W_&[.\@[DV M]JX:Y&$(DHC/CF41L&0TF9&G%60)1A85IGN;XDCS-'%RF@9N+#$K8 M'%0>>`.S-]U8OH8^A[>5!\SUH\D\6C](YHS7+(7HL+PCSQ?!]DU#9HUMIAP+&\`C'Y'4&,.8LJ@'8*5NR(!(2,N\!\;B,T3#;RUO0VE!X`8LK`I%BN`$' M!&=9O-"//H:L%9>0[SIX@TON$FS/KLM)4"@3]"=A/R:J(Z*"BVF\7MRLLECY-^P%4Y_@_>`V2*CP1165 M39"#F(I&*[",[_@Y*&6AR6FPLT%-GCWK_!G7GGOX1TM)M"1-9AAC3KJ"U^RB MGPET-8MP(8KZ'U/[>?([[1HP]TT%%;HP\_1)![7)=P,KST$E#U.*64X]YF#B M`806#Y-*&YQ)XIVJ:!U4F/,9Y0%>T=18F`7><%]G9]C5F!VRF3DO=TX8H2"N MW=V=;+<__+5+N"LSM:BDU"&>.Q=-F9]$5R8&-:0&K4N+T:)=+2W.,G=POZ50 M$N&$ZX07<>.W(%L%`4W^0F=\PP.],MNPSI1O5G[B.(Z4ZT MRH1$C%.4[!A]:BP^EG^9$7_]F*HBYQ"L6!YC!A0_['YY_&-FD+<_*C)W99F8 M3<6Z,$NR?*+]DD-8'[C`%HM,F[@QEH)G=G MHXD5^928K5[H**BS:)39ZK40^^G@L+3T56K4I5XT'PZ$RA!KS3_#KE!13*V4 MRVR9]QGTA3>881OV79W%0HORI"H5FJMNIUBF?TCD/(^E7)D#5D8;EE3RMKTR MU1P1=1:54GMHQ"$0JQM*3^%0L0^7@*01KLTKD+7*+^H-A14*@!M9Y5EWE1_Z&K8XH*+Z!VU`/R>;)*;U1DPD,FTV270(7B*#^]9?_]WMNNY M#]B`\"WV0@ROZ:QUD6ROI5"0KRG,2@#T'AOQPLI--A/P#0LO3N*EF;!T;9KA M#?K8)PN%-A82('^I_/?V*.OWH(GM>UIR!?LUSEKT& MVN7RDDU6ND"['J3UO>;-;6FMQ97Q6OEJ6]?8[-NGP4[62NN6M=+Z&1Z`)V)- M:=C/-\]86_LSA1F>@$?X]ZN8Y+O'T][-N^V"+%>FO29(X1G'FI5BPE:_#G]D M10\,0=UT[026>(T'IFHSG/3'1X<\8BEDU(^9]\2E!2!XH]2$*(_8J"DHI<3: M%%J!0[LW1;V$`>._:%M^UEZ75V/H%/,6PS>'NKP2!E[\H3]L1_)XV&/"&8^# MV(4ZNT^!M`ZY:<)?'7=[T70==0`/"IT`61/DX!P_XY*W!+'$<3>M)4O_1&J-]P0T03?J&,&_W]`3GX2!C5D#I?83.?DCAG MF>U]W!:_^Y8I-#^7^Z+H*G>&[*%<`SJ>H$;A+.DH^;&Q_'A42=S4C-L+H*%\^BIR"%:)7W/!8-?&^W.11OVUJ;=>S&T MAVWM$M'6U($F5+1Q+HAWL/ML18A7T8\Z/R_D00^NMU[JSE\$>^&DX'8X[0OG MO/3/IY2L=T9%3N,SPF605R9:5CI55>H$?>J>N$1WI@M^P>L3,>T:)F+WSH9E MKL0Y)BU9]H08B'7[KO5B#(]10E?A$?SM]H%U[,((+Q[']2+OL7?MRQ<5BOJS M87JQ^SJG4JM76G6B9:<$\B5-`>!_M,J\\W_/A=WCU"Q:.-N8NM&K( M-^P=X^ZSLR4?3=26!#R<@#2U_0@$W*__33.U_R+NCB=]8')2G*C-UF$]6" MT'*8_6LVE&>"/5?#RHO22RVN/7M%:25`I^#58..UPVVW,;\LOZA9@8$LOY#E M%[L]./5.1JUSF8"DZQDD_39V!66Z^_FENY\E'24_-I8?"TCB$KS%-4_F+P)> MN=1Y^>+"Z'/J`H8/]/9@=!!@_PF#7\F7LS]+S^HNU7J*Y7NGC3MH'9S]?3"8 M9:-Z4@+B`"B,$\8CMD=BO@Z>GPA4#N>_CCX&U$]<'7T`PH>0OGFDEKQZ`;QZ M_(S5>\/]ZWJ.+EUZDS1Q/<71O;(35\LM*#QT<=NM\8^IJZNUVC\>O+PGNKZM M7H3M91%V7("P)>B2M2?<2'+D43FRT^I4QY'5:._X^0_;U#W#-+SU.6X#K=W. MV`;M(JLEM\$XDZZ:E,MY=,M2%"0_5L2/HQI(Y=*4ZO<&=@*U9LK:(&9:L+7. M"\D5CT+P-)N5!2G0:'%8QFJ?BP@K=]W%,_1*[!X;Y5&E95F=MD\U"]Q@)UZ0 MM/KC9NX9307?G8&V;^(9-KAOMSI#UGFXW>IO-1`N`R:A7#@&4G<0@C1,`RFM M-74<#D7'Q[%GMT`399Q[(PU/,--M-*Q]IINHYE*Y_))=O"3H30"]#CF-Z8C^ MB\OGJJ%NZN(5R2R3XE*"+F7.Z63.Z2CP\L4N&MPP=5B*72EV+T\`!'<>Y>4_ M733[UWKUCB2ZZDN`>[+4#2N]"^B%D.`FN'FK4K!KKJ%0D95ONAKA64$Y97> M5W)AD_`H65=6]31Z?WWEL-2:"EVUUQ^H[:[0'2;G1X:>.AHTF`S%+C%KMT8- MQ;NDY1\>7AG=Y'47:_)^VAID_/P;RYHMZT@NZ>Z5KO`I4H(.4AT^_=%`[?3/ M!Y^A5A-\7KXH":-VJW<^5Q=5->W9H51=9?!'VYD3HW:"5>ATJC5#7'4ZJN!] MR/2]FMT2>"9HM%MB-P/5FK6D^#QA"2]^_O!]93AU$YU7L$T/4DIKME6OM+XZ M.N!RTKJAT3\//-JMX?E<-"DE9RUN>LJ\.NZ=;DV)F5L[(2_=DQ<61LII7]B9 MGTD#T8"U)%SEA"N;_U.\HYD#@L50[$*F8V[-4Q+J)`#6"YJ:DDO>MBJU.XF2 M1$FBU%A+B8(3=%*ZIJV4@I,`H6/=E;8S=38;^`B[2+.*T1-7DK9[XJD^ MC;V6M&IJ=M7Q<*2.^WU)SC+(">:7UCQRE@_1'IIS;,AV:R3DB[QX@@U;0DD# M%T^O\>!()X8TS:0Z*5$*'WCYX@R1DBB='*6Z&&=_$)=VB;5F"@FO2K-A,M?# MOJKV7%ILTF*3%EN=R2DMMD,4ZA,!63^()-G.C6S2A)-*IT1)HB11N@`#CK=T M8_=<2(.->TN[7;7;[35*1:DM+=5A%TR,H5A-MJ1FAK765@>#D=K+;511/W*> M6G\6[@EPZ00;M"2]1.BE]4X17SO9+6I&"I1&\.-/X6/[7ZQ6.G#WQ/4<@_JC M'^@E8;3=@ELH^H$6B/>GA1>J.<34N6??B>C* M+E^CE[^YBA&_1TVY,BP8P?9=W9JYK]]$RY/$=7_RE\C$@O>[C=NUO]]--L>N M0U?DHUR/4Z0ILF23.K!)<`U'."4]F"332*;)NWD'K^P(Y_NH&T[TUZY6J@WC MGPR#`,N"7KYH8JO;AX7NR/[@95#RCL38GI+U^$C+#L+'!>4H76&'`]X&\*MM M/?&,)NH+;WYCV`/JH<^D'V2[-11+:9$M(3-5B\)=:EA?.+2&RTBA8[L2=[TP7NDN4?^E.26D4Y\+# M-ZFGC$I9]9V]7.G66EGH,V!%1CG%CMK9P%0.?7`5T!>&ZJJ=X4`=#(;!%H#O M#'AO:B^!ZUG2A:KHIHD_@%HU72C/Q"$*B1)Y6\HM3>"``8-I5453.P,V+GW< M<%T?]HYAP<"6A7L!!G\VO`4%Z&;E&"9BHMTYQA/NSCLX;\@2R*9XW*#" M%>PLY9^^&:YTKZ7D<<`SSPE0=!;U#58)EAROZ,07<253F8,*KW9K.,R:@L+$ M5JK;9DYJ/FLPG!%&(CDE'Z+9&[*],2?N/GWSW^E'75V_>PZ*9MNL[Y':.&X98KHXL<\]RCM[9 MKN?26,];V""S.WU-U^,;[..W)FR%7U^^^,?4G3AO[LF,`(S`_N_H3J&2Z\:: MT7\#`<;E5_@V10;^N"?S7UZ]8Y__''_Y\&=7NP9R7R.97_TJ*%:H%"E+$@=L M'*&G,/QX6AN2.UU(7[IDOK4B83-*$\M4FZ+"PK,577D@4]`RJ$P)27D#R@D3 M3%2`N01W@XD"`UY$MQR\C"J*[;BA,'=UDVUL*Z;<:"-UP/SH,;$>`X91;=31 MAC^[&POL`6SA`1&*#9`,_;:R`JE'QU.9Z`KG6SGVE)`9G>:'<:NK+`W3A%VE MTA>#OV)'"$@&US9IBI\]G\,D?"O/0.)-*7Y)@%&P&B["0R7X*I3@(!M@!S.I MCQL;:&1OKX1RA6,%6'?:/^>?"^&#VL^OJ3AM+&]D[@##:;\_`PW!6`4WQ-0HL2U"%P]LA"3Z@7Z/\3&A;LU"G8G`N"/#_ M9!WH5OAH-)L8OX($\93;%9(QSKITDTYU=Y&R@QDU=`5`LQXI->A!:P,L#IY,UGB[WE^L#IT7M`151-.:0V51RGAC/UETC$*=,H00\S#8LI MDCAF_MD02/Y\>NY%\XCAZ.ZG[!W`BC+/F!JKW-TY]SV?RAJZ`M9CFMPF="G# M7W:`!(/[IA?1@FY?:QJ><3,X"`$@6&Q-;0]ZZJ`_VEA$OC`1;GSBR,I(F=8' M,V$ M^D]'[=.BRFYY^L^PO[?^TSNI_L/XG*_!UDF2MPN.I/<$G@%QO6?<+D'O83(I MG_\>;6`]*W`"YDH./#=!7KJAX,P6(`'/1K*#@G*`DN60.6PF$(OPU@1@#70K MMY&ZU=!S0-[[)%BI?;DOD"/[ MVP`@RZ:.,0D$W*:+V]UPH_)?(]&TSXI2L':`!#-Y9+FR'7R&>6I5?HK#F0AR MV&1M"",%DRN*.%VG#(]SA@("99Q%4U3HT3#13:H1 MNPL2B@'/]E!36B))4'S8TZ"$DLK5]/F9AW;4&H4:RGZV!8]NM3I;[^7N'^7C M7J.K3-W@2.#H!O61`WX<'89LEM-)`7GE,F)FD"-R@%.M(E37*%X&-X8LX@4" MC6EE[%<+=%&$$@"8HK,8A;$-@A*'WS?LP*;5@FDCPN21[T"RQ'114;J,\^@B M3)/P1J*V+D+W6R+2DAGTFMC[D'L/NEOE8FP)8S)!_&W^'DAQ_!TE[8OCG;$/V@.'&W M`^H>8<1R2_I;-A6;H!5S+1B^HV;;QM>1]L8WB,Y$\1U\3T-!2!V`^@J--M1$ M4(O"[3`C\[B&49#BKP.#9@>E$QX2/:(5HQXS"NU]J!XQT4[HY\"6W/Z"L:DK ML49;]/0;,ZZ7!%ZB&1RXL.AI=EA&L)IIN-PQMZ%%!PI4\ENJ=)AK;J>^?!$M M+C)Z6;(@8,P0>K!?9MQ@8W9:(,,WS+6Y89)T@Y0:N2S4C>A33D8[P)@;>!P! MD7%;&C:W0.W01$0P,@::D:FIHX>)S.&L==GGW9R1F&+&.(.O M\\_*PGY&]ZN:D=C*!9)C^X],QM"(8N`JA(U/[\^*;XJ93=CVFA`3/0Z)5328 MWWY"58<):Y."Z3A@#3F8GH+)(BA<\7WTD$U,`ZR?&?4L3J<.[B/$=WL14B@G M/?991]>V2;V'QEF2D:V':5:PXW4>QT_18K;4H0U'`?>4AX,EC'7D)GS02Z1_ MIEO>6?:VRG8RP7RFF.4,8U(;#(^7P`^&_O@]PUZAI!5.OTHFLGI)GSA+P4K8 M<9@^$-F$B80I*J>X[Q)]@'DC([],"+%8$A<_\51*XT?+^"_/B*>^.5`84(!? MX94-EDM>!Q1/"X`YBE&KJC=[[7C9?JJ" M%A\U[+/"]W@T)6SV(V%00VI0X1:C1;M:6M2ES4P36Z,(EC;)%C/9=,SK]''< MIC*U+:,L13#Q"K52QJJ^S+*9*!^ARWQ:"Y6PG\Z]X?YU/0=%&I.,"/8.!2O9 MR^V&57HGF5)/T5B/F=1Q80`4!XE#T07EFZEH0>^)WN#'"(+KZ".VJ?Z10H0O MAAICHQKW')/<8#C]6!&%JA+)?]AHV*`=7$/Y%#;P.I2U1[W6.)VUM7;G<,ZN MOV3/HUR(>C.%.LLP,3"9S9HI:X.8)3>CJ7P!VJ62_Y)PE37JWS:C2!B&-RR6 M<,4BO'&_;,QG2M,2%RPFD/3=^3""R5RINF,:Q`EIWP+Z=Y(1<&QJ*PD#4:#=V<02R3>HH=ZDY[ M]$%28:8A^](R"/40TZ%]1EN6VB@P%8,4"V,1^N42$'0P4,2"3@'@48IFY!V- MV/IXI5KD'!+"^,O=,=;_TMR@!WHT+:TLM;2RUF'6`Q*W/]4AR4.!*4 M7,TI6BTX;4"'%:5#+)T_%M./?SDAWC,AB5W"\KU@(])H*=_M*@!FZ8\\4$SC M=G.,`*+IQ6.?\6$3=?,L7&C;GH6+Q2KZV8R6[2QI0IGO\&T4>OU9R`&?71(= M67`6A%_(=QZ^8''66/`GEO?&TK)C&4#)B"+\/P9CJ(#AT0):"T5$`X?-Y))P M^^`'VG0#MC)F'&%<[($X3\:4R(XI<$? MG(U+LIP0)TS+>VMCMTU'[(:CM;AJL5)^)@'4YXX$V$[L>!H`` M-6?F!ZTY)G0R#H$@;BDHZ?&RC+B"$U\0-EL>NMTP'R,%H9;RU69Y"T&J`FHH M2QV$L4@;HDX9V*X<.UB"!"DW(K3LG1]&:K=,M+81NHFJ8)CD=AF@80:0$SO0 MD`-HO@\&I14>:I[5*-6C+M+\GCP1BU_A("6XJ`3?J&G5'8`9*0BKRC`3,Y(])ZBSK9%N< MI7;5$3`2XK8%FB0&37AUP21Y1TW=1P(V#6F,>3%L*3$LZ+F0P*-AFZMT:7/+ ME';@]L^@JDO%4:R5FTEIQJQ]FD!$]39]&G0C8_FBEFU=3S%#S:0>"3LD.7V= M63.4/??+/CI%XB-+3>+`L%FN/7M%9XKB*&W,3MI[2@YM&#VG88,RTI(`L'1G M-H>S,PS[<>Z.A(WBSVY%/.;ZTC#7;Q1WO9S89H**H^[/AT0X@M7E+1N(\KL% MZI[CHM_ISM3_JZO*@V^`9.NVAZKR/_KT+VR1ADT`OP*=_PE/DK72'@[:&C>N M@=P&9D=^M9^8)LQ:/Z`BR)3R[%0_!\LJ8:H%T6=_PS;P",O_QOQ-RKJLI)\Z M-,,4TUXR0SQ,ZORAWXGL'_X9-IC#ZM*X0LB.9=1OJ1(93A3DNPJ90-O-YHHY ML[-$'/VWUP^2/^1^:^Q^&_7[L$\<;Z'\RS;G1'GP0#1[P8X;:&-5>8O9\*Q1 MPA?@.Y.RF]9I]P-?%G5=N2P1%@0^[B#;,7B)$&LFHB#!"3Q/-EHH8':M/\5W M(U]:S)Q&`Q:V&;V4E1MR.")!;144OY";,K;H/WW8/'2'1H^F;]7!.-JJO;'8 M5@W<@[7=J>U6W[#D5FWX5M6&@S MED#2#F1K7O`2#.4M,)!.2]AY*6(8RC5@C"B4FZ8>1^%=F-T("MA9\?=F%4R= M^8FEPE7@QHQ5^?$^SXD#MK-UE2C:H M+US[#IM6IG;[XHDW04%]9D%S6.W.6G?Z)J@NL7)W=4<]=%[]?/J(07%^?F4T MZQ.068*=-7A2V&Y5#QL>/4.":F&Z@&%%.&_;'N8JT;A3V*-(G&526OWSOGLP MB)I>IDSKDGDI+0N$I11\9Q17PRO)4L]4K[N8^SQL7?^9=IV#1T/\&N-M'[64 M$/IH>4[F9`\/I:2D/P"2TF7^)TOY2"9.(&S;>;U8K5A+0IOW:TMV8M65=V#L MS`S="D-+R-8\N<;C\6-V9P6KWOVAQX)35\&+K^-QWW1]QP7A2X&E[3O9_M^" M)VBODI#/+/.'HQ!K(OED`(T^P;3V:H$GR3O8JPJH5383.2`W9H[_2''"3&8U ME!%@\.E>T-7D"42U[;.T#+I?J;/=47G6%"*U!#%NP5JH-(:.(D55)C"&RQ.B M3!^+RNEK880P.BP3$4&.,9)@(TA/')IR,`L!^N;#^?B;H\\!74)=0MPW$L
B#'@%48QVA MD@V@]:BI2!8O;&:F*QA'8C MCQ13EZ#KB M'GR1+NU&?5EI?P)B4"N2VTC MTVVUP[X1!O:'>2*FO:(01RUA56RYPUO(@H3Y';O*8C\=W$EPQOU7W^X6S>QA MFH"P,?E2_XN$%$0V8/W=PMDBO8XE<-,>MD'J0V;?C/C9TV.=>&^SN<[^E2@7T M5.$XGK94Y2K6)C;X+=YO&D_;YX4-%O`UZX>,*8D&<",38=_(DZ[<+71G"3:T M3WWQ,/`,D*#.98P1'FZ^P$XW4=:4&AF#KA>J#7$*90/-NHU("0)A[U MORW(DDX3*!9N=+$+"*^07V"N&6&"C?`&.V`5HMAG;BS8O&ZL8THT&MX]$9I* M4Q,$+,X&*VA,@Z8OD<"+R;9P9A1L*L^-B"HV+':0P5JBD(L3(%"G`I6"-?&F M0HWV`@H26V-2C[?0`G4H44O"5;2XM$[BA44S'"'4V'#XX-JY&5D1RJ6\-S?_ M.3X&]3L$[[O$\^B-&S3N-_'X?6D?W]\H^@I71#=;REU(R!0I2FWF*17'K)Z' MP+D2[V0<&<"L>=D/G6%X)S$BU_&K'^X1'>9C!T4"Y@9Y5GR*=(F^-HL6D M\&TN&9/6G$,9$T>'#F;=.3;C:7YLI:-%X8Z&BL`.:4%[J-$&I\ MF:F5P'K6[ECMK:7UV)6T_K;$V^Y\]B_'\&"_H_L)+1C4HD/1G(1.H;T@IYP( M,;HF_P=67CL19.Z MLX-^^-QU/,.+2E`="K@A)^*5Z+.79AQJE">6]HR86*0*L#\&ETAP*\(A*]NA M%:ST1,4+0^%KQC);H!@)VY1>W(&*#@R`!J]'SW:#GMO,P4N!"TW*-`R"D?FP MS/]O@QV&Q6/*?9"EC93M:L,H;#\8:=&-MC&8#KN(>MM*R38[$NG8NKOX:-K/ M#_YJ9?*&[I$QXY9EJI0;$*1VBM9N*7&HE0?04F<^NYD$T5(0+]`]J'9&KW2Y M<"/F&\T->Z:Q"MZ7&*7`G-ZMPGOGV&'K1D__CJUQBW.C**N%AO-OZ/;]1*&I MM\F,0HH"JS!H:Q,1J`WKP3%T._5LGBJ\$9E@'.GQK@)HH!A,&<$T"Z;'T&LF MD&,?P\LJJ,'SW<#L"CB$X-2*[ER+%*?_YP-J<]K>%;E?7U%[64&VP]N^ULJ= M8],.TS`6#+T$.P6]>RXSY]DX+H]X]T;O`_7]$VX7](]R\0ZHS+!G='#7VQ9L MD5LMEGKY=P0<]Q8G$J=I,X`5!C3`4*7!\*E/S[(M=V]PU7:,!#NFV?8(A,T4 M,"<49]J>1J.67#SG>V,A0^5Q/_SQ50H]!0O,P.U\FVA$FAMC)EQU&?C25(3X MD'C,AX$QK;L57;WLK0FFT8W_B$U&1OSZP+WVIDNXTL?B^7!:`,UUZM'&]>!% M]%L;A1>3)UQ@G^X?$K>MV<'M%"N3NW]8%B7FGHDD\Y?\QD3'[X<+!TS%B)ME=P`*,N-=>-\?Z]@\GZ/F2"]21YWT M9DKYE;)Z8*AWVNUQ<%RV*?7H]86,^^.$G++(1E(QY&8^3S+%P1.Q'QP#B(J; M0*<'->W>,+57A._N\"Z'>`2*K3U`XA#8-E9(&U8\EZ>S!:N;`"2.']5Q MZ=4*)';-Z]S&*P)SL8A3(O&[QGH\;PU)PUVI(_)<6MV?L6L*,.F'V:8Q(E#- MAB8:)&P0-9*R%+%X4-*RXP$SI!^&)ZF_$V47LL&VY"NPGA![1$-^-T8 MOV!&`:&Z>7!@J^@JQI10[OJEP<+HA?@P<$+&[U*@<:\@_$K3CZ*SF?=2B/6- M2GBV30/@G''O/14["["3K^E52/!Z<'-(Z,XW+-=S?';=PF:/]H4!`M:9+NC5 M'4O??`P"G[_=W-PEZEO8GC31ARN+%X]3H3%N2H%&+-L>V`.=IE'&;WCWHM;Y M&8YVFLT-!/V+WAQ!VXA0IP[-<63?L^(,;#K(8FCLBE5D]MA^$>Q8)_FB!GSA M/=L9?/')6OE><$<%O?7-##@)V(/^1I5<5-MX2@;KR&.NF6LD^FN"D2!<[9]1 MU$HN:1Z7X$&3P2>_6]'Z!HP1"RO27%0,UBYI(C<]:J,[0^+QN^@E;A$Q;S5] M'\0.3WKA+G1X`'MWQ(;BW!@*,IK@9ZS0U<2"I+Y+SJ$HXN^0B\* M#T"YU.2*AIA%:CR[H(N;*-LE3"B)(JCBO>Z2UQ=A2C_Z@Q!!&K.(=)2\?(@&K()=-]NX@V?O&X_B=NW! M=P1Q$6!&@H1+B>T%1?N0*1;AR2*PJL$ED`YOE!B-EE13#NS/13#TBZ'P!=^V/-E=EE*_`H(?*/?[Q>9 M_,@W/F3#%=PDA'\!6[>T#O:H8`()^[7-:;FRK5QA`[G7"M_.*:@?OC"'K2F_ MPP8?NRYSMF-?59.W`#2B>?6(-:FO%=`,71(V9*9*&F8@8J9GO9:CHYUD/4K= M#HF+M7*6*&B4CO4.+J923[FEATFX9G`%M$6\')*DS;G_(HA<2":XOB)#Q]:_ MIPV%1.,A^%>S2W=2YH2[ZL07U3%UTZ^?(4!<%!8^LY'N.'N]H$>:-]N'WAL MG,40T?H+,ECS&@4'(U&?!HT/8B4H-471C1FEJ@?^GT[>:+PF+W$%=-IU)V$* M15;9;(?>7\]2%C#S!S@""'?]OUF>NHT"'IHK$6`6QD-7CCTWF,L0E#76Q32Q*6]DNUZ."^SA< MVM=CB<_KK,W,4O\+WYP!0B[O5_BHTV8;K!K"!)$4YH1,]96!RG0\+N[:H+SA MGG`,]R]*(=>-;BHARY5IKPE)+)&**P$3)+HY\3!VTG4#1/"7V,KEOR1J'L#Z ME[A!R1KFGT<]>8,&3I-UV+LJ).0ACI**A=6%WAE>ZKUI.RX!K@:2&E[P33T- MS(FNFU6#WN`5;"KHI[A1O89L?@>'!7(X5O`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`3*ZEV M2,%)?RCDS"N)<"]?G`'IAH+M]BHN.JG^$F]9=W)F&7:USH^4=2?G#;I,%)=U M)S)=7M:=2'$B-Y*L.Y%U)^MJN]OX M&P4P^M1K/!9GE)7<58=BC7V+YEE=9NE);]SXLHVK@5B3S#KB<$8;5U,U,:VK MZ,:5Q2>-YI;>8,^DCY1R1+4&09A:3=1=`.1/VX M*W:KK"Q"J9QNL@Q%%CA(E,X3I1IH8;(,)?)2B#7(D`45=-3AN+1JBH.TKH:3 M[ZJG=ONGJ$C="_S,I"N.I;U M*!>$=5\=#H1R`F4]RI%32FNLHLBO.Y\4`?4#,KC*#2+^T,=R7\ZBIPS,), ML#;Z(TP$<.GP:I3&@3X1PWWY(@#)LCW%1R_)9,U?H@>V9ROD23=]>$6!V128 M:VX[\,"4(*@&0.RRL]UME<#MH2Y!OS2L&;'"\J7-+<#^94M8VFX0@&J,^Z/@ MMKPQ320C4O8=\)!N\=S"44<;_NP&*2>X/L`B*-5@K2SZ^.^6@:OXX,'*,!9Q M_8GKZ99GZ"9R&AL9%\BT03R9QA,\KKLN@6]TAZ2.TXK(\8^??/?Z4==7;[CN M=D]6MH-L]MYPIZ"_^0[Y!N1X:\(&^/7EBW^$CP,8Y&\?WOCPA&P1/H3LAP2\ M)_-?7KUCG_\[_J=N76,S[U>_9BX"D[9%Q2",/L$/7VU@:*W74B)P M%08O)<$D%""[>*,R-1W#,\@[@%GJ,RPHR4'6[ M^!OLH[EMFO8S2F%VH#ID;H)4=^DF\VQ/-Y45\!S=GG`N`%[7S"MM6*[G^%2" M*K;OX1;&$U'1/86G&RM=3540.;K-,_!!J4'$RW%;6;I(J@9"Y_CE%9OCU<9)/>B7 M5!=;70WLY>2(#E)AB3'K\;$M4F1P.0N7GMQ[ZDLTSHB.)RC_*,#Y)3A%8R0I M/MI1ISN>?S21:SH<_!@W'.W5KO*Y2C)M#W17!\.,@]SR/OKGU'%?K'-';1*. M2R3#H*>.!D)Y:"?./L;/_](=1[?JEI3853O#@3HX(/VSKA$>3>UII6-T;`&6 M&5>^)V#`&%/T(K@HU`3/P":'YX>P\]O%+FZ_[+R0[E#M'X&`50G0N@H<&25O MB!"-!8N^41]1X)2AVB'YVS>>=).D']$G#\%5,7K\U!RIW6%;'70NI"5AU>0< MJ'UMK+:[I84W]]U74>0GYD(NW3L<]SW?.1@4\]9W)JBW-];L`VRD%;I8B_B2 M(Q_C3Q:&P,S]@J`Q-^F>WFCJ%'"-_Y)K?8:/O5$LVR+!]YY#O.D"OT,8V$H$ M^%(',0F0I?$^PT7%C,>8(B?U%0W_V+X+;[BOL]V_-49Z5T@[W:$LC%!@['5W M>Z#WA_^H7NCL[;ZO^VD_@5'`=[:?\[@XN+5!^&;E&*;2;5>!;MG.<#%S9&^? M9E$:*XFS,%#4Z(FX^5O@:D'PDK_0&=]P*^6DKG))Y6,XTD^W5VHC>JY\2_=G MF/61E_%4`-S"6.WN3W;@K&*KK62;@7DY:.CBSU#Q/_J@O-+`/"IJ<^,[?A;Q M_N_SY`$)DY%#.\MZZ.>EX>Z<^P(Q+,QJS!6UGU^!/L7,).+$#`":%F;/O6
%&'73?^``OW30=L9'>"F/ZZ@20?BLS[!1I0VJ-$A!YR.C-I0O"+Z MA-`>$ILY_9;_3'27+.!P5HSERK&?:,YN9CCO"'NG04M>`JS5[O+LHG8NT17# MNH95?P050L0_'`5,!`A0@1D@O&P5P5!67;=<@4-AZ&ABF1/[T[,*D7Q:L=4@ M"5MW`9L.!(O#K5(]ZJ>CY7`@?G'\":'M"L7T:Z!.9 M5@3'4@W2`]RJ8I&T,WF?5(Y*=S^;*'WO\32-G1[+,B3`OG#T>N7EV,CE*`Q' M?U!,).<1=K^:['+3/A+!*K$<#_.X>2E%((R2FW:G'Z47RGY8KDQ[3<@#:P!` M\YO>8I'HNUA_@1MV=1E-AKHG4_O1PNOL[@!+&YYSRRNXKJY>EG5ES&G*^*RS M@G>&&W8S8)E+;EK>TH0N0S(9:)++//6H:2WMKM?ZU;2>])ZN]/+4;PN'[+SH MZ3@8U9`Z^]R"525"LGZW<.%U!-))*K`E76M7WWM!*R@KV\^OLOTLZ2CYL;'\ M>%1)7*(^>-3;7B7H$O0R=E75?3CZ'9YP^ANQB*.;U+&LSY:&9;@>ME-\:LA% MCT$3"M$RZMHTX2B&]E"PS>V9H*VI`[%[<\X%\0[6!%>$^+&N0X@";BG7Q*7@ M=CCM#UNV>.KV`9G;-6T@T#L@'[FFJ&CC,\)%[,[6FJD3]*E[XA+=F2[H1IZ1 M)V+:N=EB)^+_LV&9J\;?62G6@Z'6BS$\((^^3D?PM]N'Z(9E/([K1=[SV;5" M>GJ],3D?I>@TF[?JCG1W>^SIW?FAS>RH5E8EQ25VHQ.J!'KY0E(OR7E")922 M>$>^7%3V0&S\:2U1NER43JU<;76J='JTAOY9#><3K$;#BUW?HS5YXE1?FD5-/OV581%G25&F%8(9TSGU=SP1[ M?H5E#$>_;FN2PIN3X$=9MQ`,7L/,?%FW(.L6=KL^ZIW%6>?\>DG7,\B6;>P* MRCSQ\\L3/TLZ2GYL+#_6YH;(.F;!%P%/4J<`\J?.^__P?47HG76PF9>*82EK MHCM'O8BS5-LIEB:=-NZ@=7#2],%@EHWJ20F(`Z`H3IB.V"B$>3IX6A]0.9S_ M.OH84!]?"ITN!R!\".F;1VK)JQ?`J\=/]+PWW+^NY^B\-9"*Q/441_?*SO/#R'D-%J3UA>UF$'1<@;`F:9.T)-Y(<>52.[+0Z MU7%D-=H[?O[#-G7/,`UO?8[;0&NW,[9!N\AJR6TPSJ2K)N5R'MVR%`7)CQ7Q MXZ@&4KDTI?J]\63,B#53U@8QTT*M=5Y(KGCL'.3EBSR(FLW,^]+@'`2B(*YG M+<3*77>!U+8RLLYVY;/%L^3B(]],/9!7WKHA.6S?%D1!5'2+!_-''6WXL\LR MKWF.FJ)SG&!LAR:H[9&6ANUUJI7OK-E8R@)>A-`KT.V M7SJB_Z)/5Y_OV-3%*Y)S)<6E!%W*G-/)G/I2X`;DA_Z85\\GA:X4NF>Z_=\; M#IEZ=FYFT$6S?ZU7[TBBJ[X$N"=+W;#2VTI>"`EN'A\=\JA[U7)!;4Z!^B[$ M5]O*ZW)RYFRH6])L;>*Z??A.G*F1V\[BS#D77>*./O5\W;Q<(GP"&AB6:TPO MZA0YE\*;H)^":"-`6<4DB5DM,6DO)4G(XH2\S:N3-!H]T2NVJFUJPEQ><)BUOQ\X?O*\.I MF^B\@FUZD$I:LZUZI?75T0&W7=8-C?YYX-%N#<_G[D(I.6MQ=5#F763O=&M* MS-S*"7F+F[P!+U).^\*N_$P:B`:L)>$J)US9_)_B&\T<$"R&8C?\''-KGI)0 M)P&P7M#4E%SR^DZIW4F4)$H2I3I92B]?B#=1"UH$7=,>0<%9@/"QMD';F3J; M#7P$SM*CWB)6R[;/?%4G\;>=%DU-;OJ>#A2Q_V^)&<9Y`0#3&L>./,&&+:&T@8NGUWAPI!-#&F=2H90H290D2G4RSBHRS?X@ M+MX;AG=[D_`2,1LF.T2=/A&0]8-(DNW$LW=LN%--BXK[3;5;O=7J-4E-K24AUVP<08BE5D2VIF M6&MM=3`8J;W<-A7U(^>I]6?AC@"73K!!2])+A%Y:[Q31M7UO%Q.[`RSG1K') MYFCWQ/4<`]V^=-P;:[;QS>^6X37MKK$;Q?672]2!0!W":\3">\4<8NKV$ M>"KL#K)'[.;@*D;\.C'ERK!@!-MW=6OFOMZZ72P5L:"M6D$L-IA([$ZS<;OV M=YK)EM!UZ`5\E"MABK0"EFQ2!S8)+I\(IZ2];R332*;)NV\&+ZH(Y_NH&T[T MUZX&H@WCGPPUN*GM7:FR*'MBET#).Q)C>DK6XR,MN^8>%Y2C]$$=#GCCNZ^V M]<2S>*C_M_FM4`^H`3Z3#HCMUE`LC4,V0`34SIR0D7;EIP,H/GYV'Q-E"7%L(N)CFKB5Z7&F_&N/;4G3BI(?([ M?;TDEG?SK#MLH'_I#@WHHJ.93GWCNOZ2Q.(%9\EX6M0=I,?0QBT\#V M7#<P_B3%&::!#_*>':-`S?\`(JFA)/H M2!C4D!HW*\HK&P5>JX M,`"*@\2AZ!K_)4Q%"]S9O<&/$037T4?,]OZ10H0OAAICHV*!QR1WNS7XL2(* M5262_[#!AC%,L/%J*)_"G(!#67O4:XW365MK=P[G[/I+]CS*A:@W4ZBSC#;C MR0#[?J:L#6*6'-^J?`':I9+_DG#-='M5X8Z*EV]@SB3-E/QLZ!,4EP9QOQ#= M]1TRN[7NR=1W'%#$84K#_=VR)RYQGG"P3];*]^!GVYK"6W2^^KN[OJ%#B_JJ M`"6%.856H"P16I9AS6UG23%1](GM>]3_A:Y%W>*.BE%'&_[L1OXOD]-LK>+I M-%W`+RY]R[;,M3(W+!VHHYLPM.LY/BZ7LN2T570OX5N#.14GH+8R07(KOHN? M72"*,0>I`F_[L16`46$)7.7J,WDBIM)]C4-N.O9WE9?LX1@;G=0Q5FY*VRBX MVONM;N)]*R>]UKM8(E=?L!W/:36RW6$"5G7>;FF=OF'Q[0J[S)T3QT6W]-4< M>.JUPIF]W,.BB(V)CS4H74)L`6P/I-?5HPX"[+5BVJY+4$Y.37\&$@PD"]$= M"]Y-,S-/N!R=4J^+/F"]`'0,H:<-ZC4'-ILSV7>)Y)\,R! MGRR25TES;GDP/4WHPLMJ_TW(A,A3%`JTW1@+Y7I6 M%<^OP@#)J$\GCR@.[\G*!AZR'C]%"O_;-?^QD3:,RZO1C?\"0P-.U`19P2OV M#(_K&>P7C\Q4Q8;O=,0<2]-]$VR'R5J9H)5!7!B#4>"@@G3&(;(<79:,)B&I M8:R=&A4FW?6Z637H#5[!IH)^BN2&&K+Y'9C-R.%P)E3;>:'65+BU4'M\3`L! M70@%?@<>`'U&K[H!AY083><4N5<>;-.GX9++)<$[VP'K"+MJ2&%1NK#8TZNU M)WV_+3#=YPL\O'"5#Q9Z9`LX,YJ:1QCN6>7J[O9!]#YNF9J9`LO5-TG(`:B0Z8>R&/7PY(_C+<8 MT]1,\L/I7S@8>348B`?Y:]9MY:K??!S.I^7)E:9V.D(]\S/6XQ19PP^ZR=,^ MEKKS%Z$Q/MS`==NUW>9S_%6GT_@^3V>T:_NC,CCJ^*?LK;<@3BPBCW>C6F[= MCMDS8I1!1TA%J^.VO1IT3X?#RQ.H'@=M=IH@+;^X5F@K$CAVHUXD MP:Y6KC11AUHU#AC9ATS2[GQI=]4?%FOH%!+@DG9KE51K6K^%HF=;5=-*E"1* M)T#IU!I6+,6>&YYRA<5((E*ZXN)"0CN%_0633U'9W4!;= M#M*I&DY`--;:Q:JI+I/SKH9B;D(QLF54U;"_3U>AD0S1E5:2P<$.RQ]I\6-E M91HIQ`NJ>2XHSZW668JRAN.\02\AR;*D[5O?/2`+/'!8F;0N"SRD.)$;259_ MR.J/9D@2$2]]V$5`I"0D`I_5AD1_TR*1Z,_4'NSA'Z=IT'P8G4K9]2%0LI!$ M%I+4BY!G74CR\L61J7DII23AZ<']<;U14ZM)M#9_?2`8!6EX@4&(MZ8.>U55 M&-0;\XLJ*`FQ[JC=L5C4=:RI MW8[0D54TD:HTK8%91PVI*^GTRJC<.3&K#(4:.M<1AS/:N((]9(MNVS+/6EE: MK#=C`JHS;O!":ZK"V1]1&2=C6FW=6P5ZQ=]F76EE1( MM9/H5G75061)@T3IC%"J@08F:T\BO5KL0AU9`1!X8B75#BDXZ0^%G'F2<`'A MAH+-]BHN.0E%JZPZD54G9Y`=>9E5)R]?-!AXF2A>^BZ0=2=2AM!3!UVQT,^Y8'Z992<#M2?63EV6G922O:ZVNXV_4P#C3[W&8W%& M6VJH^->1R0+4&01A:3=:6DG?C'2H<44FCKNBMTJ*XM0 M*J>;+$.1!0X2I?-$J09ZF"Q#B;P48@TR9%T`'74X+JV:XB"]J^'DN^JIW;ZL M1SF(<)UNA1M6UJ/(>A19CW)Y]2B7`[I,'Y?5*#*)7E:C2'$B-Y*L1I'5*.J`"E7$:U"`/4M:C7%)-A:1=[6D' M(G*0&QR1U2@GH)NL1I%U#A*E\T2I!EJ8K$:)W%EB-K&L"@B<"6TQ!Y4D'"-< M7]7$;O:6A./.1-%H1M5U*$'<_CAE*+QJQ+-7=*98D`T+4X2K3P*:X%"E5)\` M8.D'$H>SW>K02A>*,HOB?&X\T`?4S`HCJ/1+.\-=";^Z"ARS,!.LC?X($P%< M.KP:)7*@3\1P`X`LVU-\])%,UOP5>EQ[MD*>=-.'%Q282X&9YK8##TP)`FH` MO"X[V=W6OKS^CY]\]_I1UU=O'J8+,O--FD#M7U^^^$R`.9^H[A&<3]P,G[$:C[#I;&]^A0M_,/ MNF/!\.X=<1X6ND-NEJ`)(>4M7.![,O_EU3OV^<_QEP]_=K7K?^K6->;UO5)\ MRV!/N/BF^TJ9D:FQU$T7>?=7;=#7QNUN-\*N%-!.@NN?!6=ZNTX?X.:[X?[Y M+]UQ=,O[0I83XNRD:D\;#`9#2=0=1*52Z'9%LS+WI&R_/>B-!@-)VAVDO2>N MYQA3D)B4R/M1MSOLM]MG0-KN3C8:=8?M0:=S#KC61^QU.\,S$7O5$O4@L:>- MQOV^)&T58@^E7I5B[Z,/3W@^_&3-/AK?\9/[FV.[;BJY;MP_;^=_=MO7-RMG M4X?[_>%]'/;K[JM?^Z,$\)ES%08H5;J6!-`[?65XK,"5T19H:<^]9R!G:83J MC(8)P';-619\>].M,S@8OB_Z=&%8Q(&M,?OPMV^LT/(HC7+:($FY[-F*P[0O MM;3A^`"8/A/=)0O;G'U:KAS[B5J+Y6W%3@*B[+F*0[0OE0Z!Z,Y!R]Q;WYEP M\,>IR;*,RJ"3EN3T_!G+@6U?BI4+5FFL->RV]R/9_LM9&I,-!_T#8;N93OVE M;Z)?YSU9.3`J/5/ALTGP`[P,IZGC&?^EWV<.7(J0&R8I7!9LQ\9WWU7K=KK5 MXQNT*V"*&V8SO8NY'#]PCV,:-MU,/U8:!_8V<-EKWFH@_3-R#WY8KDQ[34") MI([1]*'YS%25O"=3^]'"$Q^42<.&YUS/?;MF_L7/<+P%.B[1G>D"J/Z>/!'3 MIG3G(&YIO"GDNA[5B%J@1M.#Z*WO`H*NR]VF3)V/=;P("]:#$LD],%6,V2^O M/MJV9]D>N=;^U"Z-57XCH!+I)N[=V=*P##".=#1K!)AEV-8NB&")=E-!HXRP M)%Q0=(H,ZE2:!X M[ZJB^ZDV1,OED%R,#V"9QB">+SL/P+QW.LRSPZAI]NQ`ZYQN2V]&E>JO?P[K M1*UCZI_]B^.5$A303G?3,C]KBI6J@5X2JQ730+7!"8UB,:%44`4=7)P0.@<= M5(Q%RM9!ATU!O'0==%07[7M7]/"4A^0&I`U007LU(M8Q-=#QI7%*"0HH1K4K8%J6FT4L6.KH%JG+MKW MKIRL$`G\SS;3^2FCWA(&@+6H=-0Y_>W71B,[NC(Z*(@Z?7"RQ[QQX@F8L=%8>(KB260BY)!K/$%$RL[:))!K&,*JY,0BPGO4F26=E3. M8H#7AEBB,BO>X>CBB"4JL[3V!1-+5&:=%;$"T_0/&UVEIN&M&V4V=E[]JL%> MKVA!THE3A[6HA5VRI^5(=\VH5]7A)1>I#./Q`C92.>8C9B2UQE4=`;F0UXA> M^VMCDEYB"AG;B)=.K_UU,L9?QSU<3D2O4DQ)QE_:<>EU$B6V'&N2T:LJ-T53 MZ"4JOXZK2-2/7D+RZVSI]=YX,F;$FN6;E/NK$94?BW&`3T\=027KPJA34W?$ M9:[#_JK:A5%'4)&];.K(/7SX9+RI_JWON9YNX0U-7WW$5+A!K(O#;U_K,AH, MVMTRU.`L0&M`A3_?DSEQG,Q9_V5XBT\P*BR=KYN,+6&*+5#<&VMV9[N>0SS# M8?`2B\P-S$K_9GB8Y!X-0YGS/;U0RG;PS2#_?=\+$KJ]OER:ZI;FJVV)KDA/ M2Q;YGL^""-PSLW5OQSE2H:$28SR42U,KB='N-4AB_(9ZE/O)8M5695Q*-=0& MG7Z)Z"4FF96J5["+NRJ![Z2(-U(\R-6H@4BH<@'*$C-_$-UAB9%:N3#$Y,N["_Y51S'Z,]8@)HW\1XW&!`NN) M./HCX=.2.\>8IB?6[+@!^,\5#W;V=1N4B4)%>L\QCXQJU$(AHDUV3SD1/J7NR5(W,"T7 M:>3H4P_4-6Q\U]FS"]^PC"Y\AT-9W%WXX6_?\-:?+%!E?15@D&9W)?-\%GS[]\#F'F`W5!9PSP3PY+?:Y`00MRT%5^7L[Z%$.:R8G2=\L8@31>ML$J036 M4CADI\3[:EM/U&BW-UP=*(>A:!;R!W! MJHA<#\>GZ-%1._+QM*&Y4PGT7O=(6.%9A3ZPPVU51C"[1`HT:44.9?_,%=FX M'KT.^%=78W$8Z;-;?>3S>;_$P+8@'G4C878_D!TD%`D3G#<)V30%M+8-4WK4*Z$.(AVV$^*<'RCH#&J, M,V\:%8_'E).UV^T,!P/,WRD=OA+J7?:.]E:9(#$L3)P#\3B.'G-`"#V5P!__ MG6B#2._M3`MAUP6)9E%W.T&@]^_.%ZW3".KB*?W)=7TR>^\[H72DP+@W4YC= M->@\J9B_\UW/7O[9Z5U_T2EK:3LC0)T^IE?'%>!](2@?[-'^]1.CP6;H2@1L M*J)@Y9>V1=^[\YWI0L\3B;F4W>WTS9VP&$2I1-MA[[3W@&@'8>E9G;Z-?G-L M]P#^W+S,N__JUW%OOU7>!4S5^&2MP18^W3K@4\K2;-6B"X-1(1+[KD4'I_?UBMF?$3ONZL M\:'-9_9,46"2_B2(;EG665B"(F>8N&P'XGC"Q=P;Q\M8R4W];M].*65@EC!H M@O;(96LCXTTP4V69.[DU*[C'<"=7[7?.4`EJK*E`688T$F;G8HQVE%=;R)%ZY ML4)GU;$.R#PK0!CH$V`J*-(R+82#<`WTV/3WZK"4&PIW/J#'0JG@FFT:J;N1 MHHO[R9JRDGG=C%L4[VS7.^$*)?@O!\3JT2BX*IHH(@FQJ;N+.V+I)MY$4=H% MQ/G3Q+D]8!;8W_?H1"P4RT@ASFB#9?/F2ZXT'"#O"?OWDQ6\EA]8VO1VYT(V MV%JV_!D+0[=WV.MZ$#"5('@!D>^)"4P\N],=;_T-'G/U*?4Z+VT?'>I!9@@ND$Z'&69'QK8[QK'O:J>;<` MKEGJUCZ4;'I7K2PS1EQMAO,Y-9#UH*()VS-<^BVWFAW M?NED++*M-_IS7SHI#]_6)8G')V+Y!/7XV`C[:83Y.4.=S2V3,5%9T.1G\XA" M\AF5G2AU"],6]RK5!UW?7A%8`UC7_\#F^&;?.C=/NF%BA?!'V[F%'W5,":(3 M4`Y@4NA_B#[[&XP!+UK\7W'`Z_;P.IX\FP;8B0#_K$]L^,YV\"H[:\;P>%B! M`1-#H'?='M05@7>VLT(,LH@/L/?$84<#@YIAV,/16R6AU._"5E^$"G'?X$C<5[:0*Y7[@%[P%?J; M]LD(;,SM9V3RD-\;*$YLU6$E#G[N7-N>:M9-EP0L-D'9RUW_E&LV7S. M/"$L-[,93??2S9UDR.N?DTF(G$GB:_#6=PV+N/$$-)P6>!`X!3ZYQHRPX_+. M]@A5=*E/D"G,PIZ^#7`C?VYLZ8J!E%!([;5N>FN!'9I+V8W[-Y.C%YLW%HJ\ MM0B:,:#XS_8Y.0='`>J!P/,S`;A&HWWA"FPWKM@'+%O0:$!?:&>XR5I9<^7` M`X,#QH&!*"@FTKS^F\&8W/ER`>/_3.U'R_AO1I16Q.8;C+1\R#8F+!FX?!.P MJPT/!BYF,_Z6'8W+/N'2EG$S,V]KCE#2_S]?-XWY&N07Y_XRID^X^;=G*#;Y MGIF5.7,'5&&D@%4AQA,J.>]\6+/\T`3QF"^@';F.Z&KZG?+GKC$>6)MR58^'<:VIH9IT&/O'J^@QZ2MM[IKN)\- M?0*_<+\1;`KW*]DOL!G._W8=?OP?`\Y69[I8?P9^9CZN\#<&"_VANS/`F>Q= M42&JJ12]<5U"W7G!*P8V(&>0;N`_$\DV2?IL>F;V_C8#DZ%4)9_<'U`"Z/ M1*6&._)'!!IK;D6N\R8K#-%AT>I=(`4KA$;,[?P!U@*,FG0X-OK"_/G@P;C4 MH<^-BP?RR#S^R#N_@X%DVE.<.K2W;Y^(LP";6U#0)6&K%&HTA6S3F"'8^T"I M=3M)1\<18;T#68UF*&IFM];4-NW']8-M^E3[W@?X?F=T*MCI86/JS(X^"/A1 M6RL/^$V/9C-86PQJ4=;N=@?#4U&X,&MKO4'W5,`7YVUMW.Y5M3.[#6%N,:B% MY7:GTSD5A0LS]V!0HN@3@[TX;_?+!'Y3KVT&:XM!+2RWA\/VJ2A[) M@"]!;@][^T)/.PB$L2FP(>TEX+%?# M(V0*[YEZHE5\-UV/^MKQ%NVX)L!UIS';'[T[QYX;WN>L_DY'MK.T_C#IBHK`JPQH\2-H..P> M&\C"O`\'IW9LH,LP>[8*R\6!/K(U`X9:"92NV$H9;$J,(P!9G(>[O=ZQ@2Y# M.KMT^\<&LC@3#X9'![HX$P_'>>R0TV_HGLP(6=(L2]9YB/74 MC5H/?;(V&[042Y:.WSU0&D@G03(O00N0'&OCC+J6Q]R-UJ=3`B"_<1B>V!P?B1DWR3A_"*/;J(W M[<;P4:G3=.KX9'9C6;YN\D*0D@J(HJJ<73-%.8V\%.MVSANB?[-O+?+-6!+^ M`H"?U_`N2E#?<>O&*)[:N,>D4:.@<&M%]5OQK?7-_D3OZ[.=TKJ5M\'@Z(^" MKD'[SY_6&?R>K.*MN@7[A);4-4RPW7D&S&6A=]Q6HVG=TW,0#/8O;%FVOO=D M:NJN:\P-,OMF?]&M&:VL-=2AG"CSD;I12%$:D*1@KWE M1IO]TPK3A"D`<1[Z;"P-+VH65[`)'>7`!`DHQ6FP2QMLACI82!_4=BB$6B,T0JV02JCMT`FU1BB%6B&M M4-NA%FJ-T`NU0HJAMD,SU!JA&FJ%=$-MAW*H-4([3(4R`:)#7-MWID3$]Q`! M]WUI`GVLQU]>$>OZ]X<-DL6`_#6XI"MVE1_A3;,,5W$7]K.EN&2E8[S;7"NZ M-P``%0`<`&-S8G(M,C`Q M,S`Q,S%?8V%L+GAM;%54"0`#LM]`4;+?0%%U>`L``00E#@``!#D!``#M7>US MXC83_]Z9_@]^Z-<2`N3:"W-IA[S=,)-_+QSOGFKIA`$0X][+-$(/G3+$8.S??ZU\P3($Y7Q9] M.;*KDWB:_VRNF/B;?GA$'1\XL MPB]J8R$FG49C.IV>S)Z9?T+9J-$Z/6TWE@UKBY:=&<>)UM/VLFVS\??]W<`= M0X#JF'"!B+NB4MVDT37/S\\;T7]E4XX[/**_HRX2T5S/ES+A74S9@U(='&#H1^XZ83^"BQG$P\978T7MC!L.+FLN?65W947Y' MU+]<4>(!X>#)%YSZV$,"O$OD*Y4'8P#!:X[J_?-C[U4%=XR""5;MI>?RZ6A^ MXM*@H5HU#+IK*(%=Y+NA'UGF3HJ7$!QF`F0OWE)TU?&>>$?CA;H)=KY"B+*D MH6)N$0Q#Q)\C+$)>'R$TD9@T6PWP!5^^HTS:JI\V8TA^B=_^VN5<+C+O'4KYM_0_R"?"D%[XHKQ-A\J6[Z.%0Y@&3 MH5M&[I!+(>E$"8#\FC,%/!H+^:_2(>RZ+@VEL(_@@A3\V8=/(`S&G8[,?L#T M6LFUAK])42L8'/ M[#'P'4;/V,<"@T%(3VE`$2&DR;#()*().EK'W!;4TG,Z=K"0!9 MEM=,!HN9JIAKT$EI M7/:#1.QY(DGRUB'36A]Q`&6;.F5%9%M-^Z;Y%0T"2HR@V&I:"1RV%;1O`C\Q M0#QDJ M+]HN-!H(^5/M^_"'X<,$6,2^6/'43@P.5DZUDS0E;\D/D`\\7I8<`'O!+G#] M)F,6A7DQP?;`4.]\[!AL"61`=-1:CAS3+N>KB>[[ MK9C*L/\30X0O[(1\8P!RJ"J#0)[V-A9#Q6Z#C.)2(-V2_79;TR0G8[A<42X3 MX)TFK0GI$2-NIED3`\9(_WTFFUH<=IN\1K0506(_$[CD8BU0M?DRK;N63LJG M4=5+K*J^/DM#9S-\E>I?42*E M#J7@JR6\2QA2%F\4/:$9\)N9C,92$TP0F_>D`7GZ(K4&\D-R/>)X*<&8F;%J M/:Q9'HJ/8*9*S4GIYHV2R&2[8_K)-($W(3@HZO:%PUB&'5AL:A[&Z\39D20\J)'(B/;WTZ/5C$>.W?ADCQ*DSY_E7Q[C/Z@J6& ME_//4LH>>7WXZE%/N>G^EP2R\!:#9M*[OH8Q. MNFAU^`JN8?&[1^)+$U:7;&65XYB05A0M<]/D[U0?!J7X5JWE4?WE5F;R>BUS MY,RZ^['0-#1A_GF90@CO;?EQ0YOD%5+Z=4@]:451-C=-C.CO-H703&>SO+RF M$**;M#\%(5UD_Q'1';+1#&XYW:#NW%M3B%D-VE_.%BW MC/.Z'F`3J!F:]\B+#"%O7(A*ZZ3DZU70/'K(>*)=]]\0,\B\RU"C78%.CKNS M61#(K4M:"A@K?VVK_/+!=`/<8H*(^\:1G-;)&X^%2!8N@!?5#O0X#]4=[@_# MU3G9^'H)M5"E$O2_$&,2!:Z2>/40#1(4%S)&[IX9V#>J-:`FC^WMS\CV%62L M*Q=+?C,#YF+]03,M626A-C.(?651Z3OG8/44.J:E?[Q(QB/) M1Z8O-,@A+/]C4C+$B1;B=]%C07C4510S<(P_7B`VA8UE%'?**:F[>WK!1`:; M13E1WA#4$%40-IT);"RCN$?N&!-@\R)>0T-40/2ONXE'O_"WO[_-O+-7PC@-_%_? M==Y_>'=&?"=PJ3_Y]=UOS_?GO[S[^W_]^[_][3_.S_]Y/7P\NPV<:$;\\.P+ MM!E3XIY]I^'T[.[/\]\I^4[8V>_)6&%F>W=F@_ M,]OYQA6S7EYU+Z\Z'\\&C<[Z\Y68N.E9/UU=PJS=9F?M=*Y^^G35Z=0QZ_,T M8EN3?DPG[5Y]^'AU68LRR2;]"/]=KB?UJ/_MQ>;D#+XLG__Z;AJ&\ZN+B^_? MO[]_>V'>^X!-+KH?/EQ>I`W?)2VOWCC=:OW],FW;N?CGE\>1,R4S^YSZ/+1] M9]U+#)/5K_/ITZ>+^%^A*:=7/.[_&#AV&'_K2KK.QD@4>&9'RV_/&WX<-^-^J'%RZ=72S; M7-B>!S,)&J["Q9S\^H[3V=PCZ>^FC(QS(:;S"\I_$C3_18QV<0`U\#/QA0:= MNV1L1UY8(6W[8U=$:3"SJ5\/H^2$- M%P_^.&"S>(EZ=[:+SIG:LSG\"P_@B.(%D\5[)YA=Q/BD`QU(Y$W@NR`"XMZ( MJ3WJVB%QKVU/+,.C*2$A+T2JQG"'$MQ_NKU[&MW=P@^C_N/#;>_Y[O:Z]]A[ MNKD;_>/N[GDTL!DP:TI"ZMA>,>H+CGT@E-]\.X(].F;6/M=&(?Q?B)WWQWWX M8&)Q%Y-&J0D:`W43S.:,3,4"\$H>`UX7MOUYFH-H\^F]%WRO#=IJ_`,A]=G$ M]NF?L0K\QDE_?,=#"BL,X;#H7-NY):%-O6*PRLYQ(+0!"T"Y MPX58/?^(Z%RPK@SYLG'J(_&9O(51P65,8[@#"1Y-81T$D1%W8"]B72S#T?Q1 MZB*O4PU]G=H([%9#8+66IC+C-P^IC&0.F.9@@)[8;>'`%RZ>87AN._'Y MZ"`P6D,>?**?S6@8:S$P"DX.(?4GQ'K1#N4WF4]L+_-7XA_!8,=:!I'X6'\D#S#HCRX'#$D3FCW(@>?LV"FP:YTRD!![%G`7,)^?0<](@Z4 M!'-!L_@0$YO=E0,[$6C@G1=W@V\HT>/UOWL!'.M^?1>RB)04$B?.^TGP>N$2 MFL@'?M@5"_S*2K1X2":4AV*1?+)G68+):VIUZQ!-IJVYG)`DA*=BZNS)J0F6 MWP#=S/8>8!5Z^Q^RD/)\IZUUV1JF[U.>4.[;W?\1F=[Y[ M"U!R&)_7W/K8`MY+B$_9?VE$Z>^I1]@-4#()F%SEMUI:/[6`Z=ETI_S^V#"_ MX:HF0D9&B]E+X.5P>JN-]7,+>+Q+<O;?6R,X?TH%+$`@D3Y>B[I M:/VU!7+0@I$*Y^>&A9.>T9]AV!PQ;#:Q?FD!PW<(3EG[UX99VP,:7$''O6?G MJ?A6&^M3"YB[2W'*W5\,*>Z`,!JX\O-)9ENK\Z$%[,XE/>7[)T-\3\Y+"5GW M\+NL^[2TO=6IY:9:$_\SR5]?BHP*01Q:]46P:FUUVG`?E1"_8G_.I?1BVZ95 MDY5+(R#F9.LZV;JPV+K*"ZG'.2AS[T78A9Q0(J3MANBM7KED5VWS*L]Z$04D MG'+PAXCW>+6]V$T7WMB,+>`"$3LA)!+1ZF_44K;/_&PAZ2+)_=0:_VH<)XB` MQ"%Q")`+"\$3"9YV,5!M_KAE+`$ MIEI.&KV-&N1TQ:6'HVI[]*&;D<9WM(7`I-E.^\/9H;AJ(W1YG@\)T$X=$;:: MN0H_P>%8*1#]0=`;]TI!PO,)I4&D`[BJA)N1I+!02U>\_&[HS8.:(/!\JMV_)1G\B.U7Z@'7(LS`F)G MR#3P@#@N/L!PH7&YU!T"OWFQ#**JW42'WVL&]B(.WM6^T6QW,&N$+,1Z^3UG M'Q:F*RB+B+L!5DM:V7VLCDDS034"RT>&YUIZ2\8$R'*'Y)7XD<;WE=W!ZI@T M%E0@KGQ8>$[2A;ZL+,4S:2&H0$;9D/`(_H&B7K?E]4Q:4*H]L,26/`\TM;IFXR5*2",+`IZ+]#,C-H_80DL:^XVMKMD$HA+RR`:! MY[K<9.E?DZBR/$0`YZ?5;;D510>@(O.EH:C_@H4D3RD`NA2?4@#PI@`\D]D\8#9;)%\CJ'B? MQ1#=^)HQ("S.;95=L/1&:$W2@#X>1#?B;9IUTK%UNZ*OME$`")X+\[:YJ\17 MIS<`^G(=A>'@N3%ODYRH6R\*IP&C?ZY/'TK1[79$7^Q#&P:>JW$6J0^<1X7% ME'1"7RM$"P*>"VT6F7J;EZ)G:_(-U#CP7'8W3)@E]BV-WJU).=##@LP M1FN[DO1J37Z"'`,>S^\>GY(:)`"J+HA2H5STMB=IA:C69#.H4%1> M,Z4BSW!"K*YK.&F-OX**@G@<%51*/6)S,JB>#*KM-Z@N%5I$"Z9N1(VH.TFO MUAA.Y1BJ,);N%U87O['@L,W%2.(XUU^N1:/`BY)E99_IZDY&C9X*/FXS7PM+ M!5%T.:R/G\3P[&0X;=[+>QDU6A9GOA(,'C?!R/8(7Z9=C0A[I0[A\M(`.3V, M&BD+B4@-!(]38`5L6;.ET,:QV\>HD;*4B&10JC#[YRQA-P$/^^-2>XA&5Z,F M2"E',Y8R/3SU[2;)_.7V%)V^1BV+Y82A!(1G=QD23H`GHES.+2RT7A"77UFB ME2QATGY&38P%1*8+!L]N,R)Q4A,0^L5FW\@&3-EY(+>368MC"4G)H>#Q,W\F M/F#S@,Z>.P/."EPBO5+&6/,UD@Y[#B]C0+/%_(4^,$VC6FM2O6U1]G7;)64(F8S+2AXC@V?`;_0 MI;Z_KC3QX`.E<4UW<:<>,!)*\TMTAS!;145/+CD[50&$:%)(3`H)SR*ZWI+O`7Y26B0"DM?>T&LR#M@R M%>W9?B/\[@VP`P#JVVP1;RG9Q2DD\JYQ5K/%7@[1F)J9@N<>N0*PY,TUW*;& MTK3>G!YFZ[L<+NM,0(B.Q234NJ5LM3-;F^6@%7L7!IY;8YKYG09S7MN<.L*P M1[THE$;E*7J:K<]RB+0T@.&)5/Y*Z&0*5/5>`>V$/$6"+_UQ3/A&#)N^6,L- M:+;^RR'2+H]7$?2,+0IM*_\_7G=/P6BG8+3V!Z.5/$NTQ7*V0S6>V[BLJ,@] M7";HQ$_*ZCJ+V,$+R[!@L^]NN'M[[K\B'BY?L%"5;*EGPM;D_M8&'X_)(`.= MAEY(>K4F-UB.07'!1G?2L/GTW@N^GTX8IQ/&D9PPA$H/6/!*X<.Y7OP&M#SX M*^=C#U;:UZ3ZCX97K_!@;3JK%(>&YT!3[B!I\OA0CN$Z!TU,3Y&NSBS\.1@2 M6"D<&C_+N2;W.:CN^ZQC.J/'D"J5I";FX%D#4H.?.-S,A`DI/C;+]N7,#F8? M3ZU)2#E[?1X#T"P@MP2.U@Y527*SF=DG5QN5WPYL/)]BDT$X)D,!FA5W`9;@ ML0L`)T0F.+DER9\;V#=+;ZHW]V(#&4VE:%8M"C.FQF2E?5J6KQ6N'V7/$+%N M5Z/)%L79O"VN`B#KRV#:GW_Y#'OZZ-TJI'KK/79]F6D-9S87HR9!:B/'LTWO M@]A^6+S0:KS=U6SRQJ$B+H(2\U:[\U1L(7GN]#6;\E&?0#-@HHJ)VR=WYRW9 MHD+=Z6XV2ZT]=L=DE]0LV`B2<<3]]85XF+P7#V M2;7FZP*8\>RW.70_^*]P2*C(MR09S&SB2@7.)04V/(*&L\'R,M]S_H@H(X`$ ME#-<##S;#^&$+TJZSV?RAYWU!S&5?-&&LU.J%'@Q MT'BNPCETWU/?]IV*UG+)8&9S5BI8RQ78:C0Y`B4.(6Z<'B5J\P(9I#]>OY&\ M+`^;E%7VW:\V8[#T<&&P$39T`BN10W+6[FHG,)P$4TYP&;:O2AF"9LW?1+4D M^>Z-,(?*:V/(NAG.HZE"X+HPV[B25[*"&\Z>J5+&Q4#C.9[?CY%8]4>Z=D@E,R MP3$D$_3\D+HBB9B^DA%Q(A8?AF!G]2+XEI+Z'+-YE*@^?!N[R>B+[`%Z;U2F MGS7.6D]ZPA1Z,B=Z(>?P6Y$6M8[=E*C32D6R5:E>+J"YA693^63/R&V\]Q36 MDW77FM(=4A&?NUL$9D3%U2O!(FJSQ90?0_;6+1G;D1?6K`/+2=JF!"ONH%&& M^-VD?CP[_[)UWLP\%.PV-IJVHO/1Y1T8,H"@DW-9HF4EDH>%CS&N`,7^-Y,1./5=QI.QF_-P[M5H55\ODI[;IS6U`V0(\!P; M;NPY#9-7@Y(U$];(8!Q^AV52)2)5U];4(=(`@NT7*E'E=VI- M/2$I!#RY"8_"M30-//=A-F?!:U)`2"6>_$Y&KTE%Q".%@,=[FAMH&6>CR0-: M)!V-WIN*B$D)`X]'-)=4U=]VH0KO$I@VGJF=!T^%43*I.MK+7Q\Z2B5;,42938\>DJ MO@`SQ6OERK`:K?Y&G2[UK3O9NJ/+$30J,"+Q>Y!`\!>;?2,;[Z.K(PX578VZ MAMU$34M>CU^5.%4SRE_L/%" MD.WUE^:(42!"Q@*?"S3]\N","Y&$E#*R[K8 M*$;]2(V*NC!?\'C[ERP@;C:'U&^MZPW0&A>4-AS<-N/.R6A\,AH?@=%X*"I/ M**R[JS8M,L-NTHSF5A<3I3[(KUN9MDQN<5'"Z!6U;68U$@M;49[CLU]]`<;- MHIF2^UOMC-JC=I0XF^N[Y.+AM_VFQ^_-=D;-0'K\WB$7CZ$F/A6^[%UV1%KF M)-ZNW?I?=@7NO`'%+^[9X1\@"'4$9X**J,J;2LSKE;$_OYI4O24)K0F_;I`A>)*7Z@>='"N,*F)"0FML=@TR!(_AME+0Z6'C]T`X+#P: M+IK-H5<\P1/%E\MN&^I**_NNR;VYLVYS;[\9US]=EF!(BTQUQ/:IZKG9% M1%2,_'ATZ'/ZNF6<<%"C`FU/=/PA#GFPCR">80GM/F!C$I?.;4)_,F8[_B@% M*?8C"$CHKZR:E"5[?`.:E#';\8<92+%7$5&0TZMS?7#^"KET$_`I?\_EWT*Z&3J?B07@FS)R1]SW[`J%.+8[X8!3^`>[XX M0Q1.>DQZR`M=:^O2Q>JHL#IM>4"C8::D.OFI_3J9<4LVI9@%2;$Z;7D_Q`1G MUL;6]NMHQOW;E(X6),7J'(W!OP;.K'3T$(]`61.*"L_N);^@QC5/A-7![AXP MPY.5EK7?>:"V`ABZX!Q&F-7Y47P2A_-IILA M[IFJG77B%:IP\>#SD$7QP2=^I_!Y:ONEP?*L0B\(J;2ZV!TW2)FV4F0DSIT# M/N7"9Z$\SM12W*AR(JUNJ]Q):'BVTG@DCJ@#&)-_NC*AVB6HL;JM!=7GE-YDPLBD2;4L39/5/1I/4YTL6JDODB24:HXH MVS@;.C3N3&IUL;N?FN'!2L-RW$V&JXI:#V-NK[];+W(PX]&H/4YX9X"_S6^ M3-:77%24!J.%1!JYQ9?@R!$4CE"BKK^D1$$2CK]427&&'$$9"B7HQ+QF5!&W M23C^JB?%&7($52R4H)=)+X9U<8^*XZ^?4HHG&*MA*(&L?CKP&#CUO'4[)!F4C>CR>4H^7&*R91@ MS!%4`REXRL:Y!A>D\0>H85,'RZJH.=+X87;O5+X#5::X6$C#7P$'$Z>J*$-B M\,Z5MP,95-0"Q.$OCH.+5ZJ")(;CHIYAQ`AH.45'G:*C3$9'Y:S'`T9?@<*! M9SL)F<+)FQWZ)&W?@A@H%?WUO0F1-6EN:(FBAZDP(R7W-)E=9'"F-V?4@U]W=NF0/X.BZ&8D=$9#C3/XKT92'_/_V_8CFRW$/Q1CO[*C MD1"2<@+0P5)%\$>.#':/N'+&9['#B9E];1,:/SV6' M3KT!6A-2H`WG"$*D6N\_./K`@-)\J6*!J=I0)2V0:XP32F=\X#PB[FW$UBH8,*!^%OAQ MB'N>='7[XW<4%X93172-7"IK:['8'!0BV&Z,WXDII[V*V`XYR>K0/8TJ+'2)HL36@D%*8$G4?T9$33;%/$ M&C3CO1T2EP"1+Q[9.+_T_"1S<1`QZ,K))OKC.YN)#YG#>3]9)A;9`RBJ9]0X M:PL=3:56N455%U-U]RH68)%U`9G.8Y:98^D3`92)\_&WD=5(-I"B/,>WLG\!QLVBF9+[6^V,!DOL*'$VUW?)Q<-O M^TV/WYOMC,81Z/%[AUP\ZWAIL]G*2=WC/)HEEK(AY=_N&1%%7@DC/!QF.ZX: MFQM]T$"3G#A2G4MK6O\>>#",1\-%DUJ7/3O^2(6&F8$G7K(6P+?TE;K$=TUH MWN;<^.,L&F6%(G8*K0?FE%EW\W.CI^Q<;N0!;X>"W`)9T>N27*;6C0&X!*L M1N?LT./YL3@[L!C?_ZKG[/@%$;]+.3M,VK3U^+U#+IYU/+:Y[&?WQ)8FWG/^ MB"B/.2HW?&B.T2(C8FJ^*\NJ?5P?[>4P$@-28%PS0.T&E/2'^< M<>3)?4!$U<_J8*])I`VCQNK98M6S?04N,_!%]MWQ9346VR$&]AS&MI> MK&VJPD\'C6MUVA)F=S!,54GFPUR0@4.(RT5>S5I!MX-&TKTTWRFI/X;5Q6Z? M*`5I)2+SYJ9LTB4RU.MH=;&;-_1QK*150Z&S!]]A,:7QXKZZ?=T$/,S=ZO*[ M6%WLY@<=!"M^UU!/;.ND8_/I@,"P(JU,ZX2WV<'J8K_\J^E?<;J&&_X@"&%> M:GNK&>$J.R03RL.DD-(R8C*7\9K]K6XK;OA%X*S$4L,5?\N*^TAG-%QK2*XH M)'VL;BLN^"H(*Y:;?ZHMW7K@S#`4E5P4)0QUNEE=[&8`710K.=5@!(BW)="1 M6Y+\^>"GU"@+B6ITM;JM,`5H(EG)H09SP/Y2V9L%49&=(FEO=5MQT9>1OV*S MX0)-GJA6/;!9N'@&7>"V$[M:3ZD`IU0`1*D`U0CIEHP)8[DY/U]I.'V`[>B5 MNJ#S29T1V)OV7Z""'6P`%QI&0II<=JZ)#P(,^?7BF88>',?7PRB")$V1U(+D M!P0L0A.JM4>@0!VOW6*QGM+YD3OCB=F^FE(SOWH@3EW/JC\=P#V?*J%))+Z.EJ4I\W]F2E0-$([WK0%18 M'M^"(CO"XW@SA^)WD(RLP2FO>R"J&"4_X_I"\$C\B MPINX`2';P:3LTYK'IV0(\'QM(\)>J0-GM7M"^!/),BCF-6U/E:9]PE&4&!'! M$#1,S\6B%CW02'P'=.1D1CR9$8_.C#A@P9S`W@5GD7_!L?`YZ+/>*ZBY`'A4H`CZS&0)5 M0&(^,ZT3#52"N0G8/("IR3^([?X1P5%7>>>6=#%JR2KYV67J%6J.F%(X.&Y M)LA-&8D0GT\7)='%\IHM$SXE(QY`IU&:S>@P.=2PPVT37>/+9 MS"M*'NE,D\NU,N-VNM1TT:\Q#VX?0!4GG+RZD*L4687R2EH;O89ILSB7=CQ5 M6:XCV"0)WZS*M++WA_`3IRY9YKRDH<]Q9E)N/E`U`QN]SQ59HPZ&647=EHJ\ MH<'"]L*%^MBZW=#H;:^0WW.7[!J+L_0#H[@3%:CFWQ_VX23,:7U+Q^L*&W8!;7)0P M>D5MFUF-Q,U6E.<-N,7ZOG@_:!Y$OJNP\N\V-'KWVE'-++-]!KWUL7%$8"MP M]3B9U=;H14?-S!R2\9CN/6R=#;[=*:BXP$`![!E+U-8K_JY))= MH\4L-Y%8[T.F+WN54!`D>V]K.=SHD8UA#TX0S M_05JNU]K@IM5*/`8OO8H7?[A!!.?_IE94%2W:WMJ]NL@J<)@5HO(DO++N^50 M].66W1]_V?_"<%!8X3Z+$C5`73`C2_M;>+*_G>QOQV-_6R=8?595YMQKVQKO M?!;E-;KH_Q?6!SI>4'^R/'+G>HSW6[;#(9])-YY(PT3(<"`@]#6N9QS!CB-U M`>?T0.^[5]./(DMO5>-MN8F>=L_3[GD$N^=*K:\7JQ__00D#ODT7C[#IJ"IP MZ0W0(K^7-B`TGIH5F5_@XA$E!77X/NW*U*I"XYAVK.F+22%F3;`_NK21^/8: M%CN^:E$K6A_\>13R&/*ETDTKZ67T@%CX*U1(-1,>&MG=DOAI;A7]&Q-`*<:!QZ?6I9NBJ)+O_G!"R-Q^%9\5>2O@/!1[9'>/K> M#Q^1,$QNKEKZU10MZ)WH)CFCTIDHS[?26^E; M;\H^Z#U+.@@4A_%F%I(TZ6N4R/_!'P=LEM0D.)GB3TL*@B6E8B'M*#Q76."E M_5ID>%?A0&/&6=*EM+!NM3-M+U=R-T76/`J\*`X)EB=@:'0U&YRPJ]H9YR,]#/6Q/S9=)37>;:\@_W7ZFC4<:PA` M$T2-H5"_P2AQ>_'LR;*.7_^5L"FQ%1E(ZIYF+;(:[->"4&,NAJCI$'C4%02H MJDCNMC1KI-1@;B;)>.R+L85I&7>8U$Y7EH;/[M$:6UT^_7B\4J*H37^<4B<1 MQG;#UB2R[)&-QUTS(IXG:MSY[A>;?2/A.G94>O[,Z]2>;!4Y!CPK5C^%!``5`!P`8W-B&UL550)``.RWT!1 MLM]`475X"P`!!"4.```$.0$``.5]>W/<1I+G_Q=QWZ'.MQ&6(EJ6*-HS8^WN M;%`DY>&NI.:1]'@W'!L3(%#-QAH-]`!H2CV?_NJ!]Z,>>&05VG%S:XJL1V8B M\U=965E9__)O7WL9QXD?AOWYS]MV;;Q`.W;GAP^O_O3-O_WY M?_^O?_D_KU[]Y_N[C^@J<@\['*;H$VFS\;&'OOCI%EW_X]5???P%Q^BO?"Q$ MAOKNA^_^A,B/OV`OQ(GG'%?HDQ.[6W1VOD)OWYR=HS=_?'=^]N[[[]'%)_3J ME=H\UYZ?1O5YWG[W(WH\HBLG=1YBQ_TMD$G;W[X<=W9V=SS/JP/<2U2;_/)WW[[LWW[\YG42;1I-^3_YV7 MDP9^^-NCDV!$+"M,_O6;;9KNW[U^_>7+E^^^/L;!=U'\]/KMFS?GK_.&W_"6 M[[XF?JWUE_.\[=GK__ST\=[=XIWSR@^3U`G=LA<=IJO?V8\__OB:_94T3?QW M">O_,7*=E-FZE"[4VX+^ZU7>[!7]U:NSMZ_.S[[[FGC?4!G$48#O\`:QZ=^E MQSW^UV\2?[W_.L1/3HH].OZ?7I$I^/C_-_OU-X@V M^OGNIAB%C7!(7A^25T^.L^>#!,XC#O*AOGG]9S0#=3]2[L_^4*7N(YVV36)3 ME#_6QN*="(T0%-[BV(^\ZW`8J8W>H#3?ITZL<7DXC%)R5*9Y@,QTMGP?U/O^_K/.=,U&F.<1(?8Q5H,<[G7B7$>-8BA MBROI29U@'+[Z^?Z;/Q<^A!-ZB'=$E9[HU[SO?_\+GW\Z=HA[_A@5RFX)5Q=Q M79>(6Y331GZ4L)6U>.U&Q)/9IZ]J'VP31SM=YQL9)'ADW MN:]![.7M:QRDA?=!+>CMJS=GN=>2_?IO9/%),:7JP7DL$:9B,#T-`:RCE\2F MTA0-T*^L";C&3T]KGRDA^:.DM^]3>.['?XR:>` M'J:?G5T7JO8V!=!7`9G-3Y^MP&4[1!M":^OD!$/HJDP9GI)+"-V M@AOBP7_]#WP4*FJS+:BFM@GM^?)90\1:(M+4G+).1S.LOO8H15MANS5B+HV] M/,0QF?"#G[A.\%_8B:]#[XJ@>X_2]C8'TEL!N4TUR)HBWA;1QF3OX]&0KQ&L MG8ET*"V6*4I5D25:,B_Z?O`#'%^2V9ZB6(R]]9:@R-LDL@?#6#.4MS,'NI.0 M"XNWG6K01MLN'9A+/Q]BAYZXWA]WCU%+WAGQ]39`.MDDK/EYL[\CWL"$&HZC M$$KS.C]P5>>ZON[,OFBTVT7A?1JYO]UO'?)UUH>4'BU2,L2.J:@CK)K*]>QN:PC#QL_D&%[[*#6!$CC&V3U M!O+IWTUH\!CZH#2RZ]-6=:_CN\ZE91=D'H_.]2%P^N"VW@9(SYJ$-3]D\7=$ M&YC0M'$40NE:YP>N*EO7UYT;TXJT#<%&OKLM,,HU">V%$][0Z/9]:IJAT;!3 M*;I@L4LCYM98'BG@,W\@O^LZCA*W!];<+H)[-2$+XV0*P9J;U."I:8?6Y%YE MZ=+F/DV!T6@:^U+7Y[*U$6VN$BO3!Q:2M$23IZ';C!:W%*1?AYO:82!;8+WY MX(=.Z/K$HJ+$ER2%:74WD5$@9J?_P'Z]045'E/C1_US__>`_.P&QFN0BO73B^.B'3W]U@H,HGU&M/Z`*JS+4.H(E M'5BZ+/NATG6%+E*4]T:L^^1*GU:RWB$Y@(+D#Y/?]G(&N?9HP7IS2=+!=$#W MR76C`Z'C#KN8T/08X,\XS1)/1,Z4J!ND:R4FO^6^9,U1V7Z%2(\5ROH8<[P& M\A%7^`CQ].0KX?-XXHTZE`H6T'(OY>H/9\*W,=X[OG?]=8_#!!.(6:=;'',/ M6&[)*KT!#5J-F:9*9;U0UHVM(ZPCXCV-V_H$=WA M)(U]-\5>MRO_F7`JM3"-00#-3XNUIBJ5G9$@*%(.8%S_HNF'3:@*(L!6RF@J2_\D49IH@30D,31"F M@7(*Y%F%6TKTVH-$34-NHD[#BJ&C$M)P!'P79U:QL%'HX3NN:G1X5\)N4A`,U'@ZVFNE2Z%IX= M\GFXOW-QYN'F^O[%;J[OKJ^_G3Q_N,UNEQ_^K3^C.X?UI?_@2X^ M7_&?_K+^>'5]=_\MNKK^<'-Y\V#2:'3ULVE6FLH)?]Y]ZQSIL9WZ27>C@X$S M[A;)O0>K64OSX7)MRO>\I=ES[.&"7B&VZMEPG-VMX'T'V9W:#6J5\0%[%=10 M,LR>/K"VV4MXA];0MJC2V`8+U:8_*!L;L]-)A&Z'M8H5O\-@A5H/9[-7>(/) MS-X=?L;A06$E[>D`:*V])+?N.V4-4=;2E'GJ$QS/1+"284Y&+J0)BO6X:7]" M)3:R?Y0;GMDE4@FF;5H3E0BNYT\87Q*GI=G03E-B>E:L>;'_[*3^,ZX0HY3W M(>L)N@K*F&C#==ZC[D?-F-.A='='GY,L')^'Y\VMZ[J$_^+$K&)P;K735S%4 M7.'M(USCI&F$PGQRCNB,O6/UUMS)TPCZ_]T)#TY\1.>*$J7E?AMPNL;]E@9O5ZZO8Y%<-(=*0(Z7@0<%?B8YV.S_=L3MOH7<9A2E9 M?W'HBHU'U`OR^K.0^-95QK(U3X:MMC=V%W@4"ZZ(!=`KF'(U:EV\E.H09`ZY MA_&.71@C_!)2".]DDJ>;D#B\.$GYZ1@OZ)E?#+W8T1"]P$A&#`J:8SZ"]78Z M=CX8JH^&\N%6V0GR*BOYNBKOY/-1S:6ASR,'EU>V3>A9ZS^C?WKSW9LW9VCO MQ.B97BS^9^KXG9V?K\[/SYE%G[U=_9#]LS#N-#BB_2%-:^/Q$KE165(6.0F] MCMUT*-FH%_O8#]#YFYD<9:4UVY2`IY;HV[9$S\S>.QB+7>U["".!"[)XUX`4 M'3N2X4?5F_>O*'_OPW**^2';G!@FA]W[S]6Z/Q/JS_]0`?A4'S^ MQ]4?OW^S.O_^AQ+.48'GYS^L_G#VI]4?__!'_L_O5S^\_;$Z^2#`7Q'JDCUV M:40^,/).E4S;NT)!':H.9Y8/,7:20WQ4,LR.QH"FV4EJ^\$HWJAFGJ;,4H_B MS(Z=K]Z>_X'91'V?KKPW%YL#I#,Q_--9Y4*,84/L.`SGX4?.0XB? MG!1/S,$HC53QR"$AN1_IFJ#<"W.`^>>>QZI8.\&MXWLWX:6S]\F&H+)<"&!: MH3-D1KH**ZTLZ:(3HKW038BR?JO:BVG&TM1',D4+.'V+MV8KID)!>N>]@=`@J-5WCCN[[XV$K:&?1X2H&5]ND`[X3R M7NA%I1_*.KXT=]0T@*H4DL"*59"G9QWB+PX1L86Y"XG7BCU&2?,;I>O/@?!7Y0)HCP5[1TV12 MA"F\JFQM#,0'02_H,"]9(2+ZM@T9R^"MO@E9SFJSUE@.2'=CE_^6R)O&FF%$ M82.FL%8M*4;E8,^*,Q"D.RZ.#D!HDPD66HD59A,J1B52V),]T16<8BG.22UW M(O.KT0N>1#']]D9I(1A+ODF(U]:@;SM5*,U5R"K\"X'Z7DN3K6%9D2 M`*RTJT5%I3JTJ[N8E`4W7509:-TL6?6=!#/^Z@#'81F]\.8*/^E>G0'AN@?6 M;:J:U8<5BM:F@AQN\AA3/#@G_^-H0'_SMPPZ[[<8IQQ5MSCU72<09+$J=@1` M`F46>FX_(M8)_5KK]M\&$UC!&8*P`CU%RVU`2\L`$S7P;A_%3GSD%DB(6L?L M_5N/G5#>XOB>'L:*LC<41X!,Z5!FJH7,><_B5@WIC-8QXMWYJ3M]WAZQ$8QE M@`QFL.>>QZI,VD(O_!!Y41`X9$-'G&%^&M]:7$'/V/64M'7PKJ6AQFR/$9&L MRPPU=:-K=S5G;5ULR,V,]T*5;I;8E@H[O4;5SCJTR(QZ]4UB/WW*9NI2QH`U M2W$`8U5@8<+-OU#>PH-*OW!A4K+EF"68M66U#)NMIV*;%^Y<^I;)@ M-S:&&>5-&.21Z"Q?QZIST9DXM.=P5!$E5'#.Y"ZZDE`_8`NMTMO,!5N-W67] MSJV5.^=1C"U@SZRAA8);KM;LEBLT:6R51;W,&)'"SK)N/-;LD`/>6$&5 M!!9A?%?[K8=(">C=B7=IO4;T&->KMV01/(W@+]K\2M9=:K*&=;XL. MM6VOL)M)NQ5O.+IUR(+M[C`^K-SH3OU)K-KC3L^T(H"-'*::_!D3;T835E;!3_C&+$':@26*JR>4C-3 M.&#AU\=8F(&665>HC-O7`Q!@^HENZDMV3;!H:D'EVUF(A]1PB3'Q3<8K6]6NR%BC_4#ZRQR:-%GU64*"F[LNU M9\3%D%L<)[2D$`V%K;E%(N\04P--MQAQ7P]1RZ$_ MB[C]SM@M%R6KJ=UP43&9$6;\$#MA$CB\/)BR'4MZ01FRE/BV`U_I8(LIC^0" MP)B%`>>%\*`$2-IL*"-2*N'7'"2I(4`-DY3,'[`"B!/@)'M7^Q['S[Z+:3D2 M@5_=UP.R%D@OT:V*![1E_J#\"N6-6=D9,\_GJM-.*^/,];*\:K4296+Y+?*H MZ?8;JE(R-=F@U2[$%MDJ>2$T1P.;].NO>QPF6&N+WNIC8H/>07C_MC9O;-/. M7(&!RRC)'IS8HO>I3^\&O4=W1OCU5$CKS:!-NDI7*`]?C8TN#:&5 M%&W:R^-9!Q6_>L8[Z.8F3_WM,WYT!K6 M5G.DU4UM-!0,V^@K]84%`^T]6HX&5F[^Q_!$\$"VK30)"/HQ@6Y$D/%H,R0, MV%QKF!QDO?X$$^ZW%Z%W1?ST(-I3):3$_^&*SL04BMRQALS[2F:SV;!:J$S+?I9Y(]2ORNH9\NCL5C:2.I-/:Q.#CJRGH#((V>BJ4A9#_Z^ M6JV/:2]B'"].K8\93V).#B#M6M$TFL:M9A<&(^AW6@\7SF.;T-ZJ8H%5EJ;32<56F$MC=2X*0J)IK_F"1^9*H.GXTQ/ MK^$L5ZG1M908SNP^1V%4)R-#`(6#8WE?0)-48:25VU'I4]AHULV&;.\A//'' MGE[@G`N?]3-ZJJRL8TT#454PP'V@XX?43M?A%8[]9^:QWH2$&':D0%,^;F.< M"M\+5!X"HSE9K4T*ZYOI'B7?*:I2F%*1!8P MAE),U$5>VV">6<'K(\PEO)XR!=D>BLZ(RBE1.2?BD^:HQ*9=H=K$B,V\0O6Y M43ZYV9(-4/)D$<%'+JM]'#W["9D!D7]FB()2.H$95%R").!K8I,W$+`$%Z(94Y M:(<'C5ZM[S;X/I4'W#_A5.ELL]X.*MC8Y'?H)9T773DP+[B5Y.??W3N*[-"G9#PZIL):TK">@ MIWL_[F3(\?79R96/7PGO M>4_SL1""QV=3?-``QNBMDHQ)9%$TVR;6J-DL'/K\@OVG+9GX@EB&\X0_'W:/ M.%YO&&V5^K;JH#1P0$"L&LQR4[/S@5`V$N)#T8N-G<\7V8)NTPO`R010->]D M(N3C@QE]OV60I)1)XK>M-P_"S*^9 M)H1.B)A#9-T']YTVPD,/*Y3-A_()465&9F&5.5$Y*4M%8\44S&6B@8DQEY&; MRZA2B0`YQ0@&LSDLE@)X@LAL6-296#(7$($^4-3D0`&%1;U@GR<2$-_Q6DP_ M$I:`MK(L(CN&27.1VJFI!GZI1V83'0_U2`S"R"[JTDFV'X+HBTH)0V$W,_NC M+O*%FR':`;$>=NU[]!B)%!DQM)_I52K!YJ5/HT!/#BD1[#36P][[X\\)]F[" MXO[8!5F?G_W45RKW.6`PV#-(?5:[8NA,"_-AT/LC>D%'(DOG2U0,ALK1++"Y M25@O>7.*YF8O?PW6W8YSQV&*"V>HI5.KQ'TY#76)BXE0.Z&!_'EYP&%`C&F$XD*,87YD27Y+?W:I!`]4:'Y8*8A@ M"2#-::--R)K10`%]\NS@%;/H+=DF=%;.K/I;W1T@_?`^DEN.*VWXBK5$U:;& M_&YEPND9X*M'1KA;:9J7'3%4\G\N\D&W"T)];VT4^I6]^O^`LX+IRYCX"O/_ M5N#D8W;E5U(^=57W!$%RMOS7;AN=`A3LN9C_YD&8SO,3+DK5'ER M-38432GKBLJ^1LJ3#^,I:T.K>,]&O5(A\F'D/VPQ30;*OX:7=1;5&:?(X.S8 M%_,.&'WQTRW%BA"C(W9B]"**V3\>#XD?8N+KNT7JNPJ0F@V',K'*]\[HJ;$ M3&7YW=/L!4^IG"E1_$ M)X(*GWQZK,RG6J'&E3!;(!U2"0WBOA:T2M8"'5PUN8^]P\1C]UVB$S1HIK5S M;70UNE=ML:&X'I3]6)3:GLVHE*$*Y6X'Y69WF-U:)=]3=JJ42?/('=5;Y]BS MY53O:]1`VHSH;3H3E/6TQT3D+!6T[V>B7;5"Q>24FS7O'JN0VW>W21@V\/A` M'*(RAJ5KX\WNILV\S8ZZI=.^U3BM5<8N9RSG()B1@^$F/PG]Q@V_QUJ4;+_; M5$R:?^Z?9P]-:]E^LZ]1PV\SHFCU123DSNR3[$-8*F@W^BK[')2;-?,>JY#; M>+=)V)C6*;!TC4&L3./L4+<3)4Z+AK,/.:(6=7$GF(PNS)`)V&]Y,V2 M3,WANJMHH'+%A3/46^>8Y8E>N'\_^#$FQ!+\2(^WY".E%Z%W37[+WMP5&*C& M(("&J<5:ZU0FZTQ3L[/N*.^_0FR$%3N?*08Q983CV"1$;>E^AYWR\7Z,+3P; M6TI+_V*8TBN!N5"V'BS\9)`K@CY(-E<";82TT56;Q$6STS6;QB6SWP]3VP[Z M'2Z955M`3<[R+:`*7W9ZFN,]3%MPY8,?.J$[T190-)AYG!&SJHDWQ6"+V`+J ML5[R9O<64$%W%0U4KK@C\F')9"[&'GMHX"9)#F0FO-[<%04=+UD]1U[\DK@> MO_!WZ1*:CT5?KGGT'^;G""05*W9_]X3'PW?(3M#)GP=)*)T>H6J+IU/`$&(VK4)Z1=?T5 MQZZ?"'=?PFZ0$3Q@-I`+KBU9BVI-49[_H#6K,"F%DZ#9`DT M,J-@,*U8C-Q:;-PE3;([LG-7-,UNR/XMD"A&43V"+R,QFXZ=D561F!%-DS^#F M?+(?\(Q\JKU@8YA+T$=J!MAFZ\4:?<,$K)C<2<8MNVS:S(\4@(_6,)`UE?78 M:]5(Z4.8%>)CH(ZL9&.EE+\%V236H4^)Z359"_)6J31__6F\PAW%&J`JXS#&1U;SWV M>HH*T+!D7KR2I7G3$5!E"`L<&/.<@A;0'J"VK<+8^CIKEUVJN`UZXUAFF:*5 M2UUA+5C)K6#6-ON4+JY#=!; M)0WK3?5)B3L)]E5R5Y7WL MR#8B1J\0IH8,"UR#684R"#4L\2$F,IG!P"&TEQ'WS5HW*^@K6\2_8?_-;_9G MF=8"AV'X6%"WR`8RVJY*W;H61@=@3C#_J2B'D%^*,.<*G"[C2E?")N*OEN3UIQT-[SA9[I1':QWX4 MY\_'E!<[_!!]V?KNMKR&FFX="EH8.3S23V^Y1O09F6H]YQ5["XP,6UP](^.[ M=,($I_P.24)/`G@%KOS2*_\&S6%3O-M'L1,?,_Q$7S"9G5Z:Y93SFB!1G'Q7 M#3LY01(A#R=N[#_2DQ?2?)==?6-W<]A#Q/Q]G((UP8LZRT#F7D]S-*[!;4LS MI_?6B=/C`R$E<903&J1=`3>6"FRT48E;(^N#JITL""1!\0.YG5-5M>9^35'/ MS-N,WJF,SB@66)+:.85`"2T[D#'-IPV6IW$6HZ^M@->ER/KJISR\&WJ7$GJB/4%-;XPF M[ER)NAA3'N%_GZ'`IA>J:QF0&E!TN)`L`BQ,[@(M7DTM^+(34)LG.9" MD?>'_3Y@-#@!K?KR(8B^7`?*)5.4N@,&-A39:6I;M1NOTD0[HKRG!6%&<,8@ MPQ4Z2M@,4FAH(&P]-$I(E;C2CU1*DE8>`K@.FB);G370:-\5JNEDI;L=L4)S M+$+7"M-1T*XZ81K:.<+;_(FFF]R$;K03G8CU-H7R+[O);*H(:X5X,],[HDDI M!O.T!.I0<['Z=6$:793N>3K;&M!&$6+5/Z[I'8YU1"OM:A2IEN]GGAA?/AO) MW$Y&I.)]!F9N]_+!\>._TB3-RMJCL&L1=@/TIR3DMU[1(LT1:U_W*8QO3N;F M`](S4E&IIC>DH$]F;4)EPR'N9]@J1-#:ITX6["8`6#%M&]*M@HI>`<:[\!-= MTN_R_'V5&%=?%\BX5C_9K9`/;XJ*MA8L$#.1#QJCDBA.*RXEUAIS&J^7PZ;2 MVZ`=J)UHMW7*DAP$0VR9M!N-_#-UW8,\+WE,\-\/A*SK9^4SDIXNH.*TSS6$6F-.XY56C=X^!G5>"*5MK;%A69B-`Y.: M+\=]B?8`ZKZ[Q=XAP.O-19CZGA\<4O\9WV/W$+-[S-=?:1$'[-&7)FEEED-> M&?S:B4.R8M&74UAE%B6CF7XR2&N;0U0M)<\FH:63JM.@-55&_R&Z]T^B(Z8@$+\[+NX+--6+>1V$3!:< M83=Z"OU_8(^_NL:JN^FY#U//:<2+F%YP(F-ES&3B_<[&//9M`AU;52LO:(D\5G!HS:LQ MT9,CSD]9H8GI@1XD3C*1$1R<2$0B\.LH-(O8+*NLVEDVT0H54Z'*7%9BW=QB MBS9=I6@G%IL9/)O2*/M!;$*+-(M<5="MDG_ADLV@GQY'H97FX(812EL4JJA4 M=Q<:UI6/;CD.32>79&S\ MYN?03T?CS;33FD.BJ<4W#*/**2JU8UN_9#,O`,#`9"J$MIED:A#W9C%U"2+. M8>819U=EAN\%9IH&ZR3&]>*1XACIV@IEMY1-9NQ&$EIEH&VB-S)3N ML)#POV5UY9F&%'@\I"B-:K&;G\THV[]`+YR7"7_>8K1\ICG=L M#&8%448$7602TH62[H<$&)DLR=`O'BM]GR-ZDR>@*T[&%+WMDQZ_3?APM+U; M:>\1,/5PZ-'?>R]1[">_O=K$&*.8\/4B>ANXD_&QK('_"3O4!KPU68#=0TR5G/#E)S^' MT6."XV=*\4VX/Z0T>ANZI!=C2NLJQY33F;@!,JVX^F];K%!E)I1/A=;T^:EL M,L1F6Z'J?(A-B.HS6K`*VB;':"8Y&KG[,H,)]UZ9F=Y^C40U&GG<-R%9RG:, MO/?'[(^:`0NM$V:01"25Q*..)`SM^X<8 M@V!+/\`2X#!@9%K<^V/W`!=?_42`$W/."H@E\PJO:643I=,R-.H;ZU:KFU#-/TY`F):P`&WL2^^:W;-#Y^=G;X*MHY?BM8(Y5\I:MQI*JQH6@> M*T1[H5]Y/\N@8@:&S-MJ6]G4#*ZE:8`[B\H1[B>\>\2QP$XZ&D/N![I(;3FX MU2-[]"MO9]9=[95PRQ/M$R^<.F1Q/ZDFU-L!*D&3P.;W+]X0M>#+=PJS^=&[ M)`GYFEWM=%+ZW;O;@[Y0UTUP^XVVQE&V#0HAE';[T;5^49OVJI0]Q(L=/6Z9 M;W^9C6_>/%<5M\MIH\3/SL!/3JTSPD<:!L3;\UJA@%X M.'<@9*3TQ;G0^^!_I3\E/\51(@HQ]?>!/"83$-XZH\G;LG/EO/4*L?;&SJ<& M,[#)6AL]$9+I3>M81Z(TD/7)]W[J!/1&$+=(8H'1)OU"C%"F^=*NH/7(I6RT MBW0775#>!^6=#)O#$'9R%G!QK9?EJV3=S)885].Q=FEQ)06#,Y9/CKOU0QP? MJW>+968BZ`1H($+2F[I4-*[?$S=L%%HLD,&BF.K!L30(DS8@5YVF]DOU!D[O M/V(GP=LH\&YV^SAZYD]JR/1>T`E0[X6DMY0F;XRJK0VK_4`._$IKDXHOUYVF MXDL5QX*:*.MT*XPT23K:4`LE9T&K5,@*L6Z&34*;I]QM0'[XBNC4$Z'-J%&H MZ95R>9.J4EE@'+*50=+1!N/HPU>)<=AI%7W,/$3T4:)]UHWQTNLKC68BI9,9 M9<$*`Q>N?$J&`1@]=]W#[L`>^[W"^QB[/)&4_!Q@EE4?>A<[FFSV#_;[7NI% M`?2IIH",H4\GEE88O1P:5<=>H6)TIN/5\0D4U4%I54CWZ()5FOLT^] MX#)P'6*$K`;'DF(Y!8B28#@1UJ1T9R@,QU)DY=)=DT M;)1,2--J9YH0$#MG$UG3IJ='R9H1&TX!-BW&$7"H(D9(-)S7B)L8.*L%PR'? M3SC$L1-03]?;^:%/7_^@>3777RD36)KUJ-8?$)=4&6J]]\K[\1UPK2?*NEJ1 M)ZGUO9HZJ_.Q(%\."P+Z&*'VE$';&'V`F3@"WI3K`.W2B(GH[W$4U&C<*$KNGKS;T3X/X; M0X.&@:H#IL]>Z]"D.@+*AT#%&,Q[9-4&Z#"].C>W_PW*;23C%JR*TD#UK55) M&J:[(VR.^,L)G8OZSL--3G,4*(O39JYU:EP9P')[@^'5'FL;IK@U8QNDM8"G MN'R#B[WN_6^V^(K.:-4&@#R!566I=;Z:=^R-4.6>UO3Y#T1+Y&>F0QECE^Q> M(1XJZS6Y^W-9F MNO%E@?5.'I&IM(+6O?X("_^ZAH^4QM`(KH.2D$[K*P/>QR++].ZPDVIBO1WD MK:L&@:V+5OSO5H3U.H79NI34(4G(^W=?U;YWK1WH+;NOXN_-_V[']^X29OL2 M6EN2@,=.G:]47-"2,T_L6M#[8]FD6@6\*)M;*?Q]G15L*ABY4[/_GM0XSQ34B4`R?I'=F, MRS!\UKFAH7QF00(B.J4`41)03@.B1!C$=F#9WA4OO/BY`.A3+V9!WE(9@*,] M!&!U@CX`6IT0]F?[4)-+0$["*:T$I5C-+P@KE%%SLKC8+^T^>.P3R4G!9,.V MP=&R;MBG!)H\F&,4-#,23@HT"[%:`9J$+&&7IF7RI4]@K31/2X).)4@@W*XBT;G,2:,`'?BP5^,3[- MBOE"<#HIN`<.+8B)."WP-Q)>Z%L#3BN^H"OPBC!.+::@9-8&P/(DX@H]K,%& M%L1$G!AFFH@N"##SA,(+N@*O8N:)A124S-H$9IY26.'*?_8]''HF@@JUN9>. MD`U!F@#&G(13"R=(1%NP??1QX)W4*C"*\\4#?Q!]!S#!P?P5WN`X[N7G M%S_=WH0>I?#@!/SU,C]\:C&97(3>;92D,4[]F$L"AWCCT[)Y#WY*J_"5PTCN M:QDC"7!1,"CVEEEGI*#W47A(6-V5VS@B8[#5@=;ZH:5DZ6K!1J2W],LQ#=]B MLU&,O>OM%T)-170K5!!4N^";T\2_1(TJE)/%RGSRSQ$I?`Y(;#8-*$W(-HPF M<$C>HH*R=H=Y#91DZ^\?HNLP);L*:=U/W9$`<5.?R58QG`X0HX.@ZBCH(4)\ M'.,7):?BN(X37UHE_)Z06KJM.O"+7*.;U:,$('K\@"Y9+&=,E25$91%RBM M%)/=WHQFK?E3'_9\>`7IUS1`+OH%Q/S6?$>[/J1)2KX'<:`^'V1542>?:PDQ M/8&@9HCAK?.@766^%>(S+BYRI2VZ1['H'H]=VRXCHMNS6MOWJ1.G-HBOQO)[ M_.33E^G1>R>@A:!F8OXZE)9E`F?]FOVWC_%%!#QEP#Q9@%."RLM9PWXB#=/D M)N3U[V=6\"ZIPQ.T M@62_KA<3D+RO77O1_S*#?`@M(UVX(6 ME&YAS;F@5&:<<4$!`ELU\;%6RX7:44PN"6@%R#$UT/;#QHC3C[%$Y:Z/`#;G MF0?JG&4&`75")5*$2M0!E3E2HGPR/&2,G00[Y M;7((V(,JD>L>XAB3GO1?#JNBZ(<.ZX&?J7(E>^SZ&Y\,ZX>(`&H:.VY*\R&< MIQACGG9%7T]W>,@[C=B\"2WKGQ&)]H2I[Z!7,=-*"'9Z.A=ZUXY<9X+NY>P. M_HH3HFSTP#FOCQG17T$>WRJ3L*!]A(98Y]Q<<#)X7D11.SABOSZID^`1XJZ( M"!NGSB/`9X=&=MS+0@"NP0U;R"E MF&_I<*8BNDJ;)>-4KSE-'V'HMJ7E($\%.W_!_M.6XBM12.<)9[SAV]AO/\\V M3^Z(D((%H92Z4,&2\G(Z4$9(CFP8,5*6"FK#)2T12%5Z)Y*/-ZV`&OIUDFE\ MLTKL)+/_5-:0&7,"%180BY;F1"OI:*[E>4(J;%JB)Q7ND&4Z&9Z!N-3%>E:9 M2]%U".E+H789 M*7\SH<'DB#L,"A8$NQV).*9@5Y>4)<&NOIAGA=W.),33A=WQTI?"[A+2_V;" M@LE!=Q@0S)DX**.XF1:B":$&B+`FY7!BT0[)1TR&)B3:!IA62%P*E9:G.T*) MQ\G$LV=G&C3[<>N[6_3$0B5D.^1&A\!#6](,.>[?#W1U82F)+&\R.-(`=99) MR2HZD1]HX@7-9:DF+58S*_.D2.RULACMR?*;`VKU4@!GP%F+-@2C\W@,G46/ M),RFS<+5+"E#N*Y*P8(`7%VH M8/F1)PK&PR6M$-`YM7Q+$W"J9]W`N/DHY^M1.['E#N_X%;++\H[9`]EXO95A M*#`UT'@*+FQS^9L%5:A"%J)T&<59XU]`0U"2%$;TP@_1$3MQ\M(X.)M!D4Z@ M-@(A)B[L7__]X*?'FS!)8Q;Q2];I%LS51[@,1Z7][&_Y7^"F\>@C_0OYS_RWM MOG/2%1_FJ[/;T[WGM[=G__7#I[/SJV]I&0?R.9BAE54=R"P;0@HKXQ!B]DG) M"/XS1CM"Y99,14-?Z=8G37&(/.>86'Q^863)FJ;&P9SKU7*V=MH1P#[>NQP* M"XE9_UJ6MZ$X"2%%A0B"]"_.^'!B8_H_&R%Z'[E1#:: MTV/:U/O/R0%M.0M.?XS4Q,HRA)H%+2'#A&WNG.;TEH-IOH`6[E>F/!%`'X$9 M4R/W<,!8SC%Y91FZ(:SX8>*[[$WG&0_&^^==NO+ M\E$LRR'/8,TM2S/U-Z3RO'AZBEF=SJ8`?@^U-B:3SDG6U>A>$&:LI-&Y&BQG M+:U?8F?_NB*J`[:NJLV_H#565:"P3W6QWZ"K#E!8ZOH[5,X"=%Q"78PIS7G> MM[_$MKPK%DJZ$[Y201`_+N]8R%!$OCK M%6(86614O\X)4/"^.>DR8_1MT8&%XFT"4"AA"A#2IOL0LYKEC/'Q;IN$P[1; M\K$_.SM\\=5/!"A4:P:(&PWRFLI)_XSHW]&OM,5_F[)("9GW[A9[AX`]1#1! M&)9GJCX0IIAW(A,"I"UVJ5/3>CITR:*-6.]5?_9_J-")JY*SZPA MT]FT?1HFKCDJ6?5;!9_6&#B`RE`,+,E@9.F1H54[GQ&F.UW!*JG=6H1U@[-^ M/T?A,]NVS??^C38--J'BA(*=87.C=,=EA0I:%ON6SF3B'N6N]8H[!18WQ$'Z M5"*O"^0$SM#G$$X9(-6$7 MHH!^S]YZ`9S&$M&-9'!+1">,G<(24;RO8G25:%-Q$@M%EW#-K14%-:>\7"B+ M/%G*VT+3FS8<;/;9M95%MLIW.@18"$_#\@MD=0K65/FKDAAS,&B-O)/>EWY& MB\!PS2DE&3QL,0I97)1FM]0*1>TSU?++*5:5LE'\38H748P.H9^^+,M(E<]3 M8"Y8Y!UBVJ,L$$7_Q6/VIUCWJ1]%@:HZ]4+H*;CK13B_<3>]N"ORP?'CV2Y/ M3$G>23CX6I_#BM/P5J&)RL4V2JP%V<&V?BG@@W1#7\JN@_8A7TM-<-3UXQ_L M]WM:#R[=W]61O_(2;2`;0'5]7H#/U'F(9\0]&DC)$CRAP4*&O:5_HM[-9-+7 M!^^>Q(/QX0&\(>LL9>NG@^_1UA\[P%%DYH$=0\ MP+0S>J!+XQ(6SAD^C#W9)B>[X`)\-?VE^/>3WV'ASFD8-EEYSMDZE&UP(UH$ MK"%M^:>B.I_!U&%I1\I(&_+-X;S%7T@?WGNS499^%#M&C/2$]DOSW9\-E=\S MDQ]_YH">K3XQ^7I4OLVS7(=I_)X,3%J70??L#+=Z@)LU*@]QPRA%.'O:TT-1 MC/8'>B:<1@AO-MA-1:>[E#B'_#8Y!&E.9>2ZASC&]+TG\AN'/5;DAP[KA9^I M>29[[/H;G\Q&-HBT2_5M(^=]6 MV*`+H$/<\IT`O4]A/F)'#V MR>\YV4MY)0'/`E-=1D8LU;>Q_TRT[39P7$8U*Z'2791,W!YJ01,0W"I3QINB MHBTOL6.F9MFLQ(/9HTQ=:B8BT96)M;:W*)BLATG-[2TKU??Y#175FIT!HQK< M791*36]&:/'%/O8#\NNSYB2?<$]Y)Z5N4/HL)[]5U)3VH*\YGJ&V>OS*NYG3 M#,7/45,/M6\Q0D>R9S#I'_2T1-X12D]46&AJ2O[Z)WOYTT)=4?XL-6U1_28C M]*7I78J5I*W[P&B`5=^^Q"*9L(L]$30;*[XWN+^0)F/=-8 M'_KJ%<_T0:QLJCPNM=0PE)[$QB6CU46VFE-F\P:=E(5&PT=.40^^$C?JN_G' M?UF_`$CX3V.?/:?!8T(L]L-3JD\L]B.&MVFB.$)L,X'IOS@QRQ"L/.`Q.:!W MS6$]FG<+9GHHS^>I/@.T+!37D-0X",\G6LTJJWG16TU8]6O:"5.>+[FB1&57 M>F).,#'$+A/E%S_=,C3>^*$3NK2!4Y*T0$@6H-,T>-P/32/`.!_T)DD.V+MB MBV2&^%%,"-Q%X3U=2_N`5KD_%(AJ,-0Z"LRUEO=%O'/AN$8QXOT1&\`(\,W& MW69N[I2@:@1[%1@JT,?GG%9V MVK(Z2#B=2MK02-%M@EVPT&E_XS%`^B*LH#$P!D@?[,R_L>&G^*RD60<%I$33 ME=HO""["/,6J35.%>'+M(Z]$0#85&/.4(>.+L_CE4JFZFPB;-)-O*ON'1M)- M]GH@OHW]]HW?T1NDH718'WX9+N#I0S0=^:$58&\ MHUY0[;5L:-$KE`JR1?P2T=3ER&H`A7-$TZ3%?Q8IK^LEAAY/%U+M#V2.]!>F M"7:.=)U$;8M@',E"+1/#!C'R85+ M6$Q8%3#ARJ(\!B3J:S#6,FN6.]1U2K;BIDP,LCJ$,7@TR",HCN@J:VA@EX"@ILZ4ST>1GEC@W$C2TE7VAAKT$[#Y7NVK=\3 MOX#GU]`"&%O?W68E*,K#Z^)4N^/4VUSL7&85M2VCQ"2,+XXLG-_M-OP41\F` MI5(ZHOF%4X%IG26&#;="?7L?6H63#&K9PCJG#-J;B!X96+#PJAJ`XC*LJ/TV MV_VD)F^WM4]MZ)]QBM:;O+S6@3"Y'*N?VN"I+"*A+.RV_ND,?[J\UEITF,S+ MYI,ELW9W@LY@[2.]-[&S<0I4E*PQFJEJ+Q=:&:FJ;+`Z.#DK>6VZIO]N/(M% M;!:=>:4BFYAFPWR']U5_7V:L"CT-;*+[F1#N2SH;K?5.=+; M>-."D2$BA-!X/KMX2.:@_:.8_N:P)RT=1"8.G[*4\S`E#-"JE8D38/I?]H!A MXC]C%)!90YZ:GAP>:1@Y]9T@."+R?_+J5G2]=,+CMS1A+L&F,F@A=<5$O$(" M2GV1"S$BC2D+1%"8:OL37F\Z(B6]C^)*^X&5")(ST*JS4W2A6X7.6)Z91V+' M\1*!\:*$D0.8>>"QQ0I#/;'(1WI3FU[$CN(V3L'515*TG7IU)#7#&6'2=&=$ MTYS7FPO/8P<13I#-Q$XH'J*;7'9]UJTS!)2AZ['55*V\-[7XLG]A,&P$]!"A M8@P#?M+2.52"A7%,LES_G%'J(I6,YE#!&4VC$B'0(?18"@3QMXCC\\KS@P,O M^AE'*;\^G/`RHK32PX%X8_W@`K(.&%8$,``=@%0U+-6'*;BH[V><7^(/CFA1Z?T@^,=]C#>.8\!OG3V?NH$;"&0/<@T;ES`6/!8`335FD8S M,^6MCD@UN3(F*@=%V:C<'5J9?9P(2AKI*&E`QH,G,9!F:'@*ZQA59#5R,?:2 M#X3;$IPJ;MY%6)1=Z-U9Z8P!5XA5B[%V95/>'='^J+I`U78LY"L5A4X,E6N= MALU-C-3_2%7[@]FR.D,M_^<7_,R8^K2\;:!X4T."XD8^"D MFA7QT=_Y:8E=O1`BZ@,&&V+"6^943VEA'5#9PPPZV,V"&@AH\E!Z!!Y.W-A_ MI$>-6YI@1;G),JE*?Z#!<^X/I&P#8#Y_0<%XZG8MMQRX\%2^Z[$O3L6;A27 M<5?J!AB:DI#?F\Y,0Z2\@\FJZ3!<0`:D5-2I&8Y2T*6QP2AB;5>8__3 MOC^CTA4T."5EHS/(0Y$S[T:?(B[4Q_"C+R-9>I'W>TEKV$,PI1[$TN;JDF<@ MMVMB$];J[ZZDU:L,7C8)O5>,6<"+M(]"C([8B6GR<=`P MPW;02\D&)]U.7[`=B?KV.6MO;KM<$*RRA>2-#>3FV4GWP(UN+^DS;&S-9-#- M\KD,;K[K5BW9;-=,&LXAO]SZ>'/]%;N'U'_&Z\V&;!+BWL<457H!NN-BXMN+ M'FF-BN8H:V_TB46-S]#T8^7?`$Z+WD>T6N/FRH^Q2[?'Q+_PXYT32A5)TA%0 MEZ0L--6)=:#'.T47E/?I52FH'=Y`9B(M9B#M0TW!FB:BI%UCJK&7U_)8XL\V M"L@2FXC?HA5W`JMS+B&]5=.@;(^J'KU:!6^`!QVWN&`Y@_<.G%Z M?"`>6.*PRPW<'TC6F\KO!$"J,PH@JNHQUU2ZK#=BW5&E[2IS]A**OY7?F\+; MV=F,A&Q"(O$`=6W"LKZN0EKC,PX/F.:J5-GGS[6^0'CY#/N MBEOU-H6L:]4FL^75Y$T0;<.*+\&&J2RC5;5*UB34@M:QZE'95I6J;GT%S=_? M8P)-Q$?]'[)I>8C6\<6SXP?T[M.'*%[G`?:/-#I]\=67I/1KC@6;Y:_-:$>V M/!L#98/0:X7K&!7CL,2L8B3$AD*_TL&,[W"TS@8O7 MV1S0A^LAMP49S/68^[EY1>=K2IHAO2:1:C3=(H%>`.LR39=EET$)-;0LJ4R9 M6^VAM;F#X!;>U7WJA(:/PQ1E'8SJ]>34@VMXG$TJGB/M@#J."^V2V\WBT)J MM6:0&ETGKX5Q6:E@]G=C>CN"1E#M[/C4+:5L?^>)*DSQAP'S0NI*!:6:74S4 MCVJ3+:["PML7=?S-5X;28&`#PH!VS2R=8Q$:KA1>RXUY@[%!,Q9;3LV"A68#F,!\2/P0)]6'0.F[ MO.33$5T@/R6^A[-;\'GF/JNQT5OW8J*!(1.@QXJ@E5.<#5A]0W:%RC%1;=`5 M*N]T\)HS9FIH+$PXHR7_(9HG"7/IE'F:%+75K!O MA-E#S/BUX#QFN:'7W6:IE8\YX@PQK?A(E,*3G&VV&H(=:G:0V(J/A_Q]--K( M@F/,/J'6SR][)#KFDAHFY'EJ'[2S+=B5M&Y"VYG%M)E%7U8DX/J]LW[IPOFO M5WB#:5PANTZ0[[]%AQZ]70!]6@'9307)F^9W05;%@SK&CD;FH1[2_Y6I3=,3 MENC,"#S+([SK#8_X)@\10S=?`#[BVQI-07"N\4&6DJ2/$T\GJ3'5*P MAZ'H:D?[%BX-Z6W`=UX@4TH>]4"^:&V6YR&G,KG+3;KY1`@I%4+NCF]PN[(2 MB*L-_W'!%G$=5*DMZAJ08FR1O\,;XG!D^P.-E;[1S]QRWV)`OFKR+OG&SI:5 M?WI&##H!W6HE\00Z=;#17-XM?`RV[66,D\ M[!BUE1Y%DYI+MY89LYA;YJ0GV2-M[;9F*HP4A`HKB_QD].TU'7(W_>0:J@E25P5!+9": M'HP(J_R_@Q/X&YJLE)U>]F:Z=;2$"IET$MG\J&6C_.#83'*;-<0J!3B4J*7A MC++([-]+VG'6ITQ;RUY,<*/=W@F/U4A'C/=1S.XM\)B'N3RU?IVO;?%[%1YN MD>!63KQ`[#^S9Y"ID(6)9WT]`!>,?J*;>L5;HK+I"F6-3:T>(V@WN8)(]*2Y MCHB5!$Z]B^+J[X_%CW_Q<4RXWQX_DL4ND)2Z41P`4/F566KJ4_FBP`H5'0Q7 MK0%A!M).]!2N:39:VF;`BCZ1C$32DR*-+&ZA"KRC,> M534U7%W&$G:-V*6."O>:IX;^&K#2FW!_2!,&%^?20NFB7B8LL)-XD0+R#BO$ MNJ!S*ZJ**WR*7MWJ_0YF\?X7/]W^'$:/"8Z91\?)I.'CT/4#GVT![^@#U70[ M]MY)_.2C[SR2OV2E>#%&-BUB M\Q([RF=>H6)NHT5!805:_)DF([^@IOTRAQ8K$&4^DU19[::U1P.(=I$DF#W1 ME]/EXR3CSULW2/^)K.(?HR2Y"=W@X&'O)KQVXI#\56G#.-%,)I!K,B&)T(I/ MPNZ<5J;)0G& M8Z)WS*8#`F:3])_1V].UC0OM[D+ZOVG3,+^X`EZ8L);Z4ZY\VK(;;UIG@O MV$S:]@0\1#/RH):`K\<$/:G&!2/U-XWS]XS-'3RKF$,]RUQN"X#OOY`OQ8`A M+]UPCY\83D@.Z<3](%^&D3#06[HC;V?X.&XN^B%74R4E:CW/HJ!!D.\@LWZZ.UGA-I??$S]2!PGM$06S?]>AVX4 M1$_'^R@XL/M&XAO=*EW!ZDDJL=':&U1ZH;P;*OJ9O_^M\77JQ0N5/\T(U6'A MW,#A)=8T=4>I+Y3R*#+2>4Z0=[-2?72^4$U_-#[/"`7ZF0S.VF.O>(%C37!] MBQU),0F%GE#*H\1$4W4JG5#YB$K>S;SBJ'^9FMHH?Y91#^N$213XM%JE1$DZ M6L(]H]-!9/OUG+*1^4_>+]?&4SD]0H7SC6D9S_6&/Z[H!=9IY=&.S^0JJ^F54U34%(IT!\!-(L6$<&-6(&0PC]WL62/T M@N9$&+U"W-:4CK=E^3Y9&O_,DI'8-NM),494[/ES7;#H:W[Y%7HZW M0BP71DLG)R2Q5JE*1*`L``00E#@``!#D! M``#M?5ESVSB7Z/NMFO_@FWF=+))[<^KKF9)M.9]G'$MC.]USGU@T"4F84*0: M)!VK?_T%2%$+16PD2`"TJKHZCL,#G`W`P=GPC_]X709G+P#%,`I_?S?X\.G= M&0B]R(?A_/=WWYYNWO_V[C_^_5_^SS_^[_OW_W/Y<'=V'7GI$H3)V5?\S0P" M_^P'3!9GX[_?_P'!#X#._LC'.L-#??CYPV]G^,<_@1^"V'?7_W;VU47>XFQP M_F]GPT^#\[-/OWX^'WS^Z:>ST=>S]^_%YAG[,(D.YQE^N#A[7I]=NXG[A%SO M>\R9]?SS\/SSX.>S::>S_O*93/Q3Q[->?#['LPZ[G74P^/SSQ>?!H(U9GQ8I M.ICTIV+2X>=//WT^;T696)/^A/\[WTT:P/#[LQN#,[RRPOCW=XLD67W^^/'' MCQ\?7I]1\"%"\X_#3Y_./Q8?OLN__/P:PX.O?YP7WPX^_L_7NT=O`9;N>QC& MB1MZ.R@R3!7$C M_B^#_M="5*/0'X<)3-:WX2Q"RPSG=V=DW&\/MUODO86[7.%_B2.\9P71?/W! MBY8?R5WUZ&E\?3FZ&]U?C1__.1X_/4Y=A)FU``GTW$`.>\FQ&Y+R M+713O&@S9AUS[3'!_R=BCR>SR0J@3-QRTJ@U06=$747+%0(+_`U\`7=1W!9M MQ_-T1Z(;+VZ"Z$=KI&W';TC2!,W=$/Z=J<"W&$QFXSB!>(?PFD$-R' M:XC"C0O1'VZ0RB&P@VHX_66*]1/$\2.8$W[7E1ACF,8:]AR#OU(\Z/A%_EPH M`W=LP3R1?5X.Y9I3M&`4U$">,8QR`Z$&>M1!.C06:J!=8WA5FU(-;,NPK6U0 M-7#C#M;Q_G`-$A<&[6X0Q1PM[!!UT&>-TQZ*3^`U224=-0+#*=_4ZG"4/DI; MZ`W4X#=H#<&A&@2'K2%XK@;!\]80K+-@N(-U>,S664AUQN^>I#J2:3!-2RZ( M1L0(#:G./8$9=;7O5FB`N_BHZET7#=#FCZ;:K=&$QYRQU/D,-@,G-9"DCZ+* M=*^S`QX!*T:FCCAI8[1VKZC#./YH4NA619(#A/*Y0C`G^Q^)(U^0./+@EXR@ MS:_OW&=0P>!R4/KB8*PA.<7Y,\)G3`.L]^([P M?HH2-ZB%\1YD1[C>@WJ\W<)UQ5.`8E"/ISM(A;@FQWA*,W+'0;Q+K?:\!W<8 MC0,$\>X+0A_X!8ID@,;Y)5D>4.0=3!20S)L(\?9Q\AN'-?CH.4X0-A&+@0)" M:3:\(PSK?,KW;R$<-[S(^#QSX^>,V6G\?NZZ*\STP?`C")*X^`VA9OC^TV"3 M#O2OFU\[VPA\YIFJ0+[Z0V=SJ=Z7X0@=8NTBKQ@/_W@@P./QG*%K*<[+`)>+0<18A'Z#?WV&(-,8H1BLR$+$>,'$S@-#FW&(@GV$> M;%1;D_SP"@*W^,=81(;;CYVA%CG2A<$1VC[B)@@N!MZ'>?3RT0&_P_X")L15]C4BBLIWWN_&P% M]QGH%P(8:E'\&Q@`=(4QF4>(K?8'7SJ_6,'V:LP+CI]WS/$GY)+2C,?U\CD* M*+P^^,;YU0HNEW$N^/N3GJU\YU3.8@#Q)$U(UCU!D;VO,P"=WZR0A!`AA7A^ M[E@\A47^A(>E"&+_$^?""I:74"Z8^TO'S!UA''R"QTW@TM3\X!MG\,D*_AXA M77#X5TWJN_7Y,:R5RF^=@9[K<%V-/D*^X/QOFCB?6T\Y6C?X=U676.;WSL"0 MBZR@!"H)**1PH54*Q(85E\'V:V=@QQV5@?[NPE0M@(]ECV697&5>3('2,UU^ MILGL!H88#XC5-XHAQ_4I`W[R?LJJ.IN9)P?HR0%JL.!&<8SW,8&]X_!#"URA M5,15">P%H.=H%^+K5FZD/H8D%>$_2+[JBQMD:4;)E8O0&M]#-U4F5'$*P6MV MO1Y+KEK"HK3T0O";2M&8U(]B4O%^=0^2C?N3M7P98)I]O*)BYI!`=[3;)-XI M`BL7^N/7%;$\L59/D@5`.8OX4A:`UNQ9%A6V&"5TW[Y-,A>5[B'U>GW7PHNV MA#,]-B`IL60_9:E;>3T`3#7T2#N%RI/G'E\EN<(4'\0"WW@MHOJR8>>%0]/` MS9-ABNHA?#@Q=VHZF`6>>4$R^K$_?XDB_P<,JD**Y4]L\/I7X:QL6S;@(.6> MH#8$"HXQID=][3DY[Z#[#`.8P*Q^-8N@+J(`DQ63C2-9"_@A1(>P(191AR9Z M=-FJE;JYRTW==5:H)GQ_/030'>Z0$AS[5GM,6%_<%2C%B.X8)23K:AAGH-CU72M8UET)EUKHI"UQL93L#OKUC"M2F&?'TW%J;M*J6WX;![:%>=YP" MK6`31\_KM4GJTP+5C%A>?DG%U\Y0MT>.*21J'+J*CE[X9O;J6+CI0J5/G:'N M!+`:LJPBHA\NER<$W#A%:R%9'G_L#'77V-:09C49S1TKUHNZJWAKS%R.I'(/.!])$*@3]V48@-R'CD>>DR MS3KA78,9]"#;/N"HD%&FC)L)&ZDYX*B$\ ME1#J%]P36*XBY*)UOA%C+9Z@C$P_NY5/`DR:H'XE?A^3FBCY*DT6$X-\[FY=`%C3<$R*B'U[&*A+%#FT.I$45BWQ*^N$J MW`N3U#BO!:`M*EH4HZ8?&6!'O2J%CFD&E$T5CAPR^I&-=40D]WRF0-A4%LD@ MH1_95I)==D7`;*J(Y-&AS--O3MI.3J=HWD[^M>[Z1RGO2#7ZC':/C4797=CF M6^BF/DRR5I''/2.W;(HGL\D*H&SNSIM'YI'P+2X".;L4B%-D1W!YT/EW"NF< M0CH&"VZS29&RAB)[1F"[8$!9%+IA4Z$Y7$.)XN-K:TRP(#>;R>9P>HR"-#]G M*!%\)I#FL`M'"(>2$Z+&3,%E3QH';HZ*L.384)K#)O*BXY+3CZC9HQN`>-,* MX!&@%^B!F-TDC`*A.4PB)6`^*6(-S*FL^XX2`W!5M+0AV9#%?<'.9^A[BZ/S2Y`AW3TH6GO?11&A]05 MKS+P+[E<6-U='F4\PT+$],.N_N+"D.CP)-SUNKL-,979JWW$S!(V]*/3(ZJNI'&/M\TQ`W3TAF^@`G[)^;`EUI,Y@BU[_6!.! M,XGJ@S=[9\+<8,;EK1%33.PN=>42S"*T::WPY+Z">/R*N89)AZ&+UMDQ6MT> MCYMLTLJLNMM5-M&VEMG2AU;%6](W7+W$=^89LT4.!4)W?\KF>E))4C\AK>X4M0;4'?WRB:Z4I_B%LM=3$RT M/N@"EIT9NK)?)[-=L&"*Z> MC6Q/;G89[_[X5"D]*V_PS1[.P_QM(6^=9?7@G8A(*/3W)77 M$[2="2UJU-,:`_KAZ:W@C(!6,:`L:N3#IJ(U[ZZ1!K0;+VZ"Z(=.PWF+@YR5 M?`1V,HGE3>(J)I[LWY/]:[#@\%9-M':*HA>(]\;+]3>\O]V&V^2<$3[(7_(> MP@*Y*]*#V65)RQ/7"W.[WAU)KW%;3UHB=RCMA9%JA+JSQN.GZ`%XV.Z!`3@@ M]2E2MS6T,9UF(UFEBK7$GG[Y"/$JI]#$=(\\CCQ-C#@*\6*H=5:*@ MNNMFY:5T*&T9.AL;'LVV#F'YXLUNY4+R0EZ&T[8^+0"88]`CL0.\L4J=)(>@NNMPFRJ(#)W]*+RG[HKQU%US MXAM<6-W5N^VI0P6ANBV#%O4!I1CU'<-D5:($KKL,N%6MJ*"U'UGZQ]06Y^6F M^9>45I1@=1<+MZ<2%83VX]T)<;>RDDB<]F)BM8$:":K[4'A(H?@V?,%FE:+P M+6,PW57("N*W'.KZX3K%UM3&\3/R_DHA`I@+>%$DZVG@A@F^CY'W][(&6`SU M$!]$>ZUR/5%7ZXT6?0#0S=T%-T!C$& MTUV"K.`,XE"GVR%":Z&.(@\`/ZNR)X\)D5>Y)[,'X`.P)'?WS8LT^3-2H?^G MBQ#>,&/B%B11)H#W3P]0SARU$VBO::XG]@H?JU*6]"(58)\C&W+'KP!YD-T0 MCP6FO3!:A;J($MH/`U><94K.'NWET"HU1([L/MR:Q[,9\)+);/SJ+=QP#A[P MSC@)"1-(.2O^@YCT+VY`S'Z&OL@,XPSM*?:2I:L?#OIJ^J8`P<@ONQ]915T2 MPSA#B\J\).GJ0Q_/:II'>+M$:(UWQNP!7&E=*,$[0WO>$?V>#8LL('XMQ`I>87^2"19K& MQ)/9=&_BKFL_]_';%:;FU=?[>$UF&XO.#78UJR*O[J@87T,U:2.\KV'L!5&< M(O"$]>82H_F]+1953*6YHE65Q"D;2`O<:L^3T=T^0[(EPR18Y^]R;_)@\'Z* M[V4A_C%WVW1>6;[#XRJ["Y!-;XQ0A*XBS-6LRX-0^9?$,!KV"A'T1#8"J7$T MKW))D5`6LRS%?5BI10#P(&[:O=NS.@@IL!BYL!I6(!4GN9-89AC-ZT]$"G2? MK@R5?5ASNWK&(A[?]8K;\3;OE%C45#Z`P,V:P\1)G&'YO(^EP')L-K"&M2J, M$&\1)9OPY$UK^C&@J0L]^9//+_IRF"(/&8!/A$M\;*+%M MFJR_:8J8O-C;W.?IV?OC0\ M!,Y7'JB&$Y2&DIRQ*S&*YI-10`24LT^.QCZL.++'P+Q.VPU]+WN^9`Y"C^0N M=-_6LD`EZ_.\A\J._P(K4&H<#-R&9?E2DH3%,?E/P*K!9N M@,51T-I8Q8]&Y"DX%4"%>A\-SE5I.H1.-68QJ4J)F53T07$?T]4JR"AS@T=O M`?PT`+ONO+?A+$)++;'Z?<0*=,:!<"A>!%R'^;1!91^]W:XHY/@3'4)WKVL-QCHNI;G0=$-4NJC@8* MYGU0QQL7HCQ9K^/M<3OQWEH7V.Q98!HV^2IT1'9V)ISF[9S#8LHVSJ.H#XOE M,L67'!#'CV!.SBF=)E..P0-812BKGQ4PDR@@.IZT**$BYTX2@-9M$-%935D] M8C3U80T]IL\Q^"O%XXY?="0LE.<7NF!4@^A8.254A-8+#4;W*J&SE;9*&)3T M86W()M5G#[-TOH).J?64M;GUJ8S"!/KDP5SX`AZ!EZ*L3G3\Z@4IU@I2PK;R9YMU'*KBGKM8U$W;ZMK8KT M0RTKZY2D>WP,C)>K(%H#?`2@%^B!ZI=A1D&&2W80D,(Y>YK8VR:_>M'<9\>@HPUF],-%>0;F)*,L)BZYG$UQG"[SWV6;D)SFJIA( M\W.6[:NK(B;UH_=0%5OVV;[/EDTOG74CQ90;7/,3FUTJHS1C='?6:T4!G\NL MV#VQ4&2NEW[S+81)8]54.JWFUT,[4EK5+&NQ$9.9=3ZREXP>5_L('G*(GH5N>8K([NPH(;7' MV,OUYA\E#7.9$74'R>5326K3V8=5*!M"OP:)"X-3#-V4&'J!Q!/G,<###WL> MNR[3JFJA!EH<,PT#$?KZ@%&KY#5EKK%634[MH_5HUJ-VN5`'W7RWEV"ZVCI MPE!:L7:@FCW-+4M=1M4.>&*WONS[T;^"Y3-`S+.J_+%F1ZZ(>&A'404I=HMR MXX#B2O'@.T=OB_KZ`BQ3H2S8J$=XI4``5XB5WSMZ6\W7%R:-&F4!/%V;:[GO MNLA%8/NQ8TC7>(XY5HFXYT9\?GXCMYG.*OEWHK)OJ6W#YZ= MJD1E3=Z;OF4JV^EU:9"!W#./2M,#TP[_1?5S+%8+[B;%&W9"&HJ%_@U\)3_% M7U`4L^1'A='L:)!Y+8=%0R]2=*_<%4S<@&0BYRSZU<5<"P$Z,$YX@J8#:?8NR(B8240_$DGOR.-]BRCP;Y<.E`FKT-,L)E$M&/]RVI1N0D63`]26Q`4WP0`D+F$J+LS4HS!HH)+GY^Y<7N9*%8$[P,6PWN0>UG#\8S!E\LD8?>'040OY5]4YB MA+N1Y,REF!93=.[D=3QY'4]>QY/74;@=Q-X1SA#9_F<6^19+:*L250*0,5U$ M-(6]3FU$[#ZZ6JO?[=FYIKC_R.4ZK\`@>Q&OLM%NMOX`0(#<@WB1_"4-(#AZ2^C1^)4P!W.Q.(7C- M\=/V1%^M:J(\L5MS'D$0D.K(T/_JHN^`5#N**@T/5',PMFM]$6"'Y4FJ#UB. M6`8+3.(U>`%!E+EO1-5%`%ISA+=KC1'CB+:<=$IGF.S9U,#-<9AL+MV/$;HX^50B`T@($1X0MJAH`P1:HN M&CZ8X>L,@?V20M\-/6",8WYP\LR?//,GS[SZFYL;SGDN].TWEOBZ]_'M@73X M]^?=5YK=OP><9PAGBZS=XOF*3\MENN0*Z.`[S<[2$O^KA51&V'(QN:]B8MK_ M3K./4DQ,)80MOP,TO;T94@4B?WO[Q7K)5389'Y&^*/.,ULOUD:V5]2O>-C_= M:U%,+C:D`<<30,L!2P-:F]2\4I-?J-K4)A-Z43=*<;0=<>BHEW85AQY@_/T& M`7`;)@`K1_*`)<53T3;G-J]6AJVI+?.B'Z6OK7-J8][I5-P-"J9X7$W0WQU+ M^E'DVS[#Z(X^&JC(A8WU1T3BN`%,UEW:$-6S.P/- M'=EUJ2^='3V)A[;/K(YM"282SL`0![49>KS'%65UZ+U7YVYM"B82SL"X$C&M MZKSC2O.*]]ZJ\S5\@3X(?1U6Q?[< M\C-.^1GJU7R#(F5C^A,FB]O0)UM-Z@9Y%V,8SH^7*7DV![,4@02B?$L#(9A! M4F'U!!-2L+4;AI,.H@LE2[)/-++';E4_HHJP*ML.R%FT@*NG:!PFV!CDEE9* MCJ3[X7*-"E.MPO+\TZ5YE/*"^R@LTNTY)03'7VK.SZG!^T,ATLG2',ZER.H: M:ZN'/R;Z*R@T!HCFM!TUTF/39WNNR"G+QU;)U;TF;UZWFJ1)G+@A.;WN4UX) ML>JY;,OI44R[JKU_E96B86I08IG3;,.<+^2MKO@VS&OJ6M3`PXG>0J(.C?`W MGI6S8Z&A"^VKF.TMY-HPJ6^>5F-"G]RFO!F_KB#*[=$.]+!BMC>1 M+,,FOWE>3#--I%S%FE)[14I&`^`S]*J5>6S(7VF-\.:9*GW8U?3>+=Y"W@F+ M>&7I)?GU8AQ:JH5_@!BO(.*U*2HI(O*K+I53%(4WD5Q2@R=O/+5D:[<`Y,&8 M^+A:U]BCN=Y$Z@B+^!9312S2P;WE^2>`\P59PI@@=PXV3`-3!+U6DISD,'`& MQCTNU\7QSV-)H<6_]=_G&$NYQ-K29G58.`-#HBPJ-%HM6PJMONCWWLQC6H6' M39=:2Z+B#'H4"6J!-SMO_=O6\`K7G2X-ET3%&?0HV-0";[8:KBL@5=?]RN-% MV3THJ:_=(^$,S(])Z>'*5D??:`VX=7?`X=L):DFP9*O&C2O`>^\9UJ3?S1!S MAN9'WLSAU'8UO-&J\F.?IR:E%\3`&;Z=N)X$2[9JW(-J\F<^QYZEC\$'0)*[ M\>^OHC`K5TO=@/14&_)4NEMLG*%E(<#NV;-5=5WA0-69.N1MY61]&\8)2K-[ MRR19`/2T<,/:C(JKFC0:B*4S-#^L:"C;MLN@!Q')!IN(M`5(XVHK;4V5(^D, M+8MK&L.U[7II'/NT>KW0;4H="Z,&-L[0LCAH]^S9JGK/`Z+B/K%;S"08QM#+ M.L-TXYH\G-,9]BC$V80)NXJ/_N>@2&4Y9'^[QE+J3%F%YG>&/8I!WA&\SG*2FPZ4]_:.#GG;R>:V8A)6_7O08=K M-7>'0QYU=)\K3>J<6Q:5;(T+6_UL(>)H0-?)\U/7R5/7R5/72>7"G09N>.\N M>0^#[G]F27?&$LIVBZE^5F+VOR>,'VD:N&$)MZUB&]-I[KU85@?52<[/%M@1;K48T#MBM!TW[^1D28Y3OYV=_)\;6 M\@SNH_`ENU:W5SPNBX,I?2,/]$>Q1Z,&3TY]`;E,:[]CH"0*YK6RU*#*1RQY MXUT&N0S+_9Q:U?@0!?-:8FI0XR.6O/$FA5R&;2J:-6OR$1;F-=?4H,Q57-'] M!&CG"=2[@N36VB#6P,'`IIM'"JJ%*6_\H4\KKW+FM?LTX"ZWUPKTS;9A%&=: M*<5UFWZU?=%/KZ)ST3.PY:C.-2#$+V6M'>UU=HBTO.IF+=3#Q,"NI>K5OCYK MWGCC2,G;MIEG@"2.!C9+U>Y&$6*:LO:4MEQ,CV[G)3:QU-X4U`QLM=KU-5:* M5[J[56KTOM!.3HUJ+H&<@1U8]?EKA+CU5OI6GNZ^!G9P-?SN^ZO"GI=5OB$# M4L&?$@IIN:4$'Y*"#\EA',ML"F"+QC#:>!Z.9HDE;$ZVYOYO>%IWSS<+9`* M-2V;`Z$ILYK+<4$!:<^2IHAHM$(PP+\>E)%F/UG.`=.4!RW`_0IQ\6DQ3&;_ MZ8:IB];D'^2DQ@74E+U<3VXBU&A+:::(KFP&L^55_;6FU-]Z0J*2T#PQS.HR M`4.N?/)E`@HS4_5(;A1D@P._^BY+RN;#F&7PBPU@7CKHKS0I"Q.DZARTTR-E M?;#9N)Q.JD9VSQEEFYH/9C"$!/9+"GWR3(;&^`*)($PGK.AO4A!]30&YF@> M*5Q;="NS;@P)5/WIHFQ)[;614:Y%%7,8F!JI6(4H1!N:9EY@>QO'*?"O4[33 M_@AARI=1F-4"TW1#%-[`=,!JNS5O&ZG&`\#\Y44G\<-&'/* M5E7^6H.6S(T:>!J8WJ3^;MT6XUK,7.TND>,!^``3^1R`/:MO%.:M<:8IPJ`Q MV!QSFQ0/\=P.RBDD,RL#)&024W.FIZ(H<@9'R;0AT&:P!?P"#Q\ M?TH@B,>O7I#B17B#.4DVJ327V&0V=A'916)\QS>W8^#!=YH[!8H(I5J<92KLEMT#,7HY MI\7V&TMZ^^WC:WFL/B.%WXIS]Y7FMG@'K&=(YR@+QD[Q?,5WNF6ZY`KHX#O- MJ2\E_E<+J8RPY6)R7\7$M/^=YOP5,3&5$+9\MVN:4V9(?H=\3MF%]=F`=7UJ MVZ2!41RGR]R-]@#C[S<(D/DO'TU267ZI2W;XUG]<4I8YT^*1 M]U<*XZS"F"U2P3$,]),/&)X-":HTQVDH-X$]!T_AV&'6^-"^-]!3?"PW+@4] M"4E4JV7FXZ[VDG]!45QC^?)&-+`44WHQB]"HN[Y>E]HHU1@#RT-5*LM^_>B; MK:,W)&65>T;(4&1V(7U\4!A:Y,[S)%D)9&!9(4=\5#*45=BW9HP]@-6^<<(3 M'!_2P+[>?`.-08NR6GR531(P@A[A[3QO>%RV,ZF/5?+@G(%Q_=LHPA.A1'=I M.D5X9+,G';(FLY'OPQRC#0G9A>XINLV:PD>(&AJ6&,(9&)(@RQ6I)%'*"JAK M+4PUIO`]2'+:'H`7N'$,9Q#X3]%7-_3)E#!8[Z5(N"N8N$&FYKP>>XW&=8:& M.,%$#.3&E!KZN,X411X`?DS*$W<+XS!-IC`_Z(D*XF,X0PO\8;6HZLF3,M5D M,U1`#-`96N!/$R=%W0LIBL_\T$,9F=F1MKVLDY6)=NO)@"C!*I%18RK/92FD8)QAFZP1;;FP@]@#DD MR:($P4T"-E5N@O#.T!:7D@Q%6ZD:YE,ZB)?J.,S8K2,4IE3,O_>&=KB6V)1L)62LB+'K90DA>M]5I&$E\'(B#_148"6:!UG^1(FCO]Z528 M:A66YY_=FG>U@&`V?@5>UF-O,IOA:RSB9LTSH#1W#*PAOVI%8)-HM]`O(])" M?G:-%XM'HK-7"WP)6KHA5^YL0,V-!Y6)GDNE[FQ@VG,/Z3/Q29!;4Q976T0! M1C-FEVXR@317_S66J!"%UE=AG)[XM%-RE)M>[NB()[.]W\E?O*M&L>BQ3SFJ M>M'J[`&\@#`%)%:^1WUU#),+8TJ712%1TVG0?=(JVJ(!>H$>OKG<`!#?`Y8; MK?RI,06.`H*LPEW9X:K/54LRE6!2W#/)TS"81!!Z6$/U>FM9B,'8"Z(X14#` M=2LUSLF/*[AR9+GZ-IRZ4Q2M`#[3L5'^O_AV]11-T.@%KR%"W$V$)O@?7<*H M.Q*EXWACI<>RQ(U:AZXWI!5<'VB-T33[06M)7('R:'=B4NN=T"K">()_`M?_ M*\7F(->/P0#1[)*L*9$*3P:;1L-DB.@/JYB!:96']V*F=8>/AX^8,BNZG.+ M'(44]'OA$U_IME14BT$RFERB+:9;?;V*V3S]^F+WC1"5>(E$,V>#A'I")"@.^A'ZXV^ M;7+!63>,KTUYFY4G("KV_>AH=YGB(QO$^ZTXMP&:!/\40Q]LBB^+.I2LPI9: MFZIF8%.:K0MLKHT)U=WR3E'.1K1V@V3-OYH=?FB*=T1`T$>(&]K6;N1Y*`7^ M*`SQ56J#-*>6G`%BG@.$LD\S25#6S4YC\@58+=P`,[^X7BF^,Q^-S[LQ4P%. M]V61^S*+?6_CMBSW_(H==^-]?'L@':G75_1>B`\XSQ#.%EG#HL23D#PEN(K2 MT.>$$LL?:K[KEKA:%1NLP-@P[C\"+PI],0%4?:OY.LN7`05IRR-\31VNAEPS MY1VNUC_N512\;G+>"S>+2,UY&<2\.R3U_2\&";V(T];U`AAWR:2_X%9&W%`? M;>%&GLQRMW+\%.%C^`DNP8:"&T!M>"0":UXP_4AD,K2T5IVA;TM]`#-\TA>- M`<3WU4,X`\MN1'?78T+ZX6H](G/SAQ?-0_AW90M]45`#WQ83EW8%+;I=M*T( M/']FI=S(35SJU?`&/D\F*GHZ02V^8M*=Y_<+:<^'J8N68./S313Y?/=&YGE[ M*SX]^7E%_+S5C'L;'MY3/I2E@MNK1/_"Z])_]*U%F5%5N)N9'O7?>+^'LS4, MYYNK)S7?YOA+6Y*A*C'7?;]6LZ!R[<+&*8`OV8,N*4+L!!H*A`5Y4WP*6LR= MZLXLV_9+WAAE73<]V,V_+:(7:4_+`CM9=(++@,/$MV'=;9EPN=[^^$\($&;E M8GV'3U9>$UFQ`2RQ`H6)Z8G0O^([=IKW&(V/">:V)I`:1[-%*2Y:CFH(TMH3 M#;D-5VD29_PYYR:2,*`TFZ_2TN,H026!=HN\Z3W?$)M6_IYO?0+%-4#8.">- M?>^@^PP#2-K-W6-CEWL_X4":DEIQ("N:-YE'B:K5NHX!RJYI^?Y$XBBAAYF120[_#3,#7\POW1C&!9OR?I28?DXKOQ9G-2_W M@ZIF[7*A'VZ2+8]&<0RR=G%[2W+#-W]28LD7?.[>17%\&Y*V^,"_#<%>-.7Q)&VC#WSDH1J6WM[:4*-LT9R>V\<^D8XJ#4UYSWYJ0WP7;QE/_4I M"\&4*IMQG,`EZ6N_UNS/L*:T*,"L.DEKFK\_?JW$!2;"*PNF.(`G(3),.T5N??\-39]^1UVDW; M_0DV-1?`Y13*\R%U1PD%I"9$A+86Y]1G(["-'D"?8,U[+:+\I>Z0FH!,*I%6 MYJ.UTTMA2`!*WDNAL(1:D^1(X&!329"__,9]VZX:PKP@S&]4.5(I4&5W:"RD M)BT^)[."+(8<#S\T,`I"E=\QYLT7X44NN!#,R;ZL1W2/(`B(XR'TO[KH.TAV MM23,.QL-R,!Z:/J29%+1W$(Q0;R39`%VK]+D594;(MD[+AO0P-IGJICYE/0C M6#TJK.['!>;AI1N#K'L5IC.3#G]5BPW@#`SQT0B(7IRBYA%L$U;[%$4SF)"T M(X:8=Q\Y`^/J'*FB/,2ZZS8%'PE.SUA_\%_^/U!+`P04````"`"C@FU".1UU M_7`.``"@EP``$0`<`&-S8G(M,C`Q,S`Q,S$N>'-D550)``.RWT!1LM]`475X M"P`!!"4.```$.0$``.U=_W/:N!+__6;N?]#+3_=FCE!"VKLP;6]H(%?>)($7 M2'OOIQO%%J`Y8U/)3L+]]6\E?T%&LK&!MN:E]:XEQ-O?GA<. M>B2,4\]]=](Z?76"B&MY-G5G[T[N)U>-7T]^>__C#V__U6C\\>'N&O4\*U@0 MUT_=)IMSKGYZA[@QJ-8OWT;>I[Z7[.3B_0PPKUL(\G#%M_\2V] MMCMG[0Y=\JM.5E@Y&,V(_XM7A"^Q!9Y=S+W_66GV;3F>+&$ MOK@'T\SQ9JM3RULTA2SXUX+9YQ"AZI7'%CTRQ8'COSOY$F!'ZGV"8+JZO&/Q M!U98HF1)J)^>GDZ?VJ<>FP')JU;SCYOKL=0XENU0]Z\4]?,#8'KLU4: M&4ZLTYGWV(P:36P!8Q"!L_BB5@.C3:B9!QH,Y.39FIOI18N!@;J/A/MFEK#- MP.1B:G$SCVP2+*TT"Z>6F0$:#.3@`'^U)-SH&MEB4(O[2Y;1";08>K')DA%K MR\"!R"#'SA1;?H,\+QWL8H@NJROXG`#BN6ZP,`NQ?=84&C>!J`%4A%$KX=O. M%#&(&(1=U_.Q#T'A_5N\7%)WZHG;8AYTA(H38$#BXOYNL"6.2(OB`-IU[;[K M4W\U`(EL(7LX011`R:5(^K;)E+I4Z@6Q!S76D1DNAY?W-_W;">K>]A#\'4S^ MAP:W5\.[F^YD,+Q]V]R4$`L-.+&'[GMY#5[B($YV*P)*Q!61F#C6`HO16]BQ M`B>[@V8*Y+U0O_11V^8;S[F^[][W!)'2>R8WC"?P107",AE=H..K?R=A7QSE7W`V7W@(L MGP,-?237'B_M1UV`V9VO]W/GY?!F=-?_"'2#3WUT/1R_N#77*YC/KQSOJ;P[ M$T:S&]_LZ<;N^".ZNAY^KJ/[AFR&7?JW[.N>D^&TSWT*61[AD/A]P)P"_B/% MX-!WI;G,COM%9(F46X['`T;@@RKW9P22D3=%B6R$71M)Z>*V*K^&CKLC%MCB MK`:YLQ#P7+JUP\H3N*DAK=M*OFTZ*I:%0'%K+0VF!-?0*```Y MA+\25=.7@"X%#J$/C"UFQ"\V$8]YY01(N&L([W@.:3!$`&*/\$H9X(;[1FA; MKS:AE9P-R8IBWAH">T=L0A;XP2&0.RT\=^Q[UE\P5.7?4<"`E9//F#$U&03F`%O;P*NB)#C_%(54D/, MKZDEZC9WUITQHB8QI@8SQN>;&">L:,U;0V@OR7*.'<]-0(@&L7;;#.MK;>A& MC&M4:PCJ.%@NPQ4^[(AU-SMPR+IDU5ZK%R8(`%Q_-,.G58R"`4F. M&H+W(8`G#^%\3&9BEFH1(:?=#*]6'L824"2BYA-^'#QP\B4`>_J/2HFX>=<( M[IE>("9\*&2L(:)E7_=-1`G'=WM5&/&:O:-5C+N^,$0_A?W4<27-]"9*]5A. MN]DK6A%I?E]59\SU%U0JXIFM9KRU&M+T$JO.:)=Y-Z7Z80<^LX>T"K3\FZTZ M^R]),%7G;-XT(Z\5J>O9*L1;JJHC@XUI4HII^41F!VC%<]9R=0+["94)^39#^(=>P7HS$XH MN`*;.`%%XNKH##UY3"(UQ_;@-SM4*]3W<&B]YZ9YDY79 MB85HS0[3JO3L[5DOCDEOV()YDMI*9?)-<7*S>[1:/7W;64 M`%YCO),5I%2^K-TUHZO5Z^K"4HV3W$WX4O$CJ]$,L5:=&R"N<[S(7IY+#>CM M9&;XM=H\?QGO'S+FQ7_B^)L[,D7R7)F..'SCW0FGBZ4CSJ.1]^:,3-^=B%-Z M&O$Y/'^"2:?/"RHX%A&=-Y)_[@T(D6L1D%$V8^5/F@>P M!P`O:T_:1Y6RQL$/9:T!%N)4SA`8UV4-V9@*AS6G&9\_`U?K4VF@`2SQF(]< M[82LO..>PL.UKCU+BLEA$9\:,5]#W&JTSAKMUNDSMT/%2O2?6%2R_YBO7/_F M([0*]APSB"Y?%^@L]R"KC#YE?T;&)G%\'M]IK$45M3KG/*D\70QLT?4>.IB. MZ"JBA,H7?]A'#=.)7X7T4!F33WMHHIT+5D2+A$E>[=&[?EQ8D>[77.%E8RV@ MK`*;QX\5Z3[F$1?[=+UY*%FAOF,F>56N]VV'XA4)1@YC*2X1D2Y$$&R]V4># M@J%0Z=W?M^?\<]V*:J-*Z:^%E%,N]V"_(J,BYA$7Y69C_JESA6#8Y-K#,>:S M\LHIX;FWN^B1?\#@[L],*PA!A-X9L:E_"%/E2E-846`GS]9M MA,=@[*7'_>&TJ'<+47\]LVWR<$BK"SNZ&/D1V#UP8>1`3=IC&.2Z(2-&EIC:/3(E4%K8D-*(4]G$RN@0HC#K3 M>03SJLSN%4,FL!M[=9*#4M\E(\_^!P?N[VB_PA\"$!Y*W?'C^SL.C?U1,*SC M&WR=2U4=EYHV)23K)28?%F6HF-.T57^#RW)HJN,P34F3D_*(*N8894>`P27& MUNHX0U'/Y`9S<\4T649*V3SK>?V%TO' M6Q:;&"NG>HXQ8OL=$^IUM1"Y5A:Q91Q)Q(#ID(F',$#%D)ND^K,S!9AB& ME$M1$3C$A@)$:JB&JX.+3CVH9`GT_:+\-N-X2>L^$SJ;^\3N/A*&9Z3_3)A% M.8&RSB)E0#ULO]%(A6$*0$JYU44\RW#Q55SQ`ART#<+3XL6+ALDZS\O:63< M`6//3MT>4US:V?`KCTV)^"V&C,BQ<0#@5W9#"6UJ$NL\TM5272?*-"VG;[]AT(=X>A0&^L$$]F7)N,2DFJE"RVETRZH@]+9OZ M:NGW5LH*6?4?[`:8K<1FSJUV%:"MD&6;44(S)XN@0C;L'"(_$2Y_/T7J==#@ MFR7Y"!9\=K8Y?JVEI,2'@-(H=L]T+MR`?!"XDN4]^2LZO8"MW>XQ9"F[ M\YN.@W>]9QIZP'FOS--X&7<3GFR2"F73<3!*`3V*M#($K0RZ"EFDP'Y'EBKP M!K.*$%?(-E!*_&H;3`SY\YB;P\M.KSUL(4W9)6B_FUGK;31=VZ;A&I&ZC6;B M#>371CR6VKE4AJM"CU+S!J+T_I!XNFW==Y3%=@29IMQY)CY+MR7/#[$NMKD_ M+8OJ"*Q,S4/,YR,"P]1/?GM*GZMIFNI,TI'GPP>*G40[2%?OR(P*+828Z`FO MVE68Y1@5B*R*=7`+(+JOP[I6A83OXX-8PD[=]X*(OA*3TQRJ;Z:D8?[ M7L/0%?O)E_!8LO5YIK=5:(*-B>6Y=J;RYN8*Z1]/].$T>GH5F.#44WOED1Q`MA MEMNT6L$9F;^SN.1&Y`K:=P]Z.N)[Z^(U>Y3E#A\)FT,FI5E7A+A"MEV*$](< M*E:&=%M,C=]5]V9XB,#['W_X/U!+`0(>`Q0````(`*.";4(LTNM(>7X``"!Z M!P`1`!@```````$```"D@0````!C`Q0````(`*.";4+60:D/P`D``&1[```5 M`!@```````$```"D@<1^``!C`L``00E#@``!#D!``!02P$"'@,4````"`"C@FU"):QT"T`C``!2=0(` M%0`8```````!````I('3B```8W-B&UL550%``.R MWT!1=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`HX)M0J$"42\V2P``)X4$ M`!4`&````````0```*2!8JP``&-S8G(M,C`Q,S`Q,S%?;&%B+GAM;%54!0`# MLM]`475X"P`!!"4.```$.0$``%!+`0(>`Q0````(`*.";4(5O)M4LBL``,LT M`P`5`!@```````$```"D@>?W``!C`L``00E#@``!#D!``!02P$"'@,4````"`"C@FU".1UU_7`.``"@ MEP``$0`8```````!````I('H(P$`8W-B`L``00E#@``!#D!``!02P4&``````8`!@`:`@``HS(!```` ` end XML 13 R33.htm IDEA: XBRL DOCUMENT v2.4.0.6

Share-Based Payments (Details 3) (USD $)
3 Months Ended 9 Months Ended

Jan. 31, 2013

Jan. 31, 2012

Jan. 31, 2013

Jan. 31, 2012

Weighted Average Grant Date Fair Value Per Share, Granted $ 0.27 $ 0.52 $ 0.36 $ 0.57

Restricted Stock [Member]

Shares, Nonvested, Begining Balance 25,000

Shares, Granted 100,000

Shares, Vested (50,000)

Shares, Forfeited 0

Shares, Expired 0

Shares, Nonvested, Ending Balance 75,000 75,000

Weighted Average Grant Date Fair Value Per Share, Nonvested, Begining Balance $ 0.75

Weighted Average Grant Date Fair Value Per Share, Granted $ 0.30

Weighted Average Grant Date Fair Value Per Share, Vested $ 0.53

Weighted Average Grant Date Fair Value Per Share, Forfeited $ 0

Weighted Average Grant Date Fair Value Per Share, Expired $ 0

Weighted Average Grant Date Fair Value Per Share, Nonvested, Ending Balance $ 0 $ 0

X

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that were expired during the reporting period.

+ References

No definition available.

+ Details

Name: csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriod

Namespace Prefix: csbr_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that stock instruments of the plan that lapsed during the reporting period.

+ References

No definition available.

+ Details

Name: csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriodWeightedAverageFairValue

Namespace Prefix: csbr_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect during the reporting period as a result of the occurrence of a terminating event specified in the contractual agreement of the plan.

+ References

No definition available.

+ Details

Name: csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriodWeightedAverageFairValue

Namespace Prefix: csbr_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(e)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(c)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(d)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(2)(d)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph c(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R25.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value (Tables)
9 Months Ended

Jan. 31, 2013

Fair Value Disclosures [Abstract]

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
The following table presents information about the Company’s warrants liability, which was the only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at January 31, 2013 (in thousands):

Balance, May 1, 2012 $ 555

Transfers to (from) Level 3 -

Total (gains) losses included in earnings 21

Purchases, issuances and settlements, net 417

Balance, January 31, 2013 $ 993

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19279-110258

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 16 R42.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value (Details) (USD $)
In Thousands, unless otherwise specified
9 Months Ended

Jan. 31, 2013

Apr. 30, 2012

Jan. 31, 2013

Fair Value, Inputs, Level 3 [Member]

Balance, May 1, 2012 $ 993 $ 555 $ 555

Transfers to (from) Level 3 0

Total (gains) losses included in earnings 21

Purchases, issuances and settlements, net 417

Balance, January 31, 2013 $ 993 $ 555 $ 993

X

- Definition

Fair values as of the balance sheet date of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and which are expected to be extinguished or otherwise disposed of after one year or beyond the normal operating cycle, if longer, net of the effects of master netting arrangements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FIN39-1

-Paragraph 10A, 10B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 4, 17

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13495-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

+ Details

Name: us-gaap_DerivativeLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

This item represents the amount of the total realized and unrealized gains or losses for the period which are included in the statement of income (or changes in net assets); the fair value of which assets and liabilities was or is measured on a recurring basis using significant unobservable inputs (Level 3).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisGainLossIncludedInEarnings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of purchases, sales, issues, and settlements in relation to liabilities measured at fair value on a recurring basis using unobservable inputs (level 3).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32

-Subparagraph c(2)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

This element represents [net] transfers in to and out of liabilities measured at fair value on a recurring basis using unobservable inputs (Level 3) which have taken place during the period.

+ References

No definition available.

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 17 R37.htm IDEA: XBRL DOCUMENT v2.4.0.6

Related Party Transactions (Details Textual) (USD $)
9 Months Ended

Jan. 31, 2013

Jan. 31, 2012

Related Party Transaction, Revenues from Transactions with Related Party $ 0 $ 20,000

Servicing Fees, Net 8,300

Chief Executive Officer [Member]

Related Party Transaction, Amounts of Transaction 30,000 18,000

Board of Directors Chairman [Member]

Related Party Transaction, Amounts of Transaction 122,500 103,000

Substantial Stockholders [Member]

Related Party Transaction, Amounts of Transaction $ 3,000 $ 0

X

- Definition

Amount of transactions with related party during the financial reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 2

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_RelatedPartyTransactionAmountsOfTransaction

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Related Parties

-URI http://asc.fasb.org/extlink&oid=16382449

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.6-07.1(c))

-URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 2

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 07

-Paragraph b

-Subparagraph 1

-Article 6

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_RevenueFromRelatedParties

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Income from servicing real estate mortgages, credit cards, and other financial assets held by others. Also include any premiums received in lieu of regular servicing fees on such loans only as earned over the life of the loans. May also be net of any related impairment of fair value of capitalized service costs.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 13

-Article 9

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher OTS

-Name Federal Regulation (FR)

-Number Title 12

-Section 563c.102

-Paragraph 13

-Chapter V

-Subsection II

-LegacyDoc This is a non-GAAP reference that was included in the 2009 taxonomy. It will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.13 (d))

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_ServicingFeesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 18 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6

Property and Equipment
9 Months Ended

Jan. 31, 2013

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]
Note 3. Property and Equipment

Property and equipment is recorded at cost and consists of laboratory equipment, furniture and fixtures, and computer hardware and software. Depreciation is calculated on a straight-line basis over the estimated useful lives of the various assets ranging from three to seven years. Property and equipment consisted of the following (in thousands):

January 31, April 30,

2013 2012

(unaudited)

Furniture and fixtures $ 58 $ 58

Computer equipment and software 526 287

Laboratory equipment 179 167

Leasehold improvements 2 2

Software in-progress - 216

Total property and equipment 765 730

Less: Accumulated depreciation (323 ) (170 )

Property and equipment, net $ 442 $ 560

Depreciation expense was $51,000 and $16,000 for the three months ended January 31, 2013 and 2012, respectively, and $153,000 and $65,000 for the nine months ended January 31, 2012 and 2011, respectively.

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6360339&loc=d3e1361-107760

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13-14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6391110&loc=d3e2921-110230

+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 19 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%\R.3%B83AF9E\X8C,U7S1B.#%?8C9E-U\W.3DX M93-B8V0U860B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E5.055$251%1%]#3TY$14Y3141?0T].4T],241! M5#$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=OF%T:6]N7U5S95]O9E]%#I%>&-E;%=O M#I%>&-E;%=O#I%>&-E;%=O#I.86UE/E-H87)E M0F%S961?4&%Y;65N=',\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;6UI=&UE;G1S7V%N9%]#;VYT:6YG96YC:65S/"]X.DYA;64^ M#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I7;W)K#I7;W)K#I7;W)K#I%>&-E;%=O M#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/E-U8G-E<75E;G1?179E;G1S/"]X.DYA M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=OF%T:6]N M7U5S95]O9E]%#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E!R;W!E#I%>&-E;%=O#I7;W)K#I%>&-E;%=O#I7;W)K#I7;W)K#I% M>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/E-H87)E0F%S961?4&%Y;65N='-?1&5T86EL#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-H87)E0F%S961?4&%Y M;65N='-?1&5T86EL#I%>&-E;%=O#I7;W)K6UE;G1S7T1E=&%I;'-?,SPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-H87)E0F%S961?4&%Y;65N='-?1&5T86EL#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O5]4#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O M#I%>&-E;%=O#I%>&-E;%=O'1U86P\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I7;W)K#I3='EL97-H965T($A2968],T0B M5V]R:W-H965T&-E M;"!84"!O3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%\R.3%B83AF9E\X8C,U7S1B.#%?8C9E-U\W.3DX93-B M8V0U860-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,CDQ8F$X9F9? M.&(S-5\T8C@Q7V(V93=?-SDY.&4S8F-D-6%D+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M2!296=I'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,C`Q,SQS<&%N M/CPO7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6%B M;&4\+W1D/@T*("`@("`@("`\=&0@8VQA2`S,2P@,C`Q,R!A;F0@ M07!R:6P@,S`L(#(P,3(\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M2`S,2P@,C`Q,R!A;F0@07!R:6P@,S`L(#(P,3(\+W1D/@T* M("`@("`@("`\=&0@8VQA2`S,2P@,C`Q,R!A;F0@07!R:6P@,S`L(#(P,3(L(')E3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU M-BPP-S4\3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R.3%B83AF9E\X8C,U7S1B.#%? M8C9E-U\W.3DX93-B8V0U860-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO,CDQ8F$X9F9?.&(S-5\T8C@Q7V(V93=?-SDY.&4S8F-D-6%D+U=O'0O:'1M;#L@ M8VAA2!S;VQU=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA M2!S;VQU=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA MF5D(&]N8V]L;V=Y('-O;'5T M:6]N7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA2!T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3,\'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'!E;G-E&-H86YG M92!R871E(&5F9F5C="!O;B!C87-H(&%N9"!C87-H(&5Q=6EV86QE;G1S/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-3QS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAAF%T:6]N+"!#;VYS;VQI9&%T:6]N(&%N9"!06QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[(&UA#L@9F]N M=#H@,3!P="!T:6UEF%T:6]N+"!53L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@=&5X="UI;F1E;G0Z(#EP M=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E2!S;VQU=&EO;G,@ M86YD('-E28C.#(Q-SMS M(%1U;6]R9W)A9G0@5&5C:&YO;&]G>2!0;&%T9F]R;2!I7-I8VEA;G,@ M:6X@9&5V96QO<&EN9R!P97)S;VYA;&EZ960@=')E871M96YT(&]P=&EO;G,@ M9F]R('1H96ER(&-A;F-EF5D(&]N8V]L;V=Y('-E28C.#(Q-SMS(%1/4R!B=7-I;F5S2!4=6UO#L@9F]N=#H@,3!P="!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`Y<'0[(&UA M#L@9F]N=#H@,3!P="!T:6UE2!3:6YG87!O2!T2!O=&AE M&-H86YG92!R871E(&9L=6-T=6%T:6]N3L@=&5X M="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@=&5X="UI;F1E;G0Z(#EP M=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E2!I M;F-L=61E9"!I;B!F:6YA;F-I86P@2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E65A3L@=&5X M="UI;F1E;G0Z(#`N-6EN.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@ M=&EM97,@;F5W(')O;6%N+"!T:6UE&5S+CPO<#X-"CQP('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`P+C5I M;CL@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E2!D M:79I9&EN9R!L;W-S(&%V86EL86)L92!T;R!C;VUM;VX@2!P97)I;V0N M($1U92!T;R!T:&4@;F5T(&QO3L@;6%R9VEN.B`P<'0@,'!X.R!F M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E#L@9F]N=#H@,3!P="!T:6UE M6QE/3-$)W=I9'1H.B`V-24[(&)O6QE/3-$)W9E6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W!A M9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@.24[)SXQ-2PP,3@L.34U/"]T9#X-"CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$ M)V)A8VMG'0M86QI9VXZ(')I M9VAT.R<^-S4L,#`P/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S M='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`Q<'0@'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O M6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT.R<^,3@L,S6QE/3-$ M)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA6QE/3-$ M)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@ M,3!P="!T:6UE3L@;6%R M9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM M97,L('-E3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X M.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E&ET>2!O9B!T97-T:6YG(&EN M9&5F:6YI=&4M;&EV960@:6YT86YG:6)L92!A2!P2!T:&%N M(&YO="!T:&%T('1H92!A65A6QE/3-$)W1E>'0M86QI M9VXZ(&IU'0M:6YD96YT.B`Y<'0[(&UA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`Y<'0[(&UA#L@9F]N=#H@,3!P M="!T:6UE3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R.3%B83AF9E\X8C,U7S1B.#%?8C9E M-U\W.3DX93-B8V0U860-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,CDQ8F$X9F9?.&(S-5\T8C@Q7V(V93=?-SDY.&4S8F-D-6%D+U=O'0O:'1M;#L@8VAA M2P@4&QA M;G0@86YD($5Q=6EP;65N="!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0@0FQO8VM=/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO MF4M861J=7-T M.B!N;VYE.R!F;VYT+7-TF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L('1I;65S(&YE M=R!R;VUA;BP@=&EM97,L('-E'0M M86QI9VXZ(&IU'0M:6YD96YT.B`Y<'0[(&9O;G0MF4M861J=7-T.B!N;VYE.R!F;VYT+7-T6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E28C M,38P.S,Q+#PO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD M.R<@;F]W6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M6QE/3-$)W!A9&1I;F6QE.B!S;VQI9#LG(&-O;'-P M86X],T0R(&YO=W)A<#TS1&YO=W)A<#XR,#$R/"]T9#X-"CQT9"!S='EL93TS M1"=P861D:6YG+6)O='1O;3H@,7!T.R!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO M=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/"]T6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$ M)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\ M=&0@'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY#;VUP=71E M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^-3(V/"]T9#X- M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X- M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R<^,C@W/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R<^)B,Q-C`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`\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W9E6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[(&)O6QE/3-$)W!A M9&1I;F6QE.B!D;W5B;&4[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O;2UC;VQO6QE.B!D M;W5B;&4[)SXU-C`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E'0M86QI9VXZ(&-E;G1EF4M861J=7-T.B!N;VYE.R!F;VYT+7-TF4M861J=7-T.B!N;VYE.R!F;VYT+7-T'!E;G-E('=A#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@9F]N M="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\ M8CXF(S$V,#L\+V(^/"]P/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A6UE;G1S/"]B/CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`Y<'0[(&UA#L@9F]N=#H@ M,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD M96YT.B`Y<'0[(&UA#L@9F]N=#H@,3!P="!T:6UE2!);F-E;G1I=F4@4&QA;BP@86YD('1H92!$:7)E8W1O65E2!B92!GF5D(&9O2P@86YD("0Q+#DS-"PP,#`@86YD("0R+#8Q,BPP,#`@9F]R M('1H92!N:6YE(&UO;G1H'!E;G-E('=AF5D(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD M6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E6QE/3-$)W=I9'1H.B`Y,"4[(&)O6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E'0M86QI M9VXZ(&-E;G1E28C,38P.S,Q+#PO=&0^#0H\=&0@6QE/3-$)V)O'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W!A M9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[)SXU,#`\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^ M#0H\=&0@6QE/3-$)W=I9'1H.B`Q)3LG M/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W=I9'1H.B`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`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`[/"]T9#X- M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X- M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q M-C`[/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'!E;G-E/"]T M9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)V)O'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S M='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E M>'0M86QI9VXZ(')I9VAT.R<^-S0S/"]T9#X-"CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)W!A9&1I M;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E28C,38P.S,Q M+#PO=&0^#0H\=&0@6QE M/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$ M)W!A9&1I;F6QE/3-$ M)W9E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`U M,B4[)SY%>'!E8W1E9"!T97)M(&EN('EE87)S/"]T9#X-"CQT9"!S='EL93TS M1"=W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C M,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)W=I9'1H.B`Q)3LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG M(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SY2:7-K+69R964@:6YT97)E6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1EF4Z(#$P<'0[)SXP+CDE)B,Q-C`[+28C,38P.S$N,"4\+V9O;G0^/"]T M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<@;F]W6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1EF4Z(#$P<'0[)SXP+C0E)B,Q-C`[+28C,38P.S$N.24\+V9O;G0^ M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[ M/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^ M/&9O;G0@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R M87`^/&9O;G0@6QE/3-$ M)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C M96YT97([)R!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!N;W=R87`] M,T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^/&9O M;G0@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[)SXY,"4F(S$V,#LM)B,Q M-C`[,3`X)3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SY$:79I9&5N9"!Y M:65L9#PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R<@;F]W6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI M9VXZ(&IU'0M:6YD96YT.B`Y<'0[(&UA#L@9F]N=#H@,3!P="!T:6UE28C.#(Q-SMS M('-T;V-K(&]P=&EO;B!A8W1I=FET>2!F;W(@=&AE(&YI;F4@;6]N=&AS(&5N M9&5D($IA;G5A6QE/3-$)W=I9'1H.B`X-R4[(&)O6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E6QE/3-$)V9O;G0M=V5I M9VAT.B!B;VQD.R<@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M=V5I9VAT.B!B M;VQD.R<@;F]W6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)V9O M;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)W9E6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I M;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W=I9'1H.B`R."4[)SY/=71S=&%N9&EN M9RP@36%Y(#$L(#(P,3(\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG M/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\ M=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^ M#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`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`[/"]T M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T M9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@'!I6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#4P,"PP,#`\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXI/"]T9#X-"CQT9#XF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#$U M+#@S,SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@'0M86QI9VXZ(')I9VAT.R<^*#(U+#`P,#PO=&0^#0H\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!P861D:6YG+6)O='1O M;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X- M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O M;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!R:6=H=#L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/B8C,38P.SPO=&0^#0H\ M=&0@6QE/3-$)V)A8VMG M6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q M-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X- M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X- M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\ M='(@6QE/3-$)W1E>'0M:6YD96YT M.B`M.7!T.R!P861D:6YG+6QE9G0Z(#EP=#LG/D]U='-T86YD:6YG+"!*86YU M87)Y(#,Q+"`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`[/"]T9#X-"CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$ M)V)A8VMG2`S,2P@,C`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`S,2P@,C`Q,SPO=&0^#0H\=&0@'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE M/3-$)W!A9&1I;F'0M86QI9VXZ M(')I9VAT.R<^.2PW,S4L,#6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT.R<^,3`L-C8X+#0Q,CPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXV+C@\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!P861D M:6YG+6)O='1O;3H@,BXU<'0[)SXQ-"PP,#`\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E3L@ M=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@=&5X="UI;F1E;G0Z M(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E2!R96QA=&5D('1O(')E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W=I9'1H.B`Y,"4[ M(&)O6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E6QE/3-$)V9O;G0M M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)W9E6QE/3-$)V)O6QE/3-$)V)A8VMG2`Q+"`R,#$R/"]T9#X-"CQT9"!S='EL93TS1"=W M:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[)SXP+C6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R<^,"XS,#PO=&0^#0H\=&0@6QE/3-$)V)A M8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/"]T6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@ M6QE/3-$)W!A9&1I;F'!I'0M86QI9VXZ(&QE9G0[ M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('!A9&1I;F6QE/3-$ M)V)A8VMG2`S,2P@,C`Q,SPO=&0^#0H\=&0@ M'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)V)O6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXM M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG M+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/"]T#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`Y<'0[(&UA#L@9F]N=#H@ M,3!P="!T:6UE2`S,2P@,C`Q,R!A;F0@,C`Q,B!W M87,@)#(V+#`P,"!A;F0@)#@T+#`P,"P@6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W1E>'0M M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T M:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`Y M<'0[(&UA#L@9F]N=#H@,3!P="!T:6UE&5R8VES M92!P2P@86YD(&AA9"!W96EG:'1E9"!A=F5R86=E(')E M;6%I;FEN9R!C;VYT65A'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^/'`@3L@=&5X="UI;F1E;G0Z(#!P>#L@;6%R9VEN M.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L M('-E2!E;G1E28C.#(Q-SMS($-O;6UO;B!3=&]C:R!A="!A M('!U&5R8VES92!P2!A M;'-O(&5N=&5R960@:6YT;R!A;B!!;65N9&5D(&%N9"!297-T871E9"!296=I M2!T;R!R961E96T@=&AE('!U2`R,#$S(%!R:79A=&4@4&QA8V5M96YT(%!U="!/<'1I;VXF M(S@R,C$[*2!F;W(@8V%S:"!O9B`D,"XU,"!P97(@2!A;&P@;V8@=&AE($-O;7!A;GDF(S@R,3<[2!T;R!T:&4@ M2X@5&AE('1E6QE/3-$)W1E>'0M86QI M9VXZ(&IU'0M:6YD96YT.B`Y<'0[(&UA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`Y<'0[(&UA#L@9F]N=#H@,3!P M="!T:6UE2!E;G1E28C.#(Q-SMS($-O;6UO;B!3=&]C M:R!A="!A('!U2!A;'-O(&ES'!I2!T;R!R961E96T@=&AE('!U&-L=7-I=F4@;&EC96YS M92!O9B!S=6)S=&%N=&EA;&QY(&%L;"!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS M(&%S2!T;R!T:&4@ M6QE/3-$)W1E>'0M86QI9VXZ M(&IU'0M:6YD96YT.B`Y<'0[(&UA#L@ M9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`Y<'0[(&UA#L@9F]N=#H@,3!P="!T M:6UE2`R,#$S(%!R:79A=&4@4&QA8V5M96YT(%!U="!/<'1I;VX@9&5S M8W)I8F5D(&%B;W9E+"!T:&4@0V]M<&%N>2!H87,@86-C;W5N=&5D(&9O2`R,#$S(%!R:79A=&4@4&QA8V5M96YT M+"!T:&ES(&%L;&]C871I;VX@:7,@97%U86P@=&\@=&AE('1O=&%L('!R;V-E M961S(&]F("0Y+C,@;6EL;&EO;B!L97-S('1H92!A;6]U;G0@86QL;V-A=&5D M('1O('1H92!W87)R86YT2`R,#$S(%!R:79A=&4@4&QA8V5M96YT M(&]F("0P+C$@;6EL;&EO;BX@1F]R('1H92!!<')I;"`R,#$Q(%!R:79A=&4@ M4&QA8V5M96YT+"!T:&ES(&%L;&]C871I;VX@:7,@97%U86P@=&\@=&AE('1O M=&%L('!R;V-E961S(&]F("0Y+C0@;6EL;&EO;BP@;&5S3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@ M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!B92!A M9&IU&5R8VES92!P3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT M.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E&ES=',N(%1H97-E('!E;F%L=&EE6UE;G0@ M87)R86YG96UE;G1S+CPO<#X-"CQP('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU M'0M:6YD96YT.B`Y<'0[(&UA#L@9F]N M=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M M:6YD96YT.B`Y<'0[(&UA#L@9F]N=#H@,3!P="!T:6UE M2P@=VAI8V@@:7,@F5D(&%S(&]T:&5R(&EN8V]M92`H97AP96YS92D@;VX@=&AE($-O;7!A;GDF M(S@R,3<[6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W=I9'1H.B`Y,"4[(&)O6QE/3-$ M)W9E6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E28C,38P.S,Q+#PO=&0^ M#0H\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)W9E6QE/3-$)V)O6QE/3-$)W!A M9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<@;F]W6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG M(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A M8VMG3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<@;F]W6QE/3-$)V9O;G0M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^,3`R)3PO=&0^ M#0H\=&0@6QE/3-$)V)A8VMG6EE;&0\+W1D/@T*/'1D/B8C M,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1E2!W:6QL(&-O;G1I;G5E('1O(&%D:G5S="!T:&4@ M=V%R2!C:&%N9V5D(&ET2!F2!W:&EC:"!H860@86X@:6UM871E7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA2!46QE/3-$)W1E>'0M M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T M:6UE2!43L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P M<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E M2!T2!A;F0@:71S('-H87)E:&]L M9&5R&-H86YG92!A;6]U;G0L('=H:6-H(&ES('1H92!A;6]U;G0@ M;V8@8V]N6QE/3-$)W1E>'0M86QI9VXZ(&IU M#L@9F]N=#H@,3!P="!T:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@ M,3!P="!T:6UE6QE/3-$)W1E M>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P M="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT M.B`Y<'0[(&UA#L@9F]N=#H@,3!P="!T:6UE2`S,2P@,C`Q,R!A;F0@,C`Q,BP@=&AE($-O;7!A;GD@ M<&%I9"!O;F4@;V8@:71S(&9O&5C=71I=F4@3V9F:6-E2`S,2P@,C`Q,R!A;F0@,C`Q,BP@ M=&AE($-O;7!A;GD@<&%I9"!C97)T86EN(&UE;6)E2P@9F]R(&-O;G-U;'1I;F<@2`S,2P@,C`Q,BX@1'5R M:6YG('1H92!N:6YE(&UO;G1H2!P86ED(&$@<')O2`D."PS,#`@9F]R(&-O;G-U;'1I;F<@3L@=&5X="UI M;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E3L@;6%R9VEN.B`P<'0@ M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@=&5X="UI;F1E;G0Z M(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R M;VUA;BP@=&EM97,L('-E2!E87)N960@;F\@ M2!R96-O9VYI>F5D("0R,"PP,#`@:6X@28C.#(Q-SMS($)O87)D(&]F($1I3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\R.3%B83AF9E\X8C,U7S1B.#%?8C9E-U\W.3DX93-B8V0U860-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,CDQ8F$X9F9?.&(S-5\T8C@Q M7V(V93=?-SDY.&4S8F-D-6%D+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0@0FQO8VM=/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J M=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W M(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T M:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE M/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N M=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M M:6YD96YT.B`Y<'0[(&UA#L@9F]N=#H@,3!P="!T:6UE M3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)VUA6QE/3-$)W=I9'1H.B`R-W!T.R<^/"]T9#X-"CQT9"!S='EL M93TS1"=W:61T:#H@,3AP=#LG/CQF;VYT/B8C,3@S.SPO9F]N=#X\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU2!0;&%Z82P@4W5I=&4@,S`W+"!(86-K96YS86-K+"!.97<@2F5R'!I2X\+W1D/@T*/"]T6QE/3-$)W=I9'1H.B`Q.'!T.R<^/&9O;G0^)B,Q.#,[/"]F;VYT/CPO=&0^ M#0H\=&0@3LG/C@U-2!.;W)T M:"!7;VQF92!3=')E970L(%-U:71E(#8Q.2P@0F%L=&EM;W)E+"!-87)Y;&%N M9"`R,3(P-2P@=VAI8V@@8V]N2`S,2P@,C`Q,R!A;F0@,C`Q,BP@ M6QE M/3-$)W1E>'0M86QI9VXZ(&IU"`P<'0@ M,"XU:6X[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W=I9'1H.B`Q.'!T.R<^/&9O;G0^)B,Q.#,[ M/"]F;VYT/CPO=&0^#0H\=&0@3LG/C$W($AA=&ED:&%R(%-T2P@27-R865L+B!4:&4@;&5A2X\+W1D/@T*/"]T2!I2!T;R!C97)T86EN(&QE9V%L(&UA='1E M2!I6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M M86QI9VXZ(&IU'0M:6YD96YT.B`Y<'0[(&UA#L@9F]N=#H@,3!P="!T:6UE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA M'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S M='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[ M(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@ M9F]N=#H@,3!P="!T:6UE2`R,#$P+"!T:&4@0V]M<&%N>2!E;G1E65A2!E>&5R8VES960@:71S(&]P=&EO;B!T;R!L:6-E;G-E($ER:6YO M<&AO2!O9B`D.#4L M,#`P("A#86YA9&EA;BD@8V]M<')I65A2!O9B!T:&4@86=R965M96YT("A-87)C:"`R,#$R*2P@86X@861D M:71I;VYA;"!L:6-E;G-E(&9E92!O9B`D-#4L,#`P("A#86YA9&EA;BD@8F5C M86UE(&1U92P@=VAI8V@@=V%S(')E8V]G;FEZ960@87,@82!L:6%B:6QI='D@ M87,@;V8@07!R:6P@,S`L(#(P,3(@86YD('=A2!O9B!T:&4@86=R M965M96YT("A-87)C:"`R,#$S*2P@=&AE($-O;7!A;GD@=VEL;"!B92!O8FQI M9V%T960@=&\@<&%Y(&$@;6EN:6UU;2!A;FYU86P@2!O9B`D,3`L M,#`P("A#86YA9&EA;BDL('5N;&5S6%L='D@ M86YD('-A;&5S(&UI;&5S=&]N92!P87EM96YT6%L='D@<&%Y;65N="!O9B`D,3`L M,#`P("A#86YA9&EA;BDN/"]P/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0@0FQO8VM=/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J M=7-T:69Y.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W M(')O;6%N+"!T:6UE2!C;VUM97)C:6%L:7IE9"!P6%L='D@ M<&%Y;65N=',L('=H:6-H(&%R92`D-#8P+#`P,"!F;W(@;VYE(&-O;7!O=6YD M(&%N9"`D.#@P+#`P,"!F;W(@=&AE('-E8V]N9"!C;VUP;W5N9"X\+W`^#0H\ M<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@ M.7!T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O M;6%N+"!T:6UE2!P87EM96YT2!O M;B!$96-E;6)E6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`Y<'0[(&UA#L@9F]N=#H@ M,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD M96YT.B`Y<'0[(&UA#L@9F]N=#H@,3!P="!T:6UE28C.#(Q-SMS M(&)A;&%N8V4@F5D(&]N(&$@<')O M<&]R=&EO;F%T92!B87-IF5D M(&1U2`S,2P@,C`Q M,R!A;F0@,C`Q,BX\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\R.3%B83AF9E\X8C,U7S1B.#%?8C9E-U\W.3DX93-B8V0U M860-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,CDQ8F$X9F9?.&(S M-5\T8C@Q7V(V93=?-SDY.&4S8F-D-6%D+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0@0FQO8VM=/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM M97,@;F5W(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&IU#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&IU'0M:6YD96YT.B`Y<'0[(&UA#L@ M9F]N=#H@,3!P="!T:6UE7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3L@=&5X="UI;F1E;G0Z(#EP=#L@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@ M,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!W87,@;F]T:69I960@ M=&AA="!I="!W87,@87=A6EN9R!4 M:&5R87!E=71I8R!$:7-C;W9E2`D,2XP(&UI;&QI;VX@'!E;F1I='5R97,N(%1H92!#;VUP86YY(')E8V5I=F5D(&$@9FEN M86P@<&%Y;65N="!O9B`D,"XU(&UI;&QI;VX@2`Q,RP@,C`Q,BX\+W`^#0H\<"!S='EL M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T M:6UE2!W87,@;F]T:69I960@ M=&AA="!I="!W87,@"!Y96%R65A"!R971U&%M:6YA=&EO;G,@;V8@ M9FES8V%L(#(P,#D@86YD(#(P,3`@=V5R92!C;VUP;&5T960@:6X@=&AE(&9O M=7)T:"!Q=6%R=&5R(&]F(&9I65A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'`@'!E;G-E&EM871E('1H96ER(&9A:7(@=F%L=64@8F%S M960@;VX@=&AE(&QI<75I9&ET>2!O3L@ M=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)VUA6QE/3-$)W=I9'1H.B`Y<'0[)SX\+W1D/@T*/'1D('-T>6QE/3-$ M)W=I9'1H.B`Q.'!T.R<^/&9O;G0^)B,Q.#,[/"]F;VYT/CPO=&0^#0H\=&0@ M3LG/CQI/DQE=F5L(&]N93PO M:3X@)B,X,C$R.R!1=6]T960@;6%R:V5T('!R:6-E6QE/3-$)VUA6QE/3-$)W=I9'1H.B`Y<'0[)SX\+W1D/@T*/'1D M('-T>6QE/3-$)W=I9'1H.B`Q.'!T.R<^/&9O;G0^)B,Q.#,[/"]F;VYT/CPO M=&0^#0H\=&0@3LG/CQI/DQE M=F5L('1H3L@;6%R9VEN.B`P<'0@,'!X.R!F M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E3L@=&5X M="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I M;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!E=F%L=6%T97,@:71S(&AI97)A2!D:7-C;&]S M=7)E2`R,#$S(%!R:79A=&4@4&QA8V5M M96YT(&%N9"!!<')I;"`R,#$R(%!R:79A=&4@4&QA8V5M96YT('=H:6-H(&ES M(&1I2`S,2P@,C`Q,R!A;F0@07!R:6P@,S`L(#(P,3(L('1H97-E('=A2P@=VAI8V@@=V%S(&-A;&-U M;&%T960@8GD@=&AE($UO;G1E($-A6QE M/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`Y<'0[(&UA M#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI M9VXZ(&IU'0M:6YD96YT.B`Y<'0[(&UA#L@9F]N=#H@,3!P="!T:6UE2!F:6YA;F-I86P@:6YS=')U;65N="!M96%S=7)E M9"!A="!F86ER('9A;'5E(&]N(&$@#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG M/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[)SXU-34\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T>6QE M/3-$)V)A8VMG6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@6QE/3-$)V)A M8VMG'0M M86QI9VXZ(')I9VAT.R<^-#$W/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X- M"CPO='(^#0H\='(@6QE/3-$)V)A8VMG M2`S,2P@,C`Q,SPO=&0^#0H\=&0@'0M86QI9VXZ M(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B M;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^.3DS/"]T M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O M='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/"]T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R.3%B83AF M9E\X8C,U7S1B.#%?8C9E-U\W.3DX93-B8V0U860-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,CDQ8F$X9F9?.&(S-5\T8C@Q7V(V93=?-SDY.&4S M8F-D-6%D+U=O'0O:'1M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N M+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[(&UA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`Y<'0[(&UA#L@9F]N=#H@,3!P="!T:6UE65A2!E=F%L=6%T97,@<&5R9F]R;6%N8V4@ M;V8@:71S('-E9VUE;G1S(&)AF%T:6]N+"!I;G1EF4L(&9O6QE/3-$)W=I9'1H.B`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`Q)3LG M/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[)SXT-S,\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO M=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[)SXR+#DQ-SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SXI/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SXI/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R<^*#(R,#PO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^ M*#4X,3PO=&0^#0H\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SY/=&AE6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#8R-SPO=&0^#0H\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F'0M86QI9VXZ(&QE9G0[ M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)V)A8VMG6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[ M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[ M/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO M='(^#0H\='(@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[ M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^*#4T.3PO=&0^#0H\ M=&0@'0M86QI9VXZ(&QE9G0[)SXD M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P M="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^,2PP,S8\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[ M)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R M+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^*#$L,C`W/"]T9#X- M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O M;3H@,BXU<'0[)SXI/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O M;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)V)O6QE/3-$)W=I9'1H.B`Y,"4[(&)O6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1EF5D M/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A M<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I M9VAT.B!B;VQD.R<@;F]W3PO=&0^ M#0H\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)W9E M6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)V9O;G0M=V5I9VAT.B!B M;VQD.R<@;F]W6QE/3-$)V)O3L-"B!F;VYT+7=E:6=H=#H@8F]L9#LG(&YO=W)A<#TS M1&YO=W)A<#Y4:')E928C,38P.TUO;G1H28C,38P.S,Q+"8C,38P.S(P,3(\+W1D/@T*/'1D('-T>6QE/3-$)W!A M9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$ M)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^,2PW-#<\+W1D/@T*/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO M=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXI/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R<^*#@P,3PO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#$L M,S(Y/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO M=&0^#0H\+W1R/@T*/'1R('-T>6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SXI/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#$W-3PO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R<^*#0Q-SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#@U,3PO=&0^#0H\ M=&0@3L@<&%D9&EN9RUB M;W1T;VTZ(#%P=#LG/E-T;V-K+2!B87-E9"!C;VUP96YS871I;VX@97AP96YS M92`H,2D\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('!A9&1I;F'0M M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE M/3-$)V)A8VMG3LG M/B8C,38P.SPO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)V)A8VMG'0M86QI9VXZ(&QE9G0[)SXD/"]T M9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`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`Q)3LG/B8C,38P.SPO=&0^#0H\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E.R<^-"PV,S$\+W1D/@T*/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO M=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`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`[/"]T9#X-"CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!R:6=H=#LG/B@S+#@X,3PO=&0^#0H\=&0@3L@<&%D9&EN9RUB;W1T;VTZ(#%P=#LG/E-T;V-K+2!B87-E9"!C;VUP96YS M871I;VX@97AP96YS92`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`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`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@,3`E M.R<^,RPY,S$\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`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`[/"]T9#X-"CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`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`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^ M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^ M)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X- M"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B M;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^*#,T-#PO=&0^#0H\=&0@'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT M9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[ M('1E>'0M86QI9VXZ(')I9VAT.R<^*#$L,#$X/"]T9#X-"CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXI M/"]T9#X-"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)V)O6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1E6QE/3-$)VUA6QE M/3-$)W=I9'1H.B`P+C(U:6X[)SX\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H M.B`P+C(U:6X[)SXH,2D\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&IU&-L=61E9"!F'!E;G-E2!M M86YA9V5M96YT('1O(&5V86QU871E('1H92!P97)F;W)M86YC92!O9B!I=',@ M3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!M87)G M:6XZ(#!P="`P<'@@,'!T(#`N,C5I;CL@9F]N=#H@,3!P="!T:6UE6QE/3-$ M)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`Y<'0[(&UA#L@9F]N=#H@,3!P="!T:6UE28C.#(Q-SMS(')E=F5N=64@ M:7,@7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M'0@0FQO8VM=/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@;F5W(')O;6%N M+"!T:6UE'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQAF%T:6]N+"!5'0^/'`@3L@=&5X="UI M;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S M(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E6QE M/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I M9'1H.B`W-B4[)SY3=&]C:R!O<'1I;VYS/"]T9#X-"CQT9"!S='EL93TS1"=W M:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R!W:61T:#H@.24[)SXQ-2PP-C0L.#8V/"]T9#X-"CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D M/@T*/"]T6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R<^,RPR-S8L-C8W/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,2PT,38L-C8W/"]T9#X- M"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X- M"CPO='(^#0H\='(@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)V)O6QE/3-$)V)A8VMG6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T M9#X-"CPO='(^#0H\='(@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)V)O M6QE/3-$)W!A9&1I;F'0M86QI9VXZ(')I9VAT.R<^,38L-3$Y+#`S,SPO=&0^#0H\=&0@7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA2!A;F0@17%U:7!M96YT("A486)L97,I/&)R M/CPO'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2P@4&QA;G0@86YD($5Q=6EP;65N="!;5&%B;&4@5&5X="!";&]C:UT\+W1D M/@T*("`@("`@("`\=&0@8VQA6QE/3-$)V9O;G0Z M(#$P<'0O;F]R;6%L('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-EF4M861J=7-T.B!N;VYE.R!F M;VYT+7-T6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E2`S,2P\ M+W1D/@T*/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)W!A M9&1I;F6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD M.R<@;F]W6QE/3-$)W9E'0M86QI M9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@.24[('1E M>'0M86QI9VXZ(')I9VAT.R<^-3@\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H M.B`Q)3L@=&5X="UA;&EG;CH@;&5F=#LG/CPO=&0^#0H\=&0@'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=W:61T:#H@ M.24[('1E>'0M86QI9VXZ(')I9VAT.R<^-3@\+W1D/@T*/'1D('-T>6QE/3-$ M)W=I9'1H.B`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`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA6UE;G1S("A486)L M97,I/&)R/CPO'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$F5D(%!E6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M:6YD96YT.B`Y<'0[ M(&UA#L@9F]N=#H@,3!P="!T:6UE'!E M;G-E('=AF5D(&%S(&9O;&QO=W,@*&EN('1H;W5S86YD6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E6QE/3-$)W=I9'1H.B`Y,"4[(&)O6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ M(&-E;G1E28C,38P.S,Q+#PO=&0^#0H\=&0@6QE/3-$)V)O'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I M;F'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI M9VXZ(')I9VAT.R!W:61T:#H@.24[)SXU,#`\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\ M=&0@6QE/3-$)W=I9'1H.B`Q)3LG/B8C M,38P.SPO=&0^#0H\=&0@6QE/3-$)W=I9'1H.B`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`[/"]T9#X-"CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT M9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T M.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS M1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[ M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[ M/"]T9#X-"CPO='(^#0H\='(@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'!E;G-E/"]T9#X- M"CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE M/3-$)V)O6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M M86QI9VXZ(')I9VAT.R<^-S0S/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F'0@0FQO8VM=/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T M:69Y.R!T97AT+6EN9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z M(#$P<'0@=&EM97,@;F5W(')O;6%N+"!T:6UE#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W M6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)W9E M6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W9E6QE/3-$)V)O6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)V)O M65A6QE/3-$)W=I9'1H.B`Q)3LG/B8C M,38P.SPO=&0^#0H\=&0@F4Z(#$P<'0[)SXS+C`F M(S$V,#LM)B,Q-C`[-BXP/"]F;VYT/CPO=&0^#0H\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG(&YO=W)A<#TS1&YO=W)A M<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M6QE/3-$)V9O;G0M6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T M9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL M93TS1"=T97AT+6%L:6=N.B!L969T.R<@;F]W6QE/3-$)V9O;G0M6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P M.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1EF4Z(#$P<'0[)SXP+C@E)B,Q-C`[+28C,38P.S$N,"4\+V9O;G0^ M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<@;F]W6QE/3-$)W1E>'0M M86QI9VXZ(&-E;G1EF4Z(#$P<'0[)SXP+C0E)B,Q-C`[+28C,38P.S(N,B4\+V9O M;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q M-C`[/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[)SXQ,#`E M)B,Q-C`[+28C,38P.S$P,B4\+V9O;G0^/"]T9#X-"CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R<@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1EF4Z(#$P<'0[)SXY M,"4F(S$V,#LM)B,Q-C`[,3`Q)3PO9F]N=#X\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO M=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&-E;G1EF4Z(#$P<'0[)SXY.24F(S$V,#LM)B,Q-C`[,3`R)3PO9F]N=#X\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N M;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!N;W=R87`],T1N;W=R87`^)B,Q-C`[ M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<@;F]W6QE/3-$)V9O M;G0M6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!N M;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^,"4\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ#0H@;&5F=#LG(&YO=W)A<#TS1&YO=W)A M<#X\+W1D/@T*/'1D(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N;W=R87`^ M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT97([ M)R!N;W=R87`],T1N;W=R87`^,"4\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E M6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/@T*/"]T'0^/'`@3L@ M=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T M('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)W1E>'0M86QI M9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE M/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD M.R<@;F]W6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M=V5I9VAT.B!B M;VQD.R<@;F]W&5R8VES93PO=&0^#0H\=&0@ M6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I M;F65E6QE/3-$)V)O6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E6QE M/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A9&1I;F6QE/3-$)W9E6QE/3-$)V)A8VMG2`Q+"`R,#$R/"]T9#X-"CQT9"!S='EL93TS1"=W:61T M:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\ M=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[ M)SXQ-"PX-C8L,#,X/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R!W:61T:#H@,24[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I M9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T M:#H@.24[)SXW+C`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R<^,3,P+#`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`P,#PO=&0^#0H\=&0@6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I M;F6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R!P861D:6YG+6)O='1O;3H@,7!T.R<^,"XV,CPO M=&0^#0H\=&0@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M M86QI9VXZ(')I9VAT.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O M='1O;3H@,7!T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D M/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO M=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T M2`S,2P@,C`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`\+W1D/@T*/'1D('-T>6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)A8VMG6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T M9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T M>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S M='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^ M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^ M)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)W1E>'0M:6YD96YT.B`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`@3L@=&5X="UI;F1E;G0Z(#EP=#L@ M;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@ M=&EM97,L('-E2!R96QA M=&5D('1O(')E6QE/3-$)W1E>'0M86QI9VXZ(&-E M;G1E6QE M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD M.R<@;F]W6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)W!A M9&1I;F6QE/3-$)V)O6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H M.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE M/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W:61T:#H@.24[)SXP+C6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^,"XS M,#PO=&0^#0H\=&0@6QE/3-$)V)A8VMG6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/"]T6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V M,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W!A9&1I;F'!I M'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)V)A8VMG2`S,2P@,C`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`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M6QE/3-$)W1E M>'0M86QI9VXZ(&IU'0M:6YD96YT.B`Y<'0[(&UA#L@9F]N=#H@,3!P="!T:6UE#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V9O;G0M=V5I9VAT.B!B M;VQD.R<@;F]W6QE/3-$)V9O;G0M=V5I9VAT M.B!B;VQD.R<@;F]W6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<@;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`W-B4[)SY2 M:7-K+69R964@:6YT97)E6QE/3-$)W=I M9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO M=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)R!N;W=R87`],T1N;W=R M87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!C96YT M97([)R!N;W=R87`],T1N;W=R87`^/&9O;G0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/'1D/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SY$:79I9&5N9"!Y:65L9#PO=&0^#0H\=&0^ M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<@ M;F]W6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)R!N;W=R87`],T1N;W=R87`^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!C96YT97([)R!N;W=R87`],T1N;W=R87`^,"4\+W1D/@T* M/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T* M/"]T3X-"CPO:'1M;#X-"@T*+2TM+2TM M/5].97AT4&%R=%\R.3%B83AF9E\X8C,U7S1B.#%?8C9E-U\W.3DX93-B8V0U M860-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,CDQ8F$X9F9?.&(S M-5\T8C@Q7V(V93=?-SDY.&4S8F-D-6%D+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\<"!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN M9&5N=#H@.7!T.R!M87)G:6XZ(#!P="`P<'@[(&9O;G0Z(#$P<'0@=&EM97,@ M;F5W(')O;6%N+"!T:6UE6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`Q M)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R!W M:61T:#H@.24[)SXU-34\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\+W1R/@T*/'1R('-T M>6QE/3-$)V)A8VMG6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\=&0@6QE/3-$ M)V)A8VMG'0M86QI9VXZ(')I9VAT.R<^-#$W/"]T9#X-"CQT9"!S='EL93TS1"=T97AT M+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,7!T.R<^)B,Q-C`[/"]T M9#X-"CPO='(^#0H\='(@6QE/3-$)V)A M8VMG2`S,2P@,C`Q,SPO=&0^#0H\=&0@'0M86QI M9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^.3DS M/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!P861D:6YG M+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T*/"]T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R.3%B M83AF9E\X8C,U7S1B.#%?8C9E-U\W.3DX93-B8V0U860-"D-O;G1E;G0M3&]C M871I;VXZ(&9I;&4Z+R\O0SHO,CDQ8F$X9F9?.&(S-5\T8C@Q7V(V93=?-SDY M.&4S8F-D-6%D+U=O'0O:'1M;#L@8VAA2!396=M96YT(%M486)L92!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'`@3L@=&5X="UI;F1E;G0Z(#EP=#L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q M,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E2!B=7-I;F5S6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[(&UA#L@9F]N=#H@,3!P="!T:6UE6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD M.R<@;F]W6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1EF5D/"]T9#X-"CQT9"!S='EL93TS1"=F;VYT+7=E:6=H=#H@8F]L M9#LG(&YO=W)A<#TS1&YO=W)A<#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$ M)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W3PO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W M6QE/3-$)W9E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R<@;F]W6QE/3-$)W1E M>'0M86QI9VXZ(&-E;G1E6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E2`S,2P@,C`Q,SPO M=&0^#0H\=&0@'0M86QI9VXZ(&-E;G1E6QE M/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE M/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`U,B4[ M)SY.970@6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P M.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('=I9'1H.B`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`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`Q)3LG/B8C M,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P M.SPO=&0^#0H\=&0@6QE/3-$ M)W=I9'1H.B`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`R+C5P="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^*#$L-S3L@;6%R9VEN.B`P<'0@,'!X.R!F M;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA;BP@=&EM97,L('-E6QE/3-$)W=I9'1H.B`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`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT M.R!W:61T:#H@,3`E.R<^,2PX-3`\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P M.SPO=&0^#0H\=&0@6QE/3-$ M)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SXI/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#$L-S0P/"]T9#X-"CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO=&0^#0H\=&0^)B,Q M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q M-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H=#LG/BT\ M+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)W1E>'0M86QI M9VXZ(&QE9G0[)SXI/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#0Y-3PO=&0^#0H\=&0@ M6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[ M)SXF(S$V,#L\+W1D/@T*/'1D/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$ M)W1E>'0M86QI9VXZ(&QE9G0[)SXI/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\ M=&0@6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SXI/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D M('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^*#,L.#@Q/"]T9#X-"CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^*3PO=&0^#0H\+W1R/@T* M/'1R('-T>6QE/3-$)V)A8VMG'!E;G-E("@Q*3PO=&0^#0H\=&0@'0M86QI9VXZ(')I9VAT.R<^+3PO M=&0^#0H\=&0@'0M86QI9VXZ(')I9VAT.R<^+3PO=&0^#0H\ M=&0@6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\ M+W1D/@T*/'1D('-T>6QE/3-$)V)O6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF M(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^ M)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^ M)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E M>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9#XF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXF(S$V,#L\+W1D M/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I9VAT.R<^)B,Q-C`[/"]T M9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T M9#X-"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(&QE9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ M(')I9VAT.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R<^)B,Q-C`[/"]T9#X-"CPO='(^#0H\='(@6QE/3-$)W1E>'0M86QI9VXZ(&IU'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL M93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M M86QI9VXZ(')I9VAT.R<^*#8W-3PO=&0^#0H\=&0@'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI M9VXZ(')I9VAT.R<^-SDR/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N M.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXF(S$V,#L\+W1D/@T* M/'1D('-T>6QE/3-$)W!A9&1I;F'0M86QI9VXZ(&QE9G0[)SXD/"]T9#X-"CQT9"!S='EL93TS M1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P="!D;W5B;&4[('1E>'0M86QI M9VXZ(')I9VAT.R<^*#0L,C,U/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L M:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,BXU<'0[)SXI/"]T9#X-"CPO M='(^#0H\+W1A8FQE/@T*/'`@3L@;6%R9VEN.B`P<'0@,'!X.R!F;VYT.B`Q,'!T('1I;65S(&YE=R!R;VUA M;BP@=&EM97,L('-E6QE/3-$ M)W=I9'1H.B`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`],T1N;W=R87`^3FEN928C,38P M.TUO;G1H28C,38P.S,Q+"8C,38P M.S(P,3(\+W1D/@T*/'1D('-T>6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W!A9&1I;F6QE/3-$)W1E>'0M86QI9VXZ(&IU6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO M=&0^#0H\=&0@6QE/3-$)W1E>'0M M86QI9VXZ(&QE9G0[('=I9'1H.B`Q)3LG/B0\+W1D/@T*/'1D('-T>6QE/3-$ M)W1E>'0M86QI9VXZ(')I9VAT.PT*('=I9'1H.B`Q,"4[)SXM/"]T9#X-"CQT M9"!S='EL93TS1"=T97AT+6%L:6=N.B!L969T.R!W:61T:#H@,24[)SXF(S$V M,#L\+W1D/@T*/'1D('-T>6QE/3-$)W=I9'1H.B`Q)3LG/B8C,38P.SPO=&0^ M#0H\=&0@6QE/3-$)W1E>'0M86QI9VXZ(&QE9G0[)SXI/"]T9#X- M"CQT9#XF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&QE M9G0[)SXF(S$V,#L\+W1D/@T*/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(')I M9VAT.R<^*#$L.3`T/"]T9#X-"CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!L M969T.R<^*3PO=&0^#0H\=&0^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`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`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`[/"]T9#X-"CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!L969T.R<^)B,Q-C`[/"]T9#X-"CQT9"!S='EL93TS1"=T M97AT+6%L:6=N.B!R:6=H=#LG/B8C,38P.SPO=&0^#0H\=&0@6QE/3-$)V)A8VMG'0M86QI9VXZ(&QE9G0[)SXD M/"]T9#X-"CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M.B!B;&%C:R`R+C5P M="!D;W5B;&4[('1E>'0M86QI9VXZ(')I9VAT.R<^*#4L,3`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`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%\R.3%B83AF9E\X8C,U7S1B.#%?8C9E-U\W.3DX93-B8V0U860-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,CDQ8F$X9F9?.&(S-5\T8C@Q M7V(V93=?-SDY.&4S8F-D-6%D+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'1U2!A M;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW M-C4\2!A M;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA2!A;F0@17%U:7!M96YT("A$971A:6QS(%1E>'1U86PI("A54T0@)"D\ M8G(^26X@5&AO=7-A;F1S+"!U;FQE7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA6UE;G1S("A$971A:6QS*2`H55-$("0I/&)R M/DEN(%1H;W5S86YD'!E;G-E/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4W,#QS<&%N/CPO'!E;G-E(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\'!E;G-E/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-CQS<&%N/CPO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!3;VQU=&EO;G,@0V]S M="!O9B!386QE'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$2!3;VQU=&EO;G,@0V]S="!O9B!386QE'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA M6UE;G1S("A$971A:6QS(#$I/&)R/CPO'0^-B!Y96%R65A&EM=6T\+W1D/@T*("`@("`@("`\=&0@8VQA6EE;&0\+W1D/@T*("`@("`@("`\=&0@8VQA65A65A65A65A3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R.3%B83AF9E\X8C,U7S1B.#%? M8C9E-U\W.3DX93-B8V0U860-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO,CDQ8F$X9F9?.&(S-5\T8C@Q7V(V93=?-SDY.&4S8F-D-6%D+U=O'0O:'1M;#L@ M8VAA'!I'!E8W1E M9"!T;R!V97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PP M,3@L.34U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C;&%S&5R8VES92!0 M&5R8VES92!0&5R8VES92!0&5R8VES92!0'0^-R!Y96%R65A65E'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES86)L93PO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'!E8W1E9"!T;R!V97-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M M<#XQ,RPY-S@L.34U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$&5R8VES86)L93PO=&0^#0H@("`@("`@(#QT9"!C M;&%S3X-"CPO:'1M;#X-"@T* M+2TM+2TM/5].97AT4&%R=%\R.3%B83AF9E\X8C,U7S1B.#%?8C9E-U\W.3DX M93-B8V0U860-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,CDQ8F$X M9F9?.&(S-5\T8C@Q7V(V93=?-SDY.&4S8F-D-6%D+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C M:&%R'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R M/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA'!E;G-E/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$6UE;G0@07=A2!3:&%R92UB87-E9"!087EM96YT($%W M87)D+"!787)R86YT'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S2!3:&%R92UB87-E9"!087EM M96YT($%W87)D+"!/=&AE2!3:&%R92UB87-E9"!087EM96YT M($%W87)D+"!%<75I='D@26YS=')U;65N=',@3W1H97(@=&AA;B!/<'1I;VYS M+"!/=71S=&%N9&EN9RP@5V5I9VAT960@079E65A7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA&EM=6T@6TUE;6)E'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S6EE;&0\ M+W1D/@T*("`@("`@("`\=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA7!E/3-$=&5X="]J879A'1U86PI("A54T0@)"D\8G(^/"]S=')O;F<^/"]T M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T* M("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R M8VES92!0'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C M;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'1U86PI("A54T0@)"D\ M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L M2!42!4'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3X-"CPO:'1M M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R.3%B83AF9E\X8C,U7S1B.#%?8C9E M-U\W.3DX93-B8V0U860-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO M,CDQ8F$X9F9?.&(S-5\T8C@Q7V(V93=?-SDY.&4S8F-D-6%D+U=O'0O:'1M;#L@8VAA M'0^2G5L(#,P+`T*"0DR,#$S/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S6%L='D@17AP96YS93PO=&0^#0H@("`@("`@(#QT M9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA'1087)T7S(Y M,6)A.&9F7SAB,S5?-&(X,5]B-F4W7S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$&5R8VES92!/9B!/<'1I;VYS(%1O($]N92!4:6UE M(%)O>6%L='D@1F5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX M.#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$F5D/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$=&5X=#X\'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA6EN9R!%>'!E;G-E3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R.3%B83AF9E\X8C,U M7S1B.#%?8C9E-U\W.3DX93-B8V0U860-"D-O;G1E;G0M3&]C871I;VXZ(&9I M;&4Z+R\O0SHO,CDQ8F$X9F9?.&(S-5\T8C@Q7V(V93=?-SDY.&4S8F-D-6%D M+U=O'0O M:'1M;#L@8VAA2`S,2P@,C`Q,SPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R.3%B83AF M9E\X8C,U7S1B.#%?8C9E-U\W.3DX93-B8V0U860-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO,CDQ8F$X9F9?.&(S-5\T8C@Q7V(V93=?-SDY.&4S M8F-D-6%D+U=O'0O:'1M;#L@8VAA7!E.B!T M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT M96YT/3-$)W1E>'0O:'1M;#L@8VAA'!E;G-E'!E;G-E/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S2!3;VQU=&EO;G,@6TUE;6)E'!E;G-E&-L=61E9"!F'!E;G-E3X-"CPO M:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\R.3%B83AF9E\X8C,U7S1B.#%? M8C9E-U\W.3DX93-B8V0U860-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O M0SHO,CDQ8F$X9F9?.&(S-5\T8C@Q7V(V93=?-SDY.&4S8F-D-6%D+U=O'0O:'1M;#L@ M8VAA&UL;G,Z;STS1")U XML 20 R43.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value (Details Textual) (USD $)
In Millions, unless otherwise specified

Jan. 31, 2013

Apr. 30, 2012

Estimated Fair Value of Warrants $ 1.0 $ 0.6

X

- Definition

The estimated fair value of warrants.

+ References

No definition available.

+ Details

Name: csbr_EstimatedFairValueOfWarrants

Namespace Prefix: csbr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 21 R29.htm IDEA: XBRL DOCUMENT v2.4.0.6

Property and Equipment (Details Textual) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Jan. 31, 2013

Jan. 31, 2012

Jan. 31, 2013

Jan. 31, 2012

Depreciation $ 51 $ 16 $ 153 $ 65

X

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 22 R28.htm IDEA: XBRL DOCUMENT v2.4.0.6

Property and Equipment (Details) (USD $)
In Thousands, unless otherwise specified

Jan. 31, 2013

Apr. 30, 2012

Furniture and fixtures $ 58 $ 58

Computer equipment and software 526 287

Laboratory equipment 179 167

Leasehold improvements 2 2

Software in-progress 0 216

Total property and equipment 765 730

Less: Accumulated depreciation (323) (170)

Property and equipment, net $ 442 $ 560

X

- Definition

The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 14

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.14)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The gross amount of capitalized computer software costs as of the balance sheet date.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name: us-gaap_CapitalizedComputerSoftwareGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Gross amount, at the balance sheet date, of long-lived, depreciable assets commonly used in offices and stores. Examples include desks, chairs, and store fixtures.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_FurnitureAndFixturesGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Gross amount, at the balance sheet date, of long-lived, depreciable assets that are an addition or improvement to assets held under lease arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 4

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6812-107765

+ Details

Name: us-gaap_LeaseholdImprovementsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Gross amount, as of the balance sheet date, of long-lived, depreciable assets used in the production process to produce goods and services.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 4

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6812-107765

+ Details

Name: us-gaap_MachineryAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Gross amount of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 12

-Paragraph 5

-Subparagraph b, c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

This element represents capitalized assets classified as property, plant and equipment not otherwise defined in the taxonomy.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name: us-gaap_PropertyPlantAndEquipmentOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 23 R44.htm IDEA: XBRL DOCUMENT v2.4.0.6

Business Segment Information (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Jan. 31, 2013

Jan. 31, 2012

Jan. 31, 2013

Jan. 31, 2012

Net revenue $ 2,917 $ 2,396 $ 6,481 $ 5,768

Sales and marketing costs (658) (623) (2,047) (1,885)

Stock- based compensation expense (570) (743) (1,934) (2,612)

Personalized Oncology Solutions [Member]

Net revenue 473 649 1,850 1,837

Direct cost of services (661) (528) (2,030) (1,463)

Sales and marketing costs (361) (242) (495) (718)

Other operating expenses 0 0 0 0

Stock- based compensation expense 0 ^[1] 0 ^[1] 0 ^[1] 0 ^[1]

Segment profit (loss) (549) (121) (675) (344)

Translational Oncology Solutions [Member]

Net revenue 2,444 1,747 4,631 3,931

Direct cost of services (561) (801) (1,740) (1,904)

Sales and marketing costs (220) (175) (636) (626)

Other operating expenses (627) (851) (1,463) (2,419)

Stock- based compensation expense 0 ^[1] 0 ^[1] 0 ^[1] 0 ^[1]

Segment profit (loss) 1,036 (80) 792 (1,018)

Unallocated Corporate Overhead [Member]

Net revenue 0 0 0 0

Direct cost of services 0 0 0 0

Sales and marketing costs 0 0 0 0

Other operating expenses (637) (829) (2,418) (2,489)

Stock- based compensation expense (570) ^[1] (743) ^[1] (1,934) ^[1] (2,612) ^[1]

Segment profit (loss) (1,207) (1,572) (4,352) (5,101)

Consolidated [Member]

Net revenue 2,917 2,396 6,481 5,768

Direct cost of services (1,222) (1,329) (3,770) (3,367)

Sales and marketing costs (581) (417) (1,131) (1,344)

Other operating expenses (1,264) (1,680) (3,881) (4,908)

Stock- based compensation expense (570) ^[1] (743) ^[1] (1,934) ^[1] (2,612) ^[1]

Segment profit (loss) $ (720) $ (1,773) $ (4,235) $ (6,463)

[1] Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph g(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Total costs related to services rendered by an entity during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 2

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(d))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_CostOfServices

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.

+ References

No definition available.

+ Details

Name: us-gaap_OtherOperatingIncomeExpenseNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A1, A4, A5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=7656940&loc=SL4569616-111683

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 5

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=18733213&loc=SL4591552-111686

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=18733093&loc=SL4573702-111684

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=18733213&loc=SL4591551-111686

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueServicesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total amount of expenses directly related to the marketing or selling of products or services.

+ References

No definition available.

+ Details

Name: us-gaap_SellingAndMarketingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 24 R30.htm IDEA: XBRL DOCUMENT v2.4.0.6

Share-Based Payments (Details) (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Jan. 31, 2013

Jan. 31, 2012

Jan. 31, 2013

Jan. 31, 2012

Stock-based compensation expense $ 570 $ 743 $ 1,934 $ 2,612

General and Administrative Expense [Member]

Stock-based compensation expense 500 701 1,619 2,370

Selling and Marketing Expense [Member]

Stock-based compensation expense 56 49 199 168

Research and Development Expense [Member]

Stock-based compensation expense 4 (8) 33 72

Translational Oncology Solutions Cost of Sales [Member]

Stock-based compensation expense 4 1 16 2

Personalized Oncology Solutions Cost of Sales [Member]

Stock-based compensation expense $ 6 $ 0 $ 67 $ 0

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph g(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 25 R31.htm IDEA: XBRL DOCUMENT v2.4.0.6

Share-Based Payments (Details 1)
3 Months Ended 9 Months Ended

Jan. 31, 2013

Jan. 31, 2012

Jan. 31, 2013

Jan. 31, 2012

Expected term in years 6 years 6 years

Risk-free interest rates Minimum 0.90% 0.40% 0.80% 0.40%

Risk-free interest rates Maximum 1.00% 1.90% 1.00% 2.20%

Volatility Minimum 100.00% 90.00% 99.00% 90.00%

Volatility Maximum 102.00% 101.00% 102.00% 108.00%

Dividend yield 0.00% 0.00% 0.00% 0.00%

Minimum [Member]

Expected term in years 3 years 3 years

Maximum [Member]

Expected term in years 6 years 6 years

X

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph e(2)(c)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.D.2)

-URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section D

-Subsection 2

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 26 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6

Recently Issued Accounting Pronouncements
9 Months Ended

Jan. 31, 2013

Accounting Changes and Error Corrections [Abstract]

Accounting Changes and Error Corrections [Text Block]
Note 2. Recently Issued Accounting Pronouncements

During July 2012, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2012-02, “Testing Indefinite-Lived Intangible Assets for Impairment”. The revised standard is intended to reduce the cost and complexity of testing indefinite-lived intangible assets other than goodwill for impairment by providing entities with an option to perform a "qualitative" assessment to determine whether further impairment testing is necessary. The revised standard allows an entity first to assess qualitative factors to determine whether events and circumstances indicate that it is more likely than not that an indefinite-lived intangible asset is impaired. If it is more likely than not that the asset is impaired, the entity must calculate the fair value of the asset, compare the fair value to its carrying amount, and record an impairment charge, if the carrying amount exceeds fair value. However, if an entity concludes that it is not more likely than not that the asset is impaired, no further action is required. The qualitative assessment is not an accounting policy election. An entity can choose to perform the qualitative assessment on none, some, or all of its indefinite-lived intangible assets. Moreover, an entity can bypass the qualitative assessment for any indefinite-lived intangible asset in any period and proceed directly to the quantitative impairment test, and then choose to perform the qualitative assessment in any subsequent period. The revised standard is effective for annual and interim impairment tests performed for fiscal years beginning after September 15, 2012. The Company does not expect the adoption of this standard to have a material impact on its financial position or results of operations.

During September 2011, the FASB issued ASU No. 2011-08, “Testing Goodwill for Impairment” (“ASU 2011-08”). ASU 2011-08 is intended to simplify the testing of goodwill for impairment by permitting an entity to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount as a basis for determining whether it is necessary to perform the two-step goodwill impairment test, which is currently required for all companies that report goodwill. The amendments are effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011, although early adoption is permitted. The Company has adopted this standard, which had no impact on its financial position or results of operations.

X

- Details

Name: us-gaap_AccountingChangesAndErrorCorrectionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for reporting accounting changes and error corrections. It includes the conveyance of information necessary for a user of the Company's financial information to understand all aspects and required disclosure information concerning all changes and error corrections reported in the Company's financial statements for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6801783&loc=d3e22499-107794

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 1.N.Q3)

-URI http://asc.fasb.org/extlink&oid=6369664&loc=d3e30840-122693

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6801783&loc=d3e22644-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 1

-Section N

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 45

-Paragraph 23

-URI http://asc.fasb.org/extlink&oid=6368906&loc=d3e21914-107793

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6801783&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 154

-Paragraph 17, 22, 25, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AccountingChangesAndErrorCorrectionsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R32.htm IDEA: XBRL DOCUMENT v2.4.0.6

Share-Based Payments (Details 2) (USD $)
9 Months Ended

Jan. 31, 2013

Outstanding, Begining Balance 14,866,038

Granted 716,250

Forfeited (22,500)

Expired (515,833)

Canceled (25,000)

Outstanding, Ending Balance 15,018,955

Vested and expected to vest 15,018,955

Exercisable 10,668,412

Weighted Average Exercise Price, Outstanding, Begining Balance $ 0.88

Weighted Average Exercise Price, Granted $ 0.41

Weighted Average Exercise Price, Forfeited $ 0.67

Weighted Average Exercise Price, Expired $ 0.76

Weighted Average Exercise Price, Canceled $ 0.62

Weighted Average Exercise Price, Outstanding, Ending Balance $ 0.86

Weighted Average Exercise Price, Exercisable $ 0.88

Weighted Average Remaining Contractual Term, Outstanding, Begining Balance (in years) 7 years

Weighted Average Remaining Contractual Term, Outstanding, Ending Balance (in years) 7 years 1 month 6 days

Weighted Average Remaining Contractual Term, Exercisable (in years) 6 years 9 months 18 days

Aggregate Intrinsic Value, Outstanding, Begining Balance $ 0

Aggregate Intrinsic Value, Outstanding, Ending Balance 96,000

Aggregate Intrinsic Value, Exercisable $ 14,000

Non-Employees [Member]

Outstanding, Begining Balance 1,410,000

Granted 130,000

Forfeited 0

Expired (500,000)

Canceled 0

Outstanding, Ending Balance 1,040,000

Vested and expected to vest 1,040,000

Exercisable 933,334

Directors and Employees [Member]

Outstanding, Begining Balance 13,456,038

Granted 586,250

Forfeited (22,500)

Expired (15,833)

Canceled (25,000)

Outstanding, Ending Balance 13,978,955

Vested and expected to vest 13,978,955

Exercisable 9,735,078

X

- Definition

Weighted average remaining contractual term Ending for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name: csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1

Namespace Prefix: csbr_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.

+ References

No definition available.

+ Details

Name: csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod

Namespace Prefix: csbr_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.

+ References

No definition available.

+ Details

Name: csbr_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice

Namespace Prefix: csbr_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(c), d(2)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(c)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(g)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(f)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Net number of share options (or share units) granted during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(d)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of options outstanding.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph d(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding as of the balance sheet date, including vested options.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph b(1)(a)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph d(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance on stock options awarded.

+ References

No definition available.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 28 R40.htm IDEA: XBRL DOCUMENT v2.4.0.6

Cephalon Agreement (Details Textual)
1 Months Ended 9 Months Ended 12 Months Ended 9 Months Ended

Nov. 30, 2012

USD ($)

Jan. 31, 2013

USD ($)

Jan. 31, 2013

CAD

Jan. 31, 2012

USD ($)

Apr. 30, 2011

USD ($)

Jan. 31, 2013

One Compound [Member]

USD ($)

Jan. 31, 2013

Second Compound [Member]

USD ($)

Deferred Revenue, Additions $ 27,000,000

Royalty Expense 10,000 460,000 880,000

Exercise Of Options To One Time Royalty Fee 880,000

Deferred Revenue, Refund Payments 1,400,000

Deferred Revenue, Revenue Recognized $ 317,000 $ 681,000

X

- Definition

The value of options exercised during the period for the payment of ine time royalty fee.

+ References

No definition available.

+ Details

Name: csbr_ExerciseOfOptionsToOneTimeRoyaltyFee

Namespace Prefix: csbr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueAdditions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Amount of refund payments made to customers during the period that was previously reported as deferred revenue. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueRefundPayments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueRevenueRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_RoyaltyExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 29 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified

Jan. 31, 2013

Apr. 30, 2012

ASSETS

Cash and cash equivalents $ 10,769 $ 4,716

Accounts receivable, net 642 584

Prepaid expenses and other current assets 300 205

Total current assets 11,711 5,505

Restricted cash 190 188

Property and equipment, net 442 560

Goodwill 669 669

Total assets 13,012 6,922

LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' DEFICIT

Accounts payable 1,101 1,676

Accrued liabilities 566 625

Deferred revenue 1,017 1,185

Total current liabilities 2,684 3,486

Warrant liability 993 555

Total liabilities 3,677 4,041

Commitments and contingencies

Redeemable common stock; $0.001 par value; 31,133,333 and 12,533,333 contingently puttable common shares outstanding as of January 31, 2013 and April 30, 2012 16,936 8,159

Stockholders' equity:

Preferred stock, $10 par value; 56,075 shares authorized; no shares issued and outstanding as of January 31, 2013 and April 30, 2012 0 0

Common stock, $.001 par value; 125,000,000 shares authorized, including redeemable common stock, 38,855,003 and 37,740,345 shares is sued and 35,618,767 and 34,529,000 shares outstanding as of January 31, 2013 and April 30, 2012, respectively 39 38

Treasury stock, at cost, 3,236,000 common shares as of January 31, 2013 and April 30, 2012 (1,252) (1,252)

Additional paid-in capital 23,136 21,204

Accumulated deficit (29,425) (25,143)

Accumulated other comprehensive loss (99) (125)

Total stockholders' deficit (7,601) (5,278)

Total liabilities, redeemable common stock and stockholders' deficit $ 13,012 $ 6,922

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 20

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 14, 17, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e681-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS115-1/124-1

-Paragraph 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapitalCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Concepts (CON)

-Number 6

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6801-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 25

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14326-108349

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 17

-Article 9

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7, 8

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1)

-URI http://asc.fasb.org/extlink&oid=6600647&loc=d3e214044-122780

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

+ Details

Name: us-gaap_DeferredRevenueCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Fair values as of the balance sheet date of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and which are expected to be extinguished or otherwise disposed of after one year or beyond the normal operating cycle, if longer, net of the effects of master netting arrangements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FIN39-1

-Paragraph 10A, 10B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 7

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 4, 17

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13495-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

+ Details

Name: us-gaap_DerivativeLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date, which is the cumulative amount paid and (if applicable) the fair value of any noncontrolling interest in the acquiree, adjusted for any amortization recognized prior to the adoption of any changes in generally accepted accounting principles (as applicable) and for any impairment charges, in excess of the fair value of net assets acquired in one or more business combination transactions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph e

-Clause 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388280&loc=d3e13770-109266

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 68

-Subparagraph l

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 43

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 142

-Paragraph 45

-Subparagraph e

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141R

-Paragraph 72

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_Goodwill

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesAndStockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 21

-Article 5

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The total of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer, and the aggregate carrying amount of current assets, as of the balance sheet date, not separately presented elsewhere in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Section A

-Paragraph 4

-Chapter 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount, net of accumulated depreciation, depletion and amortization, of long-lived physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 12

-Paragraph 5

-Subparagraph b, c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

As of the reporting date, the carrying amount of noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. The noncontrolling interest holder's ownership (or holders' ownership) may be in the form of common shares (regardless of class), limited partnership units (regardless of class), non-preferential membership interests, or any other form of common equity regardless of investee entity legal form.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section S99

-Paragraph 3A

-Subparagraph 14

-URI http://asc.fasb.org/extlink&oid=14643745&loc=SL6540498-122764

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number D-98

-Paragraph 43

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section S99

-Paragraph 3A

-Subparagraph (12)(c)

-URI http://asc.fasb.org/extlink&oid=14643745&loc=SL6540498-122764

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number D-98

-Paragraph 43

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section S99

-Paragraph 3A

-Subparagraph (16)(c)

-URI http://asc.fasb.org/extlink&oid=14643745&loc=SL6540498-122764

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 480

-SubTopic 10

-Section S99

-Paragraph 3A

-Subparagraph 15

-URI http://asc.fasb.org/extlink&oid=14643745&loc=SL6540498-122764

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 27

-Subparagraph c

-Appendix A

+ Details

Name: us-gaap_RedeemableNoncontrollingInterestEquityCommonCarryingAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Cash and equivalents whose use in whole or in part is restricted for the long-term, generally by contractual agreements or regulatory requirements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_RestrictedCashAndCashEquivalentsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The cumulative amount of the reporting entity's undistributed earnings or deficit.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Technical Bulletin (FTB)

-Number 85-6

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_TreasuryStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

XML 30 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
9 Months Ended

Jan. 31, 2013

Jan. 31, 2012

Operating activities:

Net loss $ (4,284) $ (6,111)

Adjustments to reconcile net loss to net cash used in operating activities:

Stock-based compensation expense 1,934 2,612

Depreciation expense 153 65

Change in fair value of warrant liability 21 (354)

Changes in operating assets and liabilities:

Accounts receivable (58) 88

Prepaid expenses, deposits and other (96) 178

Restricted cash (2) (150)

Accounts payable (574) 43

Accrued liabilities (58) 42

Deferred revenue (168) (117)

Net cash used in operating activities (3,132) (3,704)

Investing activities:

Purchase of property and equipment (35) (371)

Net cash used in investing activities (35) (371)

Financing activities:

Private placement of common shares and warrants 9,195 0

Proceeds from exercise of options and warrants 0 98

Net cash provided by financing activities 9,195 98

Exchange rate effect on cash and cash equivalents 25 2

Increase in cash and cash equivalents 6,053 (3,975)

Cash and cash equivalents, beginning of period 4,716 10,457

Cash and cash equivalents, end of period $ 10,769 $ 6,482

X

- Definition

The (increase) decrease during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

+ References

No definition available.

+ Details

Name: csbr_IncreaseDecreaseInAccountReceivable

Namespace Prefix: csbr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The (increase) decrease during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.

+ References

No definition available.

+ Details

Name: csbr_IncreaseDecreaseInPrepaidDeferredExpensesAndOtherAssets

Namespace Prefix: csbr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from entity's raising of capital via issuance of common shares and warrants in public placement.

+ References

No definition available.

+ Details

Name: csbr_ProceedsFromIssuanceOfRedeemableCommonSharesAndWarrantsInPrivatePlacement

Namespace Prefix: csbr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The effect of exchange rate changes on cash balances held in foreign currencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450594&loc=d3e33268-110906

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

+ Details

Name: us-gaap_GainLossOnDerivativeInstrumentsNetPretax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3179-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15, 16, 17

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_IncreaseDecreaseInRestrictedCash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow from financing activity for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash inflow or outflow from investing activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3213-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 17

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow associated with the amount received from holders exercising their stock warrants.

+ References

No definition available.

+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 31 R35.htm IDEA: XBRL DOCUMENT v2.4.0.6

Redeemable Common Stock and Stock Purchase Warrant (Details)
3 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended

Jan. 31, 2013

Jan. 31, 2012

Jan. 31, 2013

Jan. 31, 2012

Apr. 30, 2012

Warrant [Member]

Jan. 31, 2013

Warrant [Member]

Jan. 31, 2013

Warrant [Member]

Minimum [Member]

Jan. 31, 2013

Warrant [Member]

Maximum [Member]

Risk-free interest rates 0.60% 0.46% 0.88%

Volatility 102.00% 84.90% 102.00%

Dividend yield 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

X

- Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph e(2)(c)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph e(2)(b)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The risk-free interest rate assumption that is used in valuing an option on its own shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)(iv)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph e(2)(d)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

XML 32 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6

Property and Equipment (Tables)
9 Months Ended

Jan. 31, 2013

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]
Property and equipment consisted of the following (in thousands):

January 31, April 30,

2013 2012

(unaudited)

Furniture and fixtures $ 58 $ 58

Computer equipment and software 526 287

Laboratory equipment 179 167

Leasehold improvements 2 2

Software in-progress - 216

Total property and equipment 765 730

Less: Accumulated depreciation (323 ) (170 )

Property and equipment, net $ 442 $ 560

X

- Details

Name: us-gaap_PropertyPlantAndEquipmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the useful life and salvage value of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph b

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PropertyPlantAndEquipmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R36.htm IDEA: XBRL DOCUMENT v2.4.0.6

Redeemable Common Stock and Stock Purchase Warrant (Details Textual) (USD $)
1 Months Ended 9 Months Ended 12 Months Ended

Jan. 28, 2013

Mar. 24, 2011

Jan. 31, 2013

Apr. 30, 2012

Stock Issued During Period, Shares, Acquisitions 18,600,000 12,533,333

Common Stock Purchase Price $ 0.50 $ 0.75

Stock Issued During Period, Value, Share-based Compensation, Gross $ 9,300,000 $ 9,400,000

Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures 500,000 500,000

Warrants Issued During Period for Common Stock 1,266,667

Warrants Exercise Price Per Share $ 0.90

Percentage of Common Stock Purchased 25.00% 25.00%

Issuance Of Additional Common Shares To Investors 1,064,658

Percentage of Cash Penalties 1.00%

Purchase Price Limit Percentage 10.00%

Warrants and Rights Outstanding 800,000

Increase (Decrease) in Warrants Fair Value 1,000,000 600,000

Minimum [Member]

Potential Penalties Amount 50,000

Maximum [Member]

Potential Penalties Amount 130,000

January 2013 Private Placement [Member]

Warrants Issued During Period for Common Stock 1,860,000 1,860,000

Warrants Exercise Price Per Share $ 0.66

Common Stock Repurchase Price Per Share $ 0.50

Net Shares Reclassified to Mandatorily Redeemable Capital Stock, Value 8,800,000

Proceeds from Issuance of Common Stock and Warrants 9,300,000

Proceeds from Issuance of Warrants 400,000

Incremental Compensation Cost 100,000

April 2011 Private Placement [Member]

Warrants Issued During Period for Common Stock 1,266,667

Common Stock Repurchase Price Per Share $ 0.75

Net Shares Reclassified to Mandatorily Redeemable Capital Stock, Value 8,200,000

Proceeds from Issuance of Common Stock and Warrants 9,400,000

Proceeds from Issuance of Warrants 900,000

Incremental Compensation Cost $ 300,000

April 2011 Private Placement [Member] | Minimum [Member]

Warrants Exercise Price Per Share $ 0.50

April 2011 Private Placement [Member] | Maximum [Member]

Warrants Exercise Price Per Share $ 0.90

X

- Definition

The price per share at which the common stock purchased during the period.

+ References

No definition available.

+ Details

Name: csbr_CommonStockPurchasePrice

Namespace Prefix: csbr_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The price per share at which the common stock of an entity that has priority upon a change of control or sale or exclusive license of substantially all of the Company's assets.

+ References

No definition available.

+ Details

Name: csbr_CommonStockRepurchasePricePerShare

Namespace Prefix: csbr_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Change during the period in fair value of the warrants decreased due within one year or operating cycle.

+ References

No definition available.

+ Details

Name: csbr_IncreaseDecreaseInWarrantsFairValue

Namespace Prefix: csbr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The incremental costs associated with the securities purchase agreement.

+ References

No definition available.

+ Details

Name: csbr_IncrementalCompensationCost

Namespace Prefix: csbr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The issuance of additional common shares to investors under the anti-dilution protections granted such investors.

+ References

No definition available.

+ Details

Name: csbr_IssuanceOfAdditionalCommonSharesToInvestors

Namespace Prefix: csbr_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Percentage of cash penalty equal to the aggregate purchase price paid by investor.

+ References

No definition available.

+ Details

Name: csbr_PercentageOfCashPenalties

Namespace Prefix: csbr_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The percentage of common stock purchased by investors.

+ References

No definition available.

+ Details

Name: csbr_PercentageOfCommonStockPurchased

Namespace Prefix: csbr_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The total amount of potential penalties under this registration payment arrangement.

+ References

No definition available.

+ Details

Name: csbr_PotentialPenaltiesAmount

Namespace Prefix: csbr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from issuance of rights to purchase common shares at predetermined price and the additional capital contribution to the entity.

+ References

No definition available.

+ Details

Name: csbr_ProceedsFromIssuanceOfCommonStockAndWarrants

Namespace Prefix: csbr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Percentage describes the limit of the aggregate Purchase Price paid by the investors.

+ References

No definition available.

+ Details

Name: csbr_PurchasePriceLimitPercentage

Namespace Prefix: csbr_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition

The warrants exercise price per share.

+ References

No definition available.

+ Details

Name: csbr_WarrantsExercisePricePerShare

Namespace Prefix: csbr_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The number warrants issued during the period for purchase of common stock.

+ References

No definition available.

+ Details

Name: csbr_WarrantsIssuedDuringPeriodForCommonStock

Namespace Prefix: csbr_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of net shares reclassified to mandatorily redeemable capital stock.

+ References

No definition available.

+ Details

Name: us-gaap_NetSharesReclassifiedToMandatorilyRedeemableCapitalStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromIssuanceOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Number of shares of stock issued during the period pursuant to acquisitions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 53

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Gross value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP). Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.

+ References

No definition available.

+ Details

Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 98-5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph i

-Article 4

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 00-27

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_WarrantsAndRightsOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 34 R24.htm IDEA: XBRL DOCUMENT v2.4.0.6

Redeemable Common Stock and Stock Purchase Warrant (Tables)
9 Months Ended

Jan. 31, 2013

Redeemable Common Stock and Stock Purchase Warrant [Abstract]

Schedule of Share-based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]
Assumptions used to calculate the fair value of these warrants were as follows:

January 31, April 30,

2013 2012

Risk-free interest rates 0.46% - 0.88% 0.6%

Volatility 84.9% - 102% 102%

Dividend yield 0% 0%

X

- Details

Name: csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract

Namespace Prefix: csbr_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

No definition available.

+ Details

Name: csbr_ScheduleOfShareBasedPaymentAwardStockWarrantsValuationAssumptionsTableTextBlock

Namespace Prefix: csbr_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 35 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "
"+ text.join( "

\n" ) +"
"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "
" + text[p] + "
\n"; } } }else{ formatted = '
' + raw + '
'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+'
'+formatted+'
'+ "\n"+'
'+ "\n"+'
'+raw+'
'+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 36 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6

Organization, Use of Estimates and Basis of Presentation
9 Months Ended

Jan. 31, 2013

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]
Note 1. Organization, Use of Estimates and Basis of Presentation

Champions Oncology, Inc. (the “Company”), is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The Company’s Tumorgraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The Company uses this technology to derive revenue for two customer groups: Personalized Oncology Solutions (“POS”) and Translational Oncology Solutions (“TOS”). POS assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug studies and related personalized oncology services. The Company’s TOS business offers a technology platform to pharmaceutical and biotechnology companies using proprietary Tumorgraft studies, which have been shown to be predictive of how drugs may perform in clinical settings.

The Company has three operating subsidiaries: Champions Oncology (Israel), Limited, Champions Biotechnology U.K., Limited and Champions Oncology Singapore, PTE LTD. For the three and nine months ended January 31, 2013 and 2012, there were no material revenues earned by these subsidiaries. All material intercompany transactions have been eliminated in consolidation. The financial statements of the Company’s foreign subsidiaries, all of which have a functional currency other than the U.S. dollar, have been translated into the U.S. dollar for each period presented. Translation gains and losses are recognized as a component of accumulated other comprehensive loss. The Company is subject to foreign exchange rate fluctuations in connection with the Company’s international operations.

These unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). All significant intercompany transactions and accounts have been eliminated. All figures are presented in U.S. dollars, except where expressly stated otherwise. Certain information related to the Company’s organization, significant accounting policies and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) has been condensed or omitted. The accounting policies followed in the preparation of these unaudited condensed consolidated financial statements are consistent with those followed in the Company’s annual consolidated financial statements for the year ended April 30, 2012, as filed on Form 10-K. In the opinion of management, these unaudited condensed consolidated financial statements contain all material adjustments necessary to fairly state the Company’s financial position, results of operations, and cash flows for the periods presented and the presentations and disclosures herein are adequate when read in conjunction with the Company’s Annual Report on Form 10-K for the year ended April 30, 2012. Certain reclassifications have been made to the prior period financial statement amounts to conform to current presentation.

The preparation of financial statements in conformity with Generally Accepted Accounting Principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include valuation assumptions used for share-based compensation and warrant liability, accrued expenses and deferred taxes.

Basic loss per share is calculated by dividing loss available to common shareholders by the weighted average number of common shares (including redeemable common stock) outstanding for the period. Diluted loss per share is calculated based on the weighted average number of common shares (including redeemable common stock) outstanding for the period, plus the dilutive effect of common stock purchase warrants, stock options and restricted stock units using the treasury stock method. Contingently issuable shares are included in the calculation of basic earnings per share when all contingencies surrounding the issuance of the shares are met and the shares are issued or issuable. Contingently issuable shares are included in the calculation of dilutive earnings per share as of the beginning of the reporting period if, at the end of the reporting period, all contingencies surrounding the issuance of the shares are satisfied, or would be satisfied, if the end of the reporting period were the end of the contingency period. Due to the net losses for the three and nine months ended January 31, 2013 and 2012, basic and diluted loss per share were the same, as the effect of potentially dilutive securities would have been anti-dilutive.



The following table reflects the total potential share-based instruments outstanding at January 31, 2013 and 2012 that could have an effect on the future computation of dilution per common share:

January 31,

2013 2012

Stock options 15,018,955 15,064,866

Warrants 3,276,667 1,416,667

Restricted stock 75,000 37,500

Total common stock equivalents 18,370,622 16,519,033

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Staff Position (FSP)

-Number FAS140-4/FIN46(R)-8

-Paragraph 8, C1, C7

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 46R

-Paragraph 4, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=7880789&loc=SL6228881-111685

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 2-6

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)

Jan. 31, 2013

Apr. 30, 2012

Redeemable common stock, par value (in dollars per share) $ 0.001 $ 0.001

Redeemable common stock, shares outstanding 31,133,333 12,533,333

Preferred stock, par value (in dollars per share) $ 10 $ 10

Preferred stock, shares authorized 56,075 56,075

Preferred stock, shares issued 0 0

Preferred stock, shares outstanding 0 0

Common stock, par value (in dollars per share) $ 0.001 $ 0.001

Common stock, shares authorized 125,000,000 125,000,000

Common stock, shares issued 38,855,003 37,740,345

Common stock, shares outstanding 35,618,767 34,529,000

Treasury stock, shares 3,236,000 3,236,000

X

- Definition

Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of stock classified as temporary equity; generally not indicative of the fair market value per share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Article 5

+ Details

Name: us-gaap_TemporaryEquityParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.27(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 28

-Subparagraph b

-Article 5

+ Details

Name: us-gaap_TemporaryEquitySharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28,29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_TreasuryStockShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 38 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6

Grant Income
9 Months Ended

Jan. 31, 2013

Grant Income [Abstract]

Grant Income [Text Block]
Note 11. Grant Income

In October 2010, the Company was notified that it was awarded total cash grants of approximately $1.5 million under the Qualifying Therapeutic Discovery Project program administered under section 48D of the Internal Revenue Code, of which approximately $1.0 million related to qualifying expenses the Company had previously incurred during fiscal 2010 and $0.5 million related to qualifying expenses which the Company expected to incur during fiscal 2011. In November 2010, the Company received approximately $1.0 million related to the 2010 expenditures. The Company received a final payment of $0.5 million related to 2011 expenditures on February 13, 2012.

On August 8, 2011 the Company was notified that it was selected for a tax examination by the Internal Revenue Service (“IRS”) on the Application for Certification of Qualified Investments Eligible for Credits and Grants Under the Qualifying Therapeutic Discovery Project program filed under the Patient Protection and Affordable Care Act of 2010 for the 2009 and 2010 tax years. The examination commenced during the second quarter of fiscal 2012. The IRS expanded its scope to include the fiscal year 2011 tax return, which was filed in January 2012. The examinations of fiscal 2009 and 2010 were completed in the fourth quarter of fiscal 2012. The examination of fiscal 2011 was completed in the first quarter of fiscal 2013. The audit of all three fiscal years ending April 30, 2011, 2010 and 2009 resulted in no additional tax due or receivable.

X

- Details

Name: csbr_GrantIncomeAbstract

Namespace Prefix: csbr_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure relating to grant income.

+ References

No definition available.

+ Details

Name: csbr_GrantIncomeTextBlock

Namespace Prefix: csbr_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 39 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6

DOCUMENT AND ENTITY INFORMATION
9 Months Ended

Jan. 31, 2013

Feb. 28, 2013

Entity Registrant Name CHAMPIONS ONCOLOGY, INC.

Entity Central Index Key 0000771856

Current Fiscal Year End Date --04-30

Entity Filer Category Smaller Reporting Company

Trading Symbol csbr

Entity Common Stock, Shares Outstanding 66,752,100

Document Type 10-Q

Amendment Flag false

Document Period End Date Jan. 31, 2013

Document Fiscal Period Focus Q3

Document Fiscal Year Focus 2013

X

- Definition

If the value is true, then the document is an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

XML 40 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6

Fair Value
9 Months Ended

Jan. 31, 2013

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]
Note 12. Fair Value

The carrying value of cash and cash equivalents, accounts receivable, prepaid expenses, deposits and other receivables, accounts payable and accrued liabilities approximate their fair value based on the liquidity or the short-term maturities of these instruments. The fair value hierarchy promulgated by GAAP consists of three levels:

· Level one — Quoted market prices in active markets for identical assets or liabilities;

· Level two — Inputs other than level one inputs that are either directly or indirectly observable; and

· Level three — Unobservable inputs developed using estimates and assumptions, which are developed by the reporting entity and reflect those assumptions that a market participant would use.

Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each quarter. The Company has one liability measured at fair value on a recurring basis, which are warrants that were issued in connection with the January 2013 Private Placement and April 2012 Private Placement which is discussed more fully in Note 5. As of January 31, 2013 and April 30, 2012, these warrants had an estimated fair value of $1 million and $0.6 million, respectively, which was calculated by the Monte Carlo simulation valuation method using level three inputs. The Company has no assets that are measured at fair value on a recurring basis and there were no assets or liabilities measured at fair value on a non-recurring basis as of January 31, 2013 and April 30, 2012 or during the nine months ended January 31, 2013 and 2012.

The following table presents information about the Company’s warrants liability, which was the only financial instrument measured at fair value on a recurring basis using significant unobservable inputs (Level 3) at January 31, 2013 (in thousands):

Balance, May 1, 2012 $ 555

Transfers to (from) Level 3 -

Total (gains) losses included in earnings 21

Purchases, issuances and settlements, net 417

Balance, January 31, 2013 $ 993

X

- Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15C, 15D

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 133

-Paragraph 44A, 44B

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15A

-Subparagraph a-d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 3, 10, 14, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 159

-Paragraph 17-22, 27, 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 107

-Paragraph 15B

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 157

-Paragraph 32, 33, 34

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified
3 Months Ended 9 Months Ended

Jan. 31, 2013

Jan. 31, 2012

Jan. 31, 2013

Jan. 31, 2012

Operating revenue:

Personalized oncology solutions $ 473 $ 649 $ 1,850 $ 1,837

Translational oncology solutions 2,444 1,747 4,631 3,931

Total operating revenue 2,917 2,396 6,481 5,768

Costs and operating expenses:

Cost of personalized oncology solutions 676 528 2,030 1,463

Cost of translational oncology solutions 566 801 1,740 1,904

Research and development 592 930 1,415 2,558

Sales and marketing 658 623 2,047 1,885

General and administrative 1,145 1,287 3,484 4,421

Total costs and operating expenses 3,637 4,169 10,716 12,231

Loss from operations (720) (1,773) (4,235) (6,463)

Other (expense) income:

Change in fair value of warrant liability (255) 66 (21) 354

Other (expense) income (10) (12) (22) (2)

Total other (expense) income (265) 54 (43) 352

Loss before provision for income taxes (985) (1,719) (4,278) (6,111)

Provision for income taxes 5 0 6 0

Net loss $ (990) $ (1,719) $ (4,284) $ (6,111)

Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share) $ (0.02) $ (0.04) $ (0.09) $ (0.13)

Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares) 47,737,000 46,738,000 47,294,000 47,000,000

X

- Definition

Total costs related to personalized oncology solutions during the reporting period.

+ References

No definition available.

+ Details

Name: csbr_CostOfPersonalizedOncologySolutions

Namespace Prefix: csbr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Total costs related to translational oncology solutions during the reporting period.

+ References

No definition available.

+ Details

Name: csbr_CostOfTranslationalOncologySolutions

Namespace Prefix: csbr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue during the period from personalized oncology solutions.

+ References

No definition available.

+ Details

Name: csbr_PersonalizedOncologySolutions

Namespace Prefix: csbr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Aggregate revenue during the period from translational oncology solutions.

+ References

No definition available.

+ Details

Name: csbr_TranslationalOncologySolutions

Namespace Prefix: csbr_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959

+ Details

Name: us-gaap_GainLossOnDerivativeInstrumentsNetPretax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 10

-Article 5

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 45

-Subparagraph a, b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 5

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_OperatingIncomeLossAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 9

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_OtherNonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 141

-Paragraph 51

-Subparagraph g

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 86

-Paragraph 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 985

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 2

-Paragraph 12, 13

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Aggregate revenue during the period from services rendered in the normal course of business, after deducting allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

+ Details

Name: us-gaap_SalesRevenueServicesNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The aggregate total amount of expenses directly related to the marketing or selling of products or services.

+ References

No definition available.

+ Details

Name: us-gaap_SellingAndMarketingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).

+ References

No definition available.

+ Details

Name: us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 42 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6

Related Party Transactions
9 Months Ended

Jan. 31, 2013

Related Party Transactions [Abstract]

Related Party Transactions Disclosure [Text Block]
Note 6. Related Party Transactions

Related party transactions include transactions between the Company and its shareholders, management, and affiliates. The transactions discussed in this footnote were in the normal course of operations and were measured at the exchange amount, which is the amount of consideration established and agreed to by the parties.

Consulting Services

During the nine months ended January 31, 2013 and 2012, the Company paid one of its former directors and former Chief Executive Officer, $30,000 and $18,000, respectively, in consulting fees. During the nine months ended January 31, 2013 and 2012, the Company paid certain members of its Board of Directors $122,500 and $103,000, respectively, for consulting services unrelated to their duties as board members. During the nine months ended January 31, 2013, the Company paid a substantial stockholder and former member of its Board of Directors $3,000 for consulting services. No such payment was made during the nine months ended January 31, 2012. During the nine months ended January 31, 2013, the Company paid a prospective board member’s company $8,300 for consulting services. No such payment was made during the nine months January 31, 2012. All of the amounts paid to these related parties have been expensed.



Revenue

During the nine months ended January 31, 2013, the Company earned no revenues through related party transactions. During the nine months ended January 31, 2012, the Company recognized $20,000 in revenues from a company whose board members were also members of the Company’s Board of Directors.

X

- Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 1-4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph b

-Article 3A

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph k

-Article 4

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 43 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6

Redeemable Common Stock and Stock Purchase Warrant
9 Months Ended

Jan. 31, 2013

Redeemable Common Stock and Stock Purchase Warrant [Abstract]

Redeemable Common Stock and Stock Purchase Warrant [Text Block]
Note 5. Redeemable Common Stock and Stock Purchase Warrant

On January 28, 2013, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale of an aggregate 18,600,000 shares of the Company’s Common Stock at a purchase price of $0.50 per share, for aggregate proceeds of $9.3 million, $0.5 million of which was sold to officers and directors of the Company. This private placement transaction closed on January 28, 2013 (the “January 2013 Private Placement”). As part of this transaction, the Company also issued warrants to purchase an aggregate 1,860,000 shares of Common Stock at an exercise price of $0.66 per share. These warrants expire five years after the closing date . The Company also entered into an Amended and Restated Registration Rights Agreement on January 28, 2013 which provided certain registration rights with respect to the shares of Common Stock issued and the shares of Common Stock issuable upon exercise of the warrants. Furthermore, certain investors will have the right to require the Company to redeem the purchased common shares held by all of the investors (the “January 2013 Private Placement Put Option”) for cash of $0.50 per share upon a change of control or sale or exclusive license of substantially all of the Company’s assets. The January 2013 Private Placement Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement for the January 2013 Private Placement. The January 2013 Private Placement investors also have certain participation rights with respect to future financings of the Company. The terms of the January 2013 Private Placement resulted in the issuance of an additional 1,064,658 common shares to the investors of the April 2011 Private Placement under the anti-dilution protections granted such investors.

On March 24, 2011, the Company entered into a Securities Purchase Agreement with several accredited investors for the sale of an aggregate 12,533,333 shares of the Company’s Common Stock at a purchase price of $0.75 per share, for aggregate proceeds of $9.4 million, $0.5 million of which was sold to officers and directors of the Company. This private placement transaction closed April 4, 2011 (the “April 2011 Private Placement”). As part of this transaction, the Company also issued warrants to purchase an aggregate 1,266,667 shares of Common Stock at an exercise price of $0.90 per share. These warrants expire five years after the closing date. The Securities Purchase Agreement governing the April 2011 Private Placement contains certain anti-dilution protections for the investors. The Amended and Restated Registration Rights Agreement referenced above provides certain registration rights with respect to the shares of Common Stock issued and the shares of Common Stock issuable upon exercise of the warrants. Furthermore, certain investors have the right to require the Company to redeem the purchased common shares held by all of the investors (the “April 2011 Private Placement Put Option”) for cash for $0.75 per share upon a change of control or sale or exclusive license of substantially all of the Company’s assets. The April 2011 Private Placement Put Option will terminate upon the achievement of certain financial milestones by the Company, the sale of 25% of the common shares purchased by an investor, with respect only to the shares owned by such investor, or in certain other circumstances as outlined in the Securities Purchase Agreement for the April 2011 Private Placement.

Due to the April 2011 Private Placement Put Option and the January 2013 Private Placement Put Option described above, the Company has accounted for the Common Stock for the April 2011 Private Placement and January 2013 Private Placement as temporary equity, which is reflected under the caption “redeemable common stock” on the accompanying condensed consolidated balance sheets. The total amount allocated to the redeemable common stock was $8.8 million for the January 2013 Private Placement and $8.2 million for the April 2011 Private Placement. For the January 2013 Private Placement, this allocation is equal to the total proceeds of $9.3 million less the amount allocated to the warrants of $0.4 million and is also net of the direct and incremental costs associated with the January 2013 Private Placement of $0.1 million. For the April 2011 Private Placement, this allocation is equal to the total proceeds of $9.4 million, less the amount allocated to the warrants of $0.9 million and is also net of direct and incremental costs associated with the April 2011 Private Placement of $0.3 million.



The warrants issued in connection with both the April 2011 Private Placement and January 2013 Private Placement contain certain exercise price reset provisions. Under these provisions, the exercise price of the warrants may be adjusted downward should the Company have future sales of its Common Stock for no consideration or for a consideration per share less than the Per Share Price (as such term is defined in the April 2011 Private Placement and January 2013 Private Placement). These exercise price reset provisions resulted in a downward adjustment to the exercise price of the warrants issued in the April 2011 Private Placement from $0.90 to $0.50.

The Company has granted demand registration rights in connection with the investment in common shares and the common shares underlying the warrants for both the April 2011 Private Placement and January 2013 Private Placement. These rights include the requirement of the Company to file certain registration statements within a specified time period and to have these registration statements declared effective within a specified time period. If the Company is not able to comply with these registration requirements, the Company will be required to pay cash penalties equal to 1.0% of the aggregate Purchase Price paid by the investors for each 30-day period in which a Registration Default, as defined in the Securities Purchase Agreement, exists. These penalties are subject to a 10% limit of the aggregate Purchase Price paid by the investors. The Company may become subject to these penalty provisions if it fails to have a registration statement for the common shares declared effective, or to maintain the effectiveness of such registration statement. The total amount of potential penalties under this registration payment arrangement ranges from $50,000 to $130,000 for each 30-day period in which a registration default exists; however, as of January 31, 2013 and through the date of this filing, the Company does not believe these penalties to be probable and accordingly, has not established an accrual for such registration payment arrangements.

The Company has accounted for the warrants issued in connection with the April 2011 Private Placement and January 2013 Private Placement as a liability based on the exercise price reset provisions described above. This liability, which is recorded at fair value on the accompanying consolidated balance sheets, totaled $0.8 million at the time of the close of the January 2013 Private Placement Agreement. As of January 31, 2013 and April 30, 2012, the fair value of these warrants was $1 million and $0.6 million, respectively. The change in fair value of these warrants has been, and will be, recognized as other income (expense) on the Company’s condensed consolidated statements of operations. The fair value of these warrants was calculated by the Monte Carlo simulation valuation method. Assumptions used to calculate the fair value of these warrants were as follows:

January 31, April 30,

2013 2012

Risk-free interest rates 0.46% - 0.88% 0.6%

Volatility 84.9% - 102% 102%

Dividend yield 0% 0%

The Company will continue to adjust the warrant liability for changes in fair value until the earlier of the exercise of the warrants, at which time the liability will be reclassified to stockholders' equity, or expiration of the warrants. As of January 31, 2013, the Company changed its method used to calculate expected volatility from an index, which was based on the Company’s historic volatility and certain comparable guideline companies, to the use of only the Company’s historic volatility which had an immaterial effect on the financial statements

X

- Details

Name: csbr_RedeemableCommonStockAndStockPurchaseWarrantAbstract

Namespace Prefix: csbr_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure related to prior period financing in which warrants that are accounted for as liabilities, due to exercise price reset provisions, and common stock accounted for as temporary equity were issued to investors. Disclosure also describes assumptions used to revalue warrants during the reporting period.

+ References

No definition available.

+ Details

Name: csbr_RedeemableCommonStockAndStockPurchaseWarrantTextBlock

Namespace Prefix: csbr_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 44 R23.htm IDEA: XBRL DOCUMENT v2.4.0.6

Share-Based Payments (Tables)
9 Months Ended

Jan. 31, 2013

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]
Stock-based compensation expense was recognized as follows (in thousands):

Three Months Ended Nine Months Ended

January 31, January 31,

2013 2012 2013 2012

General and administrative $ 500 $ 701 $ 1,619 $ 2,370

Sales and marketing 56 49 199 168

Research and development 4 (8 ) 33 72

TOS cost of sales 4 1 16 2

POS cost of sales 6 - 67 -

Total stock-based compensation expense $ 570 $ 743 $ 1,934 $ 2,612

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]
Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2013 and 2012 were as follows:

Three Months Ended Nine Months Ended

January 31, January 31,

2013 2012 2013 2012

Expected term in years 6.0 3.0 - 6.0 6.0 3.0 - 6.0

Risk-free interest rates 0.9% - 1.0% 0.4% - 1.9% 0.8% - 1.0% 0.4% - 2.2%

Volatility 100% - 102% 90% - 101% 99% - 102% 90% - 108%

Dividend yield 0% 0% 0% 0%

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]
The Company’s stock option activity for the nine months ended January 31, 2013 was as follows:

Weighted

Weighted Average

Directors Average Remaining Aggregate

Non- and Exercise Contractual Intrinsic

Employees Employees Total Price Life (Years) Value

Outstanding, May 1, 2012 1,410,000 13,456,038 14,866,038 $ 0.88 7.0 $ -

Granted 130,000 586,250 716,250 0.41

Forfeited - (22,500 ) (22,500 ) 0.67

Expired (500,000 ) (15,833 ) (515,833 ) 0.76

Canceled - (25,000 ) (25,000 ) 0.62

Outstanding, January 31, 2013 1,040,000 13,978,955 15,018,955 0.86 7.1 96,000

Vested and expected to vest as of January 31, 2013 1,040,000 13,978,955 15,018,955

Exercisable as of January 31, 2013 933,334 9,735,078 10,668,412 0.88 6.8 14,000

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]
A summary of the activity related to restricted stock grants is as follows (in thousands):

Weighted

Average Grant

Date Fair Value

Shares Per Share

Nonvested as of May 1, 2012 25,000 $ 0.75

Granted 100,000 0.30

Vested (50,000 ) 0.53

Forfeited - -

Expired - -

Nonvested as of January 31, 2013 75,000 -

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph g(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809

+ Details

Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.

+ References

No definition available.

+ Details

Name: us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (f)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 45 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6

Business Segment Information
9 Months Ended

Jan. 31, 2013

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]
Note 13. Business Segment Information

The Company operates in two segments, POS and TOS. The accounting policies of the Company’s segments are the same as those described in Note 2 of the Company’s annual consolidated financial statements for the year ended April 30, 2012, as filed on Form 10-K. The Company evaluates performance of its segments based on profit or loss from operations before stock-based compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes (“segment profit”). Management uses segment profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment, and employee compensation, among other matters. The following tables summarize, for the periods indicated, operating results by business segment (in thousands):

Translational

Personalized Oncology Unallocated

Oncology Solutions Corporate

Three Months Ended January 31, 2013 Solutions (POS) (TOS) Overhead Consolidated

Net revenue $ 473 $ 2,444 $ - $ 2,917

Direct cost of services (661 ) (561 ) - (1,222 )

Sales and marketing costs (361 ) (220 ) - (581 )

Other operating expenses - (627 ) (637 ) (1,264 )

Stock- based compensation expense (1) - - (570 ) (570 )

Segment profit (loss) $ (549 ) $ 1,036 $ (1,207 ) $ (720 )

Translational

Personalized Oncology Unallocated

Oncology Solutions Corporate

Three Months Ended January 31, 2012 Solutions (POS) (TOS) Overhead Consolidated

Net revenue $ 649 $ 1,747 $ - $ 2,396

Direct cost of services (528 ) (801 ) - (1,329 )

Sales and marketing costs (242 ) (175 ) - (417 )

Other operating expenses - (851 ) (829 ) (1,680 )

Stock- based compensation expense (1) - - (743 ) (743 )

Segment profit (loss) $ (121 ) $ (80 ) $ (1,572 ) $ (1,773 )

Translational

Personalized Oncology Unallocated

Oncology Solutions Corporate

Nine Months Ended January 31, 2013 Solutions (POS) (TOS) Overhead Consolidated

Net revenue $ 1,850 $ 4,631 $ - $ 6,481

Direct cost of services (2,030 ) (1,740 ) - (3,770 )

Sales and marketing costs (495 ) (636 ) - (1,131 )

Other operating expenses - (1,463 ) (2,418 ) (3,881 )

Stock- based compensation expense (1) - - (1,934 ) (1,934 )

Segment profit (loss) $ (675 ) $ 792 $ (4,352 ) $ (4,235 )

Translational

Personalized Oncology Unallocated

Oncology Solutions Corporate

Nine Months Ended January 31, 2012 Solutions (POS) (TOS) Overhead Consolidated

Net revenue $ 1,837 $ 3,931 $ - $ 5,768

Direct cost of services (1,463 ) (1,904 ) - (3,367 )

Sales and marketing costs (718 ) (626 ) - (1,344 )

Other operating expenses - (2,419 ) (2,489 ) (4,908 )

Stock- based compensation expense (1) - - (2,612 ) (2,612 )

Segment profit (loss) $ (344 ) $ (1,018 ) $ (5,101 ) $ (6,463 )

(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.

All of the Company’s revenue is recorded in the United States and substantially all of its long-lived assets are in the United States.

X

- Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 29

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 32

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 35

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 131

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 34

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 31

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 40

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 41

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

+ Details

Name: us-gaap_SegmentReportingDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 46 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6

Cephalon Agreement
9 Months Ended

Jan. 31, 2013

Cephalon Agreement [Abstract]

Cephalon Agreement [Text Block]
Note 9. Cephalon Agreement

On March 16, 2011, the Company entered into an agreement with Cephalon, Inc., (“Cephalon”), a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., pursuant to which the Company conducts TumorGraft studies on two proprietary chemical compounds provided by Cephalon to determine the activity or response of these compounds in potential clinical indications. Under the agreement, Cephalon will, under certain conditions, pay the Company various amounts upon achieving certain milestones, which are based on the performance of the compounds in preclinical testing and are dependent upon testing the compound in clinical settings and obtaining FDA approval. Potential milestone payments that could be received under the Agreement total $27 million per compound. No milestones have been achieved to date. In addition, under certain conditions, Cephalon would pay the Company royalties on any commercialized products developed under the Agreement. No royalties have been received or earned to date. Cephalon reserves the right to exercise and pay a one-time fee of in lieu of the milestone or royalty payments, which are $460,000 for one compound and $880,000 for the second compound.

On November 30, 2012, Cephalon exercised the option to pay the one-time fee of $880,000 to the Company, in lieu of any future milestone or royalty payments, for one compound tested under the agreement described above. Written notice was provided to the Company on December 3, 2012 and payment was received on December 19, 2012. This fee has been recognized as revenue during the three and nine months ended January 31, 2013. As of January 31, 2013, the remaining compound is still being evaluated.

In April 2011, Cephalon paid an initiation fee of $1.4 million to the Company, which was initially reflected within deferred revenue on the Company’s balance sheet as of April 30, 2011. As models, along with required reports, are delivered, the deferred revenue is recognized on a proportionate basis in accordance with the Company’s revenue recognition policies. Revenues of $317,000 and $681,000 were recognized during the nine months ended January 31, 2013 and 2012.

X

- Details

Name: csbr_CephalonAgreementAbstract

Namespace Prefix: csbr_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure relating to Cephalon Agreement.

+ References

No definition available.

+ Details

Name: csbr_CephalonAgreementTextBlock

Namespace Prefix: csbr_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 47 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6

Commitments and Contingencies
9 Months Ended

Jan. 31, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]
Note 7. Commitments and Contingencies

Operating Leases

As of January 31, 2013, the Company leases the following facilities under non-cancelable operating lease agreements:

· One University Plaza, Suite 307, Hackensack, New Jersey 07601, which, since November 2011, serves as the Company’s corporate headquarters. This lease expires in April 2014. The Company recorded $52,000 and $52,000 of rental expense relative to this lease for the nine months ended January 31, 2013 and 2012, respectively.

· 855 North Wolfe Street, Suite 619, Baltimore, Maryland 21205, which consists of laboratories and office space where the Company conducts operations related to its primary service offerings. This lease expires in June 2014. The Company recorded $69,000 and $49,000 of rental expense relative to this lease in the nine months ended January 31, 2013 and 2012, respectively.

· 17 Hatidhar Street, Ra’anana, Israel, which serves as office headquarters for Champions Oncology, Israel. The lease expires in July 2013. The Company recorded $21,000 and $18,000 of rental expense relative to this lease for the nine months ended January 31, 2013 and 2012, respectively.

Legal Matters

The Company is party to certain legal matters arising in the ordinary course of its business. The Company has evaluated its potential exposure to these legal matters and noted no such exposures. The Company is not aware of any other matters that would have a material impact on the Company’s financial position or results of operations.

Registration Payment Arrangements

The Company has entered into an Amended and Restated Registration Rights Agreement in connection with the April 2011 Private Placement and January 2013 Private Placement and is discussed more fully in Note 5 above. This Amended and Restated Registration Rights Agreement contains provisions that may call for the Company to pay penalties in certain circumstances. This registration payment arrangement primarily relates to the Company’s ability to file a registration statement within a particular time period, have a registration statement declared effective within a particular time period and to maintain the effectiveness of the registration statement for a particular time period. The Company does not believe it is probable that penalty payments will be made for the Amended and Restated Registration Rights Agreement discussed in Note 5 above and, accordingly, has not accrued for such potential penalties as of January 31, 2013 or April 30, 2012.

X

- Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name FASB Interpretation (FIN)

-Number 14

-Paragraph 3

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 9, 10, 11, 12

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 48 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6

Licensing Agreements
9 Months Ended

Jan. 31, 2013

Licensing Agreements [Abstract]

Licensing Agreements Disclosure [Text Block]
Note 8. Licensing Agreements

In February 2010, the Company entered into an exclusive option agreement with a Canadian company for which it paid and expensed $40,000 (Canadian) during the Company’s fiscal 2010 year. The option agreement granted the Company the exclusive right to review Irinophore C, a nanoparticle drug compound, for the treatment of various forms of cancer, including melanoma, prostate, breast, and lung cancer through April 2011. During the option year, the Company performed various TumorGraft tests on the nanoparticle compound. In March 2011, the Company exercised its option to license Irinophore C, a liposomal formulation of Irinotecan. Under the terms of the agreement, the Company’s exercise of the option resulted in amounts due to the Canadian company of $85,000 (Canadian) comprised of the option exercise price and reimbursement to the Canadian company for past patent costs, which was expensed in the Company’s fiscal year ended April 30, 2011. The Company satisfied this obligation during fiscal 2012. On the first anniversary of the agreement (March 2012), an additional license fee of $45,000 (Canadian) became due, which was recognized as a liability as of April 30, 2012 and was satisfied during the nine months ended January 31, 2013. Commencing with the second anniversary of the agreement (March 2013), the Company will be obligated to pay a minimum annual royalty of $10,000 (Canadian), unless the agreement is terminated by either party in advance of the anniversary date. Under the terms of the license agreement, the Company will be required to pay up to $3.0 million in development milestones, if achieved. Upon commercialization, the Company would also be required to make royalty and sales milestone payments based upon revenues. As of January 31, 2013 the Company has accrued for the annual royalty payment of $10,000 (Canadian).

X

- Details

Name: csbr_LicensingAgreementsAbstract

Namespace Prefix: csbr_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure related to several different licensing agreements.

+ References

No definition available.

+ Details

Name: csbr_LicensingAgreementsDisclosureTextBlock

Namespace Prefix: csbr_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 49 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6

Supplemental Schedule of Cash Flow Information
9 Months Ended

Jan. 31, 2013

Supplemental Cash Flow Elements [Abstract]

Cash Flow, Supplemental Disclosures [Text Block]
Note 10. Supplemental Schedule of Cash Flow Information

There was no cash paid for interest or income taxes during the nine months ended January 31, 2013 and 2012.

X

- Definition

The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 32

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_CashFlowSupplementalDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowElementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 50 R34.htm IDEA: XBRL DOCUMENT v2.4.0.6

Share-Based Payments (Details Textual) (USD $)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 9 Months Ended 1 Months Ended 9 Months Ended

Mar. 24, 2011

Jan. 31, 2013

Jan. 31, 2012

Jan. 31, 2013

Jan. 31, 2012

Apr. 30, 2012

Jan. 31, 2013

April 2011 Private Placement [Member]

Jan. 28, 2013

January 2013 Private Placement [Member]

Jan. 31, 2013

January 2013 Private Placement [Member]

Jan. 31, 2013

Equity Instrument [Member]

Allocated Share-based Compensation Expense $ 570,000 $ 743,000 $ 1,934,000 $ 2,612,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 0.27 $ 0.52 $ 0.36 $ 0.57

Share-based Compensation Arrangement by Share-based Payment Award, Vesting Period, Fair Value 26,000 84,000

Share-based Compensation Arrangement by Share-based Payment Award, Warrants, Outstanding 3,276,667 3,276,667

Warrants Issued During Period for Common Stock 1,266,667 1,266,667 1,860,000 1,860,000 150,000

Warrant Expiration Date Jul. 31, 2014

Warrant Intrinsic Value $ 13,000 $ 13,000 $ 0

Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Outstanding, Weighted Average Exercise Price $ 0.77 $ 0.77

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms 4 years 2 months 12 days 3 years 9 months 18 days

X

- Definition

Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Outstanding Weighted Average Exercise Price

+ References

No definition available.

+ Details

Name: csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: csbr_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The aggregate fair value of equity-based payment equity instruments, restricted stock that vested during the reporting period.

+ References

No definition available.

+ Details

Name: csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriodFairValue

Namespace Prefix: csbr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The number of share warrants outstanding in connection with the financing arrangement.

+ References

No definition available.

+ Details

Name: csbr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstanding

Namespace Prefix: csbr_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Expiration date of warrants.

+ References

No definition available.

+ Details

Name: csbr_WarrantExpirationDate

Namespace Prefix: csbr_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The intrinsic value of warrants as on the balance sheet date.

+ References

No definition available.

+ Details

Name: csbr_WarrantIntrinsicValue

Namespace Prefix: csbr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The number warrants issued during the period for purchase of common stock.

+ References

No definition available.

+ Details

Name: csbr_WarrantsIssuedDuringPeriodForCommonStock

Namespace Prefix: csbr_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (h)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph g(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

-Section F

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 14.F)

-URI http://asc.fasb.org/extlink&oid=6793087&loc=d3e301413-122809

+ Details

Name: us-gaap_AllocatedShareBasedCompensationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (e)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition

The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph A240

-Subparagraph c(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

XML 51 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6

Organization, Use of Estimates and Basis of Presentation (Tables)
9 Months Ended

Jan. 31, 2013

Organization, Consolidation and Presentation Of Financial Statements [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
The following table reflects the total potential share-based instruments outstanding at January 31, 2013 and 2012 that could have an effect on the future computation of dilution per common share:

January 31,

2013 2012

Stock options 15,018,955 15,064,866

Warrants 3,276,667 1,416,667

Restricted stock 75,000 37,500

Total common stock equivalents 18,370,622 16,519,033

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R26.htm IDEA: XBRL DOCUMENT v2.4.0.6

Business Segment Information (Tables)
9 Months Ended

Jan. 31, 2013

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]
The following tables summarize, for the periods indicated, operating results by business segment (in thousands):

Translational

Personalized Oncology Unallocated

Oncology Solutions Corporate

Three Months Ended January 31, 2013 Solutions (POS) (TOS) Overhead Consolidated

Net revenue $ 473 $ 2,444 $ - $ 2,917

Direct cost of services (661 ) (561 ) - (1,222 )

Sales and marketing costs (361 ) (220 ) - (581 )

Other operating expenses - (627 ) (637 ) (1,264 )

Stock- based compensation expense (1) - - (570 ) (570 )

Segment profit (loss) $ (549 ) $ 1,036 $ (1,207 ) $ (720 )

Translational

Personalized Oncology Unallocated

Oncology Solutions Corporate

Three Months Ended January 31, 2012 Solutions (POS) (TOS) Overhead Consolidated

Net revenue $ 649 $ 1,747 $ - $ 2,396

Direct cost of services (528 ) (801 ) - (1,329 )

Sales and marketing costs (242 ) (175 ) - (417 )

Other operating expenses - (851 ) (829 ) (1,680 )

Stock- based compensation expense (1) - - (743 ) (743 )

Segment profit (loss) $ (121 ) $ (80 ) $ (1,572 ) $ (1,773 )

Translational

Personalized Oncology Unallocated

Oncology Solutions Corporate

Nine Months Ended January 31, 2013 Solutions (POS) (TOS) Overhead Consolidated

Net revenue $ 1,850 $ 4,631 $ - $ 6,481

Direct cost of services (2,030 ) (1,740 ) - (3,770 )

Sales and marketing costs (495 ) (636 ) - (1,131 )

Other operating expenses - (1,463 ) (2,418 ) (3,881 )

Stock- based compensation expense (1) - - (1,934 ) (1,934 )

Segment profit (loss) $ (675 ) $ 792 $ (4,352 ) $ (4,235 )

Translational

Personalized Oncology Unallocated

Oncology Solutions Corporate

Nine Months Ended January 31, 2012 Solutions (POS) (TOS) Overhead Consolidated

Net revenue $ 1,837 $ 3,931 $ - $ 5,768

Direct cost of services (1,463 ) (1,904 ) - (3,367 )

Sales and marketing costs (718 ) (626 ) - (1,344 )

Other operating expenses - (2,419 ) (2,489 ) (4,908 )

Stock- based compensation expense (1) - - (2,612 ) (2,612 )

Segment profit (loss) $ (344 ) $ (1,018 ) $ (5,101 ) $ (6,463 )

(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 22

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8813-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=14024403&loc=d3e13816-109267

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 131

-Paragraph 27, 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8721-108599

+ Details

Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SegmentReportingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 53 R41.htm IDEA: XBRL DOCUMENT v2.4.0.6

Grant Income (DetailsTextual) (USD $)
In Millions, unless otherwise specified
12 Months Ended

Apr. 30, 2011

Apr. 30, 2010

Feb. 13, 2012

Nov. 30, 2010

Revenue from Grants $ 1.5

Qualifying Expenses 0.5 1.0

Grants Receivable $ 0.5 $ 1.0

X

- Definition

The amount of qualifying expenses incurred by the company during the reporting period.

+ References

No definition available.

+ Details

Name: csbr_QualifyingExpenses

Namespace Prefix: csbr_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.8)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_GrantsReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_RevenueFromGrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 54 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (USD $)
In Thousands, unless otherwise specified
3 Months Ended 9 Months Ended

Jan. 31, 2013

Jan. 31, 2012

Jan. 31, 2013

Jan. 31, 2012

Net loss $ (990) $ (1,719) $ (4,284) $ (6,111)

Foreign currency translation adjustment 1 (13) 24 2

Comprehensive loss $ (989) $ (1,732) $ (4,260) $ (6,109)

X

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the reporting entity. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, but excludes any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(3)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=16317811

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e557-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A5

-Appendix A

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Net of tax and reclassification adjustments of the change in the balance sheet adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency of the reporting entity. Also includes the following: gain (loss) on foreign currency forward exchange contracts; foreign currency transactions designated as hedges of net investment in a foreign entity and intercompany foreign currency transactions that are of a long-term nature, when the entities to the transaction are consolidated, combined, or accounted for by the equity method in the reporting enterprise's financial statements; and gain (loss) on a derivative instrument or nonderivative financial instrument that may give rise to a foreign currency transaction gain (loss) that has been designated and qualified as a hedging instrument for hedging of the foreign currency exposure of a net investment in a foreign operation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 45

-Paragraph 20

-Subparagraph (b,c)

-URI http://asc.fasb.org/extlink&oid=6915805&loc=d3e32211-110900

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 55 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

Share-Based Payments
9 Months Ended

Jan. 31, 2013

Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
Note 4. Share-Based Payments

The Company has in place the 2010 Equity Incentive Plan, the 2008 Equity Incentive Plan, and the Director Compensation Plan of 2010. In general, these plans provide for stock-based compensation in the form (i) Non-statutory Stock Options; (ii) Restricted Stock Awards; and (iii) Stock Appreciation Rights to the Company’s employees, directors and non-employees. The plans also provide for limits on the aggregate number of shares that may be granted, the term of grants and the strike price of option awards. Stock-based compensation in the amount of $570,000 and $743,000 was recognized for the three months ended January 31, 2013 and 2012, respectively, and $1,934,000 and $2,612,000 for the nine months ended January 31, 2013 and 2012, respectively. Stock-based compensation expense was recognized as follows (in thousands):

Three Months Ended Nine Months Ended

January 31, January 31,

2013 2012 2013 2012

General and administrative $ 500 $ 701 $ 1,619 $ 2,370

Sales and marketing 56 49 199 168

Research and development 4 (8 ) 33 72

TOS cost of sales 4 1 16 2

POS cost of sales 6 - 67 -

Total stock-based compensation expense $ 570 $ 743 $ 1,934 $ 2,612

Stock Option Grants

Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2013 and 2012 were as follows:

Three Months Ended Nine Months Ended

January 31, January 31,

2013 2012 2013 2012

Expected term in years 6.0 3.0 - 6.0 6.0 3.0 - 6.0

Risk-free interest rates 0.9% - 1.0% 0.4% - 1.9% 0.8% - 1.0% 0.4% - 2.2%

Volatility 100% - 102% 90% - 101% 99% - 102% 90% - 108%

Dividend yield 0% 0% 0% 0%

The weighted average fair value of stock options granted during the three months ended January 31, 2013 and 2012 was $0.27 and $0.52, respectively. The weighted average fair value of stock options granted during the nine months ended January 31, 2013 and 2012 was $0.36 and $0.57, respectively. The Company’s stock option activity for the nine months ended January 31, 2013 was as follows:

Weighted

Weighted Average

Directors Average Remaining Aggregate

Non- and Exercise Contractual Intrinsic

Employees Employees Total Price Life (Years) Value

Outstanding, May 1, 2012 1,410,000 13,456,038 14,866,038 $ 0.88 7.0 $ -

Granted 130,000 586,250 716,250 0.41

Forfeited - (22,500 ) (22,500 ) 0.67

Expired (500,000 ) (15,833 ) (515,833 ) 0.76

Canceled - (25,000 ) (25,000 ) 0.62

Outstanding, January 31, 2013 1,040,000 13,978,955 15,018,955 0.86 7.1 96,000

Vested and expected to vest as of January 31, 2013 1,040,000 13,978,955 15,018,955

Exercisable as of January 31, 2013 933,334 9,735,078 10,668,412 0.88 6.8 14,000

Restricted Stock Grants

A summary of the activity related to restricted stock grants is as follows (in thousands):

Weighted

Average Grant

Date Fair Value

Shares Per Share

Nonvested as of May 1, 2012 25,000 $ 0.75

Granted 100,000 0.30

Vested (50,000 ) 0.53

Forfeited - -

Expired - -

Nonvested as of January 31, 2013 75,000 -

The aggregate fair value of shares vested during the nine months ended January 31, 2013 and 2012 was $26,000 and $84,000, respectively.

Stock Purchase Warrants

As of January 31, 2013, the Company had warrants outstanding for the purchase of 3,276,667 shares of its common stock, all of which were exercisable. Of these warrants, 1,266,667 were issued in connection with the April 2011Private Placement (see Note 5) and 1,860,000 were issued in connection with the January 2013 Private Placement (see Note 5) and are accounted for as liabilities as further discussed in Note 5. The remaining 150,000 warrants are accounted for as equity instruments and expire July 31, 2014. As of January 31, 2013, the weighted average exercise price of all warrants outstanding was $0.77. As of January 31, 2013 and April 30, 2012, the warrants intrinsic value was $13,000 and $0, respectively, and had weighted average remaining contractual lives of 4.2 years and 3.8 years, respectively.

X

- Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Statement of Position (SOP)

-Number 93-6

-Paragraph 53

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 123R

-Paragraph 64, 65, A240

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 56 R27.htm IDEA: XBRL DOCUMENT v2.4.0.6

Organization, Use of Estimates and Basis of Presentation (Details)
9 Months Ended

Jan. 31, 2013

Jan. 31, 2012

Common stock equivalents 18,370,622 16,519,033

Stock Options [Member]

Common stock equivalents 15,018,955 15,064,866

Warrant [Member]

Common stock equivalents 3,276,667 1,416,667

Restricted Stock [Member]

Common stock equivalents 75,000 37,500

X

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 07-4

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 171

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 40

-Subparagraph c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 128

-Paragraph 13, 14

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 57 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 101 199 1 true 29 0 false 5 false false R1.htm 001 - Document - DOCUMENT AND ENTITY INFORMATION Sheet http://championsoncology.com/role/DocumentAndEntityInformation DOCUMENT AND ENTITY INFORMATION true false R2.htm 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://championsoncology.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS false false R3.htm 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://championsoncology.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) false false R4.htm 004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://championsoncology.com/role/UnauditedCondensedConsolidatedStatementsOfOperations UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS false false R5.htm 005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Sheet http://championsoncology.com/role/UnauditedCondensedConsolidatedStatementsOfComprehensiveLoss UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS false false R6.htm 006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://championsoncology.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS false false R7.htm 007 - Disclosure - Organization, Use of Estimates and Basis of Presentation Sheet http://championsoncology.com/role/OrganizationUseOfEstimatesAndBasisOfPresentation Organization, Use of Estimates and Basis of Presentation false false R8.htm 008 - Disclosure - Recently Issued Accounting Pronouncements Sheet http://championsoncology.com/role/RecentlyIssuedAccountingPronouncements Recently Issued Accounting Pronouncements false false R9.htm 009 - Disclosure - Property and Equipment Sheet http://championsoncology.com/role/PropertyAndEquipment Property and Equipment false false R10.htm 010 - Disclosure - Share-Based Payments Sheet http://championsoncology.com/role/ShareBasedPayments Share-Based Payments false false R11.htm 011 - Disclosure - Redeemable Common Stock and Stock Purchase Warrant Sheet http://championsoncology.com/role/RedeemableCommonStockAndStockPurchaseWarrant Redeemable Common Stock and Stock Purchase Warrant false false R12.htm 012 - Disclosure - Related Party Transactions Sheet http://championsoncology.com/role/RelatedPartyTransactions Related Party Transactions false false R13.htm 013 - Disclosure - Commitments and Contingencies Sheet http://championsoncology.com/role/Commitmentsandcontingencies Commitments and Contingencies false false R14.htm 014 - Disclosure - Licensing Agreements Sheet http://championsoncology.com/role/LicensingAgreements Licensing Agreements false false R15.htm 015 - Disclosure - Cephalon Agreement Sheet http://championsoncology.com/role/CephalonAgreement Cephalon Agreement false false R16.htm 016 - Disclosure - Supplemental Schedule of Cash Flow Information Sheet http://championsoncology.com/role/SupplementalScheduleOfCashFlowInformation Supplemental Schedule of Cash Flow Information false false R17.htm 017 - Disclosure - Grant Income Sheet http://championsoncology.com/role/GrantIncome Grant Income false false R18.htm 018 - Disclosure - Fair Value Sheet http://championsoncology.com/role/FairValue Fair Value false false R19.htm 019 - Disclosure - Business Segment Information Sheet http://championsoncology.com/role/BusinessSegmentInformation Business Segment Information false false R20.htm 020 - Disclosure - Subsequent Events Sheet http://championsoncology.com/role/SubsequentEvents Subsequent Events false false R21.htm 021 - Disclosure - Organization, Use of Estimates and Basis of Presentation (Tables) Sheet http://championsoncology.com/role/OrganizationUseOfEstimatesAndBasisOfPresentationTables Organization, Use of Estimates and Basis of Presentation (Tables) false false R22.htm 022 - Disclosure - Property and Equipment (Tables) Sheet http://championsoncology.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) false false R23.htm 023 - Disclosure - Share-Based Payments (Tables) Sheet http://championsoncology.com/role/ShareBasedPaymentsTables Share-Based Payments (Tables) false false R24.htm 024 - Disclosure - Redeemable Common Stock and Stock Purchase Warrant (Tables) Sheet http://championsoncology.com/role/RedeemableCommonStockAndStockPurchaseWarrantTables Redeemable Common Stock and Stock Purchase Warrant (Tables) false false R25.htm 025 - Disclosure - Fair Value (Tables) Sheet http://championsoncology.com/role/FairValueTables Fair Value (Tables) false false R26.htm 026 - Disclosure - Business Segment Information (Tables) Sheet http://championsoncology.com/role/BusinessSegmentInformationTables Business Segment Information (Tables) false false R27.htm 027 - Disclosure - Organization, Use of Estimates and Basis of Presentation (Details) Sheet http://championsoncology.com/role/OrganizationUseOfEstimatesAndBasisOfPresentationDetails Organization, Use of Estimates and Basis of Presentation (Details) false false R28.htm 028 - Disclosure - Property and Equipment (Details) Sheet http://championsoncology.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) false false R29.htm 029 - Disclosure - Property and Equipment (Details Textual) Sheet http://championsoncology.com/role/PropertyAndEquipmentDetailsTextual Property and Equipment (Details Textual) false false R30.htm 030 - Disclosure - Share-Based Payments (Details) Sheet http://championsoncology.com/role/ShareBasedPaymentsDetails Share-Based Payments (Details) false false R31.htm 031 - Disclosure - Share-Based Payments (Details 1) Sheet http://championsoncology.com/role/ShareBasedPaymentsDetails1 Share-Based Payments (Details 1) false false R32.htm 032 - Disclosure - Share-Based Payments (Details 2) Sheet http://championsoncology.com/role/ShareBasedPaymentsDetails2 Share-Based Payments (Details 2) false false R33.htm 033 - Disclosure - Share-Based Payments (Details 3) Sheet http://championsoncology.com/role/ShareBasedPaymentsDetails3 Share-Based Payments (Details 3) false false R34.htm 034 - Disclosure - Share-Based Payments (Details Textual) Sheet http://championsoncology.com/role/ShareBasedPaymentsDetailsTextual Share-Based Payments (Details Textual) false false R35.htm 035 - Disclosure - Redeemable Common Stock and Stock Purchase Warrant (Details) Sheet http://championsoncology.com/role/RedeemableCommonStockAndStockPurchaseWarrantDetails Redeemable Common Stock and Stock Purchase Warrant (Details) false false R36.htm 036 - Disclosure - Redeemable Common Stock and Stock Purchase Warrant (Details Textual) Sheet http://championsoncology.com/role/RedeemableCommonStockAndStockPurchaseWarrantDetailsTextual Redeemable Common Stock and Stock Purchase Warrant (Details Textual) false false R37.htm 037 - Disclosure - Related Party Transactions (Details Textual) Sheet http://championsoncology.com/role/RelatedPartyTransactionsDetailsTextual Related Party Transactions (Details Textual) false false R38.htm 038 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://championsoncology.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) false false R39.htm 039 - Disclosure - Licensing Agreements (Details Textual) Sheet http://championsoncology.com/role/LicensingAgreementsDetailsTextual Licensing Agreements (Details Textual) false false R40.htm 040 - Disclosure - Cephalon Agreement (Details Textual) Sheet http://championsoncology.com/role/CephalonAgreementDetailsTextual Cephalon Agreement (Details Textual) false false R41.htm 041 - Disclosure - Grant Income (DetailsTextual) Sheet http://championsoncology.com/role/GrantIncomeDetailstextual Grant Income (DetailsTextual) false false R42.htm 042 - Disclosure - Fair Value (Details) Sheet http://championsoncology.com/role/FairValueDetails Fair Value (Details) false false R43.htm 043 - Disclosure - Fair Value (Details Textual) Sheet http://championsoncology.com/role/FairValueDetailsTextual Fair Value (Details Textual) false false R44.htm 044 - Disclosure - Business Segment Information (Details) Sheet http://championsoncology.com/role/BusinessSegmentInformationDetails Business Segment Information (Details) false false All Reports Book All Reports Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate had a mix of decimals attribute values: 2 3. Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate had a mix of decimals attribute values: 3 4. 'Monetary' elements on report '034 - Disclosure - Share-Based Payments (Details Textual)' had a mix of different decimal attribute values. 'Monetary' elements on report '036 - Disclosure - Redeemable Common Stock and Stock Purchase Warrant (Details Textual)' had a mix of different decimal attribute values. 'Monetary' elements on report '040 - Disclosure - Cephalon Agreement (Details Textual)' had a mix of different decimal attribute values. Process Flow-Through: 002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Process Flow-Through: Removing column 'Jan. 31, 2012' Process Flow-Through: Removing column 'Apr. 30, 2011' Process Flow-Through: 003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Process Flow-Through: 004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Process Flow-Through: 005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS Process Flow-Through: 006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS csbr-20130131.xml csbr-20130131.xsd csbr-20130131_cal.xml csbr-20130131_def.xml csbr-20130131_lab.xml csbr-20130131_pre.xml true true XML 58 R38.htm IDEA: XBRL DOCUMENT v2.4.0.6

Commitments and Contingencies (Details Textual) (USD $)
9 Months Ended

Jan. 31, 2013

Jan. 31, 2012

Corporate Headquarters [Member]

Lease Expiration Date Apr. 30, 2014

Operating Leases, Rent Expense $ 52,000 $ 52,000

Laboratories and Office Space [Member]

Lease Expiration Date Jun. 30, 2014

Operating Leases, Rent Expense 69,000 49,000

Office Headquarters [Member]

Lease Expiration Date Jul. 30, 2013

Operating Leases, Rent Expense $ 21,000 $ 18,000

X

- Definition

Rental expense incurred for leased assets including furniture and equipment which has not been recognized in costs and expenses applicable to sales and revenues; for example, cost of goods sold or other operating costs and expenses.

+ References

No definition available.

+ Details

Name: us-gaap_LeaseAndRentalExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Date which lease or group of leases is set to expire, in CCYY-MM-DD format.

+ References

No definition available.

+ Details

Name: us-gaap_LeaseExpirationDate1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

XML 59 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6

Subsequent Events
9 Months Ended

Jan. 31, 2013

Subsequent Events [Abstract]

Subsequent Events [Text Block]
Note 14. Subsequent Events



None.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Share-Based Payments (Details 3) (USD $)	3 Months Ended		9 Months Ended
Share-Based Payments (Details 3) (USD $)	Jan. 31, 2013	Jan. 31, 2012	Jan. 31, 2013	Jan. 31, 2012
Weighted Average Grant Date Fair Value Per Share, Granted	$ 0.27	$ 0.52	$ 0.36	$ 0.57
Restricted Stock [Member]
Shares, Nonvested, Begining Balance			25,000
Shares, Granted			100,000
Shares, Vested			(50,000)
Shares, Forfeited			0
Shares, Expired			0
Shares, Nonvested, Ending Balance	75,000		75,000
Weighted Average Grant Date Fair Value Per Share, Nonvested, Begining Balance			$ 0.75
Weighted Average Grant Date Fair Value Per Share, Granted			$ 0.30
Weighted Average Grant Date Fair Value Per Share, Vested			$ 0.53
Weighted Average Grant Date Fair Value Per Share, Forfeited			$ 0
Weighted Average Grant Date Fair Value Per Share, Expired			$ 0
Weighted Average Grant Date Fair Value Per Share, Nonvested, Ending Balance	$ 0		$ 0

Fair Value (Details) (USD $) In Thousands, unless otherwise specified			9 Months Ended
	Jan. 31, 2013	Apr. 30, 2012	Jan. 31, 2013 Fair Value, Inputs, Level 3 [Member]
Balance, May 1, 2012	$ 993	$ 555	$ 555
Transfers to (from) Level 3			0
Total (gains) losses included in earnings			21
Purchases, issuances and settlements, net			417
Balance, January 31, 2013	$ 993	$ 555	$ 993

Related Party Transactions (Details Textual) (USD $)	9 Months Ended
Related Party Transactions (Details Textual) (USD $)	Jan. 31, 2013	Jan. 31, 2012
Related Party Transaction, Revenues from Transactions with Related Party	$ 0	$ 20,000
Servicing Fees, Net	8,300
Chief Executive Officer [Member]
Related Party Transaction, Amounts of Transaction	30,000	18,000
Board of Directors Chairman [Member]
Related Party Transaction, Amounts of Transaction	122,500	103,000
Substantial Stockholders [Member]
Related Party Transaction, Amounts of Transaction	$ 3,000	$ 0

Property and Equipment (Details) (USD $) In Thousands, unless otherwise specified	Jan. 31, 2013	Apr. 30, 2012
Furniture and fixtures	$ 58	$ 58
Computer equipment and software	526	287
Laboratory equipment	179	167
Leasehold improvements	2	2
Software in-progress	0	216
Total property and equipment	765	730
Less: Accumulated depreciation	(323)	(170)
Property and equipment, net	$ 442	$ 560

Share-Based Payments (Details 1)	3 Months Ended		9 Months Ended
Share-Based Payments (Details 1)	Jan. 31, 2013	Jan. 31, 2012	Jan. 31, 2013	Jan. 31, 2012
Expected term in years	6 years		6 years
Risk-free interest rates Minimum	0.90%	0.40%	0.80%	0.40%
Risk-free interest rates Maximum	1.00%	1.90%	1.00%	2.20%
Volatility Minimum	100.00%	90.00%	99.00%	90.00%
Volatility Maximum	102.00%	101.00%	102.00%	108.00%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Expected term in years		3 years		3 years
Maximum [Member]
Expected term in years		6 years		6 years

Share-Based Payments (Details 2) (USD $)	9 Months Ended
Share-Based Payments (Details 2) (USD $)	Jan. 31, 2013
Outstanding, Begining Balance	14,866,038
Granted	716,250
Forfeited	(22,500)
Expired	(515,833)
Canceled	(25,000)
Outstanding, Ending Balance	15,018,955
Vested and expected to vest	15,018,955
Exercisable	10,668,412
Weighted Average Exercise Price, Outstanding, Begining Balance	$ 0.88
Weighted Average Exercise Price, Granted	$ 0.41
Weighted Average Exercise Price, Forfeited	$ 0.67
Weighted Average Exercise Price, Expired	$ 0.76
Weighted Average Exercise Price, Canceled	$ 0.62
Weighted Average Exercise Price, Outstanding, Ending Balance	$ 0.86
Weighted Average Exercise Price, Exercisable	$ 0.88
Weighted Average Remaining Contractual Term, Outstanding, Begining Balance (in years)	7 years
Weighted Average Remaining Contractual Term, Outstanding, Ending Balance (in years)	7 years 1 month 6 days
Weighted Average Remaining Contractual Term, Exercisable (in years)	6 years 9 months 18 days
Aggregate Intrinsic Value, Outstanding, Begining Balance	$ 0
Aggregate Intrinsic Value, Outstanding, Ending Balance	96,000
Aggregate Intrinsic Value, Exercisable	$ 14,000
Non-Employees [Member]
Outstanding, Begining Balance	1,410,000
Granted	130,000
Forfeited	0
Expired	(500,000)
Canceled	0
Outstanding, Ending Balance	1,040,000
Vested and expected to vest	1,040,000
Exercisable	933,334
Directors and Employees [Member]
Outstanding, Begining Balance	13,456,038
Granted	586,250
Forfeited	(22,500)
Expired	(15,833)
Canceled	(25,000)
Outstanding, Ending Balance	13,978,955
Vested and expected to vest	13,978,955
Exercisable	9,735,078

Cephalon Agreement (Details Textual)	1 Months Ended	9 Months Ended			12 Months Ended	9 Months Ended
Cephalon Agreement (Details Textual)	Nov. 30, 2012 USD ($)	Jan. 31, 2013 USD ($)	Jan. 31, 2013 CAD	Jan. 31, 2012 USD ($)	Apr. 30, 2011 USD ($)	Jan. 31, 2013 One Compound [Member] USD ($)	Jan. 31, 2013 Second Compound [Member] USD ($)
Deferred Revenue, Additions		$ 27,000,000
Royalty Expense			10,000			460,000	880,000
Exercise Of Options To One Time Royalty Fee	880,000
Deferred Revenue, Refund Payments					1,400,000
Deferred Revenue, Revenue Recognized		$ 317,000		$ 681,000

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Jan. 31, 2013	Apr. 30, 2012
ASSETS
Cash and cash equivalents	$ 10,769	$ 4,716
Accounts receivable, net	642	584
Prepaid expenses and other current assets	300	205
Total current assets	11,711	5,505
Restricted cash	190	188
Property and equipment, net	442	560
Goodwill	669	669
Total assets	13,012	6,922
LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' DEFICIT
Accounts payable	1,101	1,676
Accrued liabilities	566	625
Deferred revenue	1,017	1,185
Total current liabilities	2,684	3,486
Warrant liability	993	555
Total liabilities	3,677	4,041
Commitments and contingencies
Redeemable common stock; $0.001 par value; 31,133,333 and 12,533,333 contingently puttable common shares outstanding as of January 31, 2013 and April 30, 2012	16,936	8,159
Stockholders' equity:
Preferred stock, $10 par value; 56,075 shares authorized; no shares issued and outstanding as of January 31, 2013 and April 30, 2012	0	0
Common stock, $.001 par value; 125,000,000 shares authorized, including redeemable common stock, 38,855,003 and 37,740,345 shares is sued and 35,618,767 and 34,529,000 shares outstanding as of January 31, 2013 and April 30, 2012, respectively	39	38
Treasury stock, at cost, 3,236,000 common shares as of January 31, 2013 and April 30, 2012	(1,252)	(1,252)
Additional paid-in capital	23,136	21,204
Accumulated deficit	(29,425)	(25,143)
Accumulated other comprehensive loss	(99)	(125)
Total stockholders' deficit	(7,601)	(5,278)
Total liabilities, redeemable common stock and stockholders' deficit	$ 13,012	$ 6,922

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Jan. 31, 2013	Jan. 31, 2012
Operating activities:
Net loss	$ (4,284)	$ (6,111)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	1,934	2,612
Depreciation expense	153	65
Change in fair value of warrant liability	21	(354)
Changes in operating assets and liabilities:
Accounts receivable	(58)	88
Prepaid expenses, deposits and other	(96)	178
Restricted cash	(2)	(150)
Accounts payable	(574)	43
Accrued liabilities	(58)	42
Deferred revenue	(168)	(117)
Net cash used in operating activities	(3,132)	(3,704)
Investing activities:
Purchase of property and equipment	(35)	(371)
Net cash used in investing activities	(35)	(371)
Financing activities:
Private placement of common shares and warrants	9,195	0
Proceeds from exercise of options and warrants	0	98
Net cash provided by financing activities	9,195	98
Exchange rate effect on cash and cash equivalents	25	2
Increase in cash and cash equivalents	6,053	(3,975)
Cash and cash equivalents, beginning of period	4,716	10,457
Cash and cash equivalents, end of period	$ 10,769	$ 6,482

Redeemable Common Stock and Stock Purchase Warrant (Details Textual) (USD $)	1 Months Ended		9 Months Ended	12 Months Ended
	Jan. 28, 2013	Mar. 24, 2011	Jan. 31, 2013	Apr. 30, 2012
Stock Issued During Period, Shares, Acquisitions	18,600,000	12,533,333
Common Stock Purchase Price	$ 0.50	$ 0.75
Stock Issued During Period, Value, Share-based Compensation, Gross	$ 9,300,000	$ 9,400,000
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures	500,000	500,000
Warrants Issued During Period for Common Stock		1,266,667
Warrants Exercise Price Per Share		$ 0.90
Percentage of Common Stock Purchased	25.00%	25.00%
Issuance Of Additional Common Shares To Investors	1,064,658
Percentage of Cash Penalties			1.00%
Purchase Price Limit Percentage			10.00%
Warrants and Rights Outstanding			800,000
Increase (Decrease) in Warrants Fair Value			1,000,000	600,000
Minimum [Member]
Potential Penalties Amount			50,000
Maximum [Member]
Potential Penalties Amount			130,000
January 2013 Private Placement [Member]
Warrants Issued During Period for Common Stock	1,860,000		1,860,000
Warrants Exercise Price Per Share	$ 0.66
Common Stock Repurchase Price Per Share	$ 0.50
Net Shares Reclassified to Mandatorily Redeemable Capital Stock, Value			8,800,000
Proceeds from Issuance of Common Stock and Warrants			9,300,000
Proceeds from Issuance of Warrants			400,000
Incremental Compensation Cost			100,000
April 2011 Private Placement [Member]
Warrants Issued During Period for Common Stock			1,266,667
Common Stock Repurchase Price Per Share		$ 0.75
Net Shares Reclassified to Mandatorily Redeemable Capital Stock, Value			8,200,000
Proceeds from Issuance of Common Stock and Warrants			9,400,000
Proceeds from Issuance of Warrants			900,000
Incremental Compensation Cost			$ 300,000
April 2011 Private Placement [Member] \| Minimum [Member]
Warrants Exercise Price Per Share			$ 0.50
April 2011 Private Placement [Member] \| Maximum [Member]
Warrants Exercise Price Per Share			$ 0.90

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Jan. 31, 2013	Apr. 30, 2012
Redeemable common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Redeemable common stock, shares outstanding	31,133,333	12,533,333
Preferred stock, par value (in dollars per share)	$ 10	$ 10
Preferred stock, shares authorized	56,075	56,075
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	38,855,003	37,740,345
Common stock, shares outstanding	35,618,767	34,529,000
Treasury stock, shares	3,236,000	3,236,000

DOCUMENT AND ENTITY INFORMATION	9 Months Ended
DOCUMENT AND ENTITY INFORMATION	Jan. 31, 2013	Feb. 28, 2013
Entity Registrant Name	CHAMPIONS ONCOLOGY, INC.
Entity Central Index Key	0000771856
Current Fiscal Year End Date	--04-30
Entity Filer Category	Smaller Reporting Company
Trading Symbol	csbr
Entity Common Stock, Shares Outstanding		66,752,100
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jan. 31, 2013
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2013

Share-Based Payments (Details Textual) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended	9 Months Ended	1 Months Ended	9 Months Ended
Share-Based Payments (Details Textual) (USD $)	Mar. 24, 2011	Jan. 31, 2013	Jan. 31, 2012	Jan. 31, 2013	Jan. 31, 2012	Apr. 30, 2012	Jan. 31, 2013 April 2011 Private Placement [Member]	Jan. 28, 2013 January 2013 Private Placement [Member]	Jan. 31, 2013 January 2013 Private Placement [Member]	Jan. 31, 2013 Equity Instrument [Member]
Allocated Share-based Compensation Expense		$ 570,000	$ 743,000	$ 1,934,000	$ 2,612,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value		$ 0.27	$ 0.52	$ 0.36	$ 0.57
Share-based Compensation Arrangement by Share-based Payment Award, Vesting Period, Fair Value				26,000	84,000
Share-based Compensation Arrangement by Share-based Payment Award, Warrants, Outstanding		3,276,667		3,276,667
Warrants Issued During Period for Common Stock	1,266,667						1,266,667	1,860,000	1,860,000	150,000
Warrant Expiration Date				Jul. 31, 2014
Warrant Intrinsic Value		$ 13,000		$ 13,000		$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Other than Options, Outstanding, Weighted Average Exercise Price		$ 0.77		$ 0.77
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms				4 years 2 months 12 days		3 years 9 months 18 days

Grant Income (DetailsTextual) (USD $) In Millions, unless otherwise specified	12 Months Ended
	Apr. 30, 2011	Apr. 30, 2010	Feb. 13, 2012	Nov. 30, 2010
Revenue from Grants		$ 1.5
Qualifying Expenses	0.5	1.0
Grants Receivable			$ 0.5	$ 1.0

Organization, Use of Estimates and Basis of Presentation (Details)	9 Months Ended
	Jan. 31, 2013	Jan. 31, 2012
Common stock equivalents	18,370,622	16,519,033
Stock Options [Member]
Common stock equivalents	15,018,955	15,064,866
Warrant [Member]
Common stock equivalents	3,276,667	1,416,667
Restricted Stock [Member]
Common stock equivalents	75,000	37,500

Commitments and Contingencies (Details Textual) (USD $)	9 Months Ended
Commitments and Contingencies (Details Textual) (USD $)	Jan. 31, 2013	Jan. 31, 2012
Corporate Headquarters [Member]
Lease Expiration Date	Apr. 30, 2014
Operating Leases, Rent Expense	$ 52,000	$ 52,000
Laboratories and Office Space [Member]
Lease Expiration Date	Jun. 30, 2014
Operating Leases, Rent Expense	69,000	49,000
Office Headquarters [Member]
Lease Expiration Date	Jul. 30, 2013
Operating Leases, Rent Expense	$ 21,000	$ 18,000